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Summary 
This thesis studied opioids and alcohol in forensic toxicology by LC-MS/MS, which 
avoids time-consuming procedures involving hydrolysis, extraction and 
derivatisation. Initially, a method was validated for quantification of opioids and 
unhydrolysed polar metabolites in autopsy specimens and was used to develop 
procedures for interpretation of forensic toxicology results. The LC-MS/MS 
method developed has been validated for the simultaneous determination of 24 
opioids in human whole blood, including, for the first time in human whole 
blood, naloxone-3-glucuronide. Although a large number of drugs of interest 
were included in the method, acceptance criteria for linearity, precision, and 
recovery for all analytes were achieved. The method was found useful for 
differentiating between users of heroin and other opioids, such as codeine and 
morphine, and for determining the survival time in deaths attributed to heroin 
use.  
Subsequently, the efficiencies of hydrolytic and non-hydrolytic methods for 
opioid analysis were compared for buprenorphine (BUP) analysis. The aims were 
to develop and validate a method for the direct determination (DM) of 
buprenorphine (BUP), norbuprenorphine (NBUB), buprenorphine-3-glucuronide 
(B3G) and norbuprenorphine-3-glucuronide (NBUP3G). This method was 
compared with an in house enzymatic hydrolysis method (HM) for the 
determination of total buprenorphine (TBUP) and norbuprenorphine (TNBUP), 
using real positive BUP urine case samples. A comparison between the drug and 
metabolite concentrations obtained by direct and hydrolysis methods was 
reported for the first time in this work. 
LC-MS analysis was also applied to paediatric plasma specimens obtained from a 
clinical pharmacokinetic study of intravenous and intranasal administration of 
diamorphine. This work was aimed at obtaining pharmacokinetic data for 
diamorphine and its metabolites in children following intravenous (IVDIM) and 
intranasal (INDIM) administration in a blind study. It was intended that the 
concentrations of active metabolites would be used to evaluate whether or not 
IN-DIM can deliver rapid and efficient analgesia in children comparable to that 
obtained with IV-DIM. The pharmacokinetics of DIM and its metabolites following 
INDIM and IVDIM administration in children have been compared for the first 
 XXX
time in this study, which confirmed that INDIM can achieve therapeutic plasma 
concentrations of active metabolites, although these were lower than those 
obtained with IVDIM and occur at later times after administration. 
In Scotland, the number of prescriptions for oxycodone has risen by 430% since 
prescribing began in 2002. Blood samples from fatalities in the West of Scotland 
involving oxycodone were analysed using an LC-ESI-MS/MS method developed for 
the determination of oxycodone and its metabolites in post-mortem specimens. 
To the authors knowledge, this is the first report of blood and urine 
concentrations of noroxycodone and oxymorphone in acute oxycodone 
overdoses. Also, it is the first LC-MS/MS application to be reported with 
oxycodone related fatalities cases in forensic toxicology as most of previous 
reports used GC or HPLC applications. Moreover, this work reported for the first 
time vitreous humour levels of noroxycodone following oxycodone intoxication. 
Ten oxycodone-related deaths were identified in the short period of this study in 
the Strathclyde region of Scotland alone, highlighting the importance of 
including this drug in routine laboratory screening and confirmation procedures. 
Polar alcohol metabolites ethyl glucuronide and ethyl sulfate  are biomarkers of 
ante-mortem alcohol consumption and are used to test for post-mortem 
artefactual formation of alcohol. An LC-MS method for these metabolites using a 
novel hydrophilic interaction liquid chromatography column was validated and 
applied to routine forensic casework. Ninety urine case samples were divided 
into three groups depending on the ethanol concentration found in blood and 
analysed by the developed method: group A with post-mortem blood ethanol 
higher than 200 mg/100 mL; group B with ethanol concentration in the range 80 
to 200 mg/100 mL and group C with ethanol concentration less than 80 mg/100 
mL.  
It was concluded that the risk of false positive ethanol results increased in the 
low ethanol concentration group as several cases tested negative for both 
biomarkers. ETG was detected at low concentrations in some cases for which 
ETS tested negative, suggesting that either ETG may have a longer half-life in 
urine or else ETS is unstable. The data was compared with previous studies and 
confirmed that both ethanol biomarkers should be determined in heavily 
putrefied cases and when the ethanol level in post-mortem blood is low, 
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suggesting the production of ethanol after death. To the authors knowledge, 
this is the first report of the determination of ETS using an LC-ESI-ion trap-
MS/MS method, and of a HILIC-ESI-ion trap-MS/MS method for the simultaneous 
determination of ETG and ETS in post-mortem urine samples.
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1 General Introduction  
1.1 Forensic Toxicology 
Toxicology is the study of chemicals or poisons which could potentially result 
in harmful effects or death after exposure in living subjects. Forensic 
toxicology is defined as the method of identification of the presence of these 
harmful substances for the purposes of law. The toxic effects of such poisons 
depend on their quantity present or concentration and differ between 
individuals. Tolerance amongst users varies and is dependent on the individual 
patient with factors including dose, age, gender, body mass and the length of 
time the person used or abused. Everything in nature can be a poison, such as 
water if it is taken in abnormal quantities 1-5. Illicit and licit drugs have been 
described by Kintz et al 6  and Trujols et al 7 as chemical weapons whose 
effect on society is that of a double-edged sword: they may relieve pain, and 
yet they may also kill. Drug testing is also important for identifying the cause 
and manner of deaths in post-mortem cases, keeping the workplace drug free 
and reducing accidents due to driving under the influence of drugs (DUID). 
The analysis of biological fluids to obtain evidence linking to drug use which 
may cause death is one of the main activities in the field of post-mortem 
forensic toxicology. Forensic toxicology also involves the study of the 
pharmacology and biochemical properties of drugs or poisons such as route of 
administration, absorption, metabolism and excretion from the body. 
Information is also needed concerning the therapeutic and lethal dose of 
drugs, in order to interpret the cause of death and whether the drug 
concentrations detected in post-mortem specimens could lead to death or the 
amount of drug found in a specimen from a driver could lead to impairment.   
Samples collected at autopsy for toxicology analysis depend on the case under 
investigation. In most cases blood, urine and liver specimens are commonly 
used. However, in putrefied cases these common specimens may not be 
available for use and instead hair, muscular tissue and bone may be more 
suitable for analysis. However, in general, a variety of specimens can be 
processed in forensic laboratories such as blood, urine, vitreous humour, bile, 
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stomach contents, liver and other organ tissues, hair, nails and oral fluid 8-10. 
Traditionally, urine samples are the sample of choice for the screening and 
identification of unknown drugs or toxic compounds. A urine specimen is 
preferable for living subjects for drug testing such as driving under the 
influence of drugs (DUID) and workplace drug testing, as urine is non-invasive 
compared to withdrawing blood samples. Also, drug concentrations in urine 
are much higher than those detected in blood, for example, it has been found 
that the concentration of amphetamine in urine was 200 times greater than in 
blood 11. In addition, detection windows of drugs in urine are longer. 
Moreover, the volume of a urine specimens is usually enough for initial 
analysis and repeat analysis compared, for example, to hair analysis in which 
there is often not enough sample available for multiple analysis. Analytes of 
interest have been found to be stable in urine for long periods if the samples 
are frozen, which is important for re-analysis 12,13. However, it has been 
shown that urine samples can be adulterated using several substances to bring 
about a false negative results for drugs 12,14,15. Also, urine samples do not give 
information on the concentrations of drugs in blood and hence on their effects 
at the time a urine sample is collected: in driving cases this means that 
impairment cannot be assessed based on urine drug concentrations. 
The analysis of blood samples obtained at autopsy has acquired a considerably 
greater value in comparison to other specimens, particularly in forensic 
toxicology, as concentrations of drugs found in venous blood can give a close 
approximation of what the brain has been exposed to before death 8,9,16,17. In 
contrast, other matrices such as urine could be used to confirm that a person 
has taken drugs before death but the concentration cannot be linked to the 
cause of death. Hair is the matrix of choice to assess history of drug use, with 
long widows of detection, but not for the last few hours to weeks before 
death. It is standard practice in many jurisdictions such as in which hair is 
used in an investigation to take a hair sample at the time of reporting an 
alleged offence (as a control sample) and to ask the complainer to come back 
a month later to provide a second sample (which may indicate the presence of 
drugs at the time of the reported offence). Another advantage of blood is that 
repeat analysis should give the same concentration if there is sufficient 
sample. During the last 20 years of the 20th century, post-mortem toxicology 
practice has improved due to significant advances in extraction and analytical 
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procedures which make blood samples suitable as screening specimens. In 
addition, there has been improvement in the data available from case study 
samples for use as interpretive aids 8,18. 
In forensic post-mortem toxicology, one of the more important factors which 
might affect the interpretation of post-mortem toxicology results is the 
phenomenon of post-mortem redistribution, which results in changes in blood 
concentrations of drugs after death due to diffusion of drugs from surrounding 
tissues into the blood 5,9. It is believed to occur widely, with drugs diffusing 
from high to low concentration and is site-dependent, with the largest 
increases in concentration occurring in the blood vessels in or near major 
organs such as the heart and liver rather than in peripheral sites 19. 
Redistribution starts within an hour after death, with the major changes 
occurring in the first 24 hours. Post-mortem redistribution is influenced by the 
post-mortem interval time 9 and by the volume of distribution (VD) of a drug, 
as drugs with a high VD, i.e. greater than 3 L/Kg, are more susceptible to 
post-mortem redistribution 9,20. The occurrence of post-mortem redistribution 
can be determined by analysing blood samples from different collection sites 
including the body core, such as from the heart, and periphery, such as the 
femoral vein. Differences in drug concentrations in the blood from these sites 
indicates the probable presence of a post-mortem redistribution problem 18. 
Blood from the femoral vein is considered to be the specimen of choice 
because it is spared from redistribution phenomena as well as bacterial 
invasion 21.   
Post-mortem redistribution has been studied widely for many drugs, including 
the opioids studied in this thesis. Morphine, for example, exhibited little or no 
redistribution in man at either central or peripheral sites 22 whereas 
methadone concentrations changed by -30% 5. In another study, no significant 
post-mortem redistribution of morphine and its glucronides was observed in 
40 heroin related deaths. In that study, blood was analysed for morphine and 
its metabolites from subclavian, heart and femoral sites and no significant 
changes were observed 23. Skopp et al 24 studied the post-mortem 
redistribution of dihydrocodeine and its metabolites and found no significant 
changes from site to site due to the low volume of distribution (1-1.3 L/Kg for 
dihydrocodeine). The presence of oxycodone at high concentrations in blood 
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has been attributed to its accumulation in tissue following chronic 
administration and subsequent release back into the blood 25. 
1.2 Drug misuse 
In this thesis the term heroin will be used with reference to the illicit form 
of diamorphine (also referred to as street heroin), which contains impurities 
derived from opium constituents as well as diluents and adulterants. The 
pharmacological name diamorphine will be used with reference to the pure 
substance and considered to be synonymous with the chemical name 
diacetylmorphine. 
In the most recent United Nations World Drug report, published in 200926, the 
United Nations Office On Drugs and Crime estimates that between 172 and 
250 million persons used illicit drugs at least once in 2007 and 18 to 38 million 
aged 15-64 had problem drug use. The prevalence of abuse of many drug 
classes has continued to increase, for example, the number of cannabis users 
increased from 3.8% to 3.9%, cocaine from 0.34 to 0.37% and opioids from 
0.37 to 0.39% of the world population in the periods 2005-2006 to 2006-2007, 
respectively.  Heroin misuse also increased from 0.27 to 0.28% of the word 
population.   
Europe has an estimated 3-4 million opiate users (0.6-0.7% of the population 
aged 15-64). The level of use observed has been stable, despite some 
countries reporting an increase in fatalities due to opioids. The largest market 
for opioids in Western Europe is in the UK, with 404,000-434,000 users.  
According to the most recent report of the General Registrar of Scotland 27, 
published in 2009, the number of drug-related deaths (cases attributed to 
drug abuse) has increased over the last ten years, rising from an average of 
189 deaths per annum in the period 1996-2000 to 246 deaths per annum in the 
period 2003-2007. Also, unintentional/accidental drug-related deaths have 
increased from 13 (7%) to 43 deaths (17%) on average in the same periods, 
while suicide or intentional drug related deaths increased only slightly.   
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There were 574 drug-related deaths in Scotland in 2008, which represents 
increases of 26 % and 131% over those reported in 2007 and 1997, 
respectively. Heroin was involved in 336 (59 %) of the drug related deaths, 
followed by methadone which was found in 181 (32 %) and diazepam in 362 
(63%) of the deaths. Alcohol was involved in 273 cases (48%), while cocaine, 
ecstasy and amphetamine were involved in 79 (14%), 7 (1%) and 12 (2%) cases, 
respectively.  
The majority of drug related deaths were drug abusers, who increased from 
an average of 189 per year in the period 1996-2000 to an average of 277 in 
2004-2008. Also, accidental deaths showed an increase from an average of 13 
to an average of 42, and deaths due to undetermined causes rose from an 
average of 25 to an average of 74 in the same periods. Ninety six drug related 
deaths in the period 2004-2008 (21%) were 25-34 years old while 151 (35 %) 
were 35-44 years old. The number of deaths on average increses from 134 per 
year from 2004 to 2008 (31%) were 35-44 years old. One hundred and ninety 
seven (34%) of the deaths occurred in Greater Glasgow and Clyde. 
The average numbers of fatalities related to heroin/morphine, cocaine and 
alcohol increased from 128 to 229, 6 to 38 and 91 to 129 per year in the 
periods 1996-2000 and 2003-2007, respectively.  Methadone (average numbers 
of deaths 74 and 90), diazepam (average numbers 116 and 103) and ecstasy 
(average numbers 7 and 13) have shown no significant change in their trend in 
the same periods of time. In addition, temazepam related deaths declined 
sharply from 47 to 12 cases, following a decrease in the number of 
prescriptions for temazepam over the same period.    
1.3 Systematic Toxicological Analysis 
Systematic toxicological analysis is a term describing the process of how each 
forensic analysis test should be performed when searching for unknown drug 
and toxic compounds. This standard approach consists of two steps in the 
laboratory 28-31: immunoassay has been employed as a preliminary method for 
the detection of abused drugs, especially in urine, serum and plasma, due to 
its ability to detect drugs even in very low concentrations as well as being 
able to process large numbers of samples without pre-treatment. 
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Immunoassays suitable for hair and other matrices are now available. 
However, LC-tandem MS and LC-time of flight (TOF) have also been used for 
screening of drugs in several matrices. The LC-MS/MS instrument may become 
the method of choice for screening of drug and toxic compounds in the future 
10,32-40.  
The confirmation step is usually came out using chromatographic techniques 
coupled with more specific methods of identification and detection, for 
example, the most commonly used confirmation procedure is  gas 
chromatography coupled with mass spectrometry (GC-MS) or HPLC coupled 
with photo diode array (DAD) detection, LC-MS and LC-tandem MS 10,28.  
The identification of illicit or licit drug use depends on analytical toxicology 
findings which, until recently, involved tedious procedures for hydrolysis, 
extraction and derivatisation which are potentially hazardous because of the 
toxic chemicals involved, and samples might need to be analysed several 
times to achieve these requirements. The amount of blood available is 
inadequate in some cases if multiple target analytes need to be analysed 
using different confirmatory techniques plus the screening method.  
Although GC-MS has greatly enhanced the potential of analytical toxicology, 
many obstacles have been encountered due to lack of applicability towards 
polar and thermolabile compounds, and high mass molecules 41-45. The arrival 
of LC-MS techniques in analytical toxicology has allowed these expensive, 
time-consuming procedures to be replaced by methods involving a single 
extraction and chromatographic analysis. Also, LC-MS/MS has been used as 
both a screening and confirmation method 32.  
2 Method validation 
2.1 Introduction  
Reliable results are important in medico-legal investigations which in turn 
require reliable methods of analysis that provide accurate, rapid and 
reducible data. Good laboratories practices applied by well trained staff are 
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essential to accomplish those requirements for methods. Forensic laboratory 
methods should be able to distinguish between a variety of drugs in use which 
sometimes share the same chemical properties and mechanisms of toxicity 
and may be present in the analytical specimens at the same time, such as 
heroin, morphine and codeine. Also, for some drugs good separation from 
matrix components eluted at the void volume and other interferences are 
important. Therefore, the sensitivity, and selectivity of a method of analysis 
should be examined before the use of the method for forensic toxicology 
investigation in order to ensure that the method is fit for the purpose of use 
and is suitable for the equipment in daily routine use 10,46-50. 
Many useful protocols for method validation have been published in the 
literature by different organisations to ensure high quality and reliable data, 
among them, SOFT/AAFS Forensic Toxicology Laboratory Guidelines and 
United Nation Guidelines for Analytical Methodology.  These and many other 
sources were used in the work carried out for this thesis 46,49,51-57.     
The requirements for a method differ depending on whether the method will 
be used for qualitative or quantitative analysis 5,47,57,58. In the case of a 
qualitative method, few parameters need to be examined. The limit of 
detection, precision (intra and inter-day precision), specificity/selectivity and 
stability of analyte(s) in given matrices have to be investigated. In biological 
fluids there are often concentration thresholds for target analytes: the 
presence of a drug can be interpreted in three ways: concentration within the 
therapeutic range, lower than the therapeutic range and higher than the 
therapeutic range 5. For some drugs such as digoxin the therapeutic index 
between therapeutic and toxic concentrations is narrow. Therefore, positive 
results of some analytes are reported if they are higher than certain 
thresholds. Linearity, accuracy and precision should be examined for 
qualitative methods with pre-defined threshold at the threshold 
concentrations; accuracy and precision should be examined within the 
laboratory under repeatability and/or reproducibility conditions 57-59.   
Quantitative methods are more important in forensic toxicological 
investigations and require more parameters to be optimised 47. Limit of 
detection, specificity /selectivity, linearity within the quantitation range, 
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precision and accuracy, recovery and stability have to be investigated. 
Ruggedness and robustness have also been suggested for quantitative method 
but are not essential for the method validation process. In addition, it is often 
suggested that matrix effects should be determined for quantitative methods 
using LC-MS/MS 46-48,52,53,57,58,60.  
2.2 Specificity/Selectivity   
Specificity is defined as the ability of an optimised method to produce a 
response for only a single analyte, while selectivity is the ability of method to 
distinguish the response of single target analytes from other responses 
1,46,49,52,53,56. Specificity/selectivity of the method is an important issue for 
both qualitative and quantitative methods of analysis. The effects of possible 
interfering substances from unseen endogenous matrix components or 
compounds with similar structures (isomers, metabolites, etc) that commonly 
occur in real cases and degradation product from unwanted compounds and 
metabolites or endogenous material of matrices are found to interfere with 
the analyte of interest and to influence method accuracy. It has been 
recommended that selectivity/specificity should be investigated with six 
independent matrices 46. It is also recommended 10-20 different sources of 
blank specimens 47,53,61. Specificity of the method could also be examined by 
testing real case samples that are known to be positive for target analytes for 
the presence of possible interfering components and by testing real case 
samples that are known to be negative for target analytes to assess the effect 
of these interferences on the response of target analytes 47,58. In the case of 
high resolution LC-tandem mass spectrometry, one blank matrix source would 
be sufficient 46. A method can still be specific and selective even with the 
presence of small interferences which have little effect on the method 
precision and accuracy if less than ± 20% at the LLOQ 49,51,52. Specificity is 
concentration-dependent which should examined of the low end of calibration 
range 57.  
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2.3 Limit of detection and lower limit of quantification 
The limit of detection is defined as the lowest concentration that can be 
detected using an optimised method which also can be distinguished from the 
matrix background noise at a signal to noise ratio of 3:1 1,49,54. The lower limit 
of quantification (LLOQ) is described as the lowest concentration of the 
analyte of interest that can be quantified with acceptable precision and 
accuracy; in most reports a limit of ± 20% has been recommended. LLOQ is 
recommended in most guidelines to be determined as a signal to noise ratio of 
10:1 46-48,50.  
LOD and LLOQ can be determined using more than one procedure 47,58. 
Traditionally, the method of baseline noise is the most used which relies on 
signal to noise (S/N) ratios of 3 and 10, respectively 47,54. This method is time 
consuming and difficult to obtain using chromatographic techniques 54,62.   
Secondly, LLOQ is also defined in the term of concentration as the lowest 
calibrator can be detected with acceptable precision and accuracy; therefore 
no need to be determined experimentally. This is the most used procedure 
with LC-MS/MS method of quantification 46-48,52,54.    
Thirdly, LOD and LLOQ are calculated statistically as the intercept (YB) of the 
calibration graph and the standard error (SB) of regression line using equations 
2-1,2-2 and 2-3,2-4 for LOD and LLOQ respectively 3,50,62-64: 
 Equation 2-1  yLOD = yB + 3SB 
Equation 2-2  LOD = (yLOD-yB)/m    
Where yB is the intercept, SB is the standard error of the regression line and m 
is the gradient. 
LLOQ values were calculated using the same method but using 10 times the 
standard error of the regression line (equations 3 and 4). 
Equation 2-3  yLLOQ = yB + 10SB    
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Equation 2-4  LLOQ = (yLLOQ-yB)/m  
The latter procedure has been used in the current project and found 
sufficient for the intended purpose of use. This was because many target 
analytes (more than 27 analytes of interest) were detected in the thesis 
projects. Finally, the LOD and LLOQ can be estimated using especial 
calibration curve which constructed  within  expected LOD and LLOQ ranges in 
order to determined LOD and LLOQ of the optimised method 47. 
2.4 Precision and accuracy  
Precision is defined as the closeness of agreement (degree of scatter) 
between a series of measurements obtained from multiple sampling of the 
same homogeneous samples under the prescribed conditions 1,3,56,57. Method 
precision is measured using two main condition sets which are called 
repeatability and reproducibility and which are also known as intra-assay and 
inter-assay precision, respectively. Intra-assay precision is determined by 
analysing replicate specimens containing analytes of interest in the same day 
using the same extraction and analytical method 57. The inter-assay precision 
is measured in a similar manner to the intra-assay precision on different days. 
Five different determinations are carried out for each quality control standard 
which should include low, medium and high levels relative to the calibration 
curve range. Intra and inter-assay precision were assessed using the 
percentage relative standard deviation (RSD) 61. The acceptable limit for 
method validation is less than ±15 %, except at the LLOQ value where 
precision should not exceed ± 20% 1,48,49,57.  
Accuracy or trueness is the degree of closeness of the determined value to 
the nominal or known true value under method conditions; it is expressed as 
a percentage 1,3,56,57.  Both precision and accuracy should be examined using 
certified references materials. In this thesis, precision and/ or accuracy were 
usually determined using blank samples spiked at three different 
concentrations (low, medium and high) as quality control standards (QCs) 
across the calibration range. A calibration curve should be prepared with each 
batch of QCs using the optimised method. The acceptable limits for method 
accuracy are the same as for method precision. In addition, blank samples 
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which tested negative for target analytes and blank samples spiked with 
internal standards were usually included with each batch samples which could 
be to check the absence of such interferences 47,54.    
2.5 Linearity 
Linearity is described as the ability of the optimised method to produce a 
straight line response for the range of analyte concentrations in the sample 
within working range 62. The linear range is the range of concentrations over 
which a linear response is obtained. The range of the calibration curve chosen 
should depend on the concentrations of target analytes found in the body. 
Precision and accuracy are often measured using the calibration curve for the 
optimised method which can also be used in turn to demonstrate that the 
optimised method has suitable levels of precision, accuracy and linearty 46,55. 
The equation for a straight line used to describe a linear calibration curve  
given in Equation 2-5. 
Equation 2-5  y = mx + b 
Where y is the response (in forensic toxicology the peak area ratios between 
analytes versus their corresponding internal standards) 47,65, x is the 
concentration, m is the slope and b is the intercept on the y axis of the best 
fit line for the data. Calibration curve standards should be spiked into blank 
matrix and then analysed using the optimised method for more matrix 
compatibility due to the fact that the pure standard response may be not the 
same as extracted standards, because a percentage of each analyte is usually 
lost during the extraction procedure. It is recommended that five to eight 
concentrations across the calibration range are used  46,49,56. Also, a 
correlation coefficient (r2) of 0.99 or better is preferred for quantitative 
analysis 54,55,57 but less an 0.99 may still fit for purpose 57. 
2.6 Stability 
Stability is described by Shah et al 46 as the chemical stability of analyte in a 
given matrix under specific conditions for a given time interval. A study of 
the stability of analytes during the extraction and analysis was recommended 
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as part of full method validation for more reliable methods of quantitation 
16,46,47,49,52,53. It is believed that most drugs are stable in biological fluids when 
subject to proper storage condition. However, drugs which have ester bonds 
are unstable and can be easily hydrolysed in body fluids 49. The assessment of 
analyte stability in matrix during the validation process is required for reliable 
quantification, especially if no information is available from previous work 47. 
Dadgar et al 53 point out that stability studies measure the differences in 
analyte concentration that may be encountered between the time of sampling 
and the time of analysis; they suggested that two concentrations have to be 
investigated at low and high points of the calibration range. In fact, stability 
studies can be conducted in many different ways, for example, to cover the 
storage conditions before and during the analysis in the laboratory. Four 
storage conditions are most commonly used and these are described below 
47,49,53,58,60.  
Short-term temperature stability at room temperature is required for sample 
preparation.  Freeze-thaw stability should be also conducted due to the fact 
that samples are often frozen and thawed in the event of re-analysis:  
freeze/thaw stability of analytes of interest is recommended to be 
determined after at least three cycles (thawed, left at room temperature 
then refrozen) on consecutive days.  Analytes could also be lost during sample 
processing if a large batch of samples is analysed, which sometimes extends 
overnight and even over one or more days. Therefore, autosampler stability 
using reconstituted extracted samples is required for the expected period of 
an analytical run 47,49,53: it is recommended that stability is  assessed at 24 and 
48 hours 52.   
Long-term stability of analytes in a given matrix should be examined during 
method validation with the same storage conditions and times that are 
expected to be used for real samples. The stability often is expressed as 
percentage (100%) of spiked concentration which survives. Analytes are 
considered stable if the concentrations of stability samples are within the 
range of ± 10-20% compared to the spiked standard concentrations 52,53. Also, 
it is recommended that the stability of standard solutions is assessed 53.     
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2.7 Recovery 
Recovery is defined as the extraction efficiency of an analytical process, 
reported as percentages of the known amount of an analytes of interest which 
are extracted and analysed by an optimised method 46. This is to be 
compared with detector response of neat standard solution which is 
considered to be 100%. Some believe that the recovery experiments are not 
required as part of method validation as long as the LLOQ is adequate and the 
precision and accuracy of the method are within the acceptable limit for 
method validation (± 20%) 46,49,53,60. The loss of analyte during extraction 
should be investigated with at least five replicates at three QC levels or at 
least using two levels at low and high concentration. Internal standard is 
added after extraction to allow direct comparison with unextracted 
standards. Low recoveries can be accepted if LLOQ, accuracy and precision of 
the method are within the acceptable limits. The acceptable limit of 
reproducibility for recoveries should be higher than 50% of recovery value 47. 
Recovery is reported sometimes as being higher than 100%, which indicates 
the presence of matrix effects, especially when using an LC-MS/MS procedure 
51. Matrix effects should therefore be examined together with recovery during 
method validation.  
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3 Liquid Chromatography Tandem Mass 
Spectrometry 
3.1 Introduction  
A liquid chromatography column was used successfully for the first time in 
1903 for the isolation of plant pigments 2. Since then many chromatography 
techniques have been created for isolation and identification of substances in 
nature, some of which are suitable for qualitative and/ or quantitative 
analysis. Among them gas chromatography (GC) and high performance liquid 
chromatography (HPLC) are the techniques most used in forensic laboratories 
for routine analysis; both are powerful separation techniques 16,66-68.  
The basic principles of separation are similar for both techniques: two phases 
are used for the separation of compounds, the stationary phase and the 
mobile phase, but the nature of these two phases differs between GC and 
HPLC. The separation of components occurs due to their distribution between 
these two phases, determined by the partition coefficient of the analyte 
between the stationary and mobile phases. The column is the stationary phase 
in both techniques. In GC an inert gas is used as a mobile phase while in HPLC 
a liquid mobile phase using organic or non-organic solvents is used. Long 
columns (meters) are preferred for GC and shorter columns (centimetres) for 
HPLC applications. Temperature is the most important factor influencing the 
speed of analyte separation in GC while the percentage of organic solvent is 
the most important factor in HPLC. 
These mobile phases move through GC and HPLC columns towards the 
instrument detector. Many detectors have been used for both GC and HPLC 
such as the flame ionisation detector (FID) and electron capture detector 
(ECD) for GC and ultraviolet (UV), diode array detector (DAD), 
electrochemical detector (ECD) for HPLC. Detectors used with GC are not 
suitable for HPLC and vice versa and differ in their application, sensitivity and 
selectivity with the exception of one detector which used for the analysis of 
explosives, the so-called thermo energy analysis detector, which can be 
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coupled with both GC and HPLC 69-71. GC is applicable for components that are 
stable and which can be volatilised at temperatures up to 350 0C.  
GC-MS has been considered the gold standard technique in toxicology due to 
generation of reducible and repeatable mass spectra which then can be 
matched with spectra available in libraries for identification purposes 16.  
However, many limitations have been reported, for example, GC-MS is not 
suitable for the determination of non-volatile or thermally labile substances 
44,45,68,72  and heavy and thermally unstable compounds such as morphine 
glucuronides should be hydrolysed to the free (unconjugated) form in order to 
be analysed by GC-MS. New GC columns are available with ionin liquid based 
phases that can be oberated up to 450 oC for the analysis of polar compounds 
and would be available commercially in the future.  
Also, analytes of interest often need to be chemically derivatised using toxic 
reagents to enhance the sensitivity of the analysis 43,73,74. For example, in 
most reported methods for determination of diacetylmorphine (heroin) after 
extraction from biological specimens, the extract is divided into two portions, 
one injected directly for heroin analysis and other portion subjected to 
derivatisation steps for the determination of 6-monoacetyl morphine (6-MAM) 
and free morphine (MOR) 75-77. 
In forensic toxicology, drugs and their metabolites are determined for a 
better understanding of the cause of death, driver impairment and for 
workplace drug testing. Therefore, toxic components in the specimens should 
be identified accurately 59. Some drugs are extensively metabolised to polar 
metabolites such as glucuronides, and hydrolysis of specimens is necessary to 
obtain free drug which can then be analysed using GC-MS. The ratio of total 
drug to free drug can then be used for interpretation of cases. This sometimes 
requires a large volume of sample to be analysed because of the relatively 
low sensitivity often obtained in GC-MS analysis.    
HPLC is an alternative to GC for analysis of less volatile, thermolabile and 
polar analytes. More than 70% of drugs commonly encountered in routine 
forensic toxicology can be quantified using HPLC methods 78. However, the 
identification of these drugs, which is important in the toxicology field, is 
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often problematic due to interferences and overlapping of analyte peaks, 
which makes simultaneous determination of drugs and metabolites difficult. In 
some reports 79-82, two different detectors have been used for identification of 
morphine glucuronides 83. Also, some analytes cannot be oxidised, such as 
noroxycodone, and so cannot be detected using an electrochemical detector 
84. Quantitative analysis by HPLC coupled with conventional UV and DAD 
detectors is limited because not all analytes absorb UV light and identification 
of substances is limited due to the small databases of spectra available. 
However, the presence of a chromophore can allow analogous analytes such 
as metabolites to be detected. Also, the absorbance of analytes can be 
affected by the mobile phase composition, including solvent strength and pH 
44,59,72,85.  
An LC-MS/MS procedure usually requires fewer sample preparation steps and 
analytes of interest can be identified and quantified directly without the need 
for hydrolysis and derivatisation procedures 16,86-88. Different LC-MS interfaces 
are available which are applicable to many type of analysis 89. The ionisation 
of analytes can be optimised and the best instrumental settings can be chosen 
by continuous infusion of a standard solution of the analyte into the mass 
spectrometer. LC-MS is considered to be a highly selective means of 
identification, which is achieved in two dimensions: HPLC is used to obtain 
chromatographic separation of analytes from matrix components on one hand, 
and the mass spectrometer device is used to obtain mass to charge resolution 
of analytes of interest from other matrix components, interferences or other 
drugs 42,90.   
In the present work, a Thermo Finnigan LCQ Deca XP plus was used for 
identification and quantification of analytes of interest. The LCQ Deca XP 
plus consists of three main parts:  the HPLC system, electrospray interface 
(ESI)/atmospheric pressure ionisation source and ion trap mass analyser. 
Figure 3-1 shows the components of LCQ Deca XP plus system.  
3.2 Sample preparation  
Sample preparation is very important for method optimisation; clean extracts 
are often required when using HPLC analysis to reduce the interference 
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problem and concentrate the analytes into a small volume that can be 
injected into the HPLC system 65. In the work presented in this thesis, whole 
blood obtained at autopsy was used for analysis which is known to be a dirty 
matrix. In addition, whole blood material cannot be injected directly to the 
LC-MS instrument which could cause damage to the HPLC column and ion 
source contamination 65,91.  
 
Figure 3-1: Diagram of Thermo Finnigan LCQ Deca system including 
HPLC, mass spectromer detector and data system 92. 
 
In the work reported in Chapter 10, pretreatment of urine samples using 
acetonitrile followed by centrifugation was found efficient for the isolation of 
ethanol polar metabolites but a hydrophilic liquid chromatography (HILIC) 
method of separation was employed. HILIC can be used for the separation of 
very polar metabolites but is not suitable for non-polar metabolites. Reverse 
phase liquid chromatography (RPLC) was applied to simultaneous analysis of 
opioids and their metabolites and HILIC was used for very polar ethanol 
conjugates. The selectivity of the HILIC phase is opposite to that of RPLC but 
similar to that of normal phase liquid chromatography (NPLC). The mobile 
phase typically contains only a minor percentage of water, usually less than 
30%. More information about the HILIC phase is given later in Chapter 10.  
3.3 HPLC 
An HPLC system includes the mobile phase reservoir, degasser, pump, auto-
sampler and injector port, column oven containing the pre-column and 
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analytical column and connection to the detector. Sample extracts are placed 
in the auto-sampler and are then injected by syringe into the injection port 
containing the sample loop held in a six-port valve. The sample in the mobile 
phase is transferred through a connecting line to the HPLC-column which is 
connected via the sample inlet line to the detector interface system.  
The mobile phase and column are very important in traditional HPLC methods 
in achieving good peak shapes. Complete separation is required with most 
HPLC detectors used, with the exception of the mass spectrometric detector, 
which can distinguish overlapping peaks using the mass to charge ratios of 
molecular and fragment ions. Many solvents can be used depending on the 
analytes to be separated and their solubility. The separation of analytes can 
be achieved using a single solvent or using a mixture of organic solvents and 
water 55. 
In fact, RPLC is the most commonly-used system in forensic and clinical 
toxicology in which the mobile phase is more polar than the stationary phase; 
analytes of interest are partitioned between a polar mobile phase and non-
polar stationary phase. A silica support modified with C8 or C18 chemically-
bonded substituents phase is the most common non-polar stationary phase 
used for RPLC applications. The separation depends on the polarities of the 
analytes, with more polar components being eluted early, near to the void 
volume, while non-polar analytes are strongly retained and often require high 
percentages of organic modifiers to be eluted. Acetonitrile and methanol are 
the most common organic modifiers used with RPLC-MS 41,42,55.   
In NPLC, the stationary phase is more polar than the mobile phase. 
Applications have been reported involving an ion pair agent (IPA) which is 
used with polar compounds to increase their retention times. NPLC and 
mobile phases containing IPA are not often used in LC-MS applications due to 
toxic solvents used in the NPLC mobile phase such as chloroform and hexane, 
which is carcinogenic and because of accumulation and contamination of the 
ion source by non-volatile IPA42. Recently, HILIC has been introduced as an 
alternative to RPLC for separation of polar compounds but it is not efficient 
with non-polar compounds 88,93. In the current work, RPLC and HILIC were 
used for separation of drugs and metabolites.  
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Isocratic elution is common in RPLC but generally requires longer run times 
and is not suitable for separation of drugs and their polar metabolites for 
which gradient elution is preferred 55. The percentages of organic modifiers is 
fixed in isocratic elution but is changed during the run time using gradient 
elution. The latter is often used to increase retention of polar metabolites on 
RPLC columns and decrease retention of non-polar analytes to provide a 
reasonable run time suitable for routine analysis 42. In isocratic LC-MS or LC-
MS/MS, the detector response can be enhanced by increasing the percentage 
of organic modifier but interferences from the matrix are often encountered 
88,94. Gradient elution also leads to enhanced detector sensitivity while 
avoiding the interference problem. The peak width also can be narrowed by 
as much as half compared to isocratic elution which is also desirable 42,55. It is 
known that changing other parameters of the chromatographic system, such 
as buffer concentration, pH and temperature, can lead to retention time 
changes 55,65,95.   
In regular RPLC, the mobile phase contains an aqueous and an organic phase. 
Phosphate buffer is commonly used in traditional HPLC but is not used with a 
mass spectrometric detector due to the non-volatile phosphate salts, which 
would precipitate in the ion source and cause a major contamination problem 
that results in reduction of the instrument performance 88,96. In addition, 
other inorganic salts and IPAs should also be avoided in LC-MS due to the 
possibility of interference with analyte spectra, for example, trifluoroacetic 
acid (TFA) is known to decrease ionisation efficiency of analytes. Volatile 
mobile phase salts such as ammonium acetate and ammonium formate are 
more suitable for LC-MS applications. These buffers can be adjusted using 
acetic or formic acid or ammonium hydroxide to obtain the desired range of 
pH 3,41,42,65. Although the use of a higher buffer concentration often leads to 
good chromatographic separation, a low buffer concentration is preferable in 
LC-MS 97, in which buffer concentrations higher than 0.01 M have been found 
to affect the sensitivity and linearity of the method 42,88. This may be 
explained by an insufficient charge on electrospray droplets due to ion signal 
saturation by higher buffer concentrations, which decreases the ESI response 
98.  It has been found that an increase in buffer concentration leads to 
suppression of the target ion signal, this conclusion having been made after an 
investigation of the effect of different buffer concentrations (0.001, 0.005 
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and 0.01 M) in the ESI responses for some peptides. In that study the lower 
the buffer concentration used the higher the ESI response obtained 99. A 
similar observation was made by Torrance 63 for the ionisation of 
flunitrazepam during LC-MS, when it was found that the ESI response 
decreased with higher ammonium  acetate buffer concentrations. Before 
samples are submitted to LC-MS, extracts are reconstituted with initial mobile 
phase in order to ionise analytes before they are injected on-column.  
A step by step method of optimising buffer and organic modifier percentages 
was used in the present study which takes longer than using other methods of 
optimisation such as computer software programmes 42,55 or using a published 
method for analytes of interest. The analyte retention time depends on the 
flow rate, column capacity and diameter 96; the injection volume is 
recommended not to exceed 1% of column volume to preserve maximum 
separation efficiency 100. In the present work parent drugs and their polar 
metabolites were determined which were found to be well separated using 
gradient elution. Morphine-3-glucuronide, hydromorphone-3-glucuronide and 
dihydromorphine-3- glucuronide eluted with very low percentages of organic 
modifier and methadone eluted last with a high organic modifier content. 
Metabolites which are eluted early are more susceptible to matrix effects and 
sample preparation based on SPE was efficient in preventing matrix effects.   
3.4 Mass spectrometry 
3.4.1 Introduction 
Mass spectrometry is the detection system of choice in forensic toxicology 
because it is a reliable, sensitive, specific and selective method of analysis 
and because of the useful information it provides about the chemical 
structures of analytes 65,67. It is aneasy means of identification of substances 
compared to other types of spectral information obtained such as the 
ultraviolet spectrum. A wide range of analytes can be analysed with less 
sample volume and pre-treatment required 3,101. Although GC-MS methods 
have been in use since 1970 and became the methods of choice in the 1980s, 
the combination between HPLC and mass spectrometry was not achieved 
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easily 16. The most challenging problem was to find a suitable way to remove 
the aqueous mobile phase when delivered at a high flow rate of 1 mL/min 
without affecting the performance of the mass spectrometer. The use of 
interface techniques means that the combination between LC and MS 
techniques is possible. These interface systems have two main tasks: 
elimination of as much of the unwanted mobile phase solvent as possible and 
introduction of components of interest to the MS detector in the gas phase. 
These two steps require a high vacuum system 65,98,101-103. Many interfaces 
have been used such as thermospray ionisation, particle beam ionisation, fast 
atom bombardment, desorption electrospray ionisation, matrix-assisted laser 
desorption ionisation and atmospheric pressure ionisation (API). The most 
common interface in use with LC-MS is API; this interface has two main types: 
atmospheric pressure chemical ionisation (APCI) or electrospray ionisation 
(ESI). New API interfaces have been created and used but with few 
applications in toxicology such as atmospheric pressure photo-ionisation, 
atmospheric pressure laser ionisation and sonic spray ionisation 3,42,88,89,94.  
All interfaces used on LC-MS apparatus use soft ionisation, which provides 
relatively little structural information 42,59,96 compared to the hard ionisation 
mode used in GC-MS which means the library used with GC-MS is not useful 
with LC-MS. In most cases, data for analytes of interest can be optimised 
manually in LC-MS using certified standards and real case samples in order to 
obtain analyte spectra which have been found to be reproducible and 
accurate.  
Components in the matrix or generated in the ion source may interfere with 
the information obtained in the single stage mass spectrometer. The use of 
tandem stage mass spectrometry introduces more selectivity into LC-MS/MS 
techniques 31,94; analytes can be fragmented to product ions and thus the 
fragment ion is selected as the target ion in the analysis. This is one of the 
great advantages of using tandem MS, which not only provides the molecular 
weight of the parent drug, which is the single most important identification 
criterion required by the toxicologist, but which can also provide information 
regarding the structures of the components of interest 42,89,104. There are two 
types of tandem MS instruments in use. The first type is a hybrid combination 
of two mass analysers based on quadrupoles or magnetic sectors. A triple 
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quadrupole instrument is the most common construction. The second type 
uses a quadrupole prefilter and ion trap, i.e. only a single mass analyser is 
used. In hybrid instruments the product ion is created using two separate 
mass spectrometers by isolation of the ions of a given m/z ratio in the first 
mass spectrometer which are then activated by collision and allowed to 
dissociate before the product ions are scanned in the second mass 
spectrometer. In the ion trap specific masses are selected by ejecting the 
other masses and then selected ions are fragmented during a selected time 
event or retention window 42,66,94,102,104. The product ions are obtained by a 
sequence of operations in the scan function and are formed by collision-
induced dissociation (CID) of the selected ion using helium buffer gas 89. The 
latter type of tandem mass spectrometry was used for the current study. 
3.4.2 Electrospray ionisation 
In the current study, electrospray ionisation (ESI) (Figure 3-2) was used as it is 
usually recommended for highly polar compounds. The recognition of the 
value of ESI has increased since its applicability for large bio-molecules was 
discovered. It is useful for the determination of small, medium and large 
molecules; ESI is the most commonly used interface in forensic toxicology due 
to its relative ease of use, low solvent consumption and wide polarity range 
capability 88,89. APCI is less  susceptible to matrix effect phenomena compared 
to ESI 105-108; however, application of APCI is less common due to the limited 
polarity range of APCI, incompatibility with thermally labile analytes and high 
background noise compared to ESI 28,42,109.  However, both interfaces are 
sensitive, reproducible and robust and have replaced all other LC-MS 
interfaces such as fast atom bombardment, thermospray, and particle beam 
88,94,96.   
Analytes are required to be ionised in the mobile phase before passing 
through the ESI probe. The advantage of introducing analytes in solution is to 
limit the degradation of some thermally labile analytes which are successfully 
separated by HPLC 42,88.  The stream of liquid mobile phase enters the ESI 
needle by a narrow capillary sample inlet at high voltage (typically, from 3-5 
kV) then a fine mist of highly charged droplets is formed (positive or negative 
charge, depending on voltage polarity) while they pass through the ESI needle 
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tip. Once the charged droplets pass out of the ESI needle, mobile phase 
components start to be evaporated and the charged droplets become smaller 
and smaller. The size of the droplets is estimated to be 1 ìm which decreases 
upon evaporation until the droplet size becomes about 10% of the original 
size. A series of coulombic explosions occur when the electrostatic repulsion 
becomes higher than the surface tension of the charged droplets, called the 
Rayleigh limit, in which the droplet can no longer retain the ions. The 
solvated ions are ejected into the gas phase and then enter the ion transfer 
capillary and move into the mass spectrometer to be analysed 3,42,88,98.   
 
Figure 3-2: Electrospray probe of LCQ Deca system 92. 
 
In the interface system, mobile phase is partly or completely removed during 
transportation of ionised analytes under high vacuum. The ionisation of 
analytes can be influenced by many factors such as flow rate, background 
noise, mobile phase composition including additives and sample interference, 
all of which have been found to affect the ESI signal 88,97,109. Flow rate, for 
example, directly affects the size and distribution of droplets formed at the 
ESI needle and is preferred to be within the range of 5 to 10 ìL/min. 
However, flow rates used for HPLC analysis are usually higher than 1 mL/min. 
Therefore, the reduction of flow rate amount is crucial for ESI in order to 
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obtain good ionisation. Splitting the flow rate has been suggested but this 
leads to loss of sensitivity. This problem has been solved using an ESI probe 
with a concentric flow of nebulising gas which allows flow rates up to about 
200 ìL/min to be used. A heated source inlet aids the evaporation of mobile 
phase before it reaches the lens, also, a heated stainless-steel block is placed 
in the capillary for the same purpose 42. Figure 3-3 shows ESI in the positive 
ion mode using the LCQ deca system. 
 
Figure 3-3: ESI positive ion mode process in LCQ Deca system 92. 
 
Thermo Finnigan 92 recommends that the electrolyte in the mobile phase 
eluents should be at a concentration higher than 0.5 mM and less than 10 mM 
in order to promote the ESI signal. The target ion can be singly or multiple 
charged depending on its chemical structure and the mobile phase 
composition. Mobile phases with high aqueous contents reduce the efficiency 
of ESI whereas a high organic modifier content in the mobile phase enhances 
ionisation. Higher water or aqueous content in the mobile phase leads to 
higher surface tension in the charged droplets, which produces larger droplets 
that require a longer time to be evaporated during ESI. This is found to affect 
the breakdown of the initial charged droplets to smaller droplets in order to 
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facilitate the conversion of these tiny droplets to gas phase ions. However, 
applications of ESI using highly aqueous phase have been reported and some 
HPLC columns are capable of operating with 100% aqueous phase, which is 
required for the determination of very polar compounds, for example, ethyl 
glucuronide could only be determined using very low organic modifiers of 5% 
or less in RPLC applications. Many solutions can be used to tackle the loss of 
sensitivity using highly aqueous phases such as the use of sheath flow or post-
column addition of organic solvent which was found to improve ESI-MS 
sensitivity 88,95. In RPLC, a combination of polar solvents and volatile additives 
are required for two main tasks: good chromatographic separation and better 
ESI response, which makes choosing the mobile phase easy as few phases are 
recommended 65.  
Nitrogen has been used as nebuliser gas which repels charged droplets from 
the ESI needle towards the ion source 42.  Ion spray is a term often used to 
describe the use of sheath and auxiliary gas to spray the mobile phase under 
reduced pressure through the interface. A combination of an organic sheath 
liquid and aqueous mobile phase solvent reduces the surface tension which 
accelerates the evaporation of the charged droplets 42,55,66.     
3.4.3 Ion optics 
After passing the skimmer, ions are filtered and transferred into the mass 
analyser through ion optics. In the LCQ Deca XP Plus instrument, the ion 
optics system (Figure 3-4) consists of an interoctapole lens placed between 
quadrupole and octapole. Both quadrupole and octapole act as ion 
transmission devices. RF and DC offset voltages are applied to the rods which 
lead to an electric field that guides the ions through the quadrupol and 
octapole. During this transmission the offset voltage is negative for positive 
ions and vice versa. Selected masses are allowed to enter the mass analyser.  
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Figure 3-4: Cross section of LCQ Deca ion optics system 92. 
 
3.4.4 Ion trap mass analyser 
An ion trap mass analyser (IT) was used in the current study (Figure 3-5). An IT 
is also known as a quadrupole ion trap mass analyser. It is a three dimensional 
quadrupole electrodynamic field or electric field test-tube to trap ions 
which are created in the ESI interface. It is considered as a high-throughput 
analytical tool especially for providing structural information about 
substances 110. It has a wide mass range, up to m/z 70,000, making it 
applicable to protein analysis 96.  Ionised molecules enter the ion trap through 
an electrostatic gate that pulses open and closed. Ions are accumulated with 
each pulse and transferred to the ion detector which makes it highly sensitive 
in the full scan mode compared to other transmission quadrupole instruments. 
Ion masses in the IT are accumulated selectively over time in which target 
ion(s) can be selected to ensure constant signal to noise ratios over a wide 
range of concentrations 41,42,110,111. However, the discontinuous measurement 
is a noticeable drawback of using IT which allows few ions to be quantified 
during the same chromatographic retention window.  
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Figure 3-5: Ion trap mass analyser equipped with LCQ Deca plus XP 92. 
 
In the LCQ Deca Plus XP, selection of more than five target ions per retention 
time segment widow was found to reduce the data point number across 
chromatographic peaks, which can be overcome using multiple short retention 
widows for target masses during the chromatography run 90,112,113. Therefore, 
good LC separation of analytes is required using the IT in order to use many 
segment windows and avoid co-elution of analytes, allowing a higher scan 
speed and increase in the number of data points per chromatographic peaks. 
In contrast, when a triple quadrupole instrument (TQ) is used, co-elution is of 
no concern due to the selectivity of the tandem mass spectrometer, which 
allows a shorter chromatography run and increased sample throughput. 
However, the cross-talk or isobaric phenomenon occurs when the interval 
between two or more analytes of interest which share the same chemical 
structure is very short, resulting in overlapping between them. Cross-talk 
occurs in both IT and TQ mass spectrometry techniques and affects method 
accuracy 90,96,102. Cross talk or isobaric metabolites interference is different 
than matrix effects. Matrix effects are generated from non-drug related 
compounds eluting at the same time as an analyte, while cross-talk usually 
results from co-elution of an analyte with one or more other drug-like 
substances which fragment to give the same (or similar) product ions used for 
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identification. Cross talk phenomena are not specifically matrix effects 90,114 
but often interfere with the quantification of the analyte. This so-called 
isobaric metabolic interference can also be the result of in-source 
contamination or be due to degradation products of phase I and II metabolites 
28,90,115. 
The operating principle of the ion trap is that ions are generated in an 
external ion source and injected into the ion trap cavity 102. Helium gas is 
introduced into the cavity to move the ions towards the centre of the trap 110. 
Ions of a given m/z value are trapped, while all other masses are held back 
during the admission time in the trap. The ion trap uses segment windows or 
reaction times which can be extended for some time 104. Selected ions are 
fragmented to product ion(s) within the trap space and series of MSn data can 
be generated up to MS(n=10) using the LCQ Deca instrument. However, few 
applications using more than MS(n=3) have been reported 94.   
The ion trap consists of three hyperbolic electrodes: a central ring electrode 
and two virtually identical end-cap electrodes. The end-cap electrodes are 
placed at the entrance and exit of the ion trap cavity. The ring electrode is 
symmetrically placed between the end-cap electrodes. Ions are passed into 
and out of the ion trap cavity using two small holes in the end-cap electrodes. 
Trapped ion(s) are retained for collision with a damping inert gas with 
relatively high pressure (usually 10-2 to 10-3 torr of helium) and a 
radiofrequency voltage is applied to the ring electrode which makes ions of a 
certain m/z ratio become unstable and fragment to give product ions, This 
process is called collision induced dissociated (CID). The trajectories of ions 
with a given m/z value become unstable and then the ions are ejected 
through the exit lens to the detector 102,116.  
3.4.5 Detector 
The ejected ions are converted into measurable electric signals upon reaching 
the detector which is necessary to have a fast acquisition system, have a wide 
dynamic range and high sensitivity. In the LCQ Deca Plus XP detector (Figure 
3-6) ions are converted by a conversion dynode to electrons which are further 
converted into photons by means of a phosphorous screen and these are 
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amplified by an electron multiplier. When an ion strikes the conversion 
dynode, secondary particles are formed which are focused by a curved surface 
and accelerated into the electron multiplier by means of a voltage gradient. 
The secondary particles will strike the inner surface of the cathode to 
produce electrons. A cascade of electrons is created in which original signals 
are magnified and converted into a voltage that can be recorded by the data 
system 67,92.       
 
Figure 3-6: Cross section of ion detector system in the LCQ Deca 92. 
 
3.5  Matrix effects and LC-MS/MS  
The susceptibility of LC-MS/MS procedures to matrix effects has been 
reported using different methods of extraction such as protein precipitation, 
direct injection, liquid-liquid extraction and SPE 16,97,105-108,117-120.  The 
mechanism of the matrix effect in Atmospheric Pressure Interference (API), 
especially, electrospray ionisation (ESI) is unknown 51,97. It has been suggested 
that the matrix effect originated as a result of the competition between 
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analytes of interest and endogenous matrix components co-eluting at the 
same time leading to a decrease or increase of the ionisation efficiency of the 
analyte of interest in ion source 51,117.  Method validation parameters such as 
recoveries, reproducibility, accuracy, LOD and LLOQ may be affected by the 
presence of a significant matrix effect 105,117. Therefore, the assessment of 
the matrix effect during the method development process has become an 
important issue in method validation and is recommended to ensure that the 
selectivity, sensitivity and precision of the method are not compromised 
16,51,97,105-108,117-120.   
King et al 106 reported that ionisation suppression is not likely to be caused by 
reactions in the gas phase. They stressed that non-volatile solutes were most 
likely to cause ion suppression and non-volatile substances can be any type of 
chemical structure. For example, salts, sulfates and phosphates would 
compete with analytes of interest in the ionisation process. Therefore, these 
interferences should be removed using clean up procedure such as SPE before 
samples are analysed by LC-MS(MS). Although SPE methods are efficient in 
concentrating the analytes of interest, co-eluting, endogenous, matrix 
components are also concentrated 51,108,117. Chambers et al 117 also concluded 
that the cleaning steps would concentrate endogenous matrix components 
that may shorten the lifetime of the LC column, because of deposited 
materials, and require more MS maintenance. 
Matrix effects due to mobile phase additives were found to be less significant 
than those from endogenous matrix components 42,105.  In addition, 
pharmaceutical impurities or degradation products can cause matrix effects 
117. It has been reported that hydrophilic residual components i.e. organic 
salts present in urine samples are the major cause of matrix effects 108. Ion 
suppression can be the result of some ionic substance or substances at the 
surface transition zone of charged droplets 121. Ion suppression is magnified by 
increasing the injection volume 42. Many researchers believe that matrix 
effects phenomena in LC-MSn procedures are a result of inadequate sample 
preparation and the use of short analytical column with fast gradient LC- 
methods or short isocratic methods 107,119,121.  
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Elimination of matrix effects is important in order to gain more sensitivity and 
selectivity of analytes of interest, especially for early eluting (low capacity 
factor, k′) 121 analytes such as M3G and DHM3G in the present study. Many 
methods have been used to eliminate matrix effects. Nissan et al 105 
recommended two approaches: the best way is to improve the sample 
preparation and the separation of analytes of interest 108. However, this 
approach is hard to achieve, especially in methods aimed at simultaneous 
detection of a variety of drugs 105. The second approach is to change the 
mobile phase composition, use negative mode LC-API-MS/(MS) instead of the 
positive mode and use internal standards 109. Matrix effects can decrease if 
urine samples are diluted and injected directly without sample pre-treatment 
steps. However, dilution results in loss of method sensitivity 108,122.  
The use of internal standards is the best solution for overcoming matrix 
effects 42,51,105-108,117-120. However, isotopically labelled analogues are not 
available commercially for all analytes and the cost of synthesising internal 
standards is high as well as being time consuming. In this case structurally 
similar analogues are frequently used as internal standards, with a preference 
for analogues that elute close to the analytes of interest and show the same 
matrix effect profiles 118. The use of unlabeled therapeutic drugs as internal 
standards is not acceptable as these may be found in case samples even if 
they are not marketed in the country in which the laboratory is located and 
that would affect the accuracy of the method 16. The use of two solid phase 
extraction columns or LLE followed by SPE were reported although the 
recoveries obtained were very poor. Finally, matrix effects can be reduced 
using diluted samples and a small injection volume, but this leads to a 
reduction in sensitivity. LC-MS(MS) methods are still valid, even in the 
presence of matrix effects, if the internal standard shows the same matrix 
effects. If an isotopically-labeled internal standard is available and the 
precision and accuracy of the method at the LLOQ are within the acceptable 
limits of the validation procedure then a method is considered valid even in 
the presence of minor interferences 51.  
Two methods are commonly used to determine matrix effects 51,97,107: the 
post-column infusion procedure and post-extraction spiked analyte procedure. 
The latter method was used in this work as it was easier to perform with 26 
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analytes and 13 internal standards than the first method which requires 
optimising each drug separately. The post extraction method compares the 
ESI response of an unextracted standard dissolved in mobile phase with the 
response of the same standard dissolved in blank matrix extract. Matrix 
effects are determined as a percentage relative to the response of the 
unextracted standard: a value of > 100% demonstrates ion enhancement while 
a value of < 100% points to ion suppression.  
Matrix effects may also affect analyte recovery measurements, which are 
usually determined by comparing the peak area ratios of extracted analytes 
with those of unextracted standards solution at corresponding amounts. The 
effect of matrix on these ratios is not examined using the traditional method, 
which may lead to inaccurate estimates of recovery for analytes without an 
isotopically-labeled internal standard. In the present study the true extraction 
recovery was determined using the procedure of Matuszewski et al 51. In this 
method the effects of matrix interference and ESI ionisation were excluded. 
Absolute matrix effects as well as relative matrix effects were assessed. The 
latter refers to variations in response depending on the source of blank urine. 
Matrix effect (ME) and recovery (RE) are given by the following equations: 
Equation 3-1  ME (%) = B/A X100    
Equation 3-2  RE (%) = C/B X 100    
Where A is the average peak area ratio of the unextracted standard to 
internal standard, B is the average peak area ratio of the same standards 
spiked into blank extract and C is the average peak area ratio of extracted 
standard to unextracted internal standard. 
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4 Opioids  
4.1 Introduction  
Opiates are obtained from the opium poppy (Papaver somniferum) and have 
been used medicinally for more than 2000 years 2,123,124. The term opioids 
refers to all natural and synthetic drugs with morphine-like properties and 
they are one of the largest of the drug families, consisting of more than 30 
drugs 2,125. Opioid drugs have been used for many purposes including 
management of moderate to severe pain resulting from surgery or illnesses 
such as cancer, as antitussives and for the treatment of diarrhoea 125,126.  
Unfortunately, opioids are globally misused drugs. For example, it is 
estimated that approximately  0.3% of the worlds population (11 million 
people) misuse the opioid heroin each year 26. Injection heroin abuse is a 
major problem in society, contributing to the spread of infectious diseases 
and carrying adverse economic consequences. 
Opioids are defined as compounds which have similar pharmacological effects 
to those of morphine, and they can be divided into three main groups 125: 
naturally occurring (morphine and codeine); semi-synthetic or derived from 
morphine by chemical modification (oxycodone, dihydrocodeine, 
hydrocodeine, hydromorphone, etc.); and obtained synthetically (fentanyl, 
methadone, etc.). Simple modification of the morphine structure, for 
example methylation or acetylation of morphine, can result in products which 
have different molecular weights and whose pharmacological properties are 
altered. For example, codeine, which is a naturally occurring opiate, can be 
derived from morphine by the methylation process. Synthetic drugs such as 
methadone offer the same narcotic analgesic action as that of morphine but 
may differ in their potency. Some pharmacological parameters of opioids 
included in this thesis are summarised in Table 4-1 
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Table 4-1: Dose, relative potencies to morphine, half-life and bioavilability 
for selected opioids 
 
Drug Usual  
dose (mg) a 
Relative 
Potency b 
Half-life 
(h) c 
Bioavail. 
d 
Usual therapeutic 
blood 
Concentrations 
(ng/mL) 
Buprenorphinee 0.2-24 25-50 3-6 30 0.1-1 
Codeine 8-60 0.08 2-4 High 10-250 
Dihydrocodeine 30-60 0.1 2-4 High  
Heroin >5 1.5 <0.1 <1% 10-100 g 
Hydromorphone 1.3-2.6 5-10 2-5 50% 8-32 
Methadone 5-120 1 8-55 50% 100-500 
Morphine >10 1 1-8 20-30% 10-1000 
Oxycodone 10-15 0.8 2-8 80% 10-200 
a Dose range normally prescribed; b pharmacological potency relative to morphine; c plasma half-life of terminal 
elimination phase; d oral bioavailability, relative to intravenous dose; e sublingual dose; f usually given 
parenterally; g as morphine 127. 
 
Other than classifying opioids  according to chemical structure, another 
method of classification was introduced which is dependent upon the mode of 
action and divided into  three classes 2,124,125. The first class includes full 
agonist drugs that have abilities to specific type of opioid receptors. These 
compounds are toxic and potent and they are active even in amounts as small 
as a few micrograms. This group includes dihydrocodeine, hydromorphone, 
hydrocodone, methadone, pethidine and fentanyl. The second class includes 
mixed agonist-antagonists; morphine, for example, has both agonist and 
antagonist actions. These drugs have an agonist effect with certain types of 
receptors and an antagonist effect with others. Buprenorphine, butrophenol 
and pentazone belong to this group. The third class contains opioids known as 
full antagonists. Naloxone and naltrexone are two of these drugs, which have 
been used as antidotes to morphine and heroin toxicity because of their 
abilities to inhibit agonist binding; however, these drugs are themselves 
inactive. 
Opiate toxicity has attracted a great deal of interest since its side effects 
became known. It has been amply demonstrated that opiates are a double-
edged sword, they may relieve pain, and yet they may also kill. One reason is 
that tolerance of the patient or addict increases from using opiates; 
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therefore, the opiate dosage soars dramatically after the first use in order to 
attain a similar therapeutic effect. This increase may be more than 35-fold 
after three weeks of chronic use 2. As a result, sudden and unexpected deaths 
have risen sharply due to overdoses of these drugs 125. Moreover, repeated 
consumption of these drugs results in physical dependence. Although these 
side effects are common, they are also complex, and the mechanism of 
physical dependence remains unclear. One explanation holds that by 
decreasing the number of µ-receptors, the efficiency of receptor binding 
along with their biochemical responses would therefore also reduce. 
Consequently, entry of calcium into cells is affected, and thus activity of the 
adenylate cyclase enzyme and protein phosphorylation would be inhibited 125. 
Although each drug has its own toxic effect, it can be concluded that all 
opiates are expected to cause depression of respiratory centres and 
cardiovascular collapse may also occur 2,125,128. 
Opiates have been administrated by many routes: oral, intravenous, 
intramuscular, smoking, nasal insufflation and many others, but where the 
abuse of drugs is concerned, intravenous administration is optimum, owing to 
its fast analgesia effect after injection compared to the delayed effect 
obtained with other routes of administration 129. Opiates in general are rapidly 
absorbed, with some variation depending on route of administration. Drugs 
such as opiates are metabolised in the body by two types of enzymatic 
reactions: phase 1 and phase 2 metabolism. These reactions change the 
chemical structure of the drugs to be less toxic, and more water-soluble to 
facilitate excretion in urine; this process is called detoxification 43,76. 
In addition, the metabolism of opiates differs considerably depending on their 
chemical structures. Opiates are commonly metabolised by reactions, such as 
oxidation, hydroxylation, O- and N-demethylation, N and O-dealkylation and 
deacetylation, which result in phase one metabolites. The main function of 
Phase 1 metabolism is to prepare compounds for phase 2 metabolism 130. 
Phase 2 metabolites produced by glucuronidation and sulfatation reactions are 
acidic compounds with very polar and hydrophilic functional groups. These are 
usually  inactive metabolites but may also be active; for example, morphine is 
glucuronidated into morphine-3-glucuronide (M3G), which is an inactive 
metabolite, and into morphine-6-glucuronide (M6G), which is active 5,131. 
 36 
However, metabolites differ from parent drugs in potency and action 76,132. 
The process of glucuronidation is a crucial enzyme reaction in detoxification. 
Glucuronic acid is derived from glucose, which is readily available in the body 
and is readily transferred enzymatically to many functional groups such as 
hydroxyl, amino, carboxyl and sulfhydryl. Uridine diphosphate-glucuronosyl 
transferase catalyzes this process 14,76,130,133.   
It is known that codeine, dihydrocodeine, oxycodone and hydrocodone are 
prodrugs and exert their analgesia effects via their active metabolites 
produced by O-demethylation, which have much stronger ì-receptor binding 
than the parent substances. This reaction is mediated by the polymorphic 
cytochrome P450 2D6 isozyme (CYP2D6) 126,134. It is known that approximately 
10% of the Caucasian population are deficient in this isozyme and as a result 
are poor metabolisers, which reduces active metabolite production. The 
desired analgesia cannot be achieved with these four opioids at the usual 
dose. On the other hand, there may be clinical advantages in using the active 
metabolites morphine, dihydromorphine, oxymorphone and hydromorphone 
instead of the prodrugs as small dose controlled-released tablets, to provide 
strong analgesia for those patients who are poor metabolisers 134. By contrast, 
a higher opioid effect may occur with the usual dose of codeine in rapid 
opioid metabolisers, which can be explained by the formation of higher 
concentrations of morphine following codeine administration.  
Poor metabolisers may experience reduced codeine efficiency due to the 
reduction of codeine metabolism to morphine which may require higher 
concentrations of codeine to reach optimal effects, and this may lead to 
codeine toxicity 135,136. A high risk of codeine intoxication with codeine doses 
in the usual range may be encountered in ultrarapid CYP2D6 metabolisers 
126,136,137. Patients who are poor CYP2D6 metabolisers may experience 
oxycodone toxicity due to the reduction of oxymorphone production and 
accumulation of oxycodone and noroxycodone 135 although other studies have 
shown that there are no differences in the analgesic effects of oxycodone or 
dihydrocodeine between poor or extensive metabolisers 138,139. 
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4.2 Heroin  
4.2.1 Background  
Heroin (Diamorphine; Acetomorphine; Diacetylmorphine) or (5á,6á)-7,8-
didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol diacetate (ester) is a semi-
synthetic morphine derivative 1,132. It was synthesised for the first time in 
1874 by the simple modification of morphine - acetylation of the hydroxyl 
groups at positions 3- and 6- of the phenanthrene ring of morphine using 
acetic anhydride 75,128,140,141. It was intended to be used in medication as an 
antitussive agent 141, but unfortunately, the misuse of heroin has become a 
major cause of death in the world today 128,132,140,142,143.  
4.2.2 Metabolism and Excretion 
In all administration routes, heroin is quickly deacetylated to 6-
monoacetylmorphine (6-MAM), which is considered to be a specific marker of 
heroin use. Heroin has a short plasma half-life, which has been reported to be 
between 2-8 minutes after intravenous injection 144. Despite the short half-life 
of heroin, it can be detected in blood samples under certain experimental 
conditions. In particular if the blood sample has been taken directly after a 
heroin injection or in the case of a massive drug overdose 129. 
6-MAM is not always found in blood due to its short half-life, which is reported 
to be between 10-40 minutes 145,146 but can be detected in urine up to eight 
hours after heroin administration 2,147. 6-MAM is hydrolysed to morphine 
(MOR), and then morphine is conjugated to form two glucuronides: morphine-
3-glucuronide and morphine-6-glucuronide and 5% of MOR is metabolised by N-
demethylation to normorphine (NMOR). The biotransformation of heroin is 
illustrated in Figure 4-1. The plasma half-life of free morphine has been 
reported to be between 2 to 4 hours , but its glucuronide can be determined 
in urine more than 5 days after heroin use 12,128,140,148. Eighty percent  of 
heroin metabolites are eliminated within 24 hours after administration 2.  
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4.2.3 Toxicity 
Heroin is known as the drug most likely to kill as a result of an overdose 125 
and is  two times more potent than its precursor morphine. Deaths attributed 
to diamorphine may occur with a dosage as low as 200 mg but also depends on 
the tolerance of the deceased 1. The lethal dose of heroin may be much more, 
up to ten fold, for chronic drug abusers. However, deaths attributed to heroin 
have been reported following doses of 10 mg 1. As indicated earlier, heroin 
has a very short half-life and is rarely detected 5. As a result, levels of its 
active metabolite MOR have been employed for the interpretation of cause of 
death and elapsed time after heroin administration. The presence of 6-MAM in 
blood has been used as evidence of a short elapsed time after administration 
because 6-MAM has a short half-life of less than 40 minutes after 
administration 149. There is an overlap between concentrations encountered in 
fatal and non-fatal overdoses. Morphine levels determined in heroin fatalities 
vary between cases and there is an overlap between deaths attributed to 
heroin and those not attributed to heroin 149-152. The heroin overdose 
mechanism is not fully understood and many deaths are attributed to 
respiratory depression 153. 
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Toxic levels of MOR present in autopsy blood have been suggested to be equal 
to or higher than 300 ng/mL 149,154. However,  a value of 240 ng/mL was the 
Figure 4-1: Heroin metabolism. (GLU: Glucuronic acid) 
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most common concentration in actual post-mortem cases in one study 155. 
Fugelstad et al 149 found that 10 ng/mL of 6-MAM with fatal cases could be 
attributed to fatal cases. Darke and Rose 156 reported levels of MOR in 10 
cases attributed to non-injected diamoprhine fatalities; the median was 0.31 
ìg/mL and ranged from 0.06-0.99 ìg/mL. In 54 people who survived acute 
heroin overdose, the plasma concentrations of free and total morphine were 
0.088 and 0.277 ìg/mL respectively. However, levels of MOR detected in 
living subjects overlapped with those found in acute heroin overdoses 151,152. 
The median blood level of MOR detected was 0.35 ìg/mL (range 0.08-3.2 
ìg/mL) and 0.09 ìg/mL (range 0.05-1.45 ìg/mL) in fatal and non-fatal heroin 
users, respectively.  
The majority of heroin-related deaths occurred with the presence of other 
drugs such as ethanol, benzodiazepines, cocaine and other opioids. It has 
been found that these deaths may occur at low levels of MOR in blood as a 
result of poly-drug intoxication, especially with other central nervous drugs. 
Deaths involving heroin can be classified in three categories 157: intoxication 
with heroin alone, in combination with other centrally acting drugs and non-
heroin related. Heroin users are known to build their tolerance with chronic 
use and can administer high doses without leading to overdose. Heroin 
overdose deaths due to high doses would be expected to result in high 
concentrations of heroin metabolites such as morphine in post-mortem blood. 
However, lower levels of morphine are observed in many heroin deaths than 
are encountered in living heroin users.  These can be explained in many ways, 
for example death may occur due to a lack of or loss of tolerance or a long 
time may have elapsed between injection and death (delayed death). 
However, low levels of morphine are considered toxic in the presence of other 
centrally-acting drugs and may contribute to death 149-151,153,158.   
4.2.3.1 Morphine and its glucuronides  
As a result of the difficulties encountered in detecting heroin and its specific 
markers in biological fluids in post-mortem cases, great emphasis has been 
placed on the analysis of morphine and its metabolites due to their abundance 
and stability in biological fluids. Therefore, the concentrations of free 
morphine, total morphine, and 6-MAM in biological fluids have been 
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determined to be interpretative tools which provide information for the 
estimation of the survival time after heroin ingestion 159-162. Carriott and 
Sturner 162 were the first to show a relationship between the survival period 
after a heroin overdose and the free morphine level found in the deceaseds  
blood. In addition, the ratio of free to total morphine has been used by Staub 
et al 163  to differentiate between rapid and delayed deaths. 
For several reasons, difficulties have been encountered when the ratio of free 
to total morphine is used to interpret a heroin-related death, for example, 
the inability to distinguish between users of heroin and other opiates such as 
morphine and codeine 164. This is because morphine can be formed from the 
ingestion of heroin, morphine, codeine, and poppy seeds contaminated with 
opium. Burt et al 165 point out of that an accurate toxic range could not be 
established for morphine due to the considerable overlapping of therapeutic, 
toxic and lethal concentrations, and due to the differences in opiate 
tolerance between these groups. In addition, determining total morphine 
without distinguishing between morphine and its metabolites will not provide 
information useful to understanding  the mechanism of intoxication 159.  Also, 
the discovery of the role of morphine-6-glucuronide at the opioid receptor, 
which has been found to contribute to the toxic effect of  heroin in subjects 
with renal failure or with a history of heroin use over a long period, highlights 
the importance of measuring morphine glucuronides 165. 
Determination of morphine and its metabolites is crucial in interpreting both 
forensic and clinical cases, for many reasons. One reason is the lack of 
necessary data in most post-mortem cases such as route of administration, 
time of intake and dose. Therefore, the concentration of 6-MAM and the ratio 
of morphine to its glucuronides can be a useful tool to determine survival 
time between ingestion and death 166-168.  Dienes-Nagy et al 159  reported that 
the molar ratios M6G/morphine and M3G/morphine in blood are associated 
with elapsed time since the last injection. The ratios can also be used to 
interpret the mode of death and if death was delayed, if morphine is almost 
completely metabolised to its glucuronide 2,45,76. 
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4.2.4 Previous analytical work  
Specific immunoassays for morphine detection in human blood and urine have 
been described as screening methods 169. Although immunoassay techniques 
save time and effort, immunoassays can be manipulated by adulteration in 
order to bring about false negatives. Moreover, immunoassay methods lack 
the specificity to discriminate between drugs and their metabolites 170,171. Gas 
chromatography coupled with mass spectrometry (GC-MS) has been frequently 
employed to confirm positive results obtained using immunoassays 68. Only 
one method has been reported  for morphine glucuronide by GC/ negative-ion 
chemical ionisation MS 172. Although GC-MS has greatly enhanced the potential 
of analytical toxicology, many obstacles have been encountered due to lack of 
applicability towards a polar and thermolabile compounds and high mass 
molecules. Another problem which has been reported is that sample 
preparation is time-consuming owing to the sample cleaning step. Moreover, 
polar compounds have to be hydrolysed and derivatised in order to be 
analysed, which is hazardous because of the toxic chemicals used in this step 
41-43. 
Svensson et al 83,173 developed an ion-pair HPLC method with UV and 
electrochemical detectors for the detection of morphine, M3G, M6G and 
normorphine in biological fluids for the first time. Problems have been 
encountered in determining morphine glucuronides due to the difference in 
their detectability. However, these have been solved by using multiple 
detectors such as an electrochemical detector 80, a fluorescence detector for 
M3G, a colourmetric detector for other metabolites 82,174 and a fluorescence 
detector for all metabolites 81 (Table 4-1). 
In recent years, in addition to the success of HPLC for the detection of 
morphine glucuronides, the analysis of low concentrations of opiates and their 
glucuronides has become achievable due to the development of LC-MS 
techniques (Table 4-2). LC-MS has become the technique of choice and has 
been successfully used to achieve excellent separations and accurate 
identifications. Another advantage of LC-MS is its ability to determine a 
variety of compounds such as non-volatile samples, ionic, polar, thermally 
labile and high molecular weight molecules without derivatisation.   
 43 
Table 4-2: Previous HPLC and GC-MS methods for opioids and 
metabolites. 
Analyte  Sam * HPLC or GC conditions (Mobile 
phase) 
HD ** SPE Ə 
 
Findings R & 
 MOR B 
U  
TLC & UV spectrometry & GC  
 
- - Free MOR for those dying 
within 3 hours following 
heroin injection was between 
10-93 ìg/100mL and  in 
those dying from 3-24 hours 
after the last injection, it 
ranged from 3-10 ìg/100mL. 
162
 
 
 
 
MOR 
M3G 
COD 
HER 
 
P  
U 
Ion-pair HPLC  
Column: Reversed Phase (RP) 
Ultrasphere ODS 150 x 4.6mm  
(10 mM sodium dihydrogen 
phosphate buffer pH 2.1 + 1 mM 
dodecyl sulphate and 26% 
cetonitrile) 
Flow rate (FR) 1.5 mL/min 
UV  Sep-Pak 
C18  
SPE 
 
M6G was identified 
tentatively in this method 
 
173
 
 
 
MOR 
M6G 
NMOR 
P  
U 
Ion-pair HPLC  
Column: RP Ultrasphere ODS 150 x 
.6mm  
(10 mM sodium dihydrogen 
phosphate buffer pH 2.1 + 1 mM 
dodecyl sulphate and 26% 
acetonitrile), FR:  1.5 mL/min 
ECD Sep-Pak 
C18  
SPE 
 
M3G is not detectable by 
ECD detector 
83
 
 
 
 
MOR 
M3G 
M6G 
NMOR 
P Ion pair HPLC 
Column: RP Apex ODS (150 x 4.6 
mm) 
(10 mM sodium dihydrogen 
phosphate buffer pH 2.1 + 1 mM 
dodecyl sulphate and 26% 
acetonitrile) 
ECD 
UV 
Sep-Pak 
C18  
SPE 
 
The use of M6G as internal 
standard gives this method 
reliability. 
They used another electrode 
with ECD to remove an 
interference peak that eluted 
close to MOR 
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MOR 
M6G 
P Ion-pair HPLC  
Column: RP C18 Nucleosil  
25cm x 4.6mm I.D. 5 ìm particle 
size 
(10 mM sodium dihydrogen 
phosphate buffer pH 2.1 and 26% 
acetonitrile); FR: 1.5 mL/mi 
ECD Sep-Pak 
C18  
SPE 
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MOR 
M3G 
M6G 
NMOR 
P Ion-pair-HPLC 
Column: ìBondapak C18 RP  
300mm x 3.9 mm, 10 ìm particle 
size 
(10 mM sodium dihydrogen 
phosphate buffer pH 2.1 and 26% 
acetonitrile); FR: 1.0 mL/min 
FD Bond-
Elut C8 
SPE 
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MOR 
M3G 
M6G 
P HPLC 
Column: Nva-Pak 4-ìm phenyl 
3.9 x 75 mm, with Nova-Pak guard 
column 4 ìm. 
(methanol: 0.01 M phosphate 
monobasic  pH 4 (10: 90)  
FR: 1 mL/min 
ECD 
FD 
Bond 
Elute 
C2 SPE 
 
174
 
 
 
MOR 
6-MAM 
B  
U 
Immunoassay 
HPLC 
GC-MS 
- - Free MOR in blood makes up 
50-100% of the total MOR  
in rapid deaths, and 20-40% 
in those which survive for a 
long time 
165
 
* Sam.: Sample types; B: Blood; U: Urine; P: Plasma; ** HP: HPLC detector used; UV: Ultraviolet; ECD: 
Electrochemical detector; FD: fluorescence detector.  SPE: Solid phase extraction; & R: Reference.  
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Table 4-3: Previous LC-MS methods for morphine glucuronides. 
 
 
 
Analyte Sam. * HPLC or GC conditions (Mobile phase)  Extraction  
Method  Ə 
Ref.  ð 
MOR 
M3G 
U RPLC & -MS#-APCI ** + ## (SIM &&)  
Column: L-column ODS; (150 mm x 4.6 mm)  
M.P ☼: (50 mM ammonium acetate: methanol (86: 14 )  
FR : 1.0 mL/min 
Sep-Pak  
C18 SPE 
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MOR 
M3G 
M6G 
COD 
S PRLC-MS-ESI+ (SIM) 
Column: ABZ (25cm x 4.6 mm, 5 ìm) 
M.P: (water: ACN § with linear gradient from 96:4 to 
30:70 with 3 nmol/L formic acid). 
 FR: 1 mL/min. 
Ethyl SPE 
C2 
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MOR 
M3G 
M6G 
S RP-LC-MS ESI #* +(SIM) 
Column: YMC ODS-AL 100 x 4.6 mm 
(water: ACN (94/4 to 30/70 with mmol/L formic acid ) 
FR: 1 mL/min 
Sep-Pak C18 
SPE 
171
 
 
 
MOR, M3G 
M6G, COD 
C6G 
6-MA 
B 
U  
CSF 
VH 
RPLC-MS-APCI (SIM) 
Column: Supersgher RP 18 (125 x 3 mm, 4ìm) 
M.P: (50 mM ammonium formate pH3: ACN  (95: 5) 
FR:     0.6- 1.1 mL/min 
Bond Elut 
C18 SPE 
177
 
 
 
 
MOR 
M3G 
M6G 
6-MA 
B 
U  
CSF 
VH 
RP LC-MS-APCI+ (SIM) 
Column: supersgher RP 18, (125 x 3 mm, 4ìm)  
M.P: (50 mM ammonium formate pH3: ACN (90: 10))  
FR: 0.6 mL/min 
Bond Elut 
C18 SPE 
86
 
MOR, M3G 
M6G, COD 
DIM 
6-MA 
S Normal phase (NP) LC-MS-APCI+ (SIM) 
Column: Suplelcosil LC-Si (25 cm x 2.1 mm, 5 ìm) 
M.P: (methanol: ACN: Water : formic acid (59.8: 5.2: 
34.65: 35 respectively). FR: 0.230 mL/min 
Ethyl SPE 
C2 
178
 
 
 
 
M3G,M6G 
MOR,C6G 
COD, 6MA 
DHM, DHC 
BUP 
B 
U  
CSF 
VH 
RPLC - MS-APCI+ (SIM) 
Column: supersgher RP 18 (125 x 3 mm, 4 ìm) 
M.P: (50 mM ammonium formate pH3: ACN (90: 10))  
FR: 0.3 mL/min for M3G, DHM M 6G, and MOR and 
0.6 mL/min for C6G, DHC, COD, and 6-MAM. 
Bond Elut 
C18 SPE 
86
 
 
 
 
MOR 
M3G 
M6G 
P NPLC-MS/MS- turbo ion spray (MRM æ) 
Column: Inertsil silica (, 50 x 3 mm, 5ìm) 
M.P: (Formic acid: water: ACN (1: 10: 90)) 
FR: 1.0 mL/min  
Bond Elut 
C18 SPE 
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MOR,M3G 
M6G, COD 
C6G, 6-MA 
,DHC6G, 
DHC, DHM 
BUP 
B 
U 
 
RPLC-MS- APCI+ (SIM) 
Column: Supersgher RP 18 (125 x 3 mm I.D., 4 ìm)  
M.P: (50 mM ammonium formate pH3: ACN (90: 10)  
FR: 0.3 mL/min for M3G, DHM, M 6G, and MOR, 0.6 
mL/min for C6G, DHC6G, DHC, COD and 6-MAM, 
and 0.4 mL/min for BUP. 
Bond Elut 
C18 SPE 
179
 
*  Sam.: Sample types; B: Blood; U: Urine; P: Plasma; CSF:  Cerebrospinal fluid  ; VH: vitreous humour;  * 
Ref: Reference.& RPLC-MS: Reverse phase liquid chromatography, NPLC: Normal Phase liquid 
chromatography; # MS: Mass spectroscopy; ** APCI: Atmospheric pressure chemical ionisation; #* ESI: 
Electrospry ionisation;&& SIM: Selected ion monitoring, *# MRM: Multiple reaction monitoring, ##+ : positive 
ion mode.☼  M.P: Mobile phase;  FR: Flow rate. §ACN:  Acetonitrile. 
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Furthermore, LC-MS techniques  provide sensitivity, robustness, flexibility, 
and save time 78,101,180. Methods for determining morphine and its glucuronides 
have been developed using LC-MS with both API interfaces (Table 4-2.) 
Nishikawa et al 175 reported the first application for detection of MOR and 
M3G using LC-APCI-MS. Pacifici et al 176 developed the first method using LC-
ESI-MS for serum samples. Tyrefors et al 171 and others developed several 
methods using LC-ESI-MS. Bogusz developed a series of reversed phase LC-
APCI-MS methods for detecting morphine and its glucuronides 86,177,179,181. Most 
of these methods were developed using reversed phase HPLC for determining 
morphine and its glucuronides 170,178. Also, methods using normal phase have 
been developed 170,178.   
SPE methods reported for sample preparation have frequently used a single 
cartridge or two cartridges in sequence as well as automatic 96-well SPE 
methods 182,183. 
4.3 Codeine 
4.3.1 Background 
Codeine (Codeinum; Methylmorphine; Metilmorfina; Morphine Methyl Ether) or 
(5á, 6á)-7,8-didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol 
monohydrate) is a natural opioid obtained from opium. This naturally occuring 
opioid can also be prepared by methylation of morphine. Codeine was isolated 
for the first time in 1832 1,132. It has been prescribed widely for the relief of 
mild to moderate acute pain as an analgesic and antitussive agent 116,184-186 . 
Codeine is often combined with non-opioid painkillers such as acetaminophen 
and aspirin. Although codeine has been extensively used as a medication, 
illicit use of codeine has been reported 2,125,132,187.  
4.3.2 Metabolism and Excretion 
Codeine is metabolised in the liver to norcodeine via N-demethylation and to 
morphine via O-demethylation by the cytochrome P450 isoenzyme CYP2D6. 
Codeine is also conjugated to form codeine-6-glucuronide. Morphine and 
norcodeine in turn are metabolised to normorphine, M3G, M6G and 
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norcodeine glucuronide 1,132,141,186,188. The metabolites found in urine three 
days after codeine administration are the same as those obtained when 
morphine or heroin is consumed 2. Although the presence of norcodeine in 
urine is considered to be evidence of codeine use 2, norcodeine has never 
been detected without the presence of codeine 187 and so will not be present 
three days after consumption.  
Codeine glucuronides, especially codeine-6-glucuronide, have attracted a 
great deal of interest for several reasons: firstly, codeine glucuronides have 
been found to constitute 50-80% of codeine excretion 126,186. Secondly, the 
concentration of codeine glucuronides is 15 times greater than codeine itself 
125,126,189. It has been found that 10% of codeine is metabolised to morphine 
and codeine analgesia is attributed to morphine 124,126,136,190. However, many 
people are deficient in the cytochrome P-450 enzyme that is necessary for 
metabolising codeine to morphine 125,136,190 and the analgesia in poor 
metabolisers following codeine administration is attributed to codeine itself 
or codeine-6-glucuronide 126,184,191. Moreover, codeine-6-glucuronide (C6G) is 
thought to be an active metabolite 126,184,192, which gives C6G clinical 
advantages 186. It has been suggested that C6G has the same properties as 
M6G and immunocompromised patients may use C6G to relieve their pain 193.  
This hypothesis has been supported, C6G observed anti-conceptive effects in 
animal 193 and human experiments 194; ultra-rapid, extensive, intermediate 
and poor metaboliser subjects produced CNS effects after codeine 
administration which strongly indicated that C6G is an active metabolite of 
codeine 126. Biotransformation of codeine is illustrated in Figure 4-2. 
4.3.3  Toxicity 
Deaths attributed to codeine are rare, with estimated minimum lethal doses 
between 500-1000 mg 1,132.  Overdose of codeine leads to unconsciousness and 
convulsions, with death likely to happen as a result of respiratory failure 
within 2-4 hours 132. Codeine intoxication often involves other toxic 
substances which enhance its adverse respiratory effects; codeine abusers 
may increase their dose up to 10 times the normal codeine dose without 
experiencing toxic effects.  
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Blood codeine levels in eight overdose deaths ranged between 1.4-5.6 ìg/mL 
195. Concentrations of codeine in post-mortem blood from two codeine 
fatalities  was 15 ìg/mL 48 hours after the consumption of a large amount of 
codeine tablets 196. Also, blood codeine concentrations in 39 fatalities 
attributed to codeine ranged between 0.1-8.8 ìg/mL 197. 
Figure 4-2: Codeine metabolism. (GLU: glucronic acid) 
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Gerostamulos et al 198 studied the role of codeine in drug related deaths, 
finding that the average total codeine concentration in 6 deaths attributed 
solely to codeine was 4 ìg/mL (range 2.1-8 ìg/mL), free codeine was 1.3 
ìg/mL (range 0.4-2.8) in blood samples. The authors also presented an 
additional 101 deaths involving codeine but combined with other substances, 
total and free codeine was 1.8 ìg/mL (range 0.04-26 ìg/mL) and 0.82 ìg/mL 
(range 0.02-9 ìg/mL), respectively.  However, codeine deaths are dependent 
upon the tolerance of users in which lethal levels can be detected with living 
subjects after codeine administration. In one report,  blood codeine levels of 
21.6 and 7 ìg/mL were reported in two drivers under the influence of codeine 
132.  
Blood levels of active metabolites (morphine) were found to be within toxic 
levels  as detected in morphine-related fatalities after heroin administration; 
the mean concentrations of morphine found in codeine overdoses deaths were 
in the range 0.2-0.3 ìg/mL197,199,200. Blood morphine concentrations in deaths 
due to codeine ranged between 0.1-0.7 ìg/mL 197.  Alcohol, paracetamol, 
diazepam and salicylate are the most common drugs accompanying codeine 
intoxication 1,198.   
4.3.4 Previous work 
Methods for the detection of codeine and its metabolites in biological fluids 
have been reported and used for forensic toxicology analysis. 
Radioimmunoassay techniques have been used for morphine and codeine 
screening, while GC-MS has also been used for confirmation 187,201-203. HPLC 
methods have been employed successfully to determine codeine and its 
metabolites using two detectors, UV and electrochemical (ECD), as it has been 
found that using an ECD alone did not reach the selectivity obtained by using 
both UV and ECD detectors 204. Also, HPLC methods with fluorescence 
detectors 186,205 and with ECD 184,206 were reported. 
Few methods have been developed to detect codeine-6-glucuronide in 
biological fluids. Svensson et al 206 developed an HPLC method with a 
fluorescence detector to detect C6G in plasma and urine. LC-MS methods for 
detecting codeine and its glucuronides have been reported 86,159,179. An LC-ESI-
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MS/MS method for the determination of codeine and its glucuronides in human 
urine samples has been described 116.  
4.4 Dihydrocodeine 
4.4.1 Background 
Dihydrocodeine (Dihydroneopine, Drocode, hydrocodeine, 6- á-hydrocodol, 
drocol, DHC-plus, Synalgos-DC) or (5á,6á)-4,5-epoxy-3-methoxy-17-
methylmorphinan-6-ol is a semisynthetic analgesic opioid 1,132. DHC was 
prepared for the first time in 1920 by hydrogenating the double bond between 
carbon atoms 7 and 8 in codeine 2. It has been used for the relief of moderate 
to severe pain, and has also been commonly used as an antitussive and 
analgesic  207,208. Since 1961, it has been widely used in some countries for the 
treatment of opiate addicts as an alternative to methadone 209,210. In 
Germany, for instance, DHC has been used for treating heroin users since the 
late 1980s 129,179,208,209,211-213. However, abuse of DHC has soared sharply in 
recent years 24,211,212,214. Fatal intoxication has been reported due to polydrug 
use 215. 
DHC is prescribed in the UK in two forms; oral and parenteral (50 mg/mL). 
DHC is less addictive than methadone which has led to an increase in its 
prescription by general practitioners (GPs) as a safe alternative to methadone 
and less monitoring is required since DHC is a class B drug 157. DHC-related 
fatalities in the West of Scotland increased from 12 cases in 1995 to 42 cases 
in 1999; another drug was detected in most of these cases and all of the 
deceased were drug abusers with the exception of two 157.  However, no data 
is available on more recent DHC-related deaths. 
4.4.2 Metabolism and Excretion 
DHC is metabolised by N-and O-demethylation, and it is conjugated with 
glucuronic acid at the 6-hydroxy group to produce dihydrocodeine-6- 
glucuronide (DHC6G) 132.  DHC is also sulphated at this position 132. O-
demethylation is responsible for metabolising DHC to its activate metabolite 
dihydromorphone (DHM) which is then conjugated with glucuronic acid to 
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form dihydromorphine 3- and 6-glucuronide. Nordihydrocodeine (NDHC) is 
formed by N-demethylation of DHC. Cytochrome P-450 enzyme CYP2D6 has 
been found responsible for O-demethylation of DHC. However, deficiency of 
this enzyme in about 7% of the Caucasian population and 50% of Chinese has 
been reported, and formation of dihydromorphone and its glucuronides is 
inhibited because of this. It has been stated that only 1-2% of 
dihydromorphine and its glucuronides are formed in poor metabolisers 
compared to 9% in extensive metabolisers  and no differences have been 
noted between metabolism of DHC and nordihydrocodeine 207,213,216. In 
conclusion, dihydromorphone and its glucuronide are found in small amounts 
in poor metabolisers, which in some cases cannot be detected. 
Biotransformation of DHC is shown in Figure 4-3. 
4.4.3 Toxicity  
DHC is often identified due to the presence in biological specimens of 
unchanged parent drug and metabolites dihydromorphine and 
nordihydrocodeine. Toxic concentrations reported were 0.8 ìg/mL or higher 
24,196,212,213 and therapeutic levels were suggested to be 0.03-0.25 ìg/mL 217. 
Symptoms of DHC toxicity involve dizziness, drowsiness, light-headedness, 
nausea and constipation. In severe exposure respiratory depression occurs 
followed by coma, convulsion, cardiovascular collapse and death 132. In 54 
living subject cases involving DHC the mean concentration was 0.7 ìg/mL 
(range 0.1-3.3 ìg/mL) 212.  Levels of free DHC in three fatalities ranged 
between 1.92-18.45 ìg/mL 212. In four overdose deaths attributed to DHC, the 
average blood DHC was 9 ìg/mL (range 7.2-12 ìg/mL) 218.  
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However, levels of DHC that cause death may be lower in polydrug 
intoxication. Levels found at autopsy overlapped between toxic and 
therapeutic levels due to the presence of other harmful substances while 
death can occur with concentrations below lethal levels. Deaths involving DHC 
can be classified in three categories 157,219: DHC only intoxication,  poly-drug 
intoxication involving DHC or DHC related and cases in which DHC was found 
but deaths were not attributed to DHC intoxication. 
Seymour et al 219 found that DHC levels in cases attributed to DHC alone were 
higher than in the other two categories. Blood DHC levels ranged between 
Figure 4-3: DHC metabolism. (Glu: Glucronic acid) 
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0.9-19.9 ìg/mL, 0.03-17.5 ìg/mL and 0.01-1.6 ìg/mL for deaths attributed to 
DHC alone, poly-drug intoxication and non-DHC related deaths, respectively. 
However, there was obvious overlapping between these three categories with 
median concentrations of 3.8 and 0.9 ìg/mL for DHC alone and DHC-related 
categories, respectively. Skopp et al 24 reported that DHC levels of DHC alone 
cases (≤ 3 ìg/mL) overlapped with those in living subjects. Seymour 157 found 
over half of cases (57%) positive for both DHC and morphine indicating that 
both heroin and DHC have been used at the same time which increases the 
risk of overdose.      
4.4.4 Previous work  
Methods for the detection of DHC have been reported using various techniques 
such as GC-FID 196, GC-MS 201,208,211, HPLC-fluorescence detector 24,212 and LC-
MS(/MS) . DHC and its active metabolites in serum using negative ion 
chemical ionisation GC-MS/MS was reported 210. Kirkwood et al 207 described 
an HPLC method with UV detector for determining DHC , DHM, and norDHC in 
human liver microsomal incubations. HPLC equipped with fluorescence 
detector has been reported in two studies for the detection of DHC, DHM, 
NDHC, DHC6G, DHM3G and DHM-6-G in blood and serum samples after fatal 
overdose. C8 Bond Elut SPE was applied for extraction of samples 24,212. Bogusz 
179 described a method for the detection of DHC and its metabolites in 
biological samples based on SPE (Bond Elut C-18) followed by LC-APCI-MS. 
Applications using electrophoresis for the determination of DHC, DHC6G and 
DHM have been reported 220-222.  
4.5 Buprenorphine 
A thorough review of buprenorphine can be found in Chapter 7 and will not be 
repeated here. 
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4.6 Hydromorphone  
4.6.1 Background 
Hydromorphone (dihydromorphinone; dilaudid and dimorphone) or 4,5-epoxy-
3-hydroxy-17-methylmorphinan-6-one is a potent semisynthetic opioid agonist 
and strong analgesic 1,132. It has been used to relieve moderate to severe pain  
such as cancer pain and postoperative pain  and has been used as an 
alternative to morphine 132,223-226. It has been used to avoid some of the 
adverse effects of morphine due to its water solubility which is estimated to 
be five times higher than that of morphine sulphate 227, making 
hydromorphone the best choice when concentrated doses and small amounts 
have to be taken, such as in subcutaneous infusion. For this reason, 
hydromorphone has become an attractive drug for the relief of chronic cancer 
pain 225,228-230. 
Hydromorphone was synthesised in Germany in 1921, and has been used 
clinically since 1926 223. It has become a drug of abuse due to its tendency to 
induce dependence. Furthermore, although the structure of hydromorphone is 
very similar to that of morphine, slight differences in its chemical structure 
have a considerable affect on its metabolism pathway. There are two 
differences: the presence of a 6-keto group, and the hydrogenation of the 
double bound at the C7-8 position of the hydromorphine molecule 231. 
4.6.2 Metabolism and Excretion 
Hydromorphone is metabolised into hydromorphone-3-glucuronide, 
conjugated dihydromorphine, unconjugated dihydroisomorphine, 
hydromorphine-3-sulfate, norhydromorphine, and nordihydroisomorphine 
132,223. Chemical structures of hydromorphone and its metabolites are shown in 
Figure 4-4. The existence of hydromorphone-6-glucurnide (H6G) has 
continually been brought into question. It has been thought that H6G is 
formed as a hydromorphine metabolite 232. However, there was confusion in 
distinguishing between H6G, DH-6 G and DHI-6-G, and the presence of H6G 
has been assumed in the study by Cone et al 232. Theoretically, H6G can be 
 54 
formed by altering the 6-keto group on the hydromorphone molecule to the 
enol form, and then another glucuronidation process will form H6G. However, 
H6G is not likely to be formed in hydromorphone detoxification , and instead 
of forming H6G, hydromorphone is metabolised to H3G and dihydroismorphine 
223,231.    
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Figure 4-4: Chemical structures of hydromorphone and its metabolites. 
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4.6.3 Previous work 
Many methods have been developed to detect hydromorphone and its 
metabolites in plasma using GC-MS 232 and HPLC with electrochemical 233 and 
UV detectors 234. The use of LC-MS/MS for the determination of 
hydromorphone and its metabolites in biological fluid has also been reported 
224-226,235. 
4.7 Oxycodone  
A thorough review of oxycodone can be found in Chapter 8 and will not be 
repeated here.  
4.8 Naloxone 
4.8.1 Background 
Naloxone (N-allylnoroxymorphone, Narcan) or (5á)-4,5-epoxy-3,14-dihydroxy-
17-(2-propenyl) morphinan-6-one is a synthetic opioid antagonist 1,132. It has 
been used since 1962 for the treatment of opioid overdoses and 
cardiovascular depression after surgery 236. It has also been shown to raise the 
blood pressure in patients with shock and has a mild diuretic effect in patients 
with liver cirrhosis 237. Also, naloxone binds non-selectively to opioid 
receptors; it has been used in the short term to reverse opioid overdose 
effects 126. Naloxone is the drug of choice for the treatment of opioid 
overdose and appears to be safe. Its use is well established in treating 
narcotic-induced respiratory depression due to intoxication by opiates such as 
morphine, codeine, oxymorphone and hydromorphone 238. In addition, there is 
an increase in the use of combinations of buprenorphine and naloxone for 
maintenance therapy. This was found to minimise the abuse and misuse of 
buprenorphine and this combination was found to be safe and offered an 
alternative therapy to the use of methadone or buprenorphine in addiction 
programme maintenance 239.  Also, a combination of oxycodone and naloxone 
as a prolonged release tablet for the treatment of chronic pain was found to 
be safe and efficient 240,241.  
 56 
An increase in cases of heroin overdose has been observed in recent years; 
however, the danger of heroin overdose can be prevented if naloxone is 
injected within a certain suitable time and the distribution of naloxone to 
heroin users and training of heroin users to inject themselves has been piloted 
both in Glasgow 242 and elsewhere 243,244.  The detection of naloxone in 
biological fluids has not gained attention until now and, due to the use of 
naloxone with combinations of other opioids for pain management, it would 
be found with cases at autopsy. In the present work there were two cases 
found due to the fact that if naloxone was used following opioid overdose, the 
user will survive and if not the samples from the deceased will be negative. 
Also, short half-life of naloxone could be another factor causing it to be 
missed at analysis.  Chemical structures of naloxone and its glucuronide are 
shown in Figure 4-5. 
4.8.2 Metabolism and Excretion 
Naloxone is metabolised by N-dealkylation, O-glucuronidation and reduction 
of the 6-keto group to produce naloxone-3-glucuronide, nornaloxone 
(noroxymorphine) and naloxol 132. Naloxone-3-glucuronide is the major 
metabolite of naloxone which can be formed in the human brain and may 
contribute to the short duration of action of naloxone when it reaches the 
brain 126. Naloxone has a short plasma half life (30 minutes) in which 
respiratory depression caused by long-acting opioids (methadone, heroin and 
morphine) may return after the effect of naloxone has ended.  Therefore, 
monitoring of the patient is necessary after recovery when starting naloxone 
intravenous infusion. High dose or rapid infusion of naloxone may result in 
catecholamine release and consequently pulmonary oedma and cardiac 
arrhythmias 238,239.   
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Figure 4-5: Chemical structures of Naloxone and Naloxone-3-glucuronide, 
(GLU: Glucuronic acid). 
 
4.8.3 Previous work 
A few methods have been reported for the detection of naloxone in biofluids 
using different techniques such as radioimmunoassay, gas-liquid 
chromatography 245 and HPLC with electrochemical 236 or UV detectors 246. 
Until recently, no method has been described for detecting naloxone 
glucuronide 241. 
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5 Method for Quantification of Opioids and 
their Metabolites in Autopsy Blood by Liquid 
Chromatography-Tandem Mass 
Spectrometry. 
5.1 Introduction 
Until recently, opioids and their metabolites were detected in biological 
specimens as free (unconjugated) substances or as the total concentration of 
the drug following cleavage of the conjugates, particularly those formed with 
glucuronic acid. Acid and enzyme hydrolysis procedures have been reported, 
although several have been found to give inaccurate results, to be time 
consuming and to have limitations, including incomplete hydrolysis and 
introduction of interferences in the analysis 76,247. Also, this approach does not 
allow different phase II metabolites to be distinguished and measured 
individually 159. 
Success has been achieved in recent years in the detection of low 
concentrations of morphine glucuronides in biological specimens using HPLC 
80,81,83,173,174,248 and LC/MS/(MS) techniques 75,86,116,170,171,175,176,178,179,183. The 
latter has become the technique of choice to provide good selectivity and 
accurate identification and quantification of analytes of interest.  Another 
advantage of LC-MS/MS lies in its ability to determine ionic, polar, thermally 
labile, high molecular weight and other non-volatile substances without 
derivatisation. LC-MS/MS methods are also characterised by excellent 
sensitivity, robustness, flexibility and efficient sample preparation 41,78,180. 
These advantages permit the simultaneous determination of a variety of drugs 
of interest 112,142,249. LC-MS/MS has also been considered as an alternative to 
immunoassay screening which saves time, and reduces the cost of the analysis 
32.   
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5.2 Aims 
Although methods for determining morphine and its glucuronides have been 
described 75,86,116,170,171,175,176,178,179,183, few methods have been developed for 
other opioid glucuronides. The primary aim of the present study was to 
develop a reliable, sensitive, and selective method based on LC-MS/MS for the 
identification and quantification in human whole blood of the opioids and 
metabolites which are most commonly encountered in post mortem 
toxicology. The second aim was to employ this method in the routine 
toxicology laboratory for opioid-related fatalities and to evaluate its 
usefulness in interpreting the cause of death, in determining the type of 
death (rapid, sub-acute death, or delayed death) and in distinguishing 
between heroin, morphine and codeine users.  
5.3 Method and Materials  
5.3.1 Reagents and Standards 
Methanol and acetonitrile (HPLC grade) were obtained from BDH (Poole, UK). 
Ammonium carbonate, formic acid and ammonium hydroxide were also 
purchased from BDH. Ammonium formate was obtained from Acros Organics 
(New Jersey, USA). The method was developed using human blank blood 
obtained from West infirmary Hospital, Glasgow.  
Morphine (MOR), morphine-D3 (MOR-D3), 6-monoacetylmorphine (6-MAM), 6- 
monoacetylmorphine-D3 (6-MAM-D3), codeine (COD), codeine-D6 (COD-D6), 6-
acetylcodeine (6-AC), hydromorphine (HMOR), hydromorphine-D3 (HMOR-D3), 
dihydrocodeine (DHC), dihydrocodeine-D6 (DHC-D6), buprenorphine (BUP), 
buprenorphine-D4 (BUP-D4), norbuprenorphine (NBUP), norbuprenorphine-D3 
9NBUP-D3), naloxone (NAL), oxymorphone (OXYM) and oxymorphone-D3 
(OXYM-D3) were obtained from Promochem (Middlesex, UK). Morphine-3-
glucuronide (M3G), morphine-3-glucuronide-D3 (M3G-D3), morphine-6-
glucuronide (M6G), morphine-6-glucuronide-D3 (M6G-D3), normorphine 
(NORM), codeine-6-glucuronide (C6G), codeine-6-glucuronide-D3 (C6G-D3), 
norcodeine (NCOD), dihydrocodeine-6-glucuronide (DHC6G), dihydromorphine 
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(DHM), dihydromorphine-3-glucuronide (DHM3G), dihydromorphine-6-
glucuronide (DHM6G) and naloxone-3-glucuronide (NAL3G) were purchased 
from Lipomed (Arlesheim, Switzerland). All standards and internal standards 
were obtained as solutions in methanol at a concentration of 0.1 mg/mL or 
1 mg/mL and each had a purity of more than 99%.  Bond Elut LRC-C18 
cartridges were purchased from Varian (CA, USA). 
Individual working standards were prepared at a concentration of 1 µg/mL by 
dilution of the stock solutions. Working mixtures of standards and internal 
standards were similarly prepared. 
The method was developed using packed human red blood cells, which had 
passed their usable date, obtained from the Scottish National Blood 
Transfusion Service and re-suspended in an equal volume of isotonic saline. 
5.3.1.1 Preparation of 0.01M Ammonium carbonate buffer (pH 9.3) 
1.571 g of ammonium carbonate was weighed and added to a I L volumetric 
flask and 800 mL of DI H2O was added. The pH was then adjusted to 9.3 using 
concentrated ammonium hydroxide. The volume was made up to 1 L using 
deionised water. The buffer was stored at 4 0C until used and unused solution 
was discarded after 4 weeks from the date of preparation. 
5.3.1.2 Preparation of 0.01 M Ammonium Formate (pH 3 or 4.5) 
0.630 g of ammonium formate was added to a 1 L volumetric flask and 800 mL 
of DI H2O was added. The pH was adjusted to 3 or 4.5 using concentrated 
formic acid. Then volume was made up to 1 L with deionised water. 
Ammonium formate buffer was prepared freshly and stored at room 
temperature until used; unused solution was discarded after 4 weeks from the 
date of preparation. 
5.3.2 Solid Phase Extraction 
One millilitre of whole blood was added to 3 mL of 0.01 M ammonium 
carbonate, pH 9.3 and 100 ìl of the internal standard working solution was 
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added. The mixture was vortex mixed, allowed to equilibrate for 10 minutes 
and then centrifuged for 10 minutes at 2500 rpm. The supernatant was 
applied to a Bond Elut C18 SPE cartridge preconditioned with 3 mL methanol, 
3 mL of deionised water, and 3 mL of 0.01 M ammonium carbonate (pH 9.3).  
The SPE cartridge was washed twice with 3 mL 0.01 M ammonium carbonate 
(pH 9.3), and then dried for 10 minutes. Retained drugs were eluted with 3 
mL methanol, after that, the eluate was evaporated to dryness under nitrogen 
at 50 oC.  The extract was reconstituted with 150 ìl of initial mobile phase 
and the tube was centrifuged for 10 minutes at 4000 rpm before transferring 
the supernatant into an autosampler vial. 20 ìl were injected into the LC-
MS/MS instrument. 
5.3.3 Chromatography conditions 
Chromatographic separation was achieved using a Synergy Polar RP column 
(150 x 2.0 mm, 4-ìm particle size), protected by a guard column with 
identical packing material (4 x 2.0 mm, Phenomenex, Torrance, CA).  
Gradient elution was based on a mobile phase consisting of 10 mM ammonium 
formate adjusted to pH 3 (A) and acetonitrile (B) at a flow rate of 0.3 mL/min 
in the first 8 min, decreasing to 0.2 mL/min at 13 min for the next 13 min. 
After that, the initial flow rate was applied until the end of analysis. The 
gradient conditions were initially 97% of solution A for 3 min; decreasing to 
84.5% at 8 min, to 74% at 13 min and to 20% at 26 min, 5% of solution A was 
maintained for the next 3 min before returning to 97% for 7 min prior to the 
next injection. 
5.3.4 Instrumentation 
Analysis of opiates and their metabolites was performed using a Thermo 
Finnigan LCQ DECA XP Plus ion trap instrument (Thermo Finnigan, San Jose, 
USA) equipped with a surveyor LC system interface. 
Ionisation of analytes of interest was carried out using electrospray positive 
ion mode. The capillary temperature, sheath gas flow rate, auxiliary gas flow 
rate and collision energies were optimized for each analyte separately. All 
internal standards were analysed using selected ion monitoring mode (SIM), 
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Table 5-1: LC-MS/MS Parameters for Opiates and their Metabolites 
 
Analyte  Internal standard Precursor ion 
(m/z) 
Sheath 
Gas (AU) 
Auxiliary 
Gas 
(AU) 
Capillary Temp. 
(°C) 
CID 
(%) 
Product 
ion (s) 
RT # 
( min) 
 
Injection 
(segment) no. 
MOR MOR-D6 286 30 0 225 35 201, 228 7.99 2 (2) 
M3G MOR-D6 462 20 10 270 28 286 3.67 1 (1) 
M6G MOR-D6 462 20 115 270 30 286 6.83 1 (2) 
6-MAM MAM-D3 328 25 0 300 35 211, 268 14.02 1 (3) 
NMOR MOR-D6 272 25 10 270 31 254, 229 4.97 2 (1) 
COD COD-D6 300 20 0 270 35 215, 243 12.47 2 (3) 
C6G C6G-D3 476 25 10 285 30 300 11.17 1 (3) 
NCOD MOR-D6 286 30 5 270 35 268, 243 11.19 1 (3) 
6-AC MOR-D6 342 20 15 290 35 225, 225 18.44 2 (4) 
HMOR HMOR-D3 286 25 0 280 35 185, 229 10.25 1 (3) 
H3G HMOR-D3 462 30 10 290 30 286 5.01 1 (1) 
DHC DHC-D6 302 25 10 270 35 245, 201 11.90 2 (3) 
DHC6G DHC-D6 478 25 5 270 30 302 11.05 2 (3) 
DHM MOR-D6 288 25 5 270 35 213, 231 6.99 2 (2) 
DHM3G MOR-D6 464 20 15 290 28 288 3.36 2 (1) 
DHM6G MOR-D6 464 15 15 290 30 288 6.98 2 (2) 
BUP BUP-D4 468 33 10 270 36 414, 396 22.49 1 (5) 
BUP3G BUP-D4 644 30 0 295 30 644 18.30 1 (4) 
NBUP NBUP-D3 414 30 0 300 31 396, 340 19.40 1 (4) 
NBUP3G NBUP-D3 590 30 0 280 30 414 14.23 2 (3) 
NAL MOR-D6 328 20 0 300 30 310 12.34 1 (3) 
NAL3G MOR-D6 504 20 0 290 30 486, 328 8.04 1 (2) 
OXY OXY-D6 316 25 10 250 30 298 13.75 1 (3) 
OXYM OXYM-D3 302 5 5 250 25 284 9.26 2 (2) 
#
 Retention time (minutes).  
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whereas analytes were identified and quantified based on their retention 
times and product ion full scan spectra, except buprenorphine-3-glucuronide, 
which was analysed in the SIM mode. The spray voltage used was 5 kV. The 
MS/MS parameters are detailed in Table 5-1.  
5.3.5 Method Validation 
5.3.5.1 Linearity 
Analytes of interest were added to human whole blood to obtain eight 
concentrations ranging from 5-400 ng/mL. Internal standards were added at 
100 ng/mL. The blood samples were extracted by SPE as described earlier and 
analysed by LC-MS/MS.  Peak area ratios of analytes of interest to their 
internal standards were calculated (see Table 5-1). Calibration curves were 
obtained by plotting peak area ratios against concentration. The correlation 
coefficient (r2) was obtained for each linear regression curve.   
5.3.5.2 Recovery 
The recoveries of the analytes by SPE were calculated by comparing the peak 
area ratios of analytes extracted from blood at three concentrations (10, 50 
and 200 ng/mL, n=5) with those obtained with unextracted standards at 
corresponding amounts. Internal standards were added after the blood 
samples were extracted by SPE. 
5.3.5.3 Limit of Detection and Lower Limit of Quantitation 
The Limit of detection (LOD) and the Lower Limit of Quantitation (LLOQ) for 
each analyte were calculated by lowering the concentrations of calibration 
standards in blood in the range of expected LODs. Calibration curves were 
obtained for all analytes at five concentrations ranging from 0.1- 10 ng/mL. 
LODs and LLOQs for all analytes were obtained using equations 2-1, 2-2 and 2-
3, 2-4, respectively.  
 64 
5.3.5.4 Intra-assay precision 
Intra-assay precision was determined by analysing replicate human whole 
blood samples (n=5) containing analytes of interest at three concentrations 
(10, 50, and 200 ng/mL) in the same day. Concentrations of the analytes were 
obtained using calibration curves prepared with standards at 5, 10, 20, 25, 50, 
100, 200 and 400 ng/mL as well as blanks. 
5.3.5.5 Inter-assay precision 
The inter-assay precision was measured in a similar manner to the intra-assay 
precision at three concentrations over the linear dynamic range (10, 50, and 
200 ng/mL) on five different days.   
5.3.5.6 Matrix effects 
The effect of co-extracted human whole blood matrix components on opioid 
ionisation in LC-MS/MS was assessed using the procedure of Matuszewsk et al 
51. In brief, the peak area ratios of unextracted standards (n=5) prepared in 
mobile phase were compared with those of 200 ng/mL standards (n=3) 
extracted from five different blank human whole blood sources. Matrix effects 
for each analyte were calculated using equation 3-1, refer to section 3.5. 
5.3.5.7 Stability  
Stability was assessed using human whole blood spiked with the analytes of 
interest at 100 ng/mL (n=3). Short-term temperature stability at room 
temperature was investigated for human whole blood stored for 4 and 24 hrs.  
Freeze-thaw stability of analytes of interest was determined after four cycles 
(thawed, left at room temperature for 3 hrs then refrozen) on consecutive 
days. Auto-sampler stability using reconstituted extracted sample was 
determined at 48 hrs and at one week after extraction. Long-term stability for 
analytes of interest at -20 and 4 oC for period of 24hrs, 48hrs, 1 week and 1 
month were investigated. Calibration curves were prepared for each batch 
samples using standards in whole blood at 5, 10, 20, 25, 50, 100, 200 and 250 
ng/mL plus blanks. The storage temperatures were monitored daily using 
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permanently mounted digital thermometers with a resolution of 0.1 C°at the 
start of the study and subsequently at weekly intervals during the period of 
study. Temperatures were stable within a range of approximately 1 °C  
(freezer and refrigerator) or 5 °C (room temperature, average temperature 20 
°C).   
5.3.6 Case Materials 
Samples of autopsy blood were analysed using the proposed method as part of 
the investigation of medico-legal cases submitted to Forensic Medicine and 
Science, University of Glasgow which were drug-related deaths. Analyses were 
repeated after dilution of the blood sample when analyte concentrations 
outside the calibration range were obtained. A comparison of the results 
obtained by this method with those obtained by the established methods of 
the Forensic Medicine and Science Section laboratory is given in Table 9-10, 9-
11 and 9-13 and these are discussed in Chapter 9. 
5.4 Results and Discussion  
5.4.1 Solid Phase Extraction  
The SPE extraction efficiencies for all analytes were between 80.3% and 
101.4% which was acceptable taking into account the large number of 
analytes in this method. Recoveries of opioid metabolites included in the 
current work are detailed in Table 5-2. Bond Elut C18 columns were selected 
after comparing them with Bond Elut Certify (Varian, CA, USA), and Strata X-C 
(Phenomenex, Torrance, CA) columns. Bond Elut Certify was excluded due to 
significant losses of glucuronides during extraction. However, parent drugs 
were retained with good recoveries. A method involving Strata X-C columns, 
published by Murphy and Huestis 116 for urine as the matrix, was evaluated for 
use with human whole blood. However, the extracts obtained had many co-
eluting interferences, with the potential to cause column contamination and 
significant matrix effects and so Strata X-C was also excluded. Methods using 
Bond Elut C18 for the extraction of opioid glucuronides have already been 
published 170,172,177,179,250 and the method developed in the present study, 
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giving clean extracts with excellent recoveries, was based on the procedures 
of Bugusz 179  and Leis et al 172.  
5.4.2 Chromatography 
Good chromatography of all analytes was obtained using a gradient starting 
with a high percentage of aqueous buffer (97% 10 mM ammonium formate). 
Different concentrations of ammonium formate between 1-10 mM at pH 3 
were not found to have significant effects but a slight shift in retention times 
was observed at pH 4.  
Table 5-2: Extraction recovery from human whole blood 
 
Analytes    
Nominal Concentration 
 10 
(ng/mL) 
50 
(ng/mL) 
200 
(ng/mL) 
 Mean Recovery % # (R.S.D of recovery *) 
MOR 97.9 (3.4) 99.2 (5.5) 100.3 (6.1) 
M3G 96.2 (4.5) 99.5 (3.1) 99.7 (3.8) 
M6G 86.0 (1.4) 90.6 (4.7) 90.5 (2.8) 
6-MAM 91.2 (4.2) 93.6 (7.4) 96.0 (3.6) 
NMOR 91.6 (7.7) 96.1 (7.3) 99.6 (2.4) 
COD 94.6 (2.8) 101.8 (4.4) 101.4 (3.6) 
C6G 98.2 (4.8) 99.8 (4.2) 100.0 (4.9) 
NCOD 90.3 (4.9) 94.6 (3.4) 97.4 (2.9) 
6-AC 88.0 (7.7) 89.6 (5.9) 93.0 (3.0) 
HMOR 90.3 (4.2) 96.2 (4.1) 97.0 (3.2) 
H3G 92.8 (3.5) 95.6 (3.5) 100.0 (3.0) 
DHC 90.4 (2.6) 93.0 (4.5) 99.3 (3.4) 
DHC6G 91.7 (3.7) 94.6 (3.5) 96.8 (7.2) 
DHM 80.7 (4.5) 83.3 (7.2) 84.4 (5.4) 
DHM3G 80.9 (11.5) 84.0 (2.7) 84.9 (3.7) 
DHM6G 80.3 (11.2) 89.5 (0.1) 87.7 (4.8) 
BUP 82.0 (8.7) 85.8 (5.8) 94.5 (5.2) 
BUP3G 91.0 (3.8) 92.7 (6.1) 98.0 (3.9) 
NBUP 84.6 (6.2) 92.7 (5.1) 98.0 (4.3) 
NBUP3G 81.8 (2.4) 86.0 (4.7) 98.1 (1.8) 
NALOX 90.3 (6.5) 92.4 (6.3) 98.7 (4.2) 
NALOX3G 84.3 (3.4) 98.7 (2.6) 100.1 (2.9) 
OXY 89.7 (4.5) 92.0 (4.5) 99.5 (3.8) 
OXYM 97.9 (9.6) 98.4 (4.0) 99.1 (2.7) 
#
 The mean percentages for the replicate analysis (n=5). 
*  R.S.D: Relative standard deviations. 
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5.4.3 LC-MS/MS 
LC-MS/MS has the capability of analysing a variety of drugs with the same 
molecular weight and polarity, although overlapping peaks can decrease the 
number of available data points for each analyte across the peaks with an 
adverse effect on precision 112. In the present method, several analytes of 
similar polarity were shown to co-elute, including. M3G/DHM3G and 
MOR/NAL3G. As a result, two HPLC runs were used with two sets of MS/MS 
parameters to avoid more than 5 scan events per retention time window, in 
order to achieve good repeatability between injections. Mass Retention 
windows and their scan events are shown in Table 5-1.  
Deuterated internal standards were used when possible although some are not 
yet commercially available (NMOR, NCOD, 6-AC, H3G, DHC6G, DHM, DHM3G, 
DHM6G, B3G, NBUP3G, NAL and NAL3G). However, analyte co-elution with 
simultaneous mass spectral pattern overlaps occurred between M3G-
D3/DHM3G, M6G-D3/DHM6G, MOR-D3/DHM and COD-D3/DHC. The problem 
was difficult to solve, as the differences in molecular weights of analytes and 
isotopically-labelled internal standards is just 1 amu and the mass window of 
the ion trap is also ± 1, resulting in a degree of cross-talk. Analytes were still 
able to be measured and identified in the presence of partial overlap but it 
was found preferable to replace these deuterated internal standards with 
alternative deuterated analogues with similar structure. The problems 
disappeared when M3G-D3, M6G-D3, and MOR-D3 were replaced by MOR-D6 
and COD-D3 was replaced with COD-D6. The use of individual internal 
standards for each drug is recommended but the use of analogues that give a 
linear response between analytes of interest and peak area ratio is 
acceptable. Some of these problems might be solved using a triple quadrupole 
or Q-TOF instrument.  
Mass spectral data for all analytes were obtained in the electrospray positive 
ion mode. The product ion of all opiate glucuronides resulted from loss of the 
glucuronic acid moiety (m/z 176) from the protonated molecular ion. It was 
observed that there was no advantage, with the instrument used in this study, 
in performing selected reaction monitoring (SRM) rather than full MS/MS 
scanning and the latter was chosen for identification and quantitation of all 
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analytes with the exception of B3G, due to the variable peak area ratios 
obtained for its main product ion at m/z 468. Optimisation of the mobile 
phase flow rate and composition did not solve this problem. Moody et al 251 
reported the same observation when using a triple quadrupole instrument.  
The BUP product ion abundance was relatively constant at low collision 
energies (CE) up to -20eV then dropped sharply using CE above -30 eV.  
Product ion intensities were low at low CE values and could not be used for 
quantitation. Increasing the CE above -40eV formed many low intensity 
product ions and as a result the protonated molecular ion at m/z 468 was 
used for quantitation. Reproducible fragmentation was obtained even at the 
LOD concentration of 0.1 ng/mL. The same approach was used in the present 
study and B3G was determined in the SIM mode using the protonated 
molecular ion at m/z 644, which gave acceptable linearity over the 
concentration range 5-400 ng/mL.  
5.4.4 Method Validation 
5.4.4.1 Linearity 
The concentration range for calibration curves was chosen on the basis of 
previous work 75,86,112,212,252. All linear regression lines had r2 values greater 
than 0.999 which is very satisfactory. 
5.4.4.2 LOD and LLOQ 
LODs and LLOQs obtained for the analytes compared well with previously 
published work, and were in the ranges 0.16 - 1.2 ng/mL and 0.5 - 4.09 
ng/mL, respectively (Table 5-3). The calculation of LOD and LLOQ has been 
carried out by different methods  but in this work they were obtained using 
Equations 2-1, 2-2 and 2-3, 2-4, respectively 62,64,112,253,254. LODs and LLOQs of 
opioids and metabolites are listed in Table 5-3 and chromatograms of all 
analytes at 3 ng/mL are shown in Figure 5-1 and 5-2.  
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Table 5-3: LODs and LLOQs of opioids extracted from human whole 
blood. 
Analytes r2  # y-intercept Standard  
error 
Gradient 
(m) 
LOD * 
(ng/mL) 
LLOQ & 
(ng/mL) 
MOR 0.9998 -2.9E-05 
 
9.96E-05 
 
0.001422 
 
0.20 0.70 
M3G 0.9995 -2.5E-05 
 
0.000138 
 
0.001487 
 
0.28 
 
0.93 
 
M6G 0.9998 1.89E-06 
 
9.75E-05 
 
0.001461 
 
0.20 
 
0.67 
 
6-MAM 0.9999 -8.8E-06 
 
9.04E-05 
 
0.001743 
 
0.16 0.50 
NMOR 0.9997 -0.00012 
 
9.13E-05 
 
0.000402 
 
0.68 
 
2.27 
 
COD 0.9994 -4.5E-05 
 
0.000161 
 
0.001481 
 
0.32 
 
1.08 
 
C6G 0.9977 -0.00102 
 
0.000861 
 
0.00402 
 
0.38 
 
2.10 
 
NCOD 0.9994 -0.00024 
 
0.000302 
 
0.002706 
 
0.33 
 
1.10 
 
6-AC 0.9995 -0.00209 
 
0.002612 
 
0.029658 
 
0.26 
 
0.88 
 
HMOR 0.9997 -2.1E-05 
 
0.000127 
 
0.001654 
 
0.23 
 
0.77 
 
H3G 0.9995 -7.7E-05 0.000218 0.002128 0.30 1.02 
 
DHC 0.9995 3.74E-05 
 
0.000193 
 
0.001839 
 
0.3 
 
1.05 
 
DHC6G 0.9997 -5.4E-05 
 
0.000233 
 
0.000961 
 
0.7 
 
2.42 
 
DHM 0.9992 
 
-0.00023 
 
0.000305 
 
0.002897 
 
0.3 
 
1.05 
 
DHM3G 0.9992 
 
-0.00081 
 
0.000716 
 
0.006751 
 
0.3 1.06 
DHM6G 0.9996 
 
-0.00052 
 
0.000683 
 
0.002747 
 
0.7 2.50 
BUP 0.9998 -0.00022 
 
0.000199 
 
0.001084 
 
0.55 
 
1.84 
 
BUP3G 0.9992 -4E-05 
 
0.000687 
 
0.005353 
 
0.39 
 
1.28 
 
NBUP 0.9998 -0.00019 
 
0.000339 
 
0.00083 
 
1.2 
 
4.09 
 
NBUP3G 0.9987 -1.4E-05 
 
2.05E-05 
 
0.000124 
 
0.49 
 
1.65 
 
NALOX 0.9999 -0.00093 
 
0.000663 
 
0.005038 
 
0.39 
 
1.32 
 
NALOX3G 0.9996 0.00027 
 
5.73E-05 
 
0.000677 
 
0.25 
 
0.85 
 
OXY 0.9984 -0.01363 
 
0.006931 
 
0.035863 
 
0.58 
 
1.93 
 
OXYM 0.9993 -0.00011 0.000757 0.007702 0.30 0.98 
#
  r 
2: Correlation coefficients. 
*
 LOD: Limit of detection;  
&
 LLOQ: Lower limit of quantitation; 
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Figure 5-1: LC-MS/MS product ion chromatograms for opioids in blood 
(concentration 3 ng/ml) detected during the first injection. 
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Figure 5-2: LC-MS/MS product ion chromatograms for opioids in blood 
(concentration 3 ng/ml) detected during the second injection. 
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5.4.4.3 Method precision  
Intra- and inter-assay precision were assessed as the percentage relative 
standard deviation (RSD) on analyses of standards at three different 
concentrations (10, 50, and 200 ng/mL). Good precision was obtained for all 
analytes in the range 0.6 to 13.8 % RSD (Tables 5-4, 5-5).  
 Table 5-4: Intra-day precision  
 Nominal  Concentrations (ng/mL) 
  3.0 10.0 50.0 200.0 
Analytes Measured concentration ng/mL # (R.S.D % *)  
MOR 2.8 (8.9) 11.3 (7.2) 49.3  (6.0) 197.9 (4.2) 
M3G 3.1 (11.5) 11.5 (4.9) 51.2 (9.0)  206.3 (3.9) 
M6G 3.5 (14.4) 11.3  (8.8) 52.2 (10.0) 199.6  (4.4) 
6-MAM 2.7 (10.7) 11.0 (8) 52.7 (5.9) 199.0 (3.3) 
NMOR 3.1 (10.4) 10.3 (6.9) 46.4 (6.2) 197.0 (5) 
COD 2.7 (15.6) 9.6 (5.6) 47.8 (4.5) 197.0 (3.1) 
C6G 3.1 (8.9) 10.3 (12.1) 50.9 (13.0) 198.5 (4.4) 
NCOD 3.4 (9.2) 9.5 (13.4) 53.1 (4.0) 204.7  (5.6) 
6-AC 3.5 (7.5)  11.7  (9) 53.1 (1.0) 205.5 (3.3) 
HMOR 3.0 (10.0) 9.6 (11.3) 43.6 (3.0) 189.3 (3.6) 
H3G 3.4 (6.6) 11.0 (7) 50.0 (4.4) 197.0 (4.7) 
DHC 2.9 (13.0) 9.5 (11.6) 51.2 (3.6) 195.5 (3.3) 
DHC6G 2.7 (15.3)  11.4 (13.3) 51.8  (4.0) 204.7  (5.6) 
DHM 3.4  (12.2) 11.0 (6.2) 54.6 (1.9) 193.4  (1.8) 
DHM3G 3.3  (5.0) 8.2 (8.2) 45.3 (7.0) 192.6 (4) 
DHM6G 3.6 (10.4) 10.8 (4.6) 47.4  (4.3) 210.9  (1.9) 
BUP 3.1 (11.2) 11.1 (6.9) 53.4 (3.3) 199.0  (3.2) 
BUP3G 3.1 (13.5) 11.7 (13.8) 53.0 (9.5) 197.4  (2.4) 
NBUP 3.2 (15.5) 10.1  (10.5)  44.9  (4.5) 202.9 (4.1) 
NBUP3G 3.2 (13.9)  11.5  (10.3) 53.5 (8.8) 205.2 (3.8) 
NALOX 3.3 (14.2) 10.2 (13) 49.5 (7.9) 193.4 (5.3) 
NALOX3G 2.8 (14.4)  10.8  (13.4) 53.0 (10.9) 205.3 (2.8) 
OXY 2.3 (13.5) 9.4 (5.5) 43.9  (3.4) 192.2 (6.0) 
OXYM 3.4 (8.3) 9.3  (9.4) 50.9 (3.6) 199.2 (4.7) 
*
 The mean percentages for the replicate analysis (n=5). 
 
#
 R.S.D: Relative standard deviations. 
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Table 5-5: Inter-day precision  
 Nominal Concentraction 
 10.0 50.0 200.0 
 Measured concentration ng/mL # (R.S.D *)  
MOR 10.3 (3.2) 52.4 (4.6) 200.0 (0.8) 
M3G 11.0 (7.3) 49.6 (4.9) 204.6 (1.0) 
M6G 10.1  (8.7) 47.6  (6.2) 201.6  (1.0) 
6-MAM 10.8 (10.2) 51.4 (1.8) 202.5 (1.9) 
NMOR 11.2  (2.9) 46.6 (6.7) 195.0 (1.6) 
COD 11.0 (5.6) 53.6 (3.9) 201.0  (2.5) 
C6G 9.3 (13.0) 50.8 (9.2) 198.0 (2.0) 
NCOD 10.0 (6.0) 49.5 (3.5) 196.8 (1.3) 
6-AC 9.8 (5.6) 53.6 (4.4) 198.0 (1.4) 
HMOR 10.8 (3.3) 47.6 (3) 196.7 (0.9) 
H3G 10.9 (6.3) 51.8 (5.3) 201.9  (1.0) 
DHC 11.1 (3.8) 49.2 (3.9) 196.4 (0.6) 
DHC6G 10.0  (8.6) 49.0 (4.2) 197.7 (1.2) 
DHM 10.4 (9.2) 50.7 (9.2) 199.8 (4.2) 
DHM3G 9.0 (10.0) 45.7 (2.5) 199.6 (1.4) 
DHM6G 9.8 (7.2) 45.9 (7.1) 205.0 (2.7) 
BUP 10.9 (6.3) 48.8 (5.5) 200.7 (3.1) 
BUP3G 11.3 (5.0) 48.1 (2.7) 200.0 (2.2) 
NBUP 10.0 (12.0) 47.3  (8.5) 200.0 (3.4) 
NBUP3G 9.7  (11.5) 51.3  (4.0) 199.7 (2.4) 
NALOX 9.9 (12.5) 47.6 (8.1) 201.0 (2.3) 
NALOX3G 10.3 (7.5) 52.8  (8.5) 194.4  (1.4) 
OXY 10.2 (6.5) 53.7 (5.7) 197.3 (1.3) 
OXYM 9.8 (4.9) 51.1 (3.8) 201.0 (2.3) 
*
 The mean percentages for the replicate analysis (n=5). 
 
#
 R.S.D: Relative standard deviations (%). 
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5.4.4.4 Matrix effects 
Assessment of possible matrix effects indicated that ion enhancement and ion 
suppression occurred with some analytes and the average value ranged from < 
1% to 17% and from < 1% to 18%, respectively. In Table 5-6, a value of > 100% 
demonstrates ion enhancement while a value of < 100% points to ion 
suppression. Although the average value of the ion suppression and the ion 
enhancement of analytes of interest were within the accepted limit of the 
validation procedure (± 20 %), further studies were conducted to evaluate 
matrix effects due to endogenous blood components by testing samples (n=3) 
of blank blood, blank blood spiked with internal standards and blank blood 
spiked with analytes of interest at 3 ng/mL (LLOQ), refer to Figure 5-1 and 5-
2.   
The specificity of the method was investigated using a mixture of drugs that 
are routinely detected in forensic toxicology cases (cocaine, benzoylecgonine, 
cocaethylene, ecgonine methyl ester, amphetamine, methamphetamine, 
methylenedioxyamphetamine, methylenedioxyethyleamphtamine, 
methylenedioxymethamphetamine, nitrazepam, 7- aminoflunitrazepam, 
chlordiazepoxide, diazepam, oxazepam and temazepam) at a concentration of 
400 ng/mL in whole blood.  No endogenous blood components nor any of the 
drugs co-eluted with any of the analytes of interest or their internal 
standards. Matrix affects results are listed in Table 5-6. 
5.4.4.5 Stability 
The assessment of analyte stability in matrix during the validation process is 
required for reliable quantitation, especially if no information is available 
from previous work 47. The stability of heroin metabolites, including 6-MAM, 
morphine and its glucuronides have been studied and data is available in the 
literature 12,75,116,172,182,183,255. Heroin was stable for 14 months in frozen 
plasma 75 and 6-MAM was stable in frozen urine over a period of 12 months 12. 
Morphine and its glucuronides were found to be relatively stable in frozen 
specimens for a long period. However, these analytes were found unstable at 
4 oC after a few days 12. Skopp et al 255 concluded that the major factor that 
affects the stability of morphine and M6G is storage temperature. 
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Table 5-6: Blood matrix effect during extraction (% relative to drug in 
buffer). 
 Mean matrix effect (%, n=3)** All five human 
sources 
Analyte Source  1# Source 2 Source 3 Source 4 Source 
5 
Mean % R.S.D. & 
MOR 104 101 98 96 111 102 5.8 
M3G 101 89 90 97 110 97 8.6 
M6G 94 80 82 82 90 86 7 
6-MAM 101 101 105 101 87 99 7 
NMOR 94 100 82 84 100 92 9 
COD 100 99 107 96 118 104 8 
C6G 95 105 109 106 107 104 5 
NCOD 101 112 109 84 99 101 11 
6-AC 85 86 102 96 96 93 8 
HMOR 107 108 107 97 112 106 5 
H3G 83 98 82 107 106 95 13 
DHC 111 106 99 100 103 104 5 
DHC6G 103 84 76 93 90 89 11 
DHM 110 98 102 93 98 100 6 
DHM3G 93 75 84 80 85 83 8 
DHM6G 77 90 83 81 83 83 6 
BUP 95 95 109 112 108 104 8 
BUP3G 123 106 112 116 125 116 7 
NBUP 98 128 110 120 129 117 11 
NBUP3G 106 93 104 97 113 103 8 
NALOX 94 87 84 90 95 90 5 
NALOX3G 102 93 82 83 104 93 11 
OXY 104 95 82 88 102 94 10 
OXYM 101 108 109 113 113 109 4 
# Human blood was sourced from completed post-mortem blood samples that were scheduled 
for destruction and contained no analytes of interest. 
** Matrix effect is expressed as the response obtained for a standard chromatographed along 
with matrix extract compared to that obtained with an unextracted standard chromatographed in 
mobile phase only, expressed as a percentage. Standard was spiked into matrix extract at a 
concentration of 200 ng/mL. 
 
&
 R.S.D. %: Relative standard deviation expressed as a percentage. 
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They found that M3G was stable at room temperature for 4 weeks and that 
analytes were stable in the dark for at least 181 days.  BUP and its 
metabolites were stable in human plasma and urine for 119 and 85 days 
respectively at -20 oC 250, but were stable for only a short time at 4 oC  or at 
room temperature 256. Dawson et al 252 reported that oxycodone was stable for 
24hrs at room temperature in an autosampler. Hydromorphone and its 
glucuronide were found stable during storage, sample extraction and 
chromatography 235. Codeine and its glucuronide were found stable in urine 
for a short time 159 and codeine alone was stable for more than seven months 
in frozen plasma 205. 
In the present study, from the results listed in Table 5-7, analytes of interest 
were subjected to different stability experiments as the stability of some 
analytes has not previously been studied in human whole blood, such as 
NAL3G, DHC6G, DHM3G, and DHM6G. Analytes of interest were stable after 
being subjected to four freeze-thaw cycles.   
Concentration variations after 48 hours and after a week of storage in the 
auto-sampler were less than ± 10% which were within the acceptable limits of 
the validation procedure ±20% 46,53. 6-MAM was stable after 4 hours storage at 
room temperature but decreased by 21% after 24 hours at room temperature.  
Similarly, 6-AC was stable for 4 hours at room temperature but decreased by 
63% after 24 hours.  
Long-term stability studies were performed at two different storage 
temperatures used routinely in the forensic toxicology laboratory, 4 oC and      
-20oC, to assess the stability of analytes of interest. In general, opioids and 
their metabolites were stable for the whole period of this stability study 
(Table 5-7). However, the concentration of 6-AC sharply decreased by 56% 
after 24hrs at 4oC and by more than 77% after 48 hrs. 6-MAM was stable up to 
24 hours at 4oC but decreased by 15% after 48 hours and continued decreasing 
over time by more than 30 % within the week of the stability study. 
Concentration changes with other analytes were less than ± 10% which was 
within the acceptable limits of the validation procedure. MOR and COD 
concentrations increased after storage for 24 hours at 4 oC by 8 and 9% 
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Table 5-7: Stability studies (% relative to starting concentration). 
 Storage 
Conditions 
Room Temperature Auto-sampler 
 
Freeze-
thaw 
Freeze at -20 0C Refrigerate at 4 0C 
Analytes 4 hours 24 hours 48 hours week 4 cycles 24 hours 48 hours week Month 24 hours 48 hours week Month 
MOR 104 * 144 100 98 98 99 102 106 103 108 128 140 145 
M3G 105 108 104 108 111 94 103 108 104 101 104 106 103 
M6G 97 105 101 98 105 109 102 107 102 98 108 103 97 
6-MAM 102 79 99 100 102 104 101 102 108 98 85 67 67 
NMOR 109 110 101 99 98 109 101 107 101 107 105 103 95 
COD 109 142 100 104 98 105 109 105 107 109 130 136 148 
C6G 98 106 102 103 96 105 99 103 103 105 104 109 104 
NCOD 111 110 102 93 96 106 98 99 105 106 103 105 108 
6-AC 100 37 100 106 103 105 110 92 97 72 44 22 22 
HMOR 105 104 100 105 96 108 105 105 104 105 95 105 109 
H3G 105 150 103 95 104 102 95 104 103 104 95 105 95 
DHC 107 100 101 106 99 103 105 99 102 101 104 109 99 
DHC6G 92 92 104 93 100 95 99 102 105 99 93 101 98 
DHM 102 104 100 107 99 99 104 96 109 98 101 102 98 
DHM3G 99 95 102 99 100 105 102 96 97 98 105 92 95 
DHM6G 97 110 101 102 102 100 97 94 109 95 104 109 113 
BUP 99 103 99 104 100 101 104 100 99 106 109 103 93 
BUP3G 94 105 102 106 99 99 98 100 102 94 108 109 100 
NBUP 104 102 100 108 104 105 104 105 110 106 105 102 108 
NBUP3G 96 109 96 94 91 98 105 97 99 104 106 108 95 
NALOX 108 103 95 99 92 99 117 97 104 100 101 107 106 
NALOX3G 97 108 104 90 108 107 112 101 103 109 107 96 99 
OXY 109 110 103 105 105 103 105 106 111 109 107 107 103 
OXYM 105 106 101 106 99 110 103 99 97 108 99 106 97 
*
 Mean % (n=3). 
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respectively and increased by 45% and 48%, respectively, after one month of 
storage as a result of the hydrolysis of 6-MAM and 6-AC to MOR and COD 
respectively. Increases in MOR and codeine concentrations after 24 hours at 
room temperature were similar to those observed after one month at 4 oC. 
5.4.5 Case samples 
The method was employed for the quantitative determination of opioids and 
their metabolites in thirty-two post-mortem blood samples (Table 5-8).  
Seventeen cases tested positive for morphine, codeine, M3G, M6G and C6G.  
6-MAM was found in seven of these cases and NCOD was detected in six of 
these cases. 
5.4.5.1 Heroin cases 
Eleven cases (3, 5, 7, 13, 15, 17, 19, 22, 29, 30 and 31) showed of the 
presence of free morphine at concentrations ranging from 116 to 799 ng/mL. 
In addition, M3G and M6G were present at concentrations ranging from 5 to 
2477 and 5 to 175 ng/mL, respectively. NMOR was found in all of these cases 
with the exception of 31, which had a high concentration of 6-MAM and a low 
concentration of morphine glucuronide, suggesting that death occurred 
shortly after heroin was administered and before morphine was demethylated 
to NMOR (Figure 5-3).  
Total morphine (TMOR) to total codeine (TCOD) ratios were calculated to 
determine which opioid had been used (Table 5-9). The ratios were in the 
range 12 to 70, suggesting that heroin had been used by the deceased and 
that the codeine detected resulted from acetylcodeine present in the street 
drug 202,257-260. Heroin use could be confirmed in seven of these cases because 
of the presence of 6-MAM. Figure 5-4 shows a chromatogram of 6-MAM in 
heron related fatalities case detected in the current work. 
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 Figure 5-3: Morphine and its metabolites detected in heroin related 
fatalities. 
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   Table 5-8: Concentrations of opioids and their metabolites (ng/mL) in autopsy blood from 31 cases. 
Analytes  * MOR  6-MAM M3G M6G NMOR COD NCOD C6G DHC DHC6G DHM DHM3G DHM6G 
Serial no. Measured concentration (ng/mL) each samples has been analysed in duplicate 
1 N.D * N.D N.D N.D N.D N.D N.D N.D 225 66 2 5 N.D 
2 N.D N.D N.D N.D N.D N.D N.D N.D 420 1862 21 122 10 
3 799 1 208 13 2 68 N.D 13 N.D N.D N.D N.D N.D 
4 N.D N.D N.D N.D N.D N.D N.D N.D 2132 383 15 14 Trace  
5 418 N.D 4.91 6 Trace # 33 1.5 Trace  N.D N.D N.D N.D N.D 
6 N.D N.D N.D N.D N.D N.D N.D N.D 840 147 100 65 9 
7 346 1 319 34 Trace 29 N.D 5 N.D N.D N.D N.D N.D 
8 N.D N.D N.D N.D N.D N.D N.D N.D 1641 5364 1 4 N.D 
9 N.D N.D N.D N.D N.D N.D N.D N.D 42 105 2 8 N.D 
10 N.D N.D N.D N.D N.D N.D N.D N.D 518 19 44 28 trace 
11 162 N.D 874 69 84 724 Trace  496 N.D N.D N.D N.D N.D 
12 N.D N.D N.D N.D N.D N.D N.D N.D 70 18 N.D. 3 N.D 
13 559 3 490 56 Trace  36 N.D 11 N.D N.D N.D N.D N.D 
14 26 N.D 427 31 94 520 51 38145 N.D N.D N.D N.D N.D 
15 568 1 175 8 1 33 N.D 4 N.D N.D N.D N.D N.D 
16 N.D N.D N.D N.D N.D N.D N.D N.D 2882 1997 94 63 15 
17 116 N.D 1966 122 3 9 N.D 86 N.D N.D N.D N.D N.D 
18 14 N.D 206 15 Trace 2 N.D 8 N.D N.D N.D N.D N.D 
19 406 Trace  704 19 18 7 N.D 7 N.D N.D N.D N.D N.D 
20 N.D N.D N.D N.D N.D N.D N.D N.D 157 76 8 7 N.D 
21 N.D N.D N.D N.D N.D N.D N.D N.D 2013 654 5 2 3 
22 196 N.D 2476 175 5 20 N.D 118 N.D. 3 N.D. 16 6 
23 N.D N.D N.D N.D N.D N.D N.D N.D 248000 260177 25 1493 482 
24 N.D N.D N.D N.D N.D N.D N.D N.D 3735 821 18 12 4 
25 161 N.D 201 21 144 848 145 493 N.D N.D N.D N.D N.D 
26 129 N.D 859 54 127 20000 2596 5306 N.D N.D N.D N.D N.D 
27 25 N.D 33 5 19 296 42 275 N.D N.D N.D N.D N.D 
28 Trace  Trace 2 2 Trace  88 5 21 1 N.D 6 1 trace 
29 788 4 1920 161 5 90 N.D 19 N.D N.D N.D N.D N.D 
30 417 3 216 20 Trace  35 N.D 7 N.D N.D N.D N.D N.D 
31 369 87 82 5 0 34 N.D 4 N.D N.D N.D N.D N.D 
*
 N.D: not detected;  
#
 Trace: < LLOQ 
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Determination of the type of death (immediate or delayed) and survival time 
after last injection have been investigated in several previous studies 
125,162,163,165,166,177,261.  The concentration of free morphine alone has been used 
to interpret the survival time: free morphine concentrations ranging from 100-
930 ng/mL indicate a short survival time, whereas concentrations less than 60 
ng/mL was determined three days after the last injection in one case 162.  
Staub et al 163 used the concentration of free morphine as a percentage of 
total morphine in blood, and suggested that a percentage higher than 53% 
indicated rapid death, and less than 35% indicated a delayed death . Spiehler 
and Brown 166 reported an average percentage ratio of 68% in rapid deaths . 
However, the use of free morphine to interpret the cause of death has also 
been found to be unreliable because free morphine was negative in some 
heroin-related deaths 125,150,152.  In the last twenty years, the concentrations 
of morphine metabolites in blood have been used in conjunction with free 
morphine concentration to assess the survival time 125,177,248,261. Deaths 
attributed to heroin use were classified into three types using the 
concentration of free morphine and its glucuronides (in blood: immediate 
death, sub-acute death (death in less than 3h), and delayed death (death 
after 3h) 125.   
Figure 5-4: 6-MAM detected in heroin related deaths. 
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In the present study, the latter method was used for eleven cases attributed 
to heroin use. Cases 3, 13, 15 and 31 were classed as immediate deaths, i.e. 
free morphine was higher than 500 ng/mL, 6-MAM was detected and the 
percentages of free morphine to total morphine were 78, 75 and 80%, 
respectively. Three cases (5, 7, and 30) were classed as sub-acute deaths.  In 
these cases the free morphine concentration was less than 500 ng/mL, the 
ratios of free morphine to morphine glucuronides and free morphine plus 
morphine-6-glucuronide to morphine-3-glucuronide were higher than 1, and 
the total morphine was less than 1000 ng/mL. The percentages of free 
morphine to total morphine were 97, 49, 51 and 64%, respectively. Cases 17, 
19, 22 and 29 were classified as delayed deaths. These showed concentrations 
of free morphine of less than 200 ng/mL with the exception of 19 and 29 
which showed high concentrations of free morphine, 406 and 788 ng/mL 
respectively. The ratios of free morphine to morphine glucuronides and free 
morphine plus morphine-6-glucuronide to morphine-3-glucuronide were less 
than 1. Total morphine was higher than 1000 ng/mL, and the percentages of 
free morphine to total morphine were 5, 35, 7, and 27%, respectively. 
5.4.5.2 Codeine cases 
Codeine and its main metabolite C6G were found in each of these eleven 
cases with concentrations ranging from 7 to 90 and trace levels to 118 ng/mL, 
respectively. Six cases (11, 14, 25, 26, 27 and 28) were attributed to the use 
of codeine because of the presence of NCOD, which is considered a codeine 
marker and because the TMOR/TCOD ratio was less than 1 in all of these cases 
(Table 5-10). Also, the concentrations of NMOR found in codeine cases (2 to 
144 ng/mL) were generally higher than those in heroin cases (trace level to 18 
ng/mL). Figure 5-5, shows norcodeine, codeine glucuronide and codeine in 
codeine positive case sample. 
Codeine was found at concentrations within the therapeutic range in cases 27 
and 28 and at concentrations higher than the therapeutic level in cases 11 and 
25. Codeine overdose was determined in cases 14 and 26. Free codeine was 
less than 1000 ng/mL in case 14 but case 26 which had a free codeine 
concentration estimated at 20,000 ng/mL. Total codeine was found to be 
higher than 1000 ng/mL in cases 11, 14, 25 and 26; and less than 1000 ng/mL
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Table 5-9: Ratios of morphine and its glucuronide total morphine to total codeine, and free morphine to free codeine in post-
mortem blood in 11 heroin cases. 
Serial no Mode of 
deaths § 
M3G / 
MOR 
M6G  
/MOR 
M3G/ 
M6G 
TMOR # 
(ng/mL) 
FMOR */ 
CONJ  
MOR ** 
FMOR+ 
M6G/M3G 
MOR/ 
TMOR 
TCOD## 
(ng/mL) 
TMOR/ 
TCOD 
FMOR/ 
FCOD & 
3 A 0.26 0.016 15.98 1022.61 3.60 3.89 78.11 80.82 12.63 11.78 
5 SA 0.01 0.02 0.77 431.47 36.99 86.51 96.96 34.89 12.37 12.57 
7 SA 0.92 0.10 9.31 700.86 0.98 1.19 49.41 33.49 20.93 11.98 
13 A 0.87 0.10 8.78 1105.63 1.02 1.25 50.52 47.67 23.19 15.36 
15 A 0.31 0.01 22.3 753.09 3.09 3.28 75.48 36.72 20.51 17.48 
17 P 16.89 1.05 16.11 2208.26 0.06 0.12 5.28 95.3 23.17 12.40 
19 P 1.74 0.04 36.21 1148.04 0.56 0.60 35.36 16.38 70.09 59.97 
22 P 12.61 0.90 14.12 2853.48 0.07 0.15 6.89 138.58 20.59 9.59 
29 P 2.44 0.20 11.9 2874.72 0.38 0.49 27.42 108.59 26.47 8.8 
30 SA 0.52 0.05 11.01 654.66 1.77 2.02 63.75 42.57 15.38 11.89 
31 A 0.22 0.01 18.01 456.3 4.25 4.54 80.96 37.86 12.05 10.81 
# TMOR: Total morphine; * FMOR: Free morphine, ** CONJ MOR: morphine conjugates; ## TCOD: Total codeine; & FCOD: Free Codeine.  
§
 (A) acute death, (SA) Sub-acute and Prolonged (P). 
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in cases 27 and 28. In case 14 the concentration of free codeine alone would 
not give an accurate interpretation as this case showed a C6G concentration  
 
Figure 5-5: Codeine metabolites (norcodeine, codeine glucuronide and 
codeine) detected in real case samples. 
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Table 5-10: Ratios of morphine, codeine and their metabolites in post-mortem blood from 6 codeine cases. 
Serial no M3G / 
MOR  
M6G/ 
MOR 
M3G/ 
M6G  
TMOR #  
(ìg/mL) 
FMOR */ 
CONJ MOR ** 
FMOR+ 
M6G/ 
M3G 
MOR/ 
TMOR 
TCOD ## 
(ìg/mL) 
TMOR/ 
TCOD 
TCOD/ 
TMOR 
FCOD & 
/TCOD 
% 
FMOR 
/FCOD 
11 5.38 0.43 12.60 1.19 0.17 0.26 13.63 1.22 0.97 1.03 59.32 22.40 
14 16.24 1.17 13.90 0.58 0.06 0.13 4.55 4.39 0.13 7.59 11.86 5.05 
25 1.25 0.14 9.48 0.53 0.72 0.90 30.47 1.49 0.35 2.82 57.08 18.94 
26 6.67 0.42 16.05 1.17 0.14 0.21 11.03 27.89 0.04 23.88 71.66 0.64 
27 1.34 0.23 6.06 0.08 0.64 0.91 30.02 0.61 0.13 7.44 48.30 8.36 
28 3.27 3.04 1.08 0.01 0.16 1.23 8.89 0.11 0.06 18.13 76.96 0.64 
AVE 5.69 0.90 9.86 0.59 0.32 0.61 16.43 5.95 0.28 10.15 54.2 9.34 
# TMOR: Total morphine; * FMOR: Free morphine, ** CONJ MOR: Morphine conjugates; ## TCOD: Total codeine; & FCOD: Free Codeine.  
§
 A: Acute death; SA: Sub-acute; P: Prolonged. 
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six times higher than that of free codeine. The total codeine concentration is 
in the toxic range, suggesting an overdose of codeine with a long survival 
time, see Table 5-10. The ratios of total morphine to total codeine were less 
than 1 in all codeine cases. The concentration of free morphine relative to 
free codeine was less than 10 % in these cases with the exception of cases 11 
and 25, in which it was 22 and 19 % respectively. It has been reported that 
free morphine was found in serum after a single oral codeine dose at a 
concentration of more than 10% relative to free codeine 262.  
5.4.5.3 Dihydrocodeine cases 
DHC was detected in fourteen cases (1, 2, 4, 6, 8, 9-10, 12, 16, 20-21, 23, 24 
and 28, Tables 5-8 and 5-11). DHM3G, DHM and DHC6G were also found in 
each case except cases 12 and 28 which were found negative for DHM and 
DHC6G, respectively. DHM6G was found to be negative in five cases (1, 8, 9, 
12 and 20). Total DHC to DHM ratios ranged from 6 to 1319, with an average 
of 159, which was due to the high concentration of DHC determined compared 
to DHM and its glucuronide in all cases. 
The concentrations of total DHC (parent drug and its 6-glucuronide) in six 
cases (2, 4, 8, 16, 21, 23 and 24) were higher than 2000 ng/mL (average 5855 
ng/mL) which are high concentrations that would have caused death, 
especially in those who have no tolerance to the drug 212. Deaths attributed to 
DHC overdose were reported in the literature with DHC concentrations of 800 
ng/mL or higher 196. In contrast, the concentration of total DHC in four cases 
(1, 9, 12, and 20) was within the therapeutic range. Case 10 showed a DHC 
concentration of 518 ng/mL and total DHC of 537 ng/mL.  These 
concentrations were higher than the usual therapeutic level.  
DHC6G is the main metabolite of DHC and the ratio of DHC to its glucuronide 
can be used to estimate the elapsed time after drug ingestion 212. The 
concentration of DHC was higher than DHC6G in five cases (4, 6, 16, 21, and 
24) which indicates a short survival time after ingestion. In contrast, cases 2 
and 8 showed DHC6G concentrations exceeding that of the parent drug, 
indicating a longer survival time. DHM and its glucuronide were detected in 
the present study, but at lower concentrations than those reported in 
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Table 5-11: Ratios of DHC and its metabolites in autopsy blood from 13 DHC cases. 
 Serial no DHC TDHC  
(ìg/mL) 
TDHM  
(ng/mL) 
TDHC/ 
TDHM 
DHC/ 
DHC6G  
DHM3 / 
DHM  
DHM6 / 
DHM 
DHM6/ 
DHM3 
FDHM  
/DHMG  
1 222.3 0.29 6.70 44.00 3.40 2.30 n.d. # n.d. 0.40 
2 420.1 2.28 143.00 16.00 0.20 5.80 0.47 0.08 0.20 
4 2132.4 2.52 30.00 85.00 5.60 0.90 0.04 0.05 1.00 
6 840.3 0.99 166.00 6.00 5.70 0.70 0.09 0.14 1.40 
8 1640.8 7.00 5.00 1319.00 0.30 4.30 n.d. n.d. 0.20 
9 42.2 0.15 10.00 14.9.00 0.40 5.20 n.d. n.d 0.20 
10 518.3 0.54 72.00 7.5.00 27.00 0.60 0.02 0.03 1.50 
12 70.0 0.09 2.90 31.00 3.90 n.d. n.d. n.d. n.d. 
16 2881.8 4.88 156.00 31.00 1.40 0.70 0.15 0.23 1.20 
20 156.8 0.23 15.00 15.00 2.10 0.90 n.d. n.d. 1.20 
21 2013.2 2.67 6.00 416.00 3.10 0.40 0.72 2.06 0.90 
23 248000.0 123.63 694.00 178.00 1.00 2.70 0.74 0.28 0.30 
24 3735.4 4.56 30.00 150.00 4.60 0.70 0.20 0.29 1.20 
#  n.d.: Not detected. 
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Figure 5-6: Case samples positive for DHC metabolites apart 
from DHM-6-G which was not detected. 
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previous studies 24,212, and DHM6G was not detected at all in some cases, see 
Figure 5-6. This may be due to differences in DHC metabolism between 
extensive and poor metabolisers. The highest concentrations of DHM 
glucuronides detected in the present study were 1490 ng/mL and 482 ng/mL 
for DHM3G and DHM6G respectively, in the presence of high concentrations of 
DHC and its glucuronide. These results are in agreement with previous studies 
in concluding that the detection of DHC metabolites is a reliable tool for an 
accurate interpretation of the role of DHC in causing death, especially when 
the parent drug is found at a low concentration. Refer to Table 5-11. 
5.4.5.4 Poly-drug intoxication 
Overdose has been considered the most important cause of death of heroin 
users. However, polypharmacy has sharply increased the risk of acute 
respiratory depression due to additive drug interactions 127,151,158,263.  Other 
drugs that could cause respiratory depression are frequently detected in 
opioid fatalities, such as ethanol and benzodiazepines. In this study other 
drugs that could interact with opioids were investigated to provide an 
accurate interpretation of the cause of death (Table 5-12).   
Ethanol was detected in 47% of these cases with a concentration range from 
12 to 245 mg/100 mL. Diazepam metabolites were present in 62% of these 
cases. Cocaine was found with its metabolites benzoylecgonine in case 5, and 
benzoylecgonine alone was found in case 19. Chlordiazepoxide was detected 
in cases 4 and 31 at concentrations within the therapeutic range. A low 
concentration of 11-nor-Ä-9-tetrahydrocannabinol-9-carboxylic acid (0.022 
ìg/mL) was found in case 16. Paracetamol was detected in 31% of these 
cases, with concentrations ranging from 3.4 to 278 mg/mL. An overdose level 
of chlorpromazine (0.73 ìg/mL) was observed in case 26, which also found 
overdose levels of codeine and paracetamol and a high concentration of 
Mirtazapine (0.81 mg/mL).  
Ethanol is the most frequently detected drug in heroin fatalities 150,151,264-268, 
in up to one third of cases 125. Ruttenber et al 266 determined total morphine 
(TM) in many cases and reported that a low concentration of TM was detected 
in cases that had a blood alcohol concentration (BAC) greater than 100 mg/ 
 90 
100 mL. Leven et al 150 investigated the role of ethanol in heroin deaths and 
found that alcohol at a concentration of less than 100 mg/100mL may 
contribute to heroin deaths. The authors observed that morphine 
concentration increased significantly when the BAC was between 200 mg/100 
mL and 290 mg/100 mL.  They stressed that when the BAC exceeds 300 
mg/100mL, ethanol is main cause of death and the effect of morphine is a 
minor factor. Polettini et al 264 compared two groups which had morphine and 
alcohol in their blood: a low-ethanol group (LE) with BAC ≤ 100 mg/100mL, 
and a high ethanol group (HE) with BAC ≥ 100 mg/100mL. The authors found 
that the concentrations of heroin metabolites were lower in the HE group. 
Another study found that the mean morphine concentration remains 
unchanged if the BAC is less than 200 mg/100 mL 150.  
Three mechanisms have been suggested for the role of ethanol in heroin 
deaths. Many studies concluded that alcohol has an inhibitory effect on the 
phase II metabolism of morphine, thus increasing the level of free morphine in 
blood and reaching the brain. Another explanation is that the high BAC 
combined with morphine would have an additional depressant action on the 
central nervous system and then more acute deaths would occur due to the 
combined effects of these two substances. In addition, it has been suggested 
that alcohol may also inhibit the hydrolysis of 6-MAM to morphine, and 
indirectly the biotransformation of morphine would also be inhibited. The 
excretion of free morphine and total morphine would be also reduced 
150,264,265. 
In the present study, alcohol was detected in eight out of eleven cases that 
were attributed to heroin use. Cases 3, 7, 13, 15, 30, and 31 were classified  
as HE as they had a BAC above 100 mg/100 mL and  cases 5 and 29 were 
classified as LE with a BAC of less than 100 mg/ 100 mL. The average free 
morphine in LE cases was found to be slightly higher than in the HE group. 
However, the average TMOR was 782 and 1652 ng/mL for HE and LE, 
respectively. Morphine alone was detected in case five and no glucuronides 
were observed. In contrast, case 29 had high concentrations of morphine 
metabolites. In the HE group, free morphine to total morphine percentages 
ranged from 49 to 81%.  In this study, 6-MAM was detected in heroin deaths in 
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 Table 5-12: Other drugs detected in cases investigated in this study (ìg/mL). 
Serial no. Methadone Paracetamol Cocaine Benzoyl 
ecogonine 
Alcohol 
(mg/100mL) 
Chlorodiaz- 
epoxide 
Mirtazapne Amitriptyline Nortriptyline Fluoxetine Norfluoxetine 
1 #    14       
2  14.9          
3 0.18    124       
4 0.58     0.39 0.18     
5   0.01 0.42 42       
6            
7     138  0.08     
8  25.4      0.65 0.11   
9  3.4          
10            
11  41.4   58       
12 0.38    182       
13     210       
14  72          
15     180       
16        0.15    
17 0.12           
18 0.89       12.5 0.5   
19 0.32   0.06    0.16    
20 0.21           
21  129   12   0.9 0.12 0.64 0.19 
22            
23     71   0.3 0.03   
24     236       
25  220          
26  278     0.81     
27  48          
28 0.52 28   139       
29     33       
30     160       
31     245 1.63    0.09 0.14 
32            
#
 Negative. 
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the HE group, and survival times after last injection were shorter than in the 
LE group. The ranges of free morphine concentrations in both groups 
overlapped, indicating that the use of the free morphine concentration alone 
is insufficient to interpret the cause of death.In case 31, low concentrations 
of free morphine and its glucuronides along with the presence of a high 
concentration of 6-MAM perhaps met the criteria of the third mechanism for 
the role of ethanol in heroin deaths proposed by Polettini et al 264. In 
addition, the combination of alcohol, heroin, and chlordiazepoxide in this 
case would have caused enhanced respiratory depression and death probably 
occurred shortly after heroin injection.  
The combination of alcohol and codeine probably increased the risk of toxic 
side effects due to codeine in case 11. Likewise, the combination of alcohol 
and DHC in case 24 is likely to have produced enhanced sedation and 
respiratory depression 132,212.    
Methadone was detected in cases 3, 4, 12, 17, 18 19, 20 and 28 with 
concentrations ranging from 120 to 890 ng/mL; the average methadone 
concentration in these cases was 400 ng/mL. The overlap of therapeutic and 
toxic concentrations of methadone, as for morphine, makes the inclusion of 
methadone as a cause of death dependent on the circumstances, for example, 
if there is no other identifiable cause of death such as the presence of natural 
disease 125. The concentration of methadone in blood for patients on 
methadone maintenance programmes ranged from 100 to 1000 ng/mL. 
However, in a series of 10 methadone fatalities, the average methadone 
concentration in blood was 1000 ng/mL, and the range of concentrations was 
400 to 1800 ng/mL 132. In one study, methadone was detected in only one 
heroin fatality but was found in 27% of living heroin users 151.  
Methadone was within the therapeutic range in cases 3, 17 and 20 and was 
above the normal range for therapeutic administration, except in high dose 
maintenance therapy, in cases 4 and 18. The combinations of heroin and 
methadone in case 19 and methadone and alcohol in cases 12 and 28, are 
likely to have more potent effects than those for each drug on its own 132.  
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Cocaine is believed to interact with heroin as both are metabolised by 
carboxylesterases. TMOR and FMOR were lower in cocaine positive cases than 
in cocaine negative samples, whereas the FMOR/TMOR ratio was the same in 
both groups. Analysis of data on the role of ethanol in heroin deaths in the 
presence of cocaine showed that the high ethanol group had higher 
FMOR/TMOR ratios lower TMOR concentrations than the low ethanol group 265.  
In the present study, case 5 was positive for morphine (418 ng/mL), cocaine 
(10 ng/mL cocaine and 400 ng/mL benzoylecogonine) and alcohol (42 
mg/100mL).  The ratio of FMOR/TMOR was the highest found in the study 
(Table 5-9). Morphine phase 2 metabolite concentrations were less than 13 
ng/mL. This may indicate that the formation of morphine metabolites was 
inhibited by the presence of alcohol and cocaine or that the survival time was 
short. 
The concentrations of diazepam and its metabolites detected in this study 
were within the therapeutic range in most cases except case 18, which had a 
concentration higher than the usual therapeutic range. Diazepam or its 
metabolites were found in all heroin cases except cases 15 and 17. 
Benzodiazepines were found to increase the CNS depressant action of opioids 
in general 151.   
Paracetamol concentrations detected in this study were within or slightly 
higher than the therapeutic range, except in cases 21, 25 and 26 which had 
overdose levels of paracetamol plus DHC or codeine. In case 25, a high 
concentration of codeine (0.85 ìg/mL) was observed and in this case, the 
cause of death would have been attributed to codeine (respiratory depression) 
rather than paracetamol (220 ìg/mL) (liver damage) 132.    
Other opioid drugs were detected in a few cases, including naloxone and its 
glucuronide (case 14), see Figure 5-7. Buprenorphine and its metabolites were 
detected in case 29, oxycodone was found in case 23, hydromorphone and its 
glucuronide (case 32) with concentrations of 5 and 183 ng/mL, respectively, 
see Figure 5-8. Levels of hydromorphone and its glucuronide were within 
therapeutic range. The detection of multiple opiates in some cases (14, 29 
and 23) illustrated the advantages of the method which has been developed.   
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Figure 5-7: Reconstructed mass chromatograms for naloxone  
and its glucuronide in case 14.  
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Figure 5-8: Reconstructed mass chromatograms for hydromorophone 
and its glucuronide in case 32. 
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5.5 Conclusions 
The LC-MS/MS method developed has been validated for the simultaneous 
determination of 24 opioids in human whole blood, including, for the first 
time in human whole blood, naloxone-3-glucuronide. Although a large number 
of drugs of interest were included in the method, acceptance criteria for 
linearity, precision, and recovery for all analytes were achieved. The method 
was found useful for differentiating between users of heroin and other 
opioids, such as codeine and morphine, and for determining the survival time 
in deaths attributed to heroin use. 
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6 Analysis of Diamorphine and its Metabolites 
in Paediatric Plasma Samples  
6.1 Introduction  
Although diamorphine (DIM) is a widely abused drug around the world, 
pharmaceutically prepared DIM has been used successfully for the treatment 
of diamorphine-dependent patients and for the management of moderate to 
severe pain resulting from surgery or illnesses such as cancer 269,270. DIM is 
more potent and faster acting than its precursor morphine (MOR) and can pass 
the blood-brain barrier easily due to the presence of two acetyl groups in its 
structure, compared to hydroxyl groups in MOR 123. It also produces more 
euphoria and less depression than morphine. The high water solubility of DIM 
hydrochloride allows it to be injected in small volumes 269,271-274.   
DIM metabolite concentrations have been found to be influenced by the route 
of administration 270. Intravenous diamorphine (IVDIM) is considered the gold 
standard route of therapeutic administration due to the rapid delivery of the 
correct quantities of analgesic needed for pain management. However, 
alternative ways of administration are often preferred by recreational users. 
Smoking and intranasal administration (snorting) of diamorphine are less 
efficient than IVDIM but offer many advantages such as being needle free, 
leaving no external marks on the users body, being inexpensive and reducing 
HIV infection resulting from needle sharing amongst users 129,144,270.  
Clinically, the intranasal route of DIM administration provides as much 
effective analgesia as the intramuscular route, with fewer side effects 
compared to intravenous administration 270,275. It has been found to be well 
tolerated with an acceptable safety profile. High concentrations of DIM 
hydrochloride can be dissolved in small volumes of water (0.1 mL) and then 
dropped into the nasal cavity. It has been reported that the potency of 
intranasal DIM is reduced due to swallowing of DIM from the nasal cavity. DIM 
is more likely to be hydrolysed, its administration half-life is reduced to 5 min 
and it has lower bioavailability when compared to the intravenous route of 
administration 270,275.   
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Children are often exposed to accidents after which admission to hospital is 
required, including childhood fractures which result in severe pain and which 
account for 20/1000 of the population/year 276. There are still problems 
encountered in providing immediate pain relief due to limitations in the 
therapeutic armoury and to problems in route of administration and 
communication 277. Routes of administration using needles i.e. intravenous 
and intramuscular have been found to cause distress and pain In children. In 
addition, oral administration produces less efficient analgesia and rectal 
administration is not preferable for patients because of difficulty in obtaining 
consent 270,274.  
In recent years intranasal DIM (INDIM) has been recommended as an 
alternative to intravenous administration for the treatment of severe acute 
pain in children. This provides a less traumatic means of administering rapid 
powerful analgesia to children, in whom obtaining intravenous access may be 
technically difficult and distressing, without decreasing the effectiveness of 
the analgesic properties. In addition, lower side effects have been reported 
270,274,275,278.  
Questions must be answered with rewpect to each new medicine for pain 
relief regarding the potential risks and benefits of its use. However, the 
degree of efficiency of DIM analgesia for children is rarely addressed by 
scientific studies and much of the evidence and expertise comes from studies 
in adults.  
The efficiency of INDIM has been compared with intramuscular MOR (IM-MOR) 
and it was found that 0.1 mg/kg of INDIM is as efficient as 0.2 mg/kg of IM-
MOR in children aged 3-16 years with clinically diagnosed limb fractures. In 
that study the unwanted side effects of MOR were not observed with INDIM 
277. INDIM and IM-MOR were compared in these children using pain scores. 
Although both administration routes were found effective and to have 
expedient pain reduction, lower pain scores were achieved with INDIM at 5, 
10, and 20 minutes. Also, INDIM was found to provide quicker pain relief than 
IM-MOR. INDIM was considered to be much safer and was preferred by patients 
and staff as it was needle free. An INDIM spray was recommended as an 
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alternative to IM-MOR for pain relief in children and teenagers who were 
diagnosed with clinical fractures 274.  
Hallett et al 279 reported on the acceptability and effective self-
administration of INDIM, which was found to produce sufficient analgesia for 
postoperative pain management. They recommended further investigation 
into INDIM analgesia. Pharmacokinetic data was not reported but the results 
were based on questionnaires completed by both patients and nurses. The 
efficacies of IVDIM and INDIM were compared during the early postoperative 
period in 52 subjects (26 patients for each group). Pain scores recorded after 
IVDIM were significantly higher than in the INDIM patients and no side effects 
were observed with INDIM compared to IVDIM, which caused a higher 
incidence of vomiting. The authors indicated that the lack of side effects was 
due to the estimated 50% lower bioavailability, which was a consequence of 
higher body weights or else difficulties in operating the INDIM delivery device 
properly, resulting in a decrease in analgesia and associated side effects 275.          
6.2 Diamorphine metabolites and analgesia   
DIM is known to act as a pro-drug and to achieve its analgesia via its active 
metabolites due to its short half-life 5,75,270,280,281. In fact, DIM and its major 
metabolite morphine-3-glucuronide (M3G) have been found to lack affinity for 
opioid receptors. However, M3G has been reported to have CNS stimulatory 
effects and to contribute to the side effects of morphine 2,76,282. In contrast, 
6-monoacetylmorphine (6-MAM), MOR and morphine-6-glucuronide (M6G) bind 
to opioid receptors and are considered to be active DIM metabolites 283.  
Although the plasma half-life of 6-MAM is also short, it is longer than that of 
DIM 75. It is believed that the initial analgesic effects of DIM depend on the 
efficacy of 6-MAM 270,280,281. The fast degradation of DIM to 6-MAM produces a 
metabolite with increased affinity for opioid receptors 280,281.  6-MAM is 
metabolised to MOR, which is also an active metabolite of DIM and which 
reaches its peak concentration shortly after DIM intravenous injection 
together with DIM and 6-MAM.  MOR has been fully studied and it is considered 
to be one of the most effective drugs used for pain management in illness or 
disease, especially cancer 76,282.  Respiratory depression, nausea and vomiting 
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are the most common adverse effects associated with use of MOR for 
treatment 271,282. 
MOR is mostly metabolised via glucuronidation to morphine-3-glucuronide and 
less than 10% is metabolised to morphine-6-glucuronide (M6G) 141. The 
analgesic effect of M6G is equal to or more potent than MOR itself, with fewer 
side effects due to its high affinity for opioid receptors 2,282,284-286 and M6G has 
been found to be more efficient than MOR in the treatment of postoperative 
pain. However, M6G crosses the blood-brain barrier much more slowly than 
MOR and with difficulty, and so its analgesic effect is delayed compared to 
DIM or MOR 285-287. Because of this, it has been suggested that M6G is 
responsible for the late stages of diamorphine impairment in drivers 288.  
On the other hand, the role of M6G in DIM intoxication in a subject with renal 
failure or with chronic diamorphine abuse is known 125,126,132,148,165,289-294. 
Severe side effects of M6G in patients with renal failure refer to the reduction 
of its metabolism and elimination leading to accumulation in the tissues which 
is a result of acidosis and changes in plasma protein binding 283,295. 
Furthermore, only a short space of time (10 minutes) is required for M6G to 
reach the brain compared to that of normal patients 282,296.  
MOR is also known to metabolise to normorphine (NMOR), accounting for 
approximately 5% of MOR 132. However, NMOR was not detected in any of the 
published DIM pharmacokinetics studies. Also, the concentration of NMOR was 
found to be much higher in codeine cases than heroin cases and this is 
explored further in Chapter 5. The detection of NMOR may be dependent on 
the route of administration as codeine is usually ingested orally and heroin is 
usually injected and NMOR is likely to form after oral administration 248,283,297. 
NMOR is a secondary codeine metabolite produced by N-demethylation of 
norcodeine after codeine administration 298.  
In conclusion, DIM and all of its metabolites should be determined in 
pharmacokinetic studies owing to their contributions to DIM analgesia and 
toxicity 75. Re-evaluation of studies of the role of morphine glucuronides in 
clinical analgesia and their contribution to side effects after DIM or MOR 
intake has been suggested 283. 
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6.3 Aims 
IVDIM is the gold standard and the method of choice for pain relief. Many 
clinicians believe that IVDIM delivers more rapid and effective analgesia than 
INDIM but no scientific evidence has been reported 276. Although both IVDIM 
and INDIM have been used in the UK for many years for pain relief following 
fracture accidents in children 273, no direct comparison has yet been made of 
their pharmacokinetic profiles in children. Pharmacokinetic data after IVDIM 
administration in children is available but DIM concentrations have not been 
reported and no pharmacokinetic data is available after INDIM administration 
in children.  
A sensitive technique for the detection and quantification of DIM and its 
metabolites is essential due to the low concentrations of DIM and metabolites 
in childrens plasma, which is a result of the low dose of DIM given and the 
limited sample volume obtained from children (0.2 mL or less). In addition, 
DIM can be easily hydrolysed to 6-MAM during sample preparation and 
extraction, so this must be considered when developing a solid-phase 
extraction method to prevent the hydrolysis of DIM.  
The initial aim of this work was to develop and validate a method for the 
determination of DIM and its metabolites, namely 6-MAM, MOR, M3G, M6G and 
NMOR in human plasma. Previous methods for the detection of DIM and its 
metabolites were reviewed for better understanding of the chromatographic 
behaviour of the analytes of interest. The second part of this study was aimed 
at obtaining pharmacokinetic data for DIM and its metabolites in children 
following intravenous and intranasal administration in a blind study. Since DIM 
is known to act as a pro-drug and to achieve analgesia via its metabolites, it 
was intended that the concentrations of active DIM metabolites would be used 
to evaluate whether or not INDIM can deliver rapid and efficient analgesia in 
children comparable to that obtained with IVDIM.  
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6.4 Review of previous analytical methods for the 
determination of diamorphine 
Many analytical methods have been described and used in forensic and clinical 
toxicology for the quantification of DIM but have not yet been reviewed. As 
methods for the quantification of morphine and its metabolites have been 
reviewed elsewhere 76,101,299, only analytical methods for the quantification of 
DIM are reviewed below. Previous analytical methods for quantification of DIM 
and its metabolites in biological samples are summarised in Table 6-1. 
The high deposition of parent drug in hair compared to metabolites has been 
reported and many applications were published in the early 1990s, including a 
GC-MS method for the determination of DIM in hair by Goldberger et al 300. 
This method was used to differentiate between DIM and other opiate users by 
the presence of DIM and its marker (6-MAM) in hair samples, which are 
difficult to determine in blood, plasma and urine due to the short half-life of 
both metabolites. Liquid-liquid extraction was efficient for isolating DIM, 6-
MAM and MOR from hair samples with recoveries ranging from 55-75%. 
Methanolic hair extracts were diluted with 2 mL of deionised water and 
saturated sodium bicarbonate (pH 8.4). This mixture was extracted using 7 mL 
of (toluene: heptane:isoamyl alcohol 70:20:10 v:v:v). The extracts were then 
derivatised using MBTFA before analysis by GC-MS. The column used was HP-5 
(25 m X 0.32 mm, 0.17µm coating) and the quantification limit of all analytes 
was 5 ng/50 mg hair. This method suffered from interference with the 
diamorphine peak.  
Goldberger et al 301 also reported a method involving SPE and GC-MS for 
detection of the same analytes in blood, plasma, saliva and urine. 
CleanScreen SPE cartridges were used for extraction of analytes with some 
modifications. Acetonitrile was used for preparing standard solutions and as 
an SPE wash solvent instead of methanol to minimise the hydrolysis of DIM to 
6-MAM. The SPE elution solvent was methanol, as commonly used elution 
solvents for CleanScreen (methylene chloride: isopropanol: ammonia) caused 
promotion of diamorphine hydrolysis. In this method there was no interfering 
peak observed with diamorphine. The calibration curves were linear over the 
 103 
Table 6-1: Procedures for quantification of diamorphine and its 
metabolites in biological samples published  between 1991-2009 
Analytes Sample 
types  * 
Extraction SPE ¥ & LLE § 
Chromatography method  
Analytical 
method 
LOD # 
/ LOQ ** 
(ng/mL) 
Ref.    
DIM, 6-MAM 
MOR 
H LLE: 
GCCL&* : HP-5 (25 m X 0.32 mm, 0.17 µm) 
GC-MS ## 5ng/50mg 300 
DIM, 6-MAM 
MOR 
B, P 
U, Sa 
SPE: Clean Screen (ZSDAU020) 
GCCL:  RTx5    (15 m X 25 mm X 5 µm) 
GC-MS ~ 1 ng/mL 301 
DIM , 6-MAM 
MOR , NM  
P, Sa 
U, H 
SPE: Clean Screen (DAU, 200mg) 
GCCL: HP-1 (12 m X 0.2 mm X 0.33 µm) 
GC-MS ~ 1 ng/mL 302 
DIM,  
6-MAM 
MOR 
B 
U 
VH 
LLE: 
GCCL: DB-1 (30 m X 0.32 mm X 0.25 µm) 
GC-MS 10 
50 
100 
303
 
DIM 
6-MAM 
MOR 
M3G  
M6G  
S SPE: Bond Elut (C8, 50 mg)HPCL*#: RP-
C18 column 
(250 X 4 mm; 5 µm) 
GC-MS & 
HPLC- 
Fluorescence 
Detector 
n.d 
n.d 
10 
3 
10 
304
 
DIM 
6-MAM 
MOR 
M3G 
M6G 
NM 
P SPE: ODS C18 
 
HPCL:  Spherisorb C18 ODS-2 column 
(125 X 2 mm; 3 µm) 
HPLC- coupled 
with photo 
diode array 
detector 
25 
25 
25 
25 
25 
25 
305
 
DIM 
6-MAM 
MOR 
M3G 
M6G 
S SPE: C2-substituted silica 
 
HPLC:  Supelco LC-SI 
(250 X 2.1 mm; 5 µm) 
 
LC-APCI-MS 0.5 
4 
4 
1 
4 
178
 
6-MAM 
MOR 
M3G 
M6G 
B 
U 
VH 
CSF 
SPE: Bond Elut C18 (200 mg) 
HPCL:  Ecocart column (125 X 3 mm) 
LC-APCI-MS 0.5 
0.1 
1 
1 
177
 
DIM, 6-MAM 
MOR, NM 
U Direct injection 
HPCL: Synergi Polar RP 
(150 X 2 mm, 4 µm) 
LC-APCI-
MS/MS 
Between 10-
100  
142
 
DIM, 
6-MAM 
MOR 
U SPE: Online switching SPE SCX 
HPCL:  SCX   (150 X 1.5mm ) 
 
LC-ESI-MS & 0.1-3 306 
DIM 
6-MAM 
MOR 
H SPE: Chrombond drug (3 mL, 200 mg) 
GCCL: HP-5MS  (30 m X 0.25 mm X 0.25 
µm) 
GC-MS 0.04 / 0.21 
0.02/0.15 
0.03/0.11 
307
 
DIM, 6-MAM 
MOR, M3G 
M6G 
P SPE: Oasis MCX 
HPCL:  RP Zorbax Bouns column 
(150 X 4.6 mm X 5 µm) 
LC-ESI-
MS/MS && 
Not 
mentioned 
75
 
DIM 
6-MAM 
MOR 
S Direct injection 
HPCL:  Kromasil C18 
(250 X 4 mm, 5 µm) 
HPLC coupled 
with ultraviolet 
detector 
23 & 36 
15 & 28 
11 & 23 
308
 
*
 Sample types: B: Blood;  CSF: Cerebrospinal fluid ; H: Hair; P: Plasma; S: Serum, Sa: Saliva,  U: Urine; VH: 
vitreous humor; #LOD: Limit of detection; ** LOQ: Limit of quantification;  ¥ SPE: solid phase extraction; § LLE: 
liquid-liquid extraction; 
##
 GC-MS: Gas Chromatography-Mass Spectrometry;  & LC-APCI-MS or LC-(ESI)-MS: Liquid chromatography 
coupled with atmospheric pressure chemical ionisation (electrospray ionisation) mass spectrometry, &&  LC-ESI-
MS/MS:  Liquid chromatography coupled with electrospray ionisation tandem mass spectrometry, &* GCCL: Gas 
chromatography column; *# HPCL: Liquid chromatography column. 
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range 1-500 ng/mL for all analytes of interest with correlation coefficients 
greater than 0.995. The limit of detection for all analytes was 1 ng/mL and 
intra- and inter-assay precisions were between 1.1-4.2% and 5.4-8.9%, 
respectively.  This method was applied to clinical samples and was found 
sufficient for the determination of the analytes of interest.  Morphine 
glucuronides were not included in this study and no hydrolysis method was 
involved as this method determined only free morphine. 
Wang et al 302 described a method for the determination of DIM, 6-MAM, MOR 
and NMOR in hair, plasma, saliva and urine. Cocaine metabolites were also 
included in the study. The SPE method of Goldberger et al was used 301 but 
analytes of interest were eluted with methylene chloride: isopropanol: 
ammonia (80:20:2 v:v:v). Analytes were analysed by GC-MS as trimethylsilyl 
derivatives using a fused-silica capillary column (12 m X 0.2 mm X 0.33 µm). 
The method focused on hair analysis and validation parameters were not 
provided for the other biological specimens. DIM and 6-MAM tested positive in 
one urine case sample while other DIM metabolites were detected in all cases. 
In saliva, DIM and 6-MAM were determined and achieved their peak 
concentrations at 10 min. However, the authors did not exclude the presence 
of DIM, 6-MAM and MOR as a result of re-contamination of the oral cavity. 
In 1997, Guillot et al 303 described a procedure for the identification and 
quantification of DIM, 6-MAM and MOR based on liquid-liquid extraction at pH 
9.5, derivatisation at room temperature using propionyl anhydride and ion 
trap GC-MS analysis. Recoveries of analytes of interest were 95% for DIM and 
80% for 6-MAM and MOR. The limits of quantification were 10, 50 and 100 
ng/mL, respectively.  Intra and inter-assay precisions ranged from 5.3-8.1% 
and 5.2-11.6% in blood and urine matrices, respectively. There was a 
significant loss of DIM during the derivatisation process and at temperatures 
higher than 60oC. The acetyl groups of DIM were easily substituted with 
propionyl groups used for the derivatisation procedure. This problem was 
solved by using 4-dimethylaminopyridine as catalyst at room temperature. 
Skopp et al 304 developed an HPLC method coupled with fluorescence 
detection for the quantification of MOR and its glucuronides in serum, 
adapted from previous work reported by Goldberger et al 301. SPE with C8 
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columns was used for extraction of MOR glucuronide. The calibration curves 
were linear over the ranges 5-500 and 15-500 ng/mL for M3G and MOR and 
M6G, respectively. The lower limits of detection were 10, 3 and 10 ng/mL and 
recoveries were 71%, 71% and 62% for MOR, M3G and M6G, respectively. Intra 
and inter-assay precisions were less than 8%.  These methods were applied to 
pharmacokinetic analysis after intranasal and intramuscular DIM 
administration. However, validation data were not reported for DIM and 6-
MAM even though SPE columns were used which were different from those 
reported in the original GC-MS method 15.  
Bourquin et al 305 described an HPLC-DAD method for the simultaneous 
detection of DIM, 6-MAM, MOR, M3G, M6G and NMOR in human plasma. SPE 
with C18 ODS-2 cartridges was applied for extraction of analytes of interest 
using 1.5 mL of plasma diluted with 4.5 mL of 0.5 M carbonate buffer (pH 
9.3). Columns were then washed using 20 mL 0.005 M of carbonate buffer (pH 
9.3) and 0.35 mL of 40% acetonitrile in 0.01 M phosphate buffer (pH 2.1). DIM 
metabolites were eluted with 2 x 0.6 mL of 40% acetonitrile in 0.01 M 
phosphate buffer (pH 2.1). HPLC separation was achieved using a Nucleosil 
C18 ODS column. Recoveries of analytes ranged between 88-98%. Linear 
calibration curves were reported over the range 25-5000 ng/mL with 25 
ng/mL as the LLOQ for DIM and its metabolites. The intra- and inter-assay 
precisions for low, medium and high concentrations of the analytes were less 
than 5%. Plasma samples from pharmacokinetic studies and intoxication cases 
were measured by this method. 
Zuccaro et al 178 developed a normal phase LC-APCI-MS method for the 
quantification of DIM, 6-MAM, MOR, MOR, M3G and M6G in serum. Analytes of 
interest were extracted with C2 SPE cartridges; nalorphine was used as 
internal standard. One millilitre of serum was submitted to SPE which was 
pre-conditioned with one column volume of methanol and deionised water 
and two column volumes of 0.001 M carbonate buffer (pH 9.3). Then, the 
cartridge was washed with one column volume of 0.001 M carbonate buffer 
(pH 9.3) and eluted with one column volume of methanol. DIM and 
metabolites were separated using a Supelcosil LC-Si column (25 cm X 2.1 mm, 
5 µm) and mobile phase consisting of methanol: acetonitrile:water:formic 
acid  (59.8: 5.2: 34.65: 0.35 v:v:v:v). Recoveries of DIM, 6-MAM, MOR, M3G 
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and M6G ranged between 72-74%, 99.5-99.8%, 99-99.2%, 77.2-79.6% and 43-
44.6% and LOQs were 0.5, 4, 4, 1 and 4 ng/mL respectively. Pharmacokinetic 
studies in mice after diamorphine administration were carried out using this 
method.  
Bogusz et al 177 described a reverse phase LC-APCI-MS method for the 
determination of 6-MAM, MOR, M3G and M6G in blood, urine, vitreous humour 
and cerebrospinal fluid. DIM metabolites were extracted using Bond Elut C18 
SPE. One millilitre of plasma was loaded on the SPE column which was washed 
using 0.01 M of ammonium carbonate buffer (pH 9.3). Analytes of interest 
were then eluted with 0.5 mL methanol-0.5 M acetic acid (9:1 v:v). This 
method did not quantify DIM but it has been used for quantification of 
diamorphine in two different pharmacokinetic studies 309,310. Although these 
two studies used LC-ESI-MS for the analysis and a different mobile phase from 
that used by Bogusz et al 177,  no validation data was given. In these studies, 
DIM and its metabolites were separated using a mobile phase consisting of 5 
mmol/L ammonium formate buffer (pH 3), methanol, and acetonitrile309,310, 
whereas, in the method of Bogusz et al 177, separation of DIM metabolites was 
based on 50 mM ammonium formate and acetonitrile. The recoveries of 
analytes of interest ranged from 82-89%. Calibration curves were linear over 
the range 5-500 ng/mL and inter-day precision was less than 10%. 
An on-line switching SPE method using SCX cartridges coupled with LC-ESI-MS 
was developed and validated by Katagi et al 306 for the identification of DIM, 
6-MAM and morphine in human urine.  Separation of analytes of interest was 
performed using a Capcell Pak SCX column (150 X 1.5mm, 5 µm) and the 
mobile phase consisted of 10 mM ammonium acetate (pH 6): acetonitrile 
(30:70 v/v) and 30 mM ammonium acetate. The SPE recoveries were 88%, 89% 
and 86% and LODs were 0.1, 0.5 and 3 ng/mL for DIM, 6-MAM and MOR 
respectively. Linear calibration curves were obtained over the concentration 
ranges 1-100 and 10-1000 ng/mL for DIM and 6-MAM and MOR, respectively. 
Urine samples from cases of opioid intoxication were analysed using this 
method.  
Dams et al 142 reported a direct injection method for the determination of 
DIM, 6-MAM, MOR and NMOR using an LC-APCI-MS/MS method. Analytes of 
 107 
interest were separated using a Synergi Polar RP column (150 X 2mm, 4µm) 
and gradient mobile phase with 10 mM of ammonium formate-0.001% formic 
acid (pH 4.5) and acetonitrile. Although good precision and linearity were 
obtained, high LODs and LOQs were reported in the range 10-100 ng/mL, 
which are very high, and no case samples were tested. Correlation 
coefficients greater than 0.99 were obtained over the range 10-10,000, 50-
10,000 and 50-10,000 ng/mL for DIM and 6-MAM, MOR and NMOR, respectively. 
Intra-assay and inter-assay precisions were less than 15.8% and 16%, 
respectively.  
Musshoff et al 307 described a GC-MS method to quantify DIM, 6-MAM and MOR 
in hair. Hair extracts were reconstituted with phosphate buffer (pH 6) and 
loaded on Chromabond SPE cartridges. The columns were then washed using 1 
mL of water and 2 mL 0.01 phosphoric acid. DIM metabolites were eluted with 
2 mL of dichlormethane/propanol/ammonia (80:20:2 v:v:v). GC-MS was 
performed using a HP-5MS fused silica capillary column (30 m X 0.25 mm, 0.25 
µm). Recoveries ranged between 78.8-95.3%, 90.5-96.5% and 92.3-95.1% for 
DIM, 6-MAM and MOR, respectively. LODs and LOQs were determined to be 
0.04, 0.02 and 0.03 and 0.21, 0.15 and 0.11 ng/mL, respectively. Intra-assay 
and inter-assay precisions were less than 9%. Hydrolysis of DIM to 6-MAM and 
to MOR was evaluated and 5% degradation was observed during the extraction.     
Rook et al 75 reported a reverse phase LC-ESI-MS/MS method for the 
simultaneous determination of DIM, 6-MAM, MOR, M3G and M6G in human 
plasma. Acidified plasma was submitted to mixed mode SPE (MCX Oasis), 
which was then washed using acetic acid (pH 3) and eluted using 0.5% 
ammonium acetate in methanol. Samples were kept on ice during the pre-
treatment to minimise the hydrolysis of DIM; also, extracts were collected in 
elution tubes containing 50 mM ammonium acetate buffer (pH 3). In addition, 
samples were evaporated carefully until 250 µl was left before injection into 
the LC-MS/MS instrument.  
Gradient elution was used for the separation of DIM metabolites based on a 
mobile phase consisting of (A) 5 mM ammonium formate adjusted to pH 4 and 
(B) acetonitrile, at a flow rate of 1 mL/min. SPE recoveries ranged between 
79.8-86.6%. Intra-assay and inter-assay precisions were within the acceptable 
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limits and were ≤ 20% at the LLOQ and ≤ 15% for other samples. However, 
LODs and LOQs of analytes of interest were not mentioned.  
Direct injection and micellar liquid chromatography (MLC) with UV detection 
of DIM, 6-MAM and MOR in serum was described by Capella-Peiro et al 308. 
Analytes were separated using a Kromasil C18 coulmn (Scharlab, 250 x 4 mm, 
5 ìm ) at a flow rate of 1 mL/min. Good recoveries of analytes of interest 
were observed at low, medium and high concentrations and ranged between 
97.7-100.3%. Intra-assay and inter-assay precisions were lower than 2% and 3% 
respectively. LODs and LOQs ranged from 11-23 and 23-36 ng/mL respectively. 
Real case samples were tested using this method but only 6-MAM and MOR 
were detected.  
6.5 Review of previous studies of the stability of 
diamorphine 
Stability of analytes during extraction and analysis has been recommended as 
part of full method validation for a more reliable method of quantification 
46,47,53. Stability of DIM was studied in stock solutions, in the auto-sampler and 
during extraction. The stability of DIM in solution and in solid powder was 
studied by Wijesekera et al 311. DIM in both conditions was stored at ambient 
temperature (26 oC) and under refrigerated conditions (6-8 0C). They found a 
great loss of DIM in methanolic solution by 90.8% and 70% of DIM content at 
ambient and refrigerated conditions, respectively. Complete degradation of 
DIM to 6-MAM occurred after 8 weeks of storage at ambient temperature. The 
average percentage of degradation was found to be less than 21% and 17% of 
DIM content with DIM powder in ambient and refrigerated conditions, 
respectively.  
DIM detected in human hair was reported to be stable and <10% degradation 
of DIM to 6-MAM was observed during the extraction 300. Goldberger et al  301 
reported less than 5% degradation of DIM during extraction when acetonitrile 
was used for preparing standard solutions and for SPE wash solvent. Extracts 
were reconstituted in acetonitrile and analysed. DIM, 6-MAM and MOR were 
found stable in the auto-sampler for up to 18 hours.   
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In another study, sodium fluoride was added to samples during collection and 
to SPE buffer. A deuterated internal standard of DIM was spiked in order to 
monitor DIM hydrolysis. Degradation of DIM to 6-MAM was limited to 10% 302. 
DIM, 6-MAM and MOR were found stable for several weeks at room 
temperature after reconstitution with chloroform-0.1% pyridine 303.  
A procedure using C2 SPE cartridges and LC-APCI-MS reported by Zuccaro et al 
178 failed to detect DIM in mice serum despite the low limit of quantification 
obtained in this method. DIM stability was not investigated and could be the 
reason of complete hydrolysis of DIM to 6-MAM. However, an LC-ESI-MS 
method and C8 SPE procedure was successful at detecting DIM in human 
subjects 305.  
In another study, heroin was detected in heroin user urine collected 
immediately after injection 306. Stability of DIM during extraction was not 
studied in this study. Dams et al 142 found DIM unstable after storage at room 
temperature for 24 hours, but degradation of DIM was not observed when 
stored at 4 oC for 24 hours, -20 oC for five days and after being subjected to a 
5 freeze/thaw stability experiment. A slow hydrolysis rate for DIM may be due 
to the acid pH of urine. 
Musshoff et al 307 carried out an auto-sampler stability study on the 
degradation of DIM to 6-MAM and to MOR. Spiked hair samples were extracted 
and analysed after 0, 1, 3, 12, 18, and 24 hours.  No degradation of DIM was 
reported during the storage period at room temperature.  
Direct injection of serum samples by MLC failed to detect DIM in real case 
samples, however, 6-MAM and MOR were detected 308. The period of sample 
collection and sampling was not controlled in this study; therefore, it was not 
surprising that DIM was completely converted to 6-MAM and MOR. Rook et al 75 
reported a full stability study of DIM, 6-MAM, MOR, M3G, and M6G. They found 
analytes of interest stable in a short-time stability test in a water/ice bath for 
60 min. Stability of stock solutions of analytes of interest was investigated 
after storage at 4 0C for 17 days and at -20 0C for 25 months. In addition, long-
term stability was performed using 10 patient plasma samples which were 
stored at  20 0C for 14 months. Analytes of interest were also found stable 
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when subjected to three freeze-thaw cycles. In that study, degradation of DIM 
was prevented using an ice/water bath and acidified plasma after thawing 
plus an acidic mobile phase at pH 4 for analyte separation and ionisation. 
6.6 Review of previous studies on the 
pharmacokinetics of diamorphine and its 
metabolites  
Table 6-2 defines some pharmacokinetics terms that will be used in this 
Chapter. Pharmacokinetics of DIM have been reported using many routes of 
administration. Previous pharmacokinetic studies are listed in Table 6-2. In 
one study, the peak concentrations of DIM, 6-MAM and MOR in subjects 
receiving 12 mg of DIM intravenously were achieved at 2 min after injection 
and concentrations were 141, 151, and 44 ng/mL, respectively 312. In another 
study, DIM and 6-MAM reached their peak concentrations rapidly with 
concentrations of 1490 and 3410 ng/mL after injection of 200 mg of DIM, and 
levels of both analytes rapidly decreased within two minutes to 814 and 1887 
ng/mL, respectively. In that study MOR reached its peak concentration after 6 
minutes with 166 ng/mL while peak concentrations of M3G and M6G were 
detected after 15 minutes of injection and were 3850 and 399 ng/mL, 
respectively 305.  
Cone et al 144 published pharmacokinetic data after intranasal and 
intramuscular administration of 6 and 12 mg of DIM hydrochloride in six 
healthy adult subjects. Samples were collected from 8 minutes to 24 hours 
following administration. Peak concentrations of DIM were achieved at 5 min. 
Levels of DIM metabolites in blood were found dose-dependent in both routes 
of administration (INDIM and IM-DIM). In that study, MOR following INDIM had a 
longer half-life (2-4 hours) compared to DIM and 6-MAM. Blood levels of DIM 
metabolites were higher after 6 mg IM-DIM compared to 6 and 12 mg INDIM 
which suggests less absorption of DIM due to the hydrolysis of DIM to 6-MAM 
and MOR in nasal mucosa. The terminal half-life and AUC of DIM following 
INDIM was 4.2 minutes and 24.5 ìg.h/L 144, respectively. DIM was detected in 
plasma samples up to 25 minutes in most cases following INDIM regardless of 
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dose. Cmax was lower with 6 mg INDIM than 12 mg INDIM and ranged between 
4.3-13.6 and 14-24.5 ng/mL, respectively.  
 
Table 6-2: Pharmacokinetics parameters used in this study. 
 
Term  Definition 
PK Pharmacokinetics: the study of the quantitative relationship between 
administration dose of a drug and the observed plasma/blood or tissue 
concentration or the study and characterisation of the time course of drug 
absorption, distribution, metabolism and execretion.    
T ½   Half-life: a pharmacokinetic term to describe the approximate time taken 
to halve blood concentration of the drug during the terminal phase of drug 
elimination.  
Tmax: Time of maximum observed concentration. For non-steady state data, the 
entire curve is considered. For steady state data, Tmax corresponds to 
points collected during a dosing interval. 
Cmax: Maximum observed concentration, occurring at Tmax. 
AUCall: Area under the curve from the time of dosing (dosing time) to the time of 
the last observation. If the last concentration is non-zero 
AUClast=AUCall. Otherwise, AUCall will be greater than AUClast as it 
includes the additional area from the last measurable concentration 
AUClast Area under the curve from the time of dosing (dosing_time) to the last 
measurable concentration. 
Dosing 
time  
Time of last administered dose. Assumed to be zero unless otherwise 
specified. Used mainly with steady-state data, which may code time as the 
time elapsed since the first dose, or the elapsed time since the time of the 
first dose. 
ëz First order rate constant associated with the terminal (log-linear) portion 
of the curve. Estimated by linear regression of time vs. log concentration.  
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Table 6-3: Pharmacokinetics data for Diamorphine and its metabolites 
from literature.   
Dose of  
DIM (mg) 
No. of 
Cases 
R * Analytes T ½  
(min) 
Cmax 
(ng/mL) 
Tmax 
(min) 
AUC 
(ìg.hr/L) 
Ref. 
20-60 3 IV DIM 3 n.d. & n.d. 57-114 313 
6-12  6 IN DIM 4.2 n.d.  < 5 24.5 144 
3-20  2 IV DIM 
6-MAM 
3.6 
9.3 
n.d. 
n.d. 
n.d. 
n.d. 
56.5 
109 
312 
2.6-10.5 2 IH DIM 
6-MAM 
MOR 
3.3 
5.4 
18.8 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
312 
6   6 IN DIM 
6-MAM 
MOR 
M3G 
M6G 
0-6 
0-26.4 
0-102 
0-312 
n.d. 
n.d. -23.3 
3.8-10.6 
6.1-6.6 
32.4-82.3 
n.d. 
4.8-15 
4.8-10.2 
10.2-30.0 
30.0-180.0 
n.d. 
1.5-3.6 
0.9-7.1 
6.1-11.7 
112.6-412.0 
304 
12   6 IN DIM 
6-MAM 
MOR 
M3G 
M6G 
n.d. -6 
0-28.2 
0-180.0 
0-186 
n.d. 
n.d. -44.3 
4.4-17.4 
5.3-15.0 
88.2-137.4 
n.d. -23.9.0 
4.8-15 
4.8-10.2 
43.8-90.0 
60-120 
n.d. -120 
3.7-6.5 
1.7-10.0 
14.1-34.8 
381.5-906.3. 
304 
6   2 IM DIM 
6-MAM 
MOR 
M3G 
n.d. -5.4 
n.d. -19.2 
90.0-114.0 
102.0-180.0 
45.7 
22.6 
7.9 
93.0 
4.8 
n.d. -4.8 
n.d. -10.2 
10.2-30.0 
n.d. -6 
n.d. -10.1 
n.d. -16.5 
240.4-337.1 
304 
200 2 IV DIM 
6-MAM 
MOR 
1.3 
46-52 
182 
1530-2270 
4620-3400 
340-810 
n.d. 
0.7-1.5 
3.6-3.9 
5.2-8.8 
26.3-27.2 
64.3-48.7 
314 
40-210 8 IV DIM 
6-MAM 
MOR 
3.3 
n.d. 
        n.d. 
n.d. 
n.d. 
n.d. 
n.d. 
2.7 
6.4 
n.d. 
n.d. 
n.d. 
309 
146 8 IV DIM 
6-MAM 
MOR 
M3G 
M6G 
3 
3 
n.d. 
n.d. 
n.d. 
3960 
5740 
1569 
387 
55 
n.d. 
0.3 
7 
10 
58 
185 
257 
128 
1469 
230 
310 
50 5 CH-
D 
 
DIM 
6-MAM 
MOR 
M3G 
M6G 
n.d. 
n.d. 
143.0 
280.1 
269.9 
225.3 
171.5 
59.9 
341.5 
50.8 
1 
1 
2.0 
120.0 
120.0 
19.8 
34.4 
179.3 
2672.7 
390.5 
315 
 
5 HE-
d 
DIM 
6-MAM 
MOR 
M3G 
M6G 
n.d. 
n.d. 
127.0 
252.0 
216.2 
44.3 
52.4 
37.1 
230.8 
36.9 
1  
1 
2.0 
120.0 
120.0 
3.4 
10.7 
108.5 
1646.7 
224.2 
315 
133-450 10 IV DIM 
6-MAM 
MOR 
M3G 
M6G 
3.8 
22 
177 
276 
268 
3119 
1731 
829 
4287 
678 
n.d. 
n.d. 
7.8 
n.d. 
n.d. 
329 
482 
2594 
32192 
4291 
316 
133-450 12 IH DIM 
6-MAM 
MOR 
M3G 
M6G 
3.2 
26 
184 
283 
240 
685 
289 
271 
2284 
461 
2 
n.d. 
8 
n.d. 
n.d. 
174 
177 
1043 
15865 
2677 
316 
*
 R: Route of administration or method of administration  (IV: Intravenous; IN: Intranasal; IM: 
Intramuscular; IH: Inhalation; CH-D: Chasing the dragon; HE-d: Heating device).  
&
 n.d.: Not detected. 
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 In Cone et al 144, the plasma peak concentrations of 6-MAM were detected 
after 0.08 hour in all cases with the exception of one case in which 6-MAM 
peaked after 0.17 hour (no samples were collected before 8 minutes).  Cmax 
was lower with 6 mg compared to 12 mg INDIM, in the range of 7.9-13.7 and 8-
17 ng/mL, respectively. 6-MAM was determined in two cases up to 0.5 hour 
after INDIM at concentrations of 2.2 and 4 ng/mL but no DIM was detected 
after 0.25 hours. Peak concentrations of MOR were in the range of 6.2-26 
ng/mL and were little affected by the dose, except for two subjects in which 
the 12 mg dose produced peak concentrations double that of a 6 mg dose;  
Skopp et al 304 studied the pharmacokinetics of DIM and its metabolites 
including morphine glucuronides after injection of 6 mg IM-DIM and 6 and 12 
mg IVDIM in four volunteers. Findings were similar to those obtained by Cone 
at al 144. DIM reached its peak concentration within 5 min in both routes of 
administration and blood levels of DIM and 6-MAM were higher in IM-DIM 
compared to INDIM (no samples were collected before 5 minutes). T½ of DIM 
and 6-MAM for both routes of administrations were 5.4 ± 0.6 and 22.8 ± 4.2 
min, respectively. C max, Tmax and AUC of DIM were 0-44.3 ng/mL, 4.8 minutes 
and 3.7-6.5 ìg/L*hr, respectively. Interestingly, Tmax for MOR was dose 
dependent and ranged between 10.2-30.0 and 43.8-90.0 min after 6.0 and 
12.0 mg, respectively. T½ of MOR after INDIM was estimated to be in the range 
of 90.0-180.0 minutes and was likely to be higher with 12.0 mg of INDIM. The 
mean value of Tmax for M3G was higher after INDIM compared to IM-DIM, and 
also likely to be dose related with higher blood levels observed with INDIM 
than IMDIM. M3G plasma levels were 120.0 ± 42.0, 70.8 ± 63.0 and 19.8 ± 9.6 
after 6.0 mg or 12.0 mg of INDIM and 6.0 mg of IM-DIM, respectively. The 
method used could not quantify M6G. T½ of M3G was more than 2 hours and 
ranged between 132.0-312.0 minutes, Cmax ranged between 32.4-82.0 and 
88.0-137.0 ng/mL after 6.0 mg and 12.0 mg of INDIM, respectively.  
Jenkins et al 317 reported a pharmacokinetic study of IVDIM and DIM inhalation 
(IH-DIM). T½ for DIM was the same for both routes of administration. The AUC 
reported for IVDIM was 56.5 ìg/L*hr and DIM and 6-MAM were detected for up 
to 60.0 minutes. DIM peak concentrations occurred 2 minutes after IVDIM 
apart from one case in which the peak concentration was at 10 minutes 
following injection. Tmax of 6-MAM was later than for DIM and was at 2 minutes 
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for most cases. Plasma peak concentrations ranged between 1.0-320.0 ng/mL 
but 6-MAM could still be detected at levels of 1.3-2.8 ng/mL in some cases up 
to 60.0 minutes.  The Tmax of MOR was similar to that of 6-MAM and the Cmax of 
MOR ranged between 8.4-105.0 ng/mL. MOR level after 60.0 minutes was in 
the range not detected - 20.6 ng/mL.   
Girardin et al 310 found a T½ of 3 minutes for DIM and 6-MAM after IVDIM. Cmax 
was 3960 ± 1369 and 5742 ± 1837 ng/mL, respectively. The AUC was higher 
with 6-MAM than DIM and was 257 and 185 ìg/L*hr, respectively.  
MOR is considered to be the active metabolite of DIM; the analgesic effects of 
DIM are believed to be from its active metabolites MOR 313,318,319. Two 
pharmacokinetic studies have been reported in newborn infants and 
premature neonates after intravenous DIM infusion 273,320. In these two studies 
only morphine 273 or morphine and its glucronides 320 were determined. DIM 
was found safe and efficient and to have a similar metabolic pathway to 
morphine and its glucuronides as in adult subjects.  
Barrett et al 273 studied the pharmacokinetics of morphine in 26 newborn 
premature neonates after a dose of 50 ìg/kg. The mean steady state 
concentration of MOR was 62 ± 22.8 ng/mL with an elimination T½ of 8.9 ± 3.3 
hours and volume of distribution of 2.7 ± 1.01 L/kg. 6-MAM was detected in 
only two cases at low concentrations. This concentration was efficient for 
achieving analgesia and was similar to that in adult subjects, reported to be 
20 - 65 ng/mL 321-323.      
The pharmacokinetic profiles of morphine and its glucuronides were studied in 
19 ventilated newborn infants after an intravenous infusion of DIM at 15 ìg. 
kg-1.h-1 after loading doses of 50 and 200 ìg/kg. MOR, M3G and M6G were 
measured at the steady state period and ratios of M3G/MOR, M6G/MOR and 
M3G/M6G were calculated. The mean steady state concentrations for MOR, 
M3G and M6G were 86 ± 52, 703±400 and 48±28 ng/mL, respectively. The 
ratios of M3G/MOR and M6G /MOR at steady state plasma levels were 11 ± 
10.8 and 0.8 ± 0.8, respectively. There was no significant difference observed 
between the two loading doses in reaching MOR steady state, making the low 
dose preferable and much safer 320.   
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Rook et al 316 reported the pharmacokinetics of IVDIM and IH-DIM. They found 
no significant changes in T½ of DIM metabolites but a noticeable increase in 
Cmax and AUC after IVDIM compared to IH-DIM (3119 and 985 ng/mL, and 329 
and 52 ìg/L*hr, respectively). Bioavailability of IH-DIM was estimated as 52% 
of IVDIM.  
Giradin et al 310 found higher a AUC for 6-MAM than DIM, 185 and 257 ìg/L*hr, 
respectively. Gyr et al 314 reported AUCs of 5.2, 26-27 and 64.3-84.7 ìg/L*hr 
for DIM, 6-MAM and MOR, respectively. Elsewhere,  AUC of DIM was found to 
be 57-114 ìg/L*hr 313 after 3 hours of DIM infusion. Rook et al 316 found that 
the AUC was 174 and 177 ìg/L*hr for DIM and 6-MAM, respectively. 
6.7 Methods and Materials 
6.7.1 Reagents and Standards 
Methanol and acetonitrile (HPLC grade) were obtained from BDH (Poole, UK). 
Ammonium carbonate, formic acid and ammonium hydroxide were also 
purchased from BDH. Ammonium formate was obtained from Acros Organics 
(New Jersey, USA). The method was developed using human plasma, which 
had passed its usable date, obtained from the Scottish National Blood 
Transfusion Service. Ethical approval for supply of time-expired blood 
products was given by the given by the Ethics Committee of the Scottish Blood 
Transfusion Service, Edinburgh. 
DIM, DIM-D9 (DIM-D9), morphine (MOR), morphine-D3 (MOR-D3), 6-
monoacetylmorphine (6-MAM), 6-monoacetylmorphine-D3 (6-MAM-D3) was 
purchased from from Promochem (Middlesex, UK). Morphine-3-glucuronide 
(M3G), morphine-3-glucuronide-D3 (M3G-D3), morphine-6-glucuronide (M6G), 
morphine-6-glucuronide-D3 (M6G-D3), normorphine (NORM) were obtained 
from Lipomed (Arlesheim, Switzerland).   
All standards and internal standards were obtained as solutions in methanol at 
a concentration of 0.1 mg/mL or 1 mg/mL and each had a purity of more than 
99%. Bond Elut LRC-C18 cartridges were purchased from Varian (CA, USA).  
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Individual working standards were prepared at a concentration of 1 µg/mL by 
dilution of the stock solutions. Working mixtures of standards and internal 
standards were similarly prepared. 
6.7.2 Solid Phase Extraction 
250 ìl of plasma was added to 300 ìl of 0.01 M ammonium carbonate (pH 9.3) 
and 25 ìl of the internal standard working solution (1 ìg/mL) was added. The 
mixture was vortexed. The supernatant was applied to a Bond Elut C18 SPE 
cartridge preconditioned with 2 mL methanol, 1 mL of deionised water, and 2 
mL of 0.01 M ammonium carbonate (pH 9.3). The SPE cartridge was washed 
twice with 1 mL 0.01 M ammonium carbonate (pH 9.3) and then dried for 10 
minutes. Retained drugs were eluted with 2 mL methanol. After that, the 
extracts were evaporated to dryness under nitrogen at 50 oC. The residues 
were reconstituted with 80 ìl of initial mobile phase and then 20 ìl were 
injected into the LC-MS/MS instrument. 
6.7.3 Chromatography conditions 
In the current procedure, HPLC methods was as described in a previously 
method for the analysis of opioids and their metabolites in autopsy blood 
samples, refer to 5.3.3. 
6.7.4 Instrumentation 
Analysis of opiates and their metabolites was performed using a Thermo 
Finnigan LCQ DECA XP Plus ion trap instrument (Thermo Finnigan, San Jose, 
USA) equipped with a surveyor LC system interface. During the analysis auto-
sampler and column oven temperatures were maintained at 4 oC and 30 oC, 
respectively. Ionisation of analytes of interest was carried out using 
electrospray positive ion mode.  The capillary temperature, sheath gas flow 
rate, auxiliary gas flow rate and collision energies were optimized for each 
analyte separately. The spray voltage used was 5 kV.   
Analytes and their internal standards were identified and quantified based on 
their retention times and the presence of parent ion and two product ions in 
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selected reaction monitoring mode (SRM) with the exception of M3G and M6G 
which were fragmented to a single product ion as follows: m/z310, 328, and 
370 for DIM, m/z 211, 229 and 328 for 6-MAM, 201, 229 and 268 for MOR, 254, 
229 and 272 for NMOR and m/z 286 and 462 for M3G and M6G. The LC-MS/MS 
chromatogram was divided into six different segments to enhance analyte 
responses. The MS/MS parameters are detailed in Table 6-2. 
6.7.5 Method Validation 
6.7.5.1 Linearity 
Two calibration curves were prepared in plasma and extracted by the 
described method as the study was blind with respect to patient groups: one 
calibration curve covered low concentrations (0.1, 0.2, 0.3, 0.5, 0.75, 1, 5 
and 10 ng/mL) and the other covered high concentrations ( 5, 10, 20, 25, 50, 
100, and 200 and 250 ng/mL). Blanks with no internal standards and blank 
plasma samples with internal standard at 25 ng/mL were included with each 
run. Calibration curves were plotted of peak area ratios obtained versus 
concentration. The linear correlation coefficient (r2) was obtained for each 
regression curve.   
6.7.5.2 Matrix Effects and Recoveries 
Matrix effects and extraction recoveries were measured using the approach of 
Matuszewski et al 51. For matrix effects, Plasma (obtained from blood bank of 
West Infirmary Hospital Glasgow University) were obtained from six different 
human sources and spiked after solid phase extraction with analytes of 
interest at 5 and 100 ng/mL. Neat standards were diluted in initial mobile 
phase and injected directly into LC-MS/MS. Matrix effects of endogenous 
components were calculated by comparing peak areas of these two sets of 
standards.  
Recoveries were investigated for DIM and its metabolites using six different 
concentrations in plasma across the two calibrations curve ranges (0.5, 1, 5 
and 25, 50 and 200 ng/mL). Internal standards were added after extraction 
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and recoveries were calculated by comparison of the peak area ratios of the 
extracted and unextracted standards analysed under identical conditions.  
6.7.5.3 Limits of Detection and Lower Limits of Quantitation 
Sensitivity of the method was evaluated by determining the Limit of Detection 
(LOD) and the Lower Limit of Quantitation (LLOQ) for each analyte of 
interest. The lower calibration curve was used for this purpose (n=5) 
comprising spiked plasma at eight different concentrations 0.1, 0.2, 0.3, 0.5, 
0.75, 1, 5 and 10 ng/mL plus blank and blank spiked with internal standards.  
LODs and LLOQs values were then determined from the calibration curve as 
described in Chapter 5 (section 5.3.5.3). 
6.7.5.4 Intra-assay and inter-assay precision 
Three concentrations were used with each calibration curve as QCs to 
examine the Intra-assay and Inter-assay precision. For the lower concentration 
calibration curve 0.5, 1 and 5 ng/mL were used as QCs and 25, 50 and 200 
ng/mL were used as QCs with the higher concentration calibration curve. 
Intra-assay precision of DIM metabolites was determined using QCs (n=5) in 
one day.  The calibration curve of each analyte of interest was prepared using 
the two calibration concentration ranges mentioned above. The inter-assay 
precision was measured in a similar manner to the intra-assay precision on 
five different days.   
6.7.5.5 Stability  
Stability was assessed using human plasma spiked with the analytes of interest 
at 5 and 100 ng/mL (n=3).  Short-term temperature stability at room 
temperature was investigated for human plasma stored for 1, 2 and 4 hrs.  
Freeze-thaw stability of analytes of interest was determined after four cycles 
on consecutive days. Autosampler stability using reconstituted extracted 
sample was determined at 24 and 48 hrs after extraction.  Long-term stability 
was determined for analytes of interest at -20C for periods of 24hrs, 48hrs, 1 
week and 1 month. Calibration curves were prepared for each batch of 
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samples using standards spiked over two calibration curves plus blanks and 
blanks spiked with internal standards. 
6.7.5.6 Specificity  
The specificity of the described method was investigated using a mixture of 
drugs that are routinely detected in forensic toxicology cases (cocaine, 
benzoylecgonine, cocaethylene, ecgonine methyl ester, amphetamine, 
methamphetamine, methylenedioxyamphetamine, 
methylenedioxyethylamphtamine, methylenedioxymethamphetamine, 
nitrazepam, 7-aminoflunitrazepam, chlordiazepoxide, diazepam, oxazepam 
and temazepam) at a concentration of 400 ng/mL in whole blood.  
In addition, 21 commonly used opioids (codeine, codeine-6-glucuronide, 
norcodeine, acetylcodeine, hydromorphine, hydromorphone-3-glucuronide, 
dihydrocodeine, dihydrocodeine-6-glucuronide, naloxone, naloxone-3-
glucuronide, Buprenorphine, norbuprenorphine, norbuprenorphine-3-
glucuronide, buprenorphine-3-glucuronide, oxycodone, noroxycodone, 
oxymorphone, dihydromorphine, dihydromorphine-3-glucuronide, 
dihydromorphine-6-glucuronide and methadone) were extracted and injected 
at the same concentration to test the effect of the presence of opioids of 
similar structure on the specificity and selectivity of the described method. 
6.7.6 Case samples 
Plasma samples were obtained from twenty three children receiving DIM at 
the A & E department of a city-centre paediatric teaching hospital in 
Edinburgh. Ethical approval was obtained from the regional ethics committee 
by the participating paediatricians. Written informed consent was obtained 
from the parents of each child, and verbal consent from each child.  
Twelve children received IVDIM (dose 0.1mg/kg) and eleven subsequent 
children had INDIM at the same dose in 0.2 mL normal saline dripped into both 
nostrils. The children were aged 3-13 years, with clinical diagnosis of isolated 
deforming limb fractures. Sequential blood samples were taken at 2, 5, 10, 
20, 30 and 60 minutes post DIM administration. The blood tube was then 
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centrifuged at 4000 rpm for 2 minutes and plasma was transferred to plain 
Ependorph tubes that were immediately placed in a -70oC freezer until 
analysed.  
The INDM dose was administered in 0.2 mL of sterile water dropped into both 
nostrils over a period of 1 minute. At the mid point of the dose, i.e. after 30 
seconds, the timing was commenced for the subsequent samples. IVDM was 
also administered over 1 minute.  
Plasma samples were subsequently analysed for DIM, 6-monoacetyl morphine 
(6-MAM), morphine (MOR), morphine-3-glucuronide (M3G), morphine-6-
glucuronide (M6G) and normorphine (NMOR) using the method described 
earler.  
6.7.7 Data analysis 
Pharmacokinetic data was measured by Dr Alison Thomson from Glasgow 
Western Infirmary using the pharmacokinetic software package WinNonlin 
Professional Version 3·3 (Pharsight Corporation, Mountain View, California, 
USA). The elimination rate constants (k) for IV and IN plasma data were 
determined by nonlinear regression analysis of the log-linear decline with a 
1/weighting (1/concentration) and the elimination half-lives were obtained 
from 0·693/k. Area under the concentrationtime curve from 0 to the last 
sample (AUC0t) was determined by the trapezoidal rule and AUC from 0 to 
infinity (AUC 0∞) from AUC 0 t+ Cz /k −C 0/ k, where Cz is the final 
concentration measurement,  k is the elimination rate constant and C0 is the 
predose concentration measurement.  
6.8 Results  
6.8.1 SPE Optimisation  
SPE cartridges involved in this study were chosen from a previous method. 
Sample pre-treatment, washing and elution steps were then optimised. As 
described in Chapter 5, three SPE cartridges were compared for the detection 
of opioids and their metabolites including morphine glucuronides, 6-MAM, MOR 
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and NMOR. Bond Elut Certify SPE was found sufficient to isolate MOR, 6-MAM 
and NMOR but loss of morphine glucuronides was observed. Another SPE 
procedure with the same mixed mode sorbent reported by Rook et al 75 and 
used other studies 269,315,324,325 was not found to provide good recovery of 
morphine glucuronides. Variations in work environment and equipment could 
cause this difference; as a result, this method of extraction was excluded. An 
SPE method using CleanScreen, reported for quantification of DIM, 6-MAM and 
MOR 301,302,317 was also excluded due to large losses of morphine glucuronides. 
Methdod optimisation steps are detailed in Table 6-4. 
Table 6-4: Optimisation of SPE procedure. 
 
Recovery %  
DIM 6-MAM MOR M3G M6G NMOR 
Sample pre-treatment before SPE application 
0. 0.15 M Hydrochloric acid 75 93 87 40 7 31 43 
0.01 M Ammonium formate pH 
9.3 177 
67 80 76 81 80 88 
Citrate buffer pH 3 301 30 45 57 5 17 35 
SPE wash step optimisation 
Acidified water pH 3 75 70 65 83 10 55 58 
0.01 Ammonium formate pH 
9.3 177 
103 100 101 72 103 83 
0.001 M Ammonium formate  
pH 9.3 178 
100 106 105 59 103 82 
SPE elution step optimisation  
(DCM: ISO: AM) 302,307 91 84 92 0 0 98 
0.5 % Ammonium acetate in 
methanol 75 
92 87 92 102 98 104 
Methanol 178,301 91 87 94 107 99 95 
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6.8.1.1 Sample Pre-treatment  
The Bond Elut C18 SPE method used for opioid glucuronides and described in 
Chapter 5 was applied here with some modifications. Instead of 1:3 sample 
dilution with ammonium formate buffer, 0.01 M, 1:1 dilution was used to 
facilitate application of samples through the SPE cartridges and prevent 
hydrolysis of DIM.  Plasma samples were spiked at (50 ng/mL) with analytes of 
interest before SPE and 25 ng/mL of their corresponding internal standards 
were added after SPE application.  Samples were kept on ice as recommended 
by Rook et al 75 to prevent of hydrolysis of DIM to 6-MAM and to MOR.  
Samples were subjected to three different pre-treatment reagents. 0.3 mL 
pre-treatment reagent (0. 0.15 M hydrochloric acid 75, 0.01 M ammonium 
formate pH 9.3 177, or citrate buffer pH 3) 301 were added to 0.25 mL of spiked 
plasma samples. A good recovery for analytes of interest was observed using 
0.01 M ammonium formate buffer: recoveries of DIM, 6-MAM, MOR, M3G, M6G 
and NMOR were 67, 80, 76,81, 80 and  88% respectively.  
Morphine glucuronides were not retained well on SPE cartridges using a lower 
pH buffer. Recoveries of analytes of interest were 30, 45, 57, 5, 17 and 35% 
using citrate buffer (pH 3) for DIM, 6-MAM, MOR, M3G, M6G and NMOR, 
respectively. Hhydrochloric acid was efficient for providing good recoveries of 
DIM and 6-MAM, which were 93 and 87%; however, lower recoveries were 
obtained for MOR, M3G, M6G and NMOR which were 40, 7, 31 and 43 
respectively. Therefore, 0.01 M of ammonium formate was chosen for sample 
pre-treatment. 
6.8.1.2 SPE Wash Step Optimisation 
Wash steps were also investigated involving different wash volumes and 
different wash reagents: acidified water at pH 3 75, 0.01 ammonium formate 
at pH 9.3 177 and 0.001 M ammonium formate at pH 9.3 178. Recoveries of DIM, 
6-MAM, MOR, M3G, M6G and NMOR after use of acidified water were 70, 65, 
83, 10, 55, 58 %, and after using 0.001 M ammonium buffer were  100, 106, 
105, 59, 103 and 82 %, respectively. The recoveries of M3G and other DIM 
metabolites were improved with use of 0.01 M ammonium formate at pH 9.3 
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and were 103, 100, 101, 72, 103 and 83 %, respectively. Therefore, the latter 
wash buffer was chosen and 2 mL of buffer were found more efficient 
compared with 1 and 3 mL. 
6.8.1.3 Elution Step Optimisation  
Three different elution solvents were compared:  (DCM: ISO: AM) 302,307, 0.5 % 
ammonium acetate in methanol 75 and methanol 178,301. High recoveries were 
obtained for unconjugated metabolites using the first elution solvent which 
were 91, 84, 92, and 98% for DIM, 6-MAM, MOR and NMOR, but recoveries were 
zero for morphine glucuronides. However, high recoveries for all analytes of 
interest were obtained using the last two elution solvents and they were 92, 
87, 92, 102, 98, and 104% using the second solvent, and 91, 87, 94, 107, 99 
and 95% using methanol for DIM , 6-MAM, MOR, M6G, NMOR and M3G 
respectively. Therefore, methanol was chosen as the elution solvent. 2 mL of 
eluant were found more efficient when compared with 0.5, 1, 1.5, 2 and 3 mL 
of methanol.  
6.8.2 Method Validation  
6.8.2.1 LC-MS/MS Optimisation 
In Chapter 5, 6-MAM, MOR, M3G, M6G and NMOR were determined for the 
purpose of evaluating of the role of these metabolites in heroin fatalities. The 
same LC-MS/MS method was used for the analysis of DIM and its metabolites in 
the current project. DIM was not included with target analytes in the previous 
method and in addition a different matrix was used; therefore SPE and LC-
MS/MS methods were re-evaluated. In addition, more deuterated internal 
standards were used for increased accuracy and to compensate for matrix 
effects. As described in Chapter 5, morphine-3-glucuronide-D3 and morphine-
6-glucuronide-D3 were found to have cross talk with dihydromorphine-3-
glucuronide and dihydromorphine-6-glucuronide, respectively. However, these 
internal standards could be used with the current study along with deuterated 
internal standard DIM-D9 because the co-eluting drugs were absent from the 
clinical samples obtained from children.    
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Each analyte was dissolved in organic solvent at 10 ìg/mL and infused through 
a T-connection to the MS/MS instrument to obtain the best conditions and 
responses for LC-ESI-MS/MS. Ionisation of DIM metabolites was carried out 
using electrospray positive ion mode. The capillary temperature, sheath gas 
flow rate, auxiliary gas flow rate and collision energies were optimised for 
each analyte separately.  The spray voltage used was 5 kV.  Data was then 
stored as a tune page. 
The LC-MS/MS chromatogram was divided into six different time segments or 
retention widows, one for each analyte and its internal standard, in order to 
enhance analyte responses. The MS/MS parameters are detailed in Table 6-5. 
Analytes were identified and quantified based on their retention times and 
the presence of the parent ions and two product ions in selective reaction 
monitoring mode (SRM) with the exception of M3G and M6G which were 
fragmented to a single product ion as given in Table 6-5. 
Deuterated internal standards were analysed by selective ion monitoring in 
Chapter 5. In the present study, deuterated standards were analysed and 
quantified using SRM as follows; M3G-D3 and M6G-D3 were fragmented to m/z 
289, MOR-D3, 6-MAM-D3 and DIM-D9 were fragmented to m/z  201, 211 and 
316 respectively. Good chromatographic peak shapes were obtained for DIM 
metabolites at very low concentrations in the present study as shown in 
Figures 6-1 and 6-2. The major product ion was used for quantification and 
the others were used as qualifiers. In the case of M3G and M6G for which no 
other product ions were formed, 10% of survival product ion was used to 
qualify the SRM transition.  In the case of DIM, three product ions can be 
obtained and two of them were found at relatively the same amount (m/z 310 
and 328). For quantification, m/z 310 was used and m/z 328 and 268 were 
used as qualifier ions. The major product ions of 6-MAM and MOR are at the 
same m/z values as their corresponding internal standards which were 201 
and 211, respectively. The SRM transition ratios were calculated on five 
different days using five different calibration curves for both high and low 
concentrations. The ion intensity ratios of DIM metabolites were 1.0, 1.3, 1.6, 
1.4, 2.3, 5.3 and 5.6 for DIM (m/z 310/328), DIM (m/z 310/268), 6-MAM (m/z 
211/268), MOR (m/z 201/229), NMOR (m/z 254/229), M3G (m/z 286/462) and 
M6G (m/z 286/462), respectively (Table 6-5). 
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Table 6-5: LC-MS/MS parameters for Diamorphine metabolites. 
 
 Parameters DIM 6-MAM  MOR  M3G M6G NMOR 
Precursor Ion  
(m/z) 
370 328 286 462 462 272 
Product  Ion(s) 
(m/z) 
310, 328, 
268 
211, 268, 226 201, 229, 
268 
286, 462 286, 462 254, 229 
Quantifier  Ion 
(m/z) 
370 →310 
370 → 328 
 
328→ 211 
 
286→201 462→286 462→286 272→254 
Qualifier Ion(m/z) 
 
370→268 328→268 286→229 462→462 462→462 272→229 
SRM * transition  
Quan/Qual 
310/328 211/268 201/229 286/462 286/462 254/229 
SRM    Transition 
Ions ratio   
(R.S.D #) 
1 (5) 
 
1.6 (3) 1.4 (4) 5.3 (7) 5.6 (10) 2.4 (2) 
A
n
a
ly
te
s 
RT  &  (min) 18.3 14.1 8.2 3.4 6.9 5.0 
Internal  Standard 
(IS) 
DIM-D9 6-MA-D3 MOR-D3 M3G-D3 M6G-D3 MOR-D3 
IS Precursor  
Ion(s) (m/z) 
379 331 289 465 465 289 
Product Ion (m/z) 379→316 331→211 289→201 465→289 465→289 289→201 
In
te
rn
a
l s
ta
n
da
rd
s 
RT  &  (min) 
 
18.3 14.0 8.1 3.3 6.5 8.1 
Sheath Gas (AU) 15 25 30 20 20 25 
Auxiliary Gas (AU) 5 0 0 10 15 10 
Capillary 
Temperature (˚C) 
285 300 300 270 270 270 
Collision energy 
(%) 
38 38 38 28 30 35 
A
n
a
ly
te
s 
a
n
d 
in
te
rn
a
l 
st
a
n
da
rd
s 
Retention Widow 
No.  
6 
 
5 4 1 3 2 
#
 R.S.D: Relative standard deviations 
 *
 SRM: Selective reaction monitoring 
&
 Retention time of drugs. 
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Figure 6-1: SRM chromatograms of morphine-3-glucuronide, normorphine and 
morphine-6-glucuronide at their LLOQ concentrations.  
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Figure 6-2: SRM chromatograms of morphine, 6-monoacetylmorphine and 
diamorphine at their LLOQ concentrations. 
 128 
6.8.2.2 Stability  
In the present study, stability was carefully controlled during SPE and LC-ESI-
MS/MS. Working standard solutions were prepared weekly and kept at -20 oC 
until used. Stability of DIM and metabolites during the extraction and analysis 
of blank plasma samples spiked with analytes of interest were studied. 
Stability results are listed in Table 6-6. DIM and its metabolites were 
subjected to short-term stability tests after 1, 2, and 4 hours using an 
ice/water bath. Also, quick dilution of plasma samples after thawing without 
using an ice/water bath and transfer to SPE directly at room temperature at 
two concentrations (5 and 100 ng/mL) was investigated (Table 6-6). 
Degradation of DIM was observed after 1, 2 and 4 hours at room temperature. 
Most of the DIM was converted to 6-MAM after storage for 4 hours, but 
degradation was less than 45% after 2 hours and less than 10 % of DIM was 
hydrolysed after 1 hour using an ice/water bath.  However, degradation was 
also investigated at room temperature without using an ice/water bath, when 
samples were thawed and diluted quickly with ammonium carbonate buffer 
(pH 9.3) and then submitted to SPE. Degradation of DIM was limited to less 
than 4%. The later extraction procedure was used for the method validation 
process and sample analysis. 
DIM and its metabolites were found to be stable after four freeze-thaw cycles 
on consecutive days of plasma spiked at concentrations of 5 and 100 ng/mL 
and frozen at -20 °C. This method was designed to quantify DIM and 
metabolites in frozen plasma samples and the stability study was performed 
under the same conditions. Analytes of interest were spiked into blank plasma 
samples at low and high concentrations (5 and 100 ng/mL). The use of the 
lower concentration was aimed at monitoring the degradation of DIM at low 
levels, expected to be encountered in childrens plasma samples due to the 
low dosage. Plasma samples were then frozen at -20 °C. Samples were 
analysed after 24 and 48 hours for short-term stability and after 1 week, 1 
month and 6 months for long period stability.  DIM and its metabolites were 
stable in both storage conditions.  
Storage temperatures were monitored daily using permanently mounted 
digital thermometers with a resolution of 0.1 °C at the start of the study and 
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subsequently at weekly intervals during the period of study. Temperatures 
were stable within a range of approximately 1 °C  (freezer) or 5 °C (room 
temperature, average temperature 20 °C). 
Table 6-6: Stability of diamorphine and its metabolites in spiked plasma 
samples 
Mean Stability (analyte recovery)  % *  (R.S.D % #) 
St
o
ra
ge
 
co
n
di
tio
n
s 
 
Ti
m
e 
o
f s
to
ra
ge
 
 
N
o
m
in
a
l c
o
n
c.
 
 
(n
g/
m
L)
 
DIM 6-MAM MOR  M3G  M6G  NMOR 
5 52 (6) 134 (4) 113 (4) 102 (6) 114 (10) 115 (10) 4 hrs 
100 39 (10) 150 (7) 115 (7) 102 (6) 117 (15) 94 (7) 
5 83 (6) 113 (7) 104 (8) 101 (6) 99 (10) 108 (4) 2 hrs 
100 70 (11) 123 (3) 108 (3) 102 (9) 96 (8) 108 (13) 
5 91 (5) 104 (7) 108 (5) 100 (1) 102 (11) 105 (9) 
R
o
o
m
 
 
te
m
pe
ra
tu
re
 
 
 
1hrs 
100 93 (6) 109 (2) 99 (7) 102 (2) 96 (6) 97 (7) 
5 96 (11) 94 (1) 97 (4) 101 (3) 103 (3) 92 (11) 
D
ir
ec
tly
 
 
0.5 hrs 
100 98 (2) 102 (3) 97 (9) 96 (6) 101 (11) 98 (5) 
5 95 (7) 109 (5) 95 (8) 94 (5) 101 (2) 90 (2) 
Fr
ee
ze
 
&
 
th
a
w
 
4 cycles 
100 92 (5) 108 (4) 98 (7) 95 (10) 103 (7) 112 (11) 
5 97 (6) 100 (3) 100 (8) 99 (1) 102 (9) 99 (5) 
A
u
to
-
sa
m
pl
er
 
 
48  hrs 
100 94 (2) 97 (11) 94 (9) 104 (4) 98 (3) 97 (7) 
5 102 (3) 95 (9) 106 (6) 101 (7) 99 (3) 102 (9) 24 hrs 
100 98 (2) 104 (7) 101 (8) 101 (4) 95 (5) 99 (10) 
5 98 (7) 99 (12) 98 (11) 99 (11) 101 (8) 102 (7) 48 hrs 
100 95 (2) 97 (3) 96 (6) 101 (6) 95 (2) 101 (8) 
5 95 (8) 109 (5) 101 (4) 95 (9) 105 (3) 102 (11) Week 
100 103 (8) 101 (2) 100 (8) 93 (8) 108 (3) 96 (6) 
5 98 (11) 96 (2) 102 (11) 105 (2) 90 (7) 101 (2) Month 
100 95 (4) 106 (7) 94 (8) 91 (12) 103 (8) 95 (3) 
5 94 (13) 99 (4) 100 (11) 92 (1) 94 (3) 96 (5) 
Fr
ee
ze
r 
 
 
-
20
 
o
C
 
6 month 
100 97 (4) 94 (4) 93 (5) 92 (2) 93 (6) 95 (12) 
*
 The mean percentages for the replicate analysis (n=3). 
 
#
 R.S.D: Relative standard deviations. 
 130 
Plasma sample extracts were reconstituted using the initial mobile phase and 
subjected to an auto-sampler stability study. No degradation of analytes of 
interest was observed after periods of 6, 12, 24 and 48 hours in the LC-MS/MS 
auto-sampler, which was set at 4 oC.  
6.8.2.3 Linearity 
Two calibration curves were applied together for this study. Linear calibration 
curves were obtained with correlation coefficients (r2) greater than 0.999 for 
each analyte of interest.  
6.8.2.4 LODs and LLOQs 
LODs and LLOQs of analytes of interest were determined on five different days 
in duplicate. Relative standard deviations (RSD) of DIM and its metabolites 
were within the acceptable limit of method validation (less than 20% of LODs 
and less than 10% of LLOQs). LODs and LLOQs for analytes of interest ranged 
between 0.08-0.1 and 0.24-0.3 ng/mL respectively. LODs and LLOQs of the 
present method are detailed in Table 6-7.  
Table 6-7:  LODs and LLOQs of Diamorphine and its metabolites 
 
  
 Linearity 
range  
(ng/mL) 
r2 #  y-intercept Standard 
Error  
Gradient 
(m) 
LOD * 
(ng/mL) 
LLOQ ^ 
(ng/mL) 
DIM 0.1-10.0 0.999 -0.00095 0.000917 0.0330 0.08 0.20 
6-MA M 0.1-10.0 
 
0.999 -0.00094 0.00102 0.0413 0.07 0.20 
MOR   0.1-10.0 0.999 0.000862 0.00147 0.0485 0.10 0.30 
M3G  0.1-10.0 0.999 -0.00105 0.00262 0.0783 0.10 0.30 
M6G  0.1-10.0 0.999 0.000491 0.000398 0.0134 0.09 0.30 
NMOR 0.1-10.0 0.999 0.00006 0.000616 0.0233 0.08 0.26 
#
  r 
2: Correlation coefficients; 
*   LOD: Limit of detection; ^ LLOQ: Lower limit of quantitation; 
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6.8.2.5 Matrix Effects and Recoveries 
Matrix effects were within the acceptable limits of method validation (± 20 %) 
using six different plasma sources. Percentages above 100% indicate the 
presence of ion enhancement, while those below 100% indicate the presence 
of ion suppression. The highest ion suppression detected was -14 % and the 
highest ion enhancement detected was +18%. Next, recoveries of analytes of 
interest were determined at six different concentrations (0.5, 1, 2.5, 25, 50 
and 200 ng/mL) and ranged between 93-102, 90-102, 90-101, 85-102, 83-97 
and 92-103% for DIM, 6-MAM, MOR, M3G, M6G and NMOR respectively. Matrix 
effect results and recoveries of analytes of interest are detailed in Tables 6-8 
and 6-9, respectively.  
Table 6-8: Matrix effects from six different plasma sources. 
 
 
Mean Matrix effect % #  (R.S.D. % )& 
 
Drug Nominal 
concentration  
(ng/mL) Source  
1 
Source  
2 
Source 
3 
Source  
4 
Source 
5 
Source 
 6 
5 103 (2) 101 (2) 98 (5) 95 (5) 95 (3) 96 (5) DIM   
100 104 (5) 100 (7) 97 (3) 99 (8) 106 (4) 103 (8) 
5 95 (5) 90 (3) 111 (3) 92 (2) 100 (3) 108 (2) 6-MAM 
100 89 (11) 87 (9) 92 (4) 86 (3) 92 (6) 86 (2) 
5 98 (3) 88 (5) 86 (11) 82 (4) 86 (6) 90 (7) MOR  
100 96 (4) 99 (5) 94 (4) 97 (3) 118 (4) 91 (9) 
5 100  (4) 91 (1) 95 (27) 91 (2) 97 (7) 91 (4) M3G  
100 104 (5) 95 (1) 98 (3) 112 (4) 107 (3) 108 (1) 
5 108 (5) 95 (2) 96 (1) 95 (3) 92 (4) 93 (2) M6G  
100 102 (9) 101 (2) 100 (7) 97 (6) 102 (5) 106 (7) 
5 107 (7) 117 (4) 112 (4) 108 (2) 114 (3) 111 (10) NMOR  
100 104 (11) 109 (10) 94 (4) 115 (13) 111 (4) 105 (5) 
# Value calculated from the average matrix effects for the replicate analyses (n=3). 
 R.S.D: Relative standard deviations. 
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Table 6-9: Matrix effects and recoveries of diamorphine and its 
metabolites (n=5). 
 
Analytes Nominal concentration  
(ng/mL) 
Matrix effects %  
(R.S.D. % ) 
Mean Recovery % #  
(R.S.D. %) 
0.5 94 (8) 93 (13) 
1 89 (2) 92 (3) 
5 98 (1) 97 (6) 
25 102 (4)  94 (13) 
50 95 (8) 102 (9) Di
a
m
o
rp
hi
n
e 
200 98 (3) 97 (9) 
0.5 93 (6) 95 (8) 
1 98 (7) 90 (4) 
5 94 (1) 95 (10) 
25 107 (4) 102 (2) 
50 92 (1) 101 (9) 6-M
o
n
o
a
ce
ty
l-
m
o
rp
hi
n
e 
200 101 (7) 99 (10) 
0.5 84 (4) 90 (14) 
1 92 (2) 96 (2) 
5 94 (12) 98 (8) 
25 98 (5) 101 (6) 
50 93 (10) 99 (11) M
o
rp
hi
n
e 
 
200 107 (11) 98 (10) 
0.5 99 (13) 92 (8) 
1 93 (2) 85 (10) 
5 90 (4) 96 (9) 
25 97 (9) 103 (7) 
50 107 (2) 95 (9) M
o
rp
hi
n
e-
3-
gl
u
cu
ro
n
id
e 
 
200 94  (6) 102 (11) 
0.5 106 (12) 90 (13) 
1 96 (2) 83 (13) 
5 92 (6) 93 (10) 
25 105 (3) 96 (7) 
50 100 (3) 96 (4) M
o
rp
hi
n
e-
6-
gl
u
cu
ro
n
id
e 
 
200 93 (8) 97 (7) 
0.5 91 (12) 93 (6) 
1 101 (2) 92 (10) 
5 111 (14) 103 (9) 
25 108 (10) 101 (8) 
50 96 (7) 93 (9) No
rm
o
rp
hi
n
e 
200 93 (8) 97 (8) 
# Value calculated from the average recovery for the replicate analyses (n=5) 
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6.8.2.6 Precision 
Intra-assay and inter-assay precisions were measured using six different 
concentrations (0.5, 1, 5, 25, 50 and 200 ng/mL) and were based on relative 
standard deviation (RSD). Precision was found to be less than 15% for both 
intra-assay and inter-assay conditions (Table 6-10).  
6.8.2.7 Specificity and Selectivity 
Specificity and selectivity of the optimised method were examined using a 
mixture of the most common drugs detected in forensic cases. Blank plasma 
and blank plasma spiked with internal standards were also included with each 
batch to investigate the effects of unseen endogenous components on the ESI-
MS/MS responses. In addition, 23 plasma blank samples provided for the 
pharmacokinetics of DIM in children for this study were analysed with the 
optimised method (Figure 6-3). Clean base lines with little or negligible 
matrix components was found with no interferences detected from the other 
common drugs.   
6.8.3 Case samples 
Twenty three sets of childrens plasma samples were analysed by the 
optimised method for DIM and metabolites. The median doses of DIM received 
by children were 3.3 mg in the IVDIM group and were 2.8 mg in the INDIM 
children group. Plasma sample volumes used for analysis ranged between 0.1-
0.25 mL. DIM and metabolites were detected in all case samples with the 
exception of NMOR which tested negative in both study groups. Childrens 
body weights were in the range 16-59 kg. The ages of the children ranged 
from 4 to 13 years. The mean and median body weights were 31 and 33 kg in 
the IVDIM group and were 33 and 28 kg in the INDIM children group. Plasma 
samples taken before DIM administration were all negative for DIM and its 
metabolites in both the IVDIM and INDIM groups. 
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Figure 6-3: SRM chromatograms for a blank plasma sample obtained at time zero (case 1).
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Table 6-10: Intra-assay and inter-assay precision. 
 
Analytes Nominal concentration  
(ng/mL) 
Intra-assay ng/mL # 
 (R.S.D.  %) # 
Inter-assay ng/mL *    
(R.S.D. %) * 
0.5 0.5 (5.0) 0.5 (5.0) 
1.0 1.2 (10.0) 1.0 (11.0) 
5.0 4.7 (7.0) 4.9 (8.0) 
25.0 24.0 (6.0) 25.0 (2.0) 
50.0 48.0 (5.0) 50.0 (6.0) Di
a
m
o
rp
hi
n
e 
200.0 197.0 (4.0) 200.0 (2.0) 
0.5 0.49.0 (7.0) 0.5 (9.0) 
1.0 1.1 (10.0) 1.0 (9.0) 
5.0 4.9 (5.0) 4.8 (7.0) 
25.0 24.0 (5.0) 25.0 (5.0) 
50.0 51.0 (4.0) 48.0 (6.0) 6-M
o
n
o
a
ce
ty
l-
m
o
rp
hi
n
e 
200.0 203.0 (5.0) 200.0 (1.0) 
0.5 0.5 (10.0) 0.5 (11.0) 
1.0 1.1 (6.0) 1.0 (10.0) 
5.0 4.7 (10.0) 5.0 (5.0) 
25.0 25.0 (5.0) 25.0 (4.0) 
50.0 48.0 (7.0) 48.0 (8.0) M
o
rp
hi
n
e 
 
200.0 198.0 (5.0) 199.0 (1.0) 
0.5 0.5 (7.0) 0.5 (12.0) 
1.0 1.1 (10.0) 1.0 (3.0) 
5.0 4.9 (9.0) 5.0 (3.0) 
25.0 24.0 (3.0) 25.0 (6.0) 
50.0 47.0 (7.0) 49.0 (4.0) M
o
rp
hi
n
e-
3-
gl
u
cu
ro
n
id
e 
 
200.0 203.0 (3.0) 201.0 (1.0) 
0.5 0.5 (9.0) 0.5 (6.0) 
1.0 1.1 (6.0) 1.0 (11.0) 
5.0 4.9 (10.0) 4.9 (5.0) 
25.0 25.0 (6.0) 25.0 (5.0) 
50.0 47.0 (6.0) 48.0 (7.0) M
o
rp
hi
n
e-
6-
gl
u
cu
ro
n
id
e 
 
200.0 196.0 (2.0) 201.0 (1.0) 
0.5 0.5 (6.0) 0.5 (8.0) 
1.0 1.0 (9.0) 1.0 (11.0) 
5.0 4.8 (5.0) 4.6 (10.0) 
25.0 25.0 (4.0) 25.0 (6.0) 
50.0 53.0 (10.0) 50.0 (7.0) No
rm
o
rp
hi
n
e 
200.0 205.0 (2.0) 199.0 (2.0) 
#
 Value calculated from the average measured concentration for the replicate analyses (n=5) 
in the same day. 
*  
 Value calculated from the average measured concentration for the replicate analyses 
(n=5) on five different days. 
 136 
6.8.3.1 Intravenous diamorphine 
Twelve subjects received intravenous DIM (6 male and 6 female, Table 6-9, 
Figures 6-4 to 6-10). In most IVDIM subjects, The maximum measured 
concentrations of DIM, 6-MAM and MOR were in the first samples taken after 
dosing, at 2 minutes, apart from cases 2, 4 and 5 (at 5 minutes) and case 3 (at 
10 minutes). In case 2 no 2 minute sample was provided and the highest 
concentrations were measured in the 5-minute sample. M3G and M6G reached 
their peak concentrations 20 and 30 min after DIM administration 
respectively. 
Both DIM and 6-MAM were detected in all IVDIM samples collected after 2-20 
and 2-30 minutes, respectively. In some cases trace concentrations of DIM and 
6-MAM, less than 5 ng/mL, were detected 30-60 minutes after the DIM dose. 
Plasma concentrations of DIM were measurable in many cases after 20 and 30 
minutes with concentrations in the range 0.8-12 and 0.2-0.4 ng/mL, 
respectively. In addition, DIM was detected in four cases (4, 9, 10 and 19) 
after 60 minutes with concentrations in the range 0.5-1 ng/mL (Table 6-11). 
The highest concentration of DIM was found in case 1 (2062 ng/mL, 2 minutes) 
and the lowest concentration in case 10, at a trace level (estimated 0.1 
ng/mL, 60 minutes) which was below the LLOQ but above the LOD of the 
method. The mean and median peak concentrations of DIM in IVDIM were 706 
and 364 ng/mL, respectively, which were detected 2 min after DIM 
administration (Figure 6-4).   
6-MAM tested positive in many IVDIM cases after 30 min with concentrations in 
the range 1-5 ng/mL, and was detected in six cases after 60 minutes with 
concentrations in the range 0.3-3 ng/mL (Table 6-11). The highest 
concentration of 6-MAM was found in case 1 (1876 ng/mL, 2 minutes) and the 
lowest concentration in case 1 (0.3 ng/mL, 60 minutes). The mean and 
median peak concentrations of 6-MAM were 522 and 205 ng/mL, respectively, 
2 min after DIM administration (Figure 6-5).   
MOR was detected in all cases, with the exception of the last sample 
collected from case 7 at 60 minutes (Figure 6-6). The highest concentration 
was found in case 9 (227 ng/mL, 2 minutes) and the lowest concentration in 
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case 6 (0.5 ng/mL, 60 minutes). The mean and median peak concentrations of 
MOR were 61 and 33 ng/mL, 2 min after DIM administration. The peak plasma 
concentration in cases 3, 4 and 5 was delayed to 5 minutes. As no 2-minute 
sample was provided for case 2, the highest MOR plasma level was found in 
the 5-minute sample. Most cases showed a faster rate of MOR decrease 
between 2-5 minutes than after 5 minutes, which is likely to reflect the initial 
distribution phase . In most cases, the plasma MOR concentration in the last 
sample (at 60 minutes) was higher than 4 ng/mL, exceptions being cases 5 and 
6, which had MOR levels of 0.5 and 1 ng/mL, respectively.  
M3G was detectable in all IVDIM samples taken after DIM administration, with 
concentrations ranging from 3-757 ng/mL, but reached its maximum 
concentration after 20 minutes (Table 6-11 and Figure 6-7). The mean and 
median peak concentrations of M3G in IVDIM cases were 372 and 331 ng/mL 
respectively. No change in M3G concentration occurred between 20 and 30 
minutes after administration.  
The average plasma concentration versus time profile for M6G followed the 
same pattern as M3G but with lower concentrations. M6G was only detectable 
in three of the first samples taken after IVDIM, with concentrations of 0.4, 9, 
and 2 ng/mL in cases 1, 4 and 6, respectively. The concentration of M6G then 
increased in all cases to reach the peak concentration at 20 - 30 minutes but 
little or no change was observed at 60 Minutes. The highest plasma 
concentration for M6G was found in case 1 (56 ng/mL, 30 min). M6G was 
detectable in the rest of the cases, apart from case 7, with concentrations 
ranging from 0.5-8 ng/mL after 5 minutes (Figure 6-8).    
 138 
Table 6-11: Intravenous diamorphine cases. 
 
Patient No. 
  
Time  
  
DIM  6-MAM  MOR  M3G  M6G 
 (min) Measurement concentration (ng/mL) 
0 0 0 0 0 0 
2 2060 1880 223 50 0.4 
5 137 121 64 330 4 
10 19 30 54 680 17 
20 2 6 18 706 35 
30 0.6 3 17 757 56 
1 
60 0 0.3 8 415 34 
0 0 0 0 0 0 
2 0 0 0 0 0 
5 971 529 192 127 4 
10 61 25 47 342 16 
20 12 9 31 318 19 
30 4 3.5 17 312 31 
2 
60 0 0 7 241 19 
0 0 0 0 0 0 
2 228 80 14 74 0 
5 37 23 18 167 0.8 
10 9 11 19 307 5 
20 0 3 15 343 14 
30 0 2 15 373 12 
3 
60 0 0 9 359 19 
0 0 0 0 0 0 
2 430 99 20 98 9 
5 283 116 44 403 5 
10 27 38 38 582 14 
20 12 21 15 574 23 
30 2 5 10 480 20 
4 
60 1 1 7 502 19 
0 0 0 0 0 0 
2 364 57 14 44 0 
5 61 11 22 284 3 
10 10 7 16 453 8 
20 1 1 8 452 20 
30 0 0 4 383 20 
5 
60 0 0 1 386 27 
0 0 0 0 0 0 
2 1110 487 42 54 2 
5 125 150 24 161 3 
10 9 6 11 246 7 
20 0 1 9 245 12 
30 0 0 4 203 13 
6 
60 0 0 0.5 171 11 
 139 
Table 6-11: Continue. 
 
 
 
 
 
Patient No. 
  
Time  
  
DIM  6-MAM  MOR   M3G  M6G  
 (min) Measurement Concentration (ng/mL) 
0 0 0 0 0 0 
2 937 768 32 3 0 
5 24 26 8 61 0 
10 5 10 5 83 1.2 
20 4 11 3 191 12 
30 0 0 1.5 101 14 
7 
60 0 0 0 106 13 
0 0 0 0 0 0 
2 260 237 22 10 0 
5 27 34 7 118 1.4 
10 4 12 9 203 4 
20 4 9 7 310 10 
30 0.2 2 5 177 8 
8 
60 0 1 4 117 12 
0 0 0 0 0 0 
2 1600 1710 227 82 0 
5 198 237 51 374 0.5 
10 55 144 37 595 9 
20 6 14 15 588 23 
30 0.5 6 9 583 28 
9 
60 0.8 3 7 519 22 
0 0 0 0 0 0 
2 324 106 15 51 0 
5 85 45 8 258 8 
10 29 18 8 454 13 
20 4 3 7 459 18 
30 0.4 1 7 407 17 
10 
60 0.1 0 4 311 12 
0 0 0 0 0 0 
2 190 205 34 6 0 
5 36 64 22 41 1 
10 0.6 21 15 80 3 
20 0.8 6 9 107 12 
30 0.7 5 8 113 16 
19 
60 0.5 2.5 5 98 16 
0 0 0 0 0 0 
2 255 118 31 8 0 
5 58 40 20 91 4 
10 6 18 15 154 6 
20 0 5 14 172 22 
30 0 2 11 142 23 
20 
60 0 2 12 114 21 
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Figure 6-4: Semi-log plots of Diamorphine concentrations versus time 
after administration in 12 IVDIM cases. 
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Figure 6-5: Semi-log plots of 6-monoacetylmorphine concentrations 
versus time after administration in 12 IVDIM cases. 
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Figure 6-6: Semi-log plots of morphine concentrations versus time after 
administration in 12 IVDIM cases. 
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Figure 6-7: Semi-log plots of morphine-3-glucuronide concentrations 
versus time after administration in 12 IVDIM cases. 
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Figure 6-8: Semi-log plots of morphine-6-glucuronide concentrations 
versus time after administration in 12 IVDIM children. 
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Figure 6-9: Semi-log plots of of mean plasma concentrations of DIM 
metabolites versus time after administration in 12 children following 
intravenous DIM.  
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Figure 6-10: SRM chromatograms for DIM metabolies after IVDIM, M3G and M6G (Case9, 60 minutes) and MOR, 6-MAM and DIM 
(Case1, 2 minutes). 
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6.8.3.2 Intranasal diamorphine 
Eleven children received intranasal diacetylmorphine (5 male and 6 female) 
for their treatment. Table 6-12, Figures 6-11 to 6-17 summarise the analytical 
data obtained for these case. DIM and 6-MAM were detected in all INDIM cases 
from the first sample until 10 and 20 min after DIM administration, 
respectively. In six cases, the plasma concentrations of DIM ranged between 
0.2- 4 ng/mL (20 minutes after DIM administration); three cases were found 
positive for DIM with plasma levels lower than 1 ng/mL at 30 minutes and only 
one case had a concentration of DIM at the LLOQ of 0.2 ng/mL at 60 minutes. 
Maximum DIM concentrations were observed in the first samples, collected 2 
minutes after administration in most subjects although in four cases, 
maximum onbserved DIM concentrations were in the 5minute samples. 
However, levels of DIM in plasma were very similar at 2 and 5 minutes after 
administration. The highest DIM concentration detected was 43 ng/mL (case 
22, after 2 minutes). The mean and median peak concentrations of DIM were 
17 and 15.5 ng/mL, 2 minutes after administration (Table 6-12). 
6-MAM concentrations in the INDIM group were lower than those of DIM in all 
cases. Maximum observed plasma concentrations of 6-MAM were in the 5-
minute samples, with a slow rate of decline after the first sample until 6-MAM 
disappeared by 60 minutes. 6-MAM was still detectable in all 20-minute 
plasma samples, with the exception of cases 16 and 22, but was only 
detectable in three cases at 30 minutes at concentrations ranging between 
1.5-2 ng/mL (Figure 6-12). 
The highest concentration of 6-MAM was found in case 12 (16 ng/mL, 5 
minutes) and the lowest concentration in case 16 (0.3 ng/mL, 2 minutes). The 
mean and median peak concentrations of 6-MAM were 7.4 and 6 ng/mL after 5 
min, respectively.   
MOR was detected in all samples collected at 5-60 minutes after DIM 
administration (Figure 6-13). Only four cases had detectable levels of MOR in 
the first sample collected at 2 minutes with a concentration range below the 
LLOQ to 3 ng/mL in case 11, with a mean concentration of 0.6 ng/mL. The 
maximum observed plasma concentration of MOR in this group was detected 
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after 20 minutes and little change was observed until the curve started to 
decline in samples collected after 60 minutes. The highest concentration was 
found in case 12 (14 ng/mL, 10 minutes) and the lowest concentration in case 
18 (0.2 ng/mL, 2 minutes). The mean and median peak concentrations of MOR 
were 5.5 and 4 ng/mL, respectively, at 10 min after DIM administration. Little 
change in the MOR level occurred between 10 to 20 minutes with mean and 
median concentrations in the range of 5.4-5.5 and 4-5 ng/mL, respectively. 
The plasma MOR concentrations in the last samples, collected at 60 minutes, 
ranged between 0.8-8 ng/mL, with mean and median concentrations of 3 and 
2 ng/mL, respectively.  
M3G levels were detectable in all cases (concentrations ranged between 0.2 
to 250 ng/mL) from the second sample taken after 5 minutes until the last 
sample at 60 minutes, with the exception of cases 16 and 18 which tested 
negative after 5 minutes of the DIM dose. Plasma M3G levels rose after 5 
minutes of the DIM dose until the end of sampling at 60 minutes in a straight 
line which it is supposed would continue rising (Table 6-14). After 5 minutes, 
all detectable M3G levels were above the LLOQ with concentrations equal to 
or higher than 1 ng/mL, with the exception of case 17 (0.2 ng/mL). In case 15 
(female subject) high levels of M3G were observed from the second sample 
collected (129 ng/mL) and the maximum measured concentration was in the 
20 minute-sample (250 ng/mL), which was the highest plasma level of M3G 
determined in this group.  The mean and median concentrations of M3G at 60 
minutes after DIM administration were 80 and 86 ng/mL, respectively (Table 
6-12, Figures 6-14).    
The mean plasma concentration versus time profile of M6G had the same 
rising pattern as M3G (Figure 6-15), but with lower concentrations, and M6G 
was detectable after 20 minutes in all cases. M6G was detectable in four 
samples at 10 minutes with concentrations of 0.5, 1, 0.8, and 0.7 ng/mL in 
cases 11, 12, 15 and 22, respectively. Cases 11 and 21 had levels of M6G lower 
than the LLOQ at 2 minutes  but both had a concentration of 3 ng/mL at 5 
minutes. Also, the peak plasma concentration of M6G was not reached before 
the end of sampling at 60 minutes. The highest plasma concentration for M6G 
was found in case 12 (14 ng/mL, 60 min). The mean and median 
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concentrations of M6G at 60 minutes after DIM administration were 7 and 8 
ng/mL, respectively (Table 6-15).     
Table 6-12: Intranasal diamorphine cases. 
 
Patient No. 
  
Time  
  
DIM  6-MAM  MOR  M3G  M6G) 
 (min) Measured Concentration (ng/mL) 
0 0 0 0 0 0 
2 15.5 13 3 3 0 
5 14 15 6 5 0.2 
10 4 8 6 14 0.5 
20 0.6 4.5 8 35 2 
30 0 2 8 47 3 
11 
60 0 0 8 87 8 
0 0 0 0 0 0 
2 30 10 0 0 0 
5 23 16 5 1 0 
10 7 8 14 34 1 
20 0 2 5 79 5 
30 0 0 5 101 7 
12 
60 0 0 3 160 14 
0 0 0 0 0 0 
2 17 3.5 0 0 0 
5 10 9 6 2.4 0 
10 6 7 10 12 0 
20 4 3 7 21 2.2 
30 0 0 6 29 3 
13 
60 0 0 4 49 8 
0 0 0 0 0 0 
2 2.5 0 0 0 0 
5 15 9 3.5 1 0 
10 10 11 5 21 0 
20 0 2 5 47 0.4 
30 0 1.5 3 73 0.6 
14 
60 0 0 2 86 1.4 
0 0 0 0 0 0 
2 3.4 26 0 2 0 
5 3.4 8 4 129 0 
10 2.5 3 4 147 0.8 
20 0.6 3 5 250 2 
30 0 0.7 3.7 121 5.0 
15 
60 0 0 3.4 91 3.5 
0 0 0 0 0 0.0 
2 7.4 0.3 0.7 0 0.0 
5 8 1.7 0.8 0 0.0 
10 3.8 0 2.2 2 0.0 
20 1 0 2.1 17 2 
30 0.5 0 1.5 45 3 
16 
60 0.2 0 0.8 53 8 
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Table 6-12: Continue. 
Patient No. 
  
Time  
  
DIM  6-MAM  MOR  M3G  M6G) 
 (min) Measured Concentration (ng/mL) 
0 0 0 0 0 0 
2 5 7 0 0 0 
5 6 7 2 0.2 0 
10 1 5 6 11 0 
20 0 2 12 32 1 
30 0 1 10 37 2.2 
17 
60 0 0 1.3 46 4 
0 0 0 0 0 0 
2 12 3.2 0.2 0 0 
5 12 5 1.3 0 0 
10 5 10 3.4 2 0 
20 0.2 4 8 50 0.3 
30 0 0 5 69 2 
18 
60 0 0 4 87 3 
0 0 0 0 0 0 
2 17 10 1 15 1 
5 5 6 3 32 3 
10 0 2.4 4 40 4 
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Figure 6-11: Semi-log plots of diamorphine concentrations versus time 
after administration in 11 INDIM cases. 
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Figure 6-12: Semi-log plots of 6-monoacetylmorphine concentrations 
versus time after administration in 11 INDIM cases. 
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Figure 6-13: Semi-log plots of morphine concentrations versus time after 
administration in 11 INDIM cases. 
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Figure 6-14: Semi-log plots of morphine-3-glucuronide concentrations 
versus time after administration in 11 INDIM cases. 
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Figure 6-15: Semi-log plots of morphine-6-glucuronide concentrations 
versus time after administration in 11 INDIM cases. 
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Figure 6-16: Semi-log plots of of mean plasma concentrations of DIM metabolites 
versus time after administration in children following intranasal DIM. 
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Figure 6-17:  SRM chromatograms for DIM metabolies after INDIM, M3G and M6G (Case 11, 30 minutes) and MOR, 6-MAM and DIM 
(Case 12, 5 minutes).
 152 
6.8.3.3 Comparison between IVDIM and INDIM 
Concentrations of DIM metabolites were found to depend on the route of 
administration. The concentrations of DIM metabolites after INDIM were lower 
than after IVDIM at the same dose and body weight, and were in the ranges 190 
to 2062 ng/mL and 2 to 43 ng/mL for IVDIM and INDIM, respectively. The median 
peak concentrations of analytes of interest after IVDIM were achieved at 2 min 
for DIM, 6-MAM and MOR, and at 20 and 30 min for M3G and M6G respectively. 
After INDIM, median peak concentrations were achieved for DIM at 2 minutes but 
metabolites achieved their peak concentrations later: 6-MAM at 5 minutes, MOR 
at 10 minutes and the glucuronides beyond the study time window. 
Ratios of concentrations (IVDIM/INDIM) were calculated using the median peak 
concentrations or highest concentration obtained and were 34, 26.4, 6.2, 3.8 
and 2.9 for DIM, 6-MAM, MOR, M3G and M6G respectively. Following IVDIM, the 
concentrations of DIM, 6-MAM and MOR decreased sharply after 2 min whereas 
the rate of decrease was slower after INDIM.  
Plasma levels of DIM and its initial metabolite 6-MAM were found to share some 
similarities; DIM was higher than 6-MAM until 5 minutes in IVDIM and INDIM but 6-
MAM exceeded DIM after 10 minutes until both analytes were completely 
eliminated from the plasma. By contrast, some differences were found in 
relative analyte concentrations between the two groups. The plasma 
concentration of 6-MAM was 74% of the DIM concentration after 2 minutes of 
IVDIM compared to 30% of the DIM level after INDIM. The percentages at 5 
minutes were 68% and 73%, respectively and at 10 minutes were 140% and 150%, 
respectively.  
Interestingly, INDIM achieved similar DIM metabolite concentrations to IVDIM but 
at later times due to a delay in absorption and differences in metabolism in the 
nasal or gastric mucosa compared to IVDIM. For example, a mean DIM plasma 
level of 4 ng/mL was achieved following both IVDIM and INDIM administration, 
after 10 or 20 minutes, respectively. Also, the mean peak concentration of 6-
MAM after INDIM occurred at 5 minutes post-dose and was the same as the mean 
plasma concentration after IVDIM at 20 minutes post-dose and the plasma 
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concentrations of M6G at 30 and 60 minutes after INDIM (3.5 and 7.4 ng/mL, 
respectively) were close to those at 5 and 10 minutes after IVDIM (3 and 8.6 
ng/mL, respectively).  
DIM, 6-MAM and MOR were detected simultaneously for the first 10 minutes in 
the IVDIM group. 6-MAM exceeded DIM after 10 minutes and MOR exceeded DIM 
and 6-MAM after 20 minutes, when MOR levels were 2 and 3 fold higher than DIM 
and 6-MAM concentrations, respectively (Figure 6-18.) In the INDIM group, the 
plasma concentration of MOR was higher than DIM and equal to 6-MAM after 10 
minutes. The same results were obtained after 20 minutes of INDIM but the level 
of MOR was 5 and 2.5 times higher than DIM and 6-MAM (Figure 6-19). The mean 
plasma concentration 30 minutes after INDIM (5.3 ng/mL) was similar to that 
obtained 60 minutes after IVDIM (5.4 ng/mL).  
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In the IVDIM group, 2 minutes after DIM injection, the total MOR (TMOR) 
concentration was made up by free morphine (FMOR, 55%), M3G (44%) and M6G 
(1%). After 5 minutes, FMOR decreased to only 15% of TMOR and at 60 minutes 
accounted for less than 2% of TMOR (Figure 6-20). M3G accounted for 83% of 
total MOR after 5 minutes of DIM dose and 92% at 60 minutes. FMOR and M3G 
accounted for 33% and 67% of TMOR at 2 min after INDIM, respectively. The M3G 
Figure 6-18: DIM, 6-MAM and MOR levels following IVDIM. 
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plasma level increased sharply after 5 minutes to become a major portion of 
TMOR, which was the same as in the intravenous group. FMOR and M3G 
accounted for 3.3% and 89% of TMOR, respectively (Figure 6-21.) 
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Figure 6-20: Free morphine as a percentage of total morphine after  
IVDIM and INDIM. 
Figure 6-19: DIM, 6-MAM and MOR levels following INDIM. 
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M6G was the minor DIM metabolite in both groups. M6G was formed early, after 
2 minutes of IVDIM and accounted for 1% of TMOR, and after that the percentage 
of M6G increased until it exceeded that of FMOR. M6G accounted for 6.3% of 
TMOR and was three times higher than FMOR at 60 minutes.  
The same pattern was observed after INDIM but M6G accounted for 1% of TMOR 
after 10 minutes and M6G accounted for approximately 8% of TMOR, and was 
more than double FMOR at 60 minutes (Figure 6-22).  
The ratios of M6G/MOR and M3G/MOR and M3G/M6G were calculated for both 
groups. Although the peak concentrations of M6G and M3G were not determined 
in the intranasal group, the ratios of M3G/M6G were close to each other (Figure 
6-23). They were about 50 at 2 or 5 minutes after IVDIM and INDIM, respectively, 
and then declined to 14 and 11 at 60 minutes, respectively. Also, the same ratio 
of M6G/MOR was obtained at 30 and 60 minutes after IVDIM and INDIM, 
respectively. It is expected that the M6G/MOR ratio would be the same in both 
INDIM and IVDIM groups after 60 minutes (Figure 6-24). The ratio of M3G/MOR 
increased with time in both study groups. However, the ratio of M3G/MOR at 60 
minutes after IVDIM was twice that obtained with INDIM due to the delayed peak 
concentration with INDIM (Figure 6-25). 
 
 
 
 
 
 
 
 
Figure 6-21: M3G as a percentage of total morphine after IVDIM and INDIM.  
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Figure 6-22: M6G as a percentage of total morphine after IVDIM and INDIM. 
Figure 6-23: Ratio of M3G/M6G after IVDIM and INDIM. 
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Female subjects in both study groups were found to produce slightly higher 
metabolite concentrations compared to male subjects but were found to have 
Figure 6-24: Ratio of M6G/MOR after IVDIM and INDIM. 
Figure 6-25: Ratio of M3G/MOR after IVDIM and INDIM. 
 158 
the similar plasma profiles in both study groups. These relationships are 
illustrated in Figures 6-26 and 6-27. 
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Figure 6-26: Comparison of MOR profiles in males and females after IVDIM 
and INDIM. 
Figure 6-27: Comparison of M3G profiles in males and females after IVDIM 
and INDIM.  
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6.8.3.4 Pharmacokinetic data 
There was difficulty in obtaining the half-life and other pharmacokinetic data 
from the plasma time course of DIM after intravenous and intranasal mean of 
administration. For DIM and 6-MAM only two points were used to define 
elimination rate (lambda z) or there was a very poor fit in some cases. The 
experimental data were therefore used to calculate AUCs to the last time point 
(AUCall). A summary table of the mean values of the main pharmacokinetic 
parameters is given in Table 6-13. 
6.8.3.4.1 Intravenous DIM 
 
The mean terminal half-lives of DIM and 6-MAM after IVDIM were calculated to 
be 4 minutes and 7 minutes, respectively. The terminal half-life of MOR was 
found to be 41 ± 11 minutes with a median of 43 minutes. In cases 5-7, however, 
the half life was very short, ranging between 10-12 minutes.  
Tmax and Cmax for DIM and 6-MAM following IVDIM are listed in Table 6-14. The 
median Tmax was 2 minutes and median Cmax values were 728, 524 and 75 ng/mL 
for DIM, 6-MAM and MOR, respectively, although there was significant variability 
between individuals in Cmax. The median Cmax and Tmax of M£G and M6G were 358 
ng/mL and 20 minutes and 21 ng/mL and 30 minutes, respectively (Table 6-14). 
AUC calculated for all DIM metabolites are detailed in Table 6-14. DIM exhibited 
a very high inter-individual variability between subjects and ranged between 
1230 to 44150 ìg.min/L with a median of 2790 ìg.min/L. The gender of the 
subject affected the AUC, as females had higher AUC values than males with 
median AUCs of 13610 and 4710 ìg.min/L, respectively.  
6-MAM had a lower AUC than DIM, in the range 249-6603 ìg.min/L with the 
median at 1220 ìg.min/L. Male subjects had a slightly higher mean AUC for 6-
MAM compared to female subjects, with mean values of 2130 and 1980 ìg.min/L, 
respectively. 
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Table 6-13: Summary of pharmacokinetic data 
 
IVDIM average values in 12 cases INDIM average values in 11 cases Substance 
T½ 
min 
Tmax 
 min 
Cmax 
ng/mL 
AUCall 
ng.min/mL 
T½ 
min 
Tmax  
min 
Cmax 
ng/mL 
AUCall 
ng.min/mL 
Bioavailability  
DIM 4 2.0 728 9162  4 2.0 18.0 129 1.4 
6-MAM 7 2.0 524 2054  14 5.0 9.0 109 5.3 
MOR 41 3.0 75.0 873 46 13.0 7.0 242 27.7 
MOR-3-GLUC  n.d 18.0 383 18140 n.d  56.0 94.0 3260 17.9 
MOR-6-GLUC  n.d 36.0 23.0 973  n.d 57.0 8.0 208 21.4 
Table 6-14: Pharmacokinetic data for diamorphine and 6-MAM in 
IVDIM group. 
Table 6-15: Pharmacokinetic data for morphine and its glucuronides in IVDIM 
group. 
 Diamorphine 6-Monoacetyl-morphine Morphine Morphine-3-glucuronide Morphine-6-glucuronide 
Case no. Tmax Cmax AUCall Tmax Cmax AUCall Tmax Cmax AUCall Tmax Cmax AUCall Tmax Cmax AUCall 
 min ng/mL ìg.min/L min ng/mL ìg.min/L min ng/mL ìg.min/L min ng/mL ìg.min/L min ng/mL ìg.min/L 
1 2 2062 18450 2 1880 5520 2 223 1860 30 757 34970 30 56 2130 
2 5 971 44150 5 529 2990 5 192 2070 10 342 16240 30 31 1240 
3 2 228 1550 2 80 445 10 19 835 30 373 19430 60 19 706 
4 2 430 3150 5 116 1320 5 44 966 10 582 29090 20 23 1060 
5 * 2 364 2440 2 57 249 5 22 418 10 453 22610 60 27 1080 
6 2 1112 8120 2 487 1870 2 42 461 10 246 11700 30 13 615 
7 2 937 13300 2 768 2210 2 32 187 20 191 6390 30 14 604 
8 2 260 2010 2 237 964 2 22 381 20 310 10420 60 12 476 
9 2 1601 11740 2 1710 6600 2 227 1480 10 595 31490 30 28 1190 
10 2 324 2210 2 106 630 2 15 400 20 459 21960 20 18 830 
19 2 190 1230 2 205 1120 2 34 611 30 113 5580 30 16 707 
20 2 255 1600 2 118 710 2 31 810 20 172 7810 30 23 1060 
* No 2 minutes-sample provided.  
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AUC 0-60 minutes of MOR after IVDIM was in the range of 187-2070 ìg.min/L 
(median, 710 ìg.min/L). Cases 1 and 2 had the highest MOR AUCs (1860 and 
2070, respectively) while the other cases had a lower MOR AUC (median, 461 
ìg.min/L). A higher MOR AUC was observed in females compared to males 
(means of 955 and 792 ìg.min/L, respectively, Table 6-15).  
The AUC of M3G and M6G ranged between 5579-35000 ìg.min/L (mean, 18140 
ìg.min/L) and between 476-2130 ìg.min/L(mean, 973), respectively. There 
were no differences between male and female subjects for either glucuronide.   
6.8.3.4.2 Intranasal DIM 
 
The mean terminal half-lives of DIM and 6-MAM after INDIM were calculated to 4 
minutes 14 minutes for 6-MAM, respectively. The mean terminal half-life of MOR 
was 46 ± 20 minutes. The MOR half life was very long in Case 21, estimated at 
257 minutes, and could not be calculated for case 11 because the MOR 
concentration was still rising at the end of the study period. Similarly, the 
terminal half-lives of morphine glucuronides could not be calculated for either 
group because the study period was too short.  
In INDIM cases, AUCs for DIM ranged between 44-220 ìg.min/L (mean, 129 
ìg.min/L). The mean AUC value was higher with female than male subjects 
(means 143 ± 58 and 112 ± 38 ìg.min/L, respectively). After INDIM, the AUC for 
6-MAM was found to be slightly lower than for DIM and ranged between 8-238 
ìg.min/L (mean, 109 ìg.min/L); the mean Cmax and Tmax were 3 minutes and 5 
ng/mL, respectively.  Female subjects also had higher AUCs than males with 
means of 133 and 81 ìg.min/L, respectively (refer to Table 6-16).  
In INDIM cases, MOR AUCs ranged between 85-437 ìg.min/L (mean, 241 
ìg.min/L. The mean Tmax and C max was 13 minutes and 7 ng/mL, respectively. 
Female subjects had higher AUCs than males: mean MOR AUCs were 276 and 201 
ìg.min/L, respectively. A comparison of pharmacokinetics data of morphine and 
its glucuronide are detailed between IVDIM and INDIM study groups are listed in 
Table in Table 6-17.  
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Table 6-16: Pharmacokinetic data for diamorphine in 
INDIM group 
Table 6-17: Pharmacokinetic data of morphine and its glucuronide in 
INDIM group 
 Diamorphine 6-Monoacetyl-morphine Morphine Morphine-3-glucuronide Morphine-6-glucuronide 
Case 
no. 
Tmax Cmax AUCall Tmax Cmax AUCall Tmax Cmax AUCall Tmax Cmax AUCall Tmax Cmax AUCall 
 min ng/mL ìg.min/L min ng/mL ìg.min/L min ng/mL ìg.min/L min ng/mL ìg.min/L min ng/mL ìg.min/L 
11 2 16 131 5 15 238 20 8 4387 60 87 2728 60 8 205 
12 2 30 220 5 16 169 10 14 320 60 160 5469 60 14 408 
13 2 17 168 5 9 127 10 10 349 60 49 1625 60 8 202 
14 5 15 141 10 11 169 10 5 192 60 86 3382 60 1.4 37 
15 2 26 164 2 3.4 47 20 5 221 20 250 7909 30 5 179 
16 5 8 102 5 1.7 8 10 2.2 85 60 53 1880 60 8 200 
17 5 6 44 2 7 123 20 12 393 60 46 1833 60 4 114 
18 2 12 118 10 10 143 20 8 271 60 87 3200 60 3 88 
21 2 17 63 2 10 72 10 4 138 60 81 3301 60 13 420 
22 2 43 161 2 8 55 5 5 92 60 91 2882 60 13 310 
23 2 12 109 2 4 54 5 3.4 162 60 44 1593 60 5 125 
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In INDIM cases, M3G AUCs ranged between 1593-7909 (mean, 3255 ìg.min/L). 
The mean AUCs of M3G were 4034 and 2320 for female and male subjects, 
respectively. The mean Tmax and Cmax of M3G in this group were 56 minutes and 
94 ng/mL, respectively. M6G AUCs were in the range of 37-420 (mean, 208 
ìg.min/L). There was no difference in M6G AUCs between female and male 
subjects and were 209 and 207 ìg.min/L, respectively. The mean Tmax and Cmax 
were 57 minutes and 8 ng/mL, respectively.   
 
6.9 Discussion  
6.9.1 Method validation 
An LC-MS/MS method has been developed and found to be sufficient for the 
analysis of DIM and its metabolites at lower LLOQs than in previously published 
methods reviewed in Table 6-1. In most of these, the LLOQ of DIM was equal to 
or above 1 ng/mL 108,302,303,305,308,317,326 and an LOD of 0.5 ng/mL was reported in 
two studies using LC-APCI-MS 178 and GC-MS 327 which was found to be sufficient 
with adult subjects. The situation is different with children since very low levels 
in plasma from INDIM cases are expected in the range 1 - 10 ng/mL. 
In the current application, two calibration curves were required since the 
method was to be applied to the determination of DIM and its metabolites in 
plasma from children, in a study that was carried out as a blind study. The 
concentrations of DIM or 6-MAM to be expected in children after DIM intake were 
not available in the literature, but were predicted to be very low. A calibration 
curve extending to a low level was crucial for obtaining accurate results and also 
to avoid false negative results. In the present study, LODs and LLOQs of DIM and 
its metabolites were included within the calibration range, which helped in 
examining the method sensitivity at the LLOQ with each sample batch. This is 
one of the advantages of this method over previously reported methods.  
IVDIM subjects had high levels of DIM and its metabolites which were within the 
range of the high calibration curve; however, low concentrations were obtained 
when the subject had INDIM but some samples were also found within both the 
 164 
low and high calibration ranges. If the method was not validated using both 
calibration curves, it is possible that high concentrations of DIM and its 
metabolites would be not quantified accurately as they would be out of the 
calibration range and might lead to false negative results for low DIM 
concentrations. 
Dams et al 142 studied the matrix effect by using a post-column infusion of 
morphine with blank urine samples in duplicate at 10 ìg/mL. No matrix effects 
were observed after 1 min of chromatography. Rook et al 75 studied the effects 
of plasma matrix on the ionisation of DIM and its metabolites; they found that 
ion suppression was within the acceptable criteria for method validation. 
However, no information was presented in their work on how they examined the 
matrix effects and what concentration they used. 
In the current study, five human plasma samples were used for the investigation 
of matrix effects present and to calculate recovery of analytes of interest. Both 
ion suppression and enhancement were detected but no effects on DIM ionisation 
of metabolites was observed. This was accounted for by the use of SPE which 
provided clean extracts, the use of internal standards for each DIM metabolite 
with the exception of NMOR which was not available commercially and finally a 
good separation of analytes of interest which made it easy to established 
separate retention window for each analyte. Matrix effects were examined at 
low levels, 0.5 ng/mL, which is also the concentration used to measure the intra 
and inter-assay precision of the optimised method. Recoveries were calculated 
after excluding matrix effects. Good recoveries have been obtained in the 
current study which compared well with previous methods. 
6.9.2 Stability of diamorphine 
In the current method, the samples analysed were stored at -70°C in Edinburgh, 
as mentioned in Section 6.7.6 and available data indicate that they were stable 
while frozen, for example a 6-month stability study was carried out (Table 6-6) 
and a similar median concentration of morphine was obtained in IVDIM cases (31 
and 33 ng/mL in Kidd et al 276 and current study, respectively). RIA results for 
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MOR obtained for the current study samples by Kidd et al 276 are listed in Table 
6-18.  
From the review of previous methods above (Section 6-7), degradation of DIM 
during sample preparation was up to 10% but in the current method only 4% 
degradation was observed.  
Table 6-18: Morphine concentration versus time profile using (RIA) by Kidd 
et al 276.  
 
6.9.3 Case Studies    
The plasma samples from children used in this work were sent to the Forensic 
Medicine and Science Section in Glasgow University for the purpose of obtaining 
DIM levels, and at that time no method was available in the Section for DIM 
analysis. The A & E department of a city-centre paediatric teaching hospital in 
Edinburgh tested these cases prior to their delivery to the Section but the 
method used was found insufficient for the determination of DIM and only MOR 
could be determined, using a radioimmunoassay 276. In addition, HPLC coupled 
with electrochemical detection (HPLC-ECD) was trued in Edinburgh but failed to 
determine DIM, which suggested DIM may have been completely hydrolysed 
during extraction or an unsuitable SPE was used resulting in no DIM recovery. 
However, 6-MAM, MOR, M3G and M6G were detected, although this data is 
unpublished and unavailable at the time of writing. 
The samples were collected during the clinical study in 2003, stored at -70 °C 
and analysed by the current optimised method in 2007. There were many 
challenges due to the lack of an existing method and long period of storage of 
samples as DIM is known to be unstable and could be hydrolysed either in-vivo or 
  IN group n=12 
Median (range) 
IV group n=13 
Median (range) 
Cmax (ng/mL) 10.3 (7.8-18.1) 31.0 (27-56.6) 
Tmax (min) 10 (5-60) 2(2-5) 
AUC (nmol/L-h) 512 (252-650) 1070 (957-1150) 
60 min value (ng/mL) 9.0 (3.8-10.3) 13.4 (9.5-17.1) 
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in-vitro. Also, doses and routes of administration were unknown and no data 
from previous RIA or HPLC-ECD results were available when the samples were 
analysed  
Little case information data was available from Dr Kidd. Some information came 
from an abstract of a paper presented by the group, but this did not include 
detailed results such as concentrations for individual cases, only the median 
values for Tmax, Vmax and AUC and the concentration of morphine at 60 minutes 
have noted.  
Kidd et al 276 used a radioimmunoassay method for their analysis which could not 
distinguish between morphine and other opioids. Also, Kidd et al 276 analysed 
samples from more INDIM cases than were available in current study. However, 
as mentioned above, similar median concentrations of morphine were obtained 
in IVDIM cases. By contrast, different median levels of morphine were obtained 
for INDIM cases (10.3 and 5 ng/mL in Kidd et al and current study, respectively). 
This can be attributed to cross reactivity of the RIA method to both morphine 
and its glucuronides.  Also, more samples were analysed by Kidd et al (25 cases 
compared to 23 cases in the current study). 
In addition, the short period of sampling time (60 minutes) has limited the 
calculation of pharmacokinetic data for MOR and its glucuronides as a result of a 
poorly-defined declining curve, since the curve for the elimination phase is 
normally used for calculating clearance and volume of distribution. In previous 
reports 144,312, samples were collected from time zero to 24 hours following DIM 
administration which provides more data points for the elimination phase of MOR 
and its glucuronides. However, it was difficult for the clinicians to obtain 
additional plasma samples from children due to their progress through hospital 
sections to complete their treatment and due to the ethical restriction on the 
invasive procedure of obtaining blood samples for medical staff. 
However, the numbers of patients included in the current study were reasonable 
compared with published pharmacokinetic studies following DIM administration. 
The first samples were obtained at 2 minutes and these usually had the highest 
measured concentrations of DIM, indicating that peak concentrations of DIM 
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occurred no later than 2 minutes after administration. In many pharmacokinetic 
studies, sampling started after 5 min which was found insufficient to providing a 
full description of pharmacokinetics profile of DIM 144,317.   
In the present study, pharmacokinetic parameters such as Cmax, Tmax and AUCall 
were calculated for the IVDIM and INDIM study groups. INDIM AUC profiles were 
lower than those obtained with IVDIM subjects, for example, AUC of DIM after 
INDIM (Bioavilability, Table 6-13) was only 1.6% of the AUC obtained with IVDIM. 
This may suggest rapid hydrolysis of DIM following INDIM. DIM is known to convert 
rapidly to 6-MAM and MOR after IVDIM. 6-MAM and MOR were included as target 
analytes but were found to have lower AUCs after INDIM, only 5% and 28% during 
the first hour after administration compared to that of IVDIM, respectively.  
Significant losses of DIM following intranasal administration, due to absorption in 
nasal mucosa or swallowing of DIM, have been reported 304 and may lead to a 
delayed appearance in plasma and to most of the DIM being hydrolysed to 6-MAM 
and MOR before reaching the blood circulation. Also, phase I metabolites of DIM 
(6-MAM and to MOR) may have a longer half-life after INDIM than IVDIM, since 
this metabolism may take place in the stomach and possibly the presence of 
food or an empty stomach may influence the bioavailability of DIM after dosing.  
In the current study, DIM and 6-MAM similar concentrations at 2 and 5 minutes 
after INDIM, indicating that the Tmax was between 2 and 5 minutes. This may be 
explained by the delay of reaching the blood circulation after INDIM between 
DIM absorbed by nasal mucosa and that of swallowing. 6-MAM was also found to 
have the same trends of formation and elimination as its parent drug and both 
had very high hydrolysis rates shortly after DIM administration. Traces of both 
DIM and 6-MAM could be detected up to 60 minutes after IVDIM, although most 
had hydrolysed by 20 minutes following INDIM.   
MOR is generated from 6-MAM and seemed to have a steady state period 
between 20 and 30 minutes following INDIM. Levels of M3G after IVDIM were 
lower than those of MOR at its Tmax (2 minutes) but were higher than MOR levels 
at their own peak times with INDIM cases. Both had similar mean levels at 5 
minutes after INDIM administration in most cases. This indicates that some MOR 
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was conjugated in the liver to form M3G and M6G. M6G may achieve only very 
low concentrations, lower than the LLOQ of the optimised method, since it was 
only detected in one case. This may be due to the longer half-life and duration 
of morphine glucuronides in blood which need at least 30 minutes after the MOR 
peak concentration to reach their own Cmax plateau period. That can be seen 
clearly from two routes of DIM administration. The percentages of AUC within 
first hours of M3G and M6G following INDIM were 18% and 21% of that observed 
with IVDIM cases, respectively, which meant that less than 22% of morphine and 
its metabolites were metabolised in the first hour after INDIM. Comparisons 
between MOR plasma results obtained in the present study and previous studies 
are listed in Table 6-19.  
In the current study, the plasma concentration versus time curves of the two 
morphine glucuronides were parallel curves following both routes of 
administration while the curves for MOR and M6G crossed over. This cross-over 
point was found after 20 and 40 minutes of IVDIM and INDIM route of 
administration (Figure 6-10 and 6-17), respectively. In IVDIM, the MOR level 
decreased after the MOR peak concentration at 2 minutes. By contrast, the MOR 
level increased to reach its peak concentration and steady state period in INDIM 
groups. 
The mean AUC values following IVDIM and INDIM were comparable with previous 
pharmacokinetics reported in Table 6-3; in the present study the AUC of DIM was 
150 and 2.1 ìg/L*hr, and was 34 and 1.8 ìg/L*hr for 6-MAM after IVDIM and 
INDIM, respectively. AUC is dose dependent and also depends on time of sample 
analysis. The latter one is a limitation of the current study in which samples 
were collected for only an hour following administration. 
 169 
Table 6-19: Comparison of morphine pharmacokinetic data from previous 
work and current study (adapted from Kidd et al 276). 
 
Dose of  
Diamorphine 
Route of 
administration 
Cmax 
(ng/mL) 
Tmax 
(min) 
60 min of 
morphine  
(ng/mL) 
Ref. 
6mg  Snorted powder 10 <5 1.8 
12mg  Snorted powder 15 <5 10 
6mg  IM 15 <5 5 
 
144 
10.5mg IH 56 2 20 
10 IV 16 5 10 
12 IV 44 2 20 
10.5mg IH 11.9 1 4-7 
 
 
312 
4mg IM 15 15 8 
56mg Oral 140 30 60 
112 µg/hr IV infusion Not 
obtained 
10 
 
313 
112mg Snorted powder 60 11-12 304 
15ìg/kg/hr IV load+infuse 
 
 
Not 
 reported  
120 86 plateau 318 
40mg Nasal spray 200 2 180 
40mg IV 330 15 200 
 
328 
0.1mg/kg  IV 31 2 13.4 
0.1mg/kg  IN drops 10.3 10 9.0 
 
276 
0.1mg/kg  IV 33 2 6 
0.1mg/kg  IN drops 5 10 3 
Present  
study 
 170 
The AUC of 6-MAM obtained here was lower than the AUC of DIM in both routes 
of administration. This can be explained by the improved LLOQ for DIM in the 
current method, which enabled DIM to be measured at lower concentrations, 
and over a longer time period. Also, it has been found that the concentration of 
DIM was higher than that of 6-MAM following both IVDIM and INDIM in the first 
two samples, which also had the highest concentrations of each analyte.  
Analgesia produced by DIM is usually attributed to its active metabolite, MOR. 
The median MOR level followed IVDIM was 33 ng/mL in the present study, which 
was considered enough to produce analgesia (Table 6-19). Also, the level of MOR 
reported in previous work after INDIM and found to produce analgesia was also 
found with INDIM cases in the present study. Peak concentrations of MOR were in 
the range 6.2-26 ng/mL. In the study by Cone et al 144,  levels of MOR ranged 
between 2.6-13.4 ng/mL at one hour after administration and were in 
agreement with Skopp et al 304 who found that the Cmax of MOR ranged between 
6.1-13.2 ng/mL after INDIM.   
The presence of M6G at later stages was reported to be responsible for DIM 
analgesia and found to be more effective than MOR. The levels of DIM at 1 hour 
after administration were reported following oral and DIM infusion at high DIM 
doses (56 mg and 40 mg), which resulted in MOR concentrations of 60 313 and 180 
-200 ng/mL 328, respectively. In addition,  plasma MOR concentrations were 
within the range obtained in the present study following INDIM and IVDIM, which 
were 1.8-10 ng/mL 144,313,317 (Table 6-19). Therefore, it can be confirmed that 
therapeutic levels of MOR can be achieved following INDIM in children based on 
the pharmacokinetic data presented in the current study.  
The median plasma peak concentrations of DIM, 6-MAM, MOR and M3G following 
INDM in this work were similar to those reported by Cone et al 144 and Skopp et 
al 304. Data obtained after IVDIM were similar to those reported by Jenkins et al 
317. T½ was similar to most previous studies and ranged between 3-5 minutes for 
DIM (see Table 6-3). In the current study, the median T½ for DIM after IVDIM and 
INDIM was 4 min and 3 min , respectively.  
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In previous work, it has been found that peak plasma concentrations of DIM 
metabolites were lower following smoked or intranasal DIM compared to IVDIM 
which was the same as in the present work. DIM and 6-MAM were detected with 
both routes of administrations in the present work which may indicate that DIM 
and 6-MAM provided the analgesic effects at the early stage when MOR levels 
were low or not detected, especially in INDIM cases. 
In the present study, the two routes of administration can be distinguished on 
the basis of the plasma metabolite concentrations. IVDIM produces faster and 
higher pharmacokinetic profiles for DIM and its metabolites compared to INDIM. 
There is no data available in the literature regarding DIM levels in children 
treated with DIM to assist in the interpretation of DIM metabolites levels 
obtained in this study, and so these were compared with the results of studies in 
adults. 
6.10 Conclusions 
Methods of DIM analysis published between 1991 and 2009 were reviewed for the 
first time for this thesis.  
Many methods have been reported for extraction of DIM metabolites and among 
these SPE is the method of choice, producing clean extracts, good sensitivity and 
minimal matrix effects. In the present study, DIM metabolites were extracted 
and analysed using SPE and LC-MS/MS procedures. LC separation was performed 
using the Synergi Polar RP column (150 X 2mm, 4µm) and a gradient mobile 
phase. DIM and its metabolites were well separated from each other. SPE was 
sufficient to provide clean extracts and minimize the effect of matrix on the 
ionisation of analytes. Results of analysis of case samples obtained following 
intravenous and intranasal DIM were reported and DIM metabolites were 
determined with the exception of NMOR which was found to be negative in both 
case groups.  
Following IVDIM, the concentrations of DIM, 6-MAM and MOR decreased sharply 
whereas the rate of decrease was slower after INDIM. Pharmacokinetic 
parameters, Cmax, Tmax, T½ and AUC, were calculated for the two patient groups.  
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These were compared with each other and with previous studies in adult 
patients. The pharmacokinetics of DIM and its metabolites following IN and IV 
administration in children have been compared for the first time in this study, 
which confirmed that INDIM can achieve therapeutic plasma concentrations of 
DIM and its active metabolites, although these are lower than those obtained 
with IVDIM and occur at later times after administration. 
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7 Comparison of Nonhydrolysis and Hydrolysis 
Methods for the Determination of 
Buprenorphine Metabolites in Urine by LC-
MS/MS. 
7.1 Introduction 
Buprenorphine (BUP) is a semisynthetic opioid, prepared from thebaine 1,125,132 in 
a seven-step sequence 329, which is 25 to 40 times more potent than morphine 
and is therefore a powerful analgesic. It is a partial ê-opioid receptor antagonist 
and ì-opioid receptor agonist 124,126,330,331. Buprenorphine is used for the 
treatment of moderate to severe pain, for example in surgical and neoplastic 
cases, and in the treatment of opiate dependence 124,331-333. 
7.1.1 Metabolism and excretion   
BUP has a low bioavailability when taken orally due to extensive first pass 
metabolism. In addition, it retains its potency as an opioid agonist even at high 
dosage, from 2-32 mg, without leading to overdose. It appears to act as a limited 
respiratory depressant 124,126,331,332. BUP has been studied widely. It is 
metabolised by N-dealkylation to the active metabolite norbuprenorphine 
(NBUP) and both BUP and NBUP are conjugated with glucuronic acid to form 
buprenorphine-3-glucuronide (BUP3G) and norbuprenorphine-3- glucuronide 
(NBUP3G), respectively 132,250,331 (Figure 7-1).   
The first application was reported by Polettini and Huestis 332 seven years ago 
and the first method for the direct determination of polar metabolites in urine 
was reported in 2003. The determination of conjugated and free metabolites 
using a hydrolysis method was reported in 1984. Cone et al 334 analysed BUP 
metabolites following subcutaneous, sublingual and oral BUP administration in 
urine and faeces. The percentage of BUP metabolites in urine was the opposite 
of the faeces profile as NBUP metabolites exceeded BUP metabolites in urine 
and vice versa. In addition, pharmacokinetic profiles of BUP and its metabolites, 
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including glucuronides, reported by Huang et al 250 give different concentrations 
for free BUP and NBUP than those reported by Ceccato et al 335 and Polettini and 
Huestis 332. The BUP concentration exceeded that of NBUP in Ceccato et al 335  
and Polettini and Huestis 332 while the NBUP concentration exceed that of BUP in 
Huang et al 250. 
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Figure 7-1: Buprenorphine metabolism. 
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7.1.2 Toxicity  
Symptoms associated with buprenorphine overdose include confusion, dizziness, 
pinpoint pupils, hallucinations, hypotension, respiratory difficulty, seizures and 
coma 132. The mechanism of buprenorphine intoxication is not clear due to the 
low concentrations found in cases. It has been suggested that norbuprenorphine 
is responsible for burenophine deaths due to its action as a very potent 
respiratory depressant and can be detected in plasma following buprenorphine 
intoxication. However, it is not known yet if norbuprenorphine alone could 
potentially induce respiratory depression. In animal experiments, it has been 
found that administration of buprenorphine and norbuprenorphine blocks the 
norbuprenorphine-induced respiratory effect. In addition, the parent drug has 
been found to be mostly unchanged in buprenorphine fatalities 336-339. 
Buprenorphine was considered to be safe until it became an abused drug due to 
its availability in the black market, especially, if it is taken by intravenous 
injection, and the use of buprenorphine concomitant with benzodiazepines has 
been found to increase its toxicity and subsequently the incidence of fatalities 
sharply 125,340-342. 150 deaths have been reported 340,342. Blood concentrations of 
buprenorphine were reported for buprenorphine related fatalities and ranged 
between 1-76 and 2-65 ng/mL for buprenorphine and norbuprenorphine, 
respectively 343. Kintz et al 341 reported buprenorphine levels of 1.1 and 0.2 
ng/mL for buprenorphine and norburenorphine, respectively, in fatal drug-
facilitated sexual abuse cases. Unhydrolysed and hydrolysed urine were tested 
and 9.1, 9.6 and 575 and >1000 ng/mL were detected for buprenorphine, 
norbuprenorphine, respectively 341. Also, low concentrations of BUP and NBUP 
were encountered in 20 BUP fatalities which ranged between 1.1-29 and 0.2-13 
ng/mL and averaged 8.4 and 2.6 ng/mL; urine levels were in the range of 4-1033 
and 6.6-230 ng/mL and averaged 172 and 67 ng/mL for BUP and NBUP, 
respectively 340. 
7.1.3 Previous work 
Many methods have been developed for screening and quantification of BUP and 
its metabolites in biological fluids using several analysis techniques. 
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Immunoassay techniques were used in early studies for quantification of BUP 344 
and many reports describe the use of immunoassay for BUP screening 253,345,346. 
Although immunoassay methods for BUP screening are widely used and 
considered to be rapid, sensitive and capable of processing large numbers of 
samples compared to chromatographic methods, they are not sufficiently 
specific to differentiate between BUP and its metabolites due to cross reactivity 
with metabolites and structurally similar compounds. Gas chromatography with 
electron capture or mass spectrometric detectors 251,347-349 and HPLC methods 
with UV 350, fluorescence 351 or electrochemical detectors 352 were reported.  
These methods were found to lack sensitivity, being unable to detect BUP and 
NBUP with concentrations of less than 1 ng/mL. In addition, most of the methods 
were not employed for routine analysis. The methods showed some critical 
limitations such as being time-consuming due to the use of hydrolysis procedures 
and derivatisation steps.  
Methods using liquid chromatography coupled with mass spectrometry 342,353 and 
tandem mass spectrometry 250,256,332,335,354-359 have been reported. Most methods 
validated for BUP analysis used enzymatic hydrolysis although for opioids acid 
hydrolysis is often favoured for opioids 247,360,361. Feng et al 362 investigated the 
efficiency of  using acid, alkaline and enzymatic procedures for hydrolysis of 
BUP3G to BUP and found neither acid nor alkaline hydrolysis was suitable for BUP 
analysis. They reported slow acid hydrolysis rates with only 2% conversion after 2 
hours at 50oC. Degradation of analyte was observed with increased 
temperatures. In the same study, no recovery of BUP was obtained after 
hydrolysis with 10 M KOH or concentrated hydrochloric acid at room temperature 
for 16 hours. Complete hydrolysis of BUP3G was achieved enzymatically in 2 
hours at 37 oC using E.coli, 4 hours at 60 oC using H. pomatia. and in 1 hour at 60 
oC with Glusulase. Elsohly et al 348 investigated the enzymatic hydrolysis of 
NBUP3G and found that it was completely hydrolysed by â-glucuronidase from 
E.coli or H. pomatia following incubation at 60 oC for 4 hours.  
The rate of hydrolysis is different for the two glucuronide metabolites and this 
could potentially lead to false negative results for NBUP3G as it requires a longer 
hydrolysis time than BUP3G 348,354. Different rates of hydrolysis could arise due to 
differences in the laboratory environment, analysis procedure, amount of 
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enzyme used and incubation time and temperature. The sensitivity of enzymatic 
hydrolysis methods was always questionable due to limitations caused by, for 
example, incomplete hydrolysis, contamination of the enzyme preparation and 
their inability to cleave some glucuronide metabolites to their free form 76,247.  
LC-MS techniques now available should replace traditional hydrolysis methods 
since they can provide unique methods of identification and quantification of 
analytes and can detect intact glucuronides without hydrolysis or derivatisation 
procedures. 
In fact, the hydrolysis step is crucial for quantification of BUP as the free drug is 
found at very low concentration. A method for determination of the polar 
metabolites was reported which did not include BUP and NBUP 355. By contrast, a 
study by Fox et al 356 compared the amount of BUP and NBUP in urine samples 
before and after enzymatic hydrolysis. Interestingly, the contributions made by 
the free drugs to the total BUP and total NBUP were not detectable-67% (mean 
6.4%) and not detectable-100% (mean 34.7%), respectively. The authors noted 
that the ratios between free and conjugated metabolites are variable and 
advocated that hydrolysis methods should be replaced by direct determination 
of glucuronides.  
7.2 Aims 
In practice, enzymatic hydrolysis methods continue to be widely used and there 
have been few reports of simultaneous direct analysis of glucuronide metabolites 
and free drugs 250,256,355. Also, until now there has not been a direct comparison of 
these two methods of analysis using real case samples.  
In this work, a method for the simultaneous determination of BUP, NBUP, BUP3G 
and NBU3G was validated and then compared with an in-house method for 
quantification and identification of BUP and NBUP which uses enzymatic 
hydrolysis with â-glucuronidase (Helix pomatia). This comparison was carried out 
using real case urine sample testing positive for BUP. A full description of the in-
house method was reported previously by Miller et al 253.   
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7.3 Methods and Materials 
7.3.1 Reagents and Standards 
Methanol, acetonitrile and acetic acid (HPLC grade) were obtained from BDH 
(Poole, UK). Ammonium carbonate, formic acid and ammonium hydroxide were 
also purchased from BDH. Ammonium formate was obtained from Across 
Organics (New Jersey, USA). â-glucuronidase was purchased from Sigma-Aldrich 
(Dorset, UK). 
Buprenorphine (BUP), buprenorphine-D4 (BUP-D4), norbuprenorphine (NBUP), 
norbuprenorphine-D3 (NBUP-D3) and Norbuprenorphine-3-glucuronide (NBUP3G) 
were purchased from Promochem (Middlesex, UK). Buprenorphine-3-glucuronide 
(BUP3G) was purchased from ElSohly Laboratories (Oxford, MS, USA). All 
standards and internal standards were obtained as solutions in methanol at a 
concentration of 0.1 mg/mL and each had a purity of more than 99%. Bond Elut 
LRC-C18 cartridges were purchased from Varian (CA, USA).  
Individual working standards were prepared at a concentration of 1 µg/mL by 
dilution of the stock solutions. Working mixtures of standards and internal 
standards were similarly prepared. 
7.3.1.1 Preparation of 0.01M Ammonium carbonate buffer (pH 9.3) 
1.571 g of ammonium carbonate was weighed and added to a I L volumetric flask 
and 800 mL of DI H2O was added. The pH was then adjusted to 9.3 using 
concentrated ammonium hydroxide. The volume was made up to 1 L using 
deionised water. The buffer was stored at 4 0C until used and unused solution 
was discarded after 4 weeks from the date of preparation. 
7.3.1.2 Preparation of 1 M, pH 5 Sodium Acetate Buffer 
42.9 g of sodium acetate trihydrate and 10.4 mL of concentrated (17 M) glacial 
acetic acid were dissolved in 400 mL of deionised water. The pH was adjusted to 
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5.0 with 1 M acetic acid and the solution made up to 500 mL with deionised 
water. 
7.3.1.3 Preparation of 0.01 M, pH 3.0 Acetic Acid 
286 µL of concentrated (17 M) glacial acetic acid was placed in a 500 mL 
volumetric flask and this was made up to volume with deionised water. 
7.3.1.4  Preparation of Phosphate Buffer (0.1 M, pH 6.0)  
1.70 g of potassium hydrogen phosphate and 12.14 g of potassium dihydrogen 
phosphate were weighed into a 1 L beaker.  800 mL deionised water was added 
and the solid was dissolved by stirring.  After the solid had dissolved, the pH of 
the solution was adjusted to 6.0 using 1 M potassium hydroxide solution.  The 
solution was then transferred into a 1 L volumetric flask and was made up to the 
1 L mark with deionised water. 
7.3.1.5 Preparation of 0.01 M Ammonium Formate (pH 3) 
0.630 g of ammonium formate was added to a 1 L volumetric flask and 800 mL of 
DI H2O was added. The pH was adjusted to 3 or 4.5 using concentrated formic 
acid. Then volume was made up to 1 L with deionised water. Ammonium formate 
buffer was prepared freshly and stored at room temperature until used; unused 
solution was discarded after 4 weeks from the date of preparation. 
7.3.1.6 Preparation 0.001 M of ammonium formate pH 3 
100 mL of 0.01 M ammonium formate solution were added to 1 L volumetric flask 
and made up to 1L with deionised water.  
7.3.1.7 Preparation of 0.003 M Ammonium Formate + 0.001% formic acid 
0.189 g of ammonium formate and 10 µL of concentrated formic acid were 
added to a 1 L volumetric flask and made up to the mark with deionised water. 
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7.3.1.8 Preparation of 0.005 M Ammonium Acetate 
0.385 g of ammonium formate were added to I L volumetric flask and made up 
to volume with deionised water. The pH was adjusted to 4.5 using concentrated 
acetic acid.  
7.3.2 Direct determination procedure  
7.3.2.1 Solid Phase Extraction (SPE)  
One millilitre of urine was added to 3 mL of 0.01 M ammonium carbonate, pH 9.3 
and 50 ìl of the internal standard working solution was added.  The mixture was 
vortex mixed, allowed to equilibrate for 10 minutes and then centrifuged for 10 
minutes at 3000 rpm. The supernatant was applied to a Bond Elut C18 SPE 
cartridge preconditioned with 3 mL methanol, 3 mL of deionised water, and 3 
mL of 0.01 M ammonium carbonate (pH 9.3). The SPE cartridge was washed 
twice with 3 mL 0.01 M ammonium carbonate (pH 9.3), and then dried for 10 
minutes.  Retained drugs were eluted with 3 mL methanol, after which the 
eluate was evaporated to dryness under nitrogen at 500C. The extract was 
reconstituted with 150 ìl of initial mobile phase and centrifuged at 4000 rpm 
and then the supernatant was transferred to an auto-sampler vial and 20 ìl was 
injected into the LC-MS/MS instrument. 
7.3.2.2 Chromatography conditions 
Chromatographic separation was achieved using a Synergy Polar RP column (150 
x 2.0 mm, 4-ìm particle size), protected by a guard column with identical 
packing material (4 x 2.0 mm, Phenomenex, Torrance, CA). Gradient elution was 
based on a mobile phase consisting of 10 mM ammonium formate adjusted to pH 
3 (A) and acetonitrile (B) at a flow rate of 0.3 mL/min for the first 8 min, 
decreasing to 0.2 mL/min at 13 min for the next 13 min. After that, the initial 
flow rate was applied until the end of analysis.   
The gradient conditions were initially 97% of solution A for 3 min; decreasing to 
84.5% at 8 min, to 74% at 13 min, and to 20% at 26 min; 5% of solution A was 
maintained for the next 3 min before returning to 97% for 7 min prior to the next 
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injection. Three time segments were used to maximise the sensitivity of 
analysis: the first segment from 0-16 min was for NBUP3G, the second segment 
from 16-21 min was for B3G, NBUP and NBUP-D3, and the last segment from 21-
25 min was for BUP and BUP-D4.  
7.3.3 In-house Hydrolysis Procedure 
7.3.3.1 Solid Phase Extraction 
1 mL of the urine sample spiked with 50 ng/ml of internal standard (BUP-d4 and 
NBUP-D3), 40 ìl of  â-glucuronidase crude solution (Helixa pomatia) and I ml  of 
acetate buffer  (pH 5, 1M) were added to a 20 mL glass tube and incubated in an 
oven for 3 hrs at 60 0C.  Three ml of phosphate buffer (pH 6, 0.1 M) was added 
to the mixture after cooling.  Samples were centrifuged and submitted to Bond 
Elut Certify LCR SPE cartridge that was preconditioned with 2 mL of methanol 
and 2 mL phosphate buffer (pH 6, 0.1 M).  Then each column was subject to two 
washing steps using 1 mL of deionized water following by 0.5 mL acetic acid (pH 
3, 0.01 M), and full vacuum was then applied for 10 min. 50 ìL of methanol were 
added, then the columns were dried with full vacuum for 2 min. SPE cartridges 
were washed with 4 mL Acetone/Dichloromethane (1:1, V/V).  BUP and NBUP 
were eluted with 2 x 1.5 mL ethyl acetate containing 2 % v/v ammonium 
hydroxide.  The eluents were evaporated to dryness under nitrogen at 30 0C, 
reconstituted with 80 ìL of initial mobile phase and 20 ìL were injected to LC-
MS/MS.  
7.3.3.2 Chromatography conditions 
BUP and NBUP were separated using a Gemini C18 Column (150 mm X 2.0 mm, 
5 ìm particle size), protected with a guard column (4 mm x 2.0 mm, 
Phenomenex, Torrance, CA) containing identical packing material.  Gradient 
elution was based on a mobile phase consisting of 3 mM ammonium formate + 
0.001% formic acid in water (1) and acetonitrile (2) at a flow rate 0.3 ml/min.  
LC separation was started with 75% (1), decreasing to 20% at 15 min; at 17 min 
90% (2) was maintained for 2 min.  Then the initial mobile phase was applied for 
5 min. The column temperature was maintained at 35 0C. 
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7.3.4 Instrumentation 
Analysis of BUP and its metabolites was performed using a Thermo Finnigan LCQ 
DECA XP Plus ion trap instrument (Thermo Finnigan, San Jose, USA) equipped 
with a Surveyor LC system interface. The column oven and auto-sampler tray 
were maintained at 30 0C at 4 0C respectively. Ionisation of analytes was carried 
out using electrospray positive ion mode. The capillary temperature, sheath gas 
flow rate, auxiliary gas flow rate and collision energies were optimized for each 
analyte separately.  
Analytes of interest and internal standards were identified and quantified based 
on their retention times, precursor ions and two product ions using Selection 
Reaction Monitoring (SRM) with the exception of BUP3G and NBUP3G which are 
fragmented by losing the glucuronic acid moiety (m/z 176) from the protonated 
molecular ions to form single product ions at m/z 468.3 and 414.4, respectively. 
In this case it was not possible to obtain two product ions from BUP3G and 
NBUP3G. Therefore, 90% of product ions and 10% of precursor ions were used for 
the quantification and identification of BUP3G and NBUP3G, respectively. The 
spray voltage used was 5 kV. The MS/MS parameters are detailed in Table 7-1.  
7.3.5 Method Validation 
7.3.5.1 Linearity 
Eight different calibration concentrations in the range 5-250 ng/mL spiked in 
urine were extracted and analysed using the developed method. Calibration 
curves were plotted by dividing the peak area ratios obtained at each 
concentration to internal standards. The correlation coefficient (r2) was 
obtained for each linear regression curve. 
7.3.5.2 Recovery and matrix effects 
The method described by Matuzewski et al 51 was used for the assessment of the 
SPE recoveries (RE) and matrix effect (ME) of opioids and their metabolites using 
urine as matrix. REs and MEs of analytes of interest were calculated by dividing 
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the peak area ratios of analytes of interest over their internal standards using 
equations 3-1 and 3-2. 
Table 7-1: LC-MS/MS parameters, LODs and LLOQs for BUP metabolites. 
 
 
 Parameters BUP BUP3G NBUP  NBUP3G  
Precursor Ion  (m/z) 468.4 644.3 414.3 590.5 
Product  Ion(s) 
(m/z) 
414.4, 369.3 468.3, 644.3 396, 340 414.4, 590.5 
Quantifier  Ion 
(m/z) 
468.4→ 414.4 644.3→ 468.3 414.3→396 590.5→ 414.4 
Qualifier Ion(m/z) 468.4 →396..3 644.3→644.3 414.3→340 590.5 →590.5 
SRM transition 
(Quan/Qual) 
414.4/396.3 468.3/644.3 396/340 414.4/590.5 
SRM  *  Transition 
Ions  (R.S.D. #) 
2.6 (8.0) 7.0 (17.0) 1.6 (4.0) 5.8 (5.0) 
A
n
a
ly
te
s 
 
 
 
RT & (minutes) 22.49 18.3 19.4 14.2 
Internal  Standard 
(IS) 
BUP-D3 BUP-D3 NBUP-D3 NBUP-D3 
IS Precursor  Ion(s) 
(m/z) 
472 472 417 417 
In
te
rn
a
l 
St
a
n
da
rd
s 
Product Ion (m/z) 415, 400 415, 400 399, 343 399, 343 
Sheath Gas (AU) 33 30 30 30 
Auxiliary Gas (AU) 10 0 0 0 
Capillary 
Temperature (ºC) 
270 295 300 280 
Collision energy 
(%) 
36 30 31 30 
Retention Widow 
No. 
3 2 2 1 
LOD ## (ng/mL) 0.2 0.2 0.4 0.2 
A
n
a
ly
te
s 
a
n
d 
th
ei
r 
in
te
rn
a
l s
ta
n
da
rd
s 
 
LLOQ ** (ng/mL) 0.7 0.7 1.2 0.7 
* SRM: Selective reaction monitoring. 
#
 R.S.D: Relative standard deviations (%). 
&
 Retention time of drugs. 
 ## LOD: Limit of detection. 
 
** LLOQ: Lower limit of quantitation; 
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The effect of endogenous urine matrix components on analyte ionisation during 
LC-MS/MS was assessed by analysing blank urine obtained from five different 
sources. Urine samples were extracted using the developed method and spiked 
after SPE at two concentrations (5 and 100 ng/mL) of BUP and metabolites and 
50 ng/mL of internal standards. 
7.3.5.3 Limit of Detection and Lower Limit of Quantitation 
Limits of detection (LODs) and lower limits of quantitation (LLOQs) were 
obtained by extending the calibration curves to the concentration of the 
expected LODs and LLOQs of analytes of interest. A linear calibration model was 
established for each analyte of interest at eight concentrations (0.1, 0.2, 0.3, 
0.5, 0.75, 1, 2.5 and 5 ng/mL) plus blank, and 50 ng/mL of internal standard 
working solution (1 ìg/mL) was added. Spiked urine samples were then 
extracted using the developed method. LODs and LLOQs values were obtained 
using equations 2-1, 2-2 and 2-3, 2-4, respectively.  
7.3.5.4 Intra-assay and inter-assay precision 
Five replicate human urine samples (n=5) were spiked with BUP and metabolites 
at three concentrations (5, 25 and 100 ng/mL). The extracts were analysed using 
the developed method on the same day to determine Intra-assay precision. The 
inter-assay precision was measured in a similar manner to the intra-assay 
precision on five different days.  
7.3.5.5 Stability 
Stability was assessed using human urine spiked with the BUP and its metabolites 
at 100 ng/mL (n=3). Short-term temperature stability at room temperature was 
investigated using spiked urine stored at 4 and 24 hours. Freeze-thaw stability of 
analytes of interest was determined after four cycles (thawed, left at room 
temperature for 3 hours then refrozen) on consecutive days. Auto-sampler 
stability using reconstituted extracted sample was determined at 48 hours and at 
one week after extraction. Long-term stability for analytes of interest at -20 and 
4 oC for period of 24 hours, 48 hours, 1 week and 1 month were investigated. 
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Calibration curves were prepared for each batch of samples using standards 
spiked in human urine at 5, 10, 20, 25, 50, 100, 200 and 250 ng/mL plus blanks. 
7.3.5.6 Specificity  
These were similar to those described in Chapters 6 (section 6.7.5.6).  
7.4 Results  
7.4.1 Method Validation  
Linear regression lines were obtained for each analyte over the calibration range 
of 5-250 ng/mL and r2 values were greater than 0.999 for all analytes of interest. 
Low LOD and LOQ values were required as there are big differences in the 
concentrations of analytes detected in real case urine samples. The main portion 
of a BUP dose is excreted as glucuronide at high concentration levels compared 
to BUP and NBUP. Diluted urine samples are often used to bring glucuronide 
metabolites within the range of the calibration curve, as concentrations of more 
than 500 ng/mL for total BUP (TBUP) and total NBUP (TNBUP) have been 
reported 250,251,253,256,335,354. If a high LLOQ is obtained, the BUP and NBUP result 
could result in false negatives. In the present study, lower LODs and LLOQs were 
aimed at filling the gaps between analytes of interest, and these were in the 
range of 0.2-0.4 and 0.7-1.2 respectively. LODs and LLOQs for analytes of 
interest are given in Table 7-1, Figure 7-2. 
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Figure 7-2: Mass chromatograms for buprenorphine and metabolites at 1 ng/ml. 
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The recoveries of BUP metabolites were calculated using equation 3-2. Good 
recoveries were obtained for BUP3G, NBUP, BUP and NBUP3G at all three 
concentrations investigated and were in the ranges 76-93%, 78-95% and 87-96% 
at 5, 25 and 100 ng/mL, respectively. Recoveries are listed in Table 7-2.   
Matrix effects were measured at two concentrations (5 and 100 ng/mL) using 
equation equation 3-1. From the results listed in Table 7-3, both ion suppression 
and ion enhancement were observed using urine obtained from five different 
sources. Percentages above 100% indicate the presence of ion enhancement, 
while those below 100% indicate the presence of ion suppression. Ion suppression 
was observed with BUP and NBUP3G at the higher concentration (100 ng/mL) 
amounting to -4% and -8%, respectively. Ion enhancement was detected with all 
analytes of interest at the lower concentration (5 ng/mL) and with BUP3G and 
NBUP at the higher concentration (100 ng/mL).  
Table 7-2: Recoveries of buprenorphine metabolites 
 
 
Drug Nominal  
Conc.  
Matrix effects #  Recovery ## 
 ng/mL Mean % * (R.S.D &) 
BUP  5 112 (6) 76 (3) 
 
25 N/A § 78 (6) 
 
100 96 (7) 87 (10) 
BUP3G  5 110 (3) 85 (12) 
 
25 N/A 91 (12) 
 
100 105 (5) 96 (3) 
NBUP 5 110 (6) 77 (9) 
 
25 N/A 88 (13) 
 
100 103 (6) 89 (11) 
NBUP3G  5 103 (12) 93 (10) 
 
25 N/A 95 (3) 
 
100 92 (8) 92 (4) 
#
 Human urine was sourced from completed urine samples that were scheduled for 
destruction and contained no analytes of interest. 
* Matrix effect is expressed as the response obtained for a standard chromatographed along 
with matrix extract compared to that obtained with an unextracted standard chromatographed 
in mobile phase only, expressed as a percentage. Standard was spiked into matrix extract at a 
concentration of 5, 25 and 100 ng/mL. 
## Value calculated from the average recovery for the replicate analyses (n=5) 
 
&
 R.S.D. %: Relative standard deviation expressed as a percentage. 
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Percentage relative standard deviations (RSD) were used to assess the intra- and 
inter-assay precision of the method for BUP and its metabolites at three 
concentrations. RSD values better than 12% and 14% were for intra- and inter-
assay precision, respectively (Table 7-2).   
BUP and metabolites were stable after being subjected to different storage 
conditions, namely: short-term stability at room temperature for 4 hours and 24 
hours, for four freeze/thaw cycles, in the auto-sampler for up to one week and 
long-term at -20 0C and 4 0C for up to 1 month (Table 7-3). The stability of BUP 
and its metabolites has previously been studied and the results agreed with 
those obtained in the present study 250,256,332,335,363. 
Table 7-3: Matrix effects 
 
 
Analytes Nominal  
Conc.  
 
Source 1 # Source 2 Source 3 Source 4 Source 5 
 ng/mL Mean % **    (R.S.D &) 
BUP  5 115 (12) 118 (1) 105 (11) 117 (3) 103 (3) 
 
100 103 (1) 103 (4) 91 (8) 88 (1) 95 (5) 
BUP3G  5 113 (13) 109 (10) 108 (13) 114 (2) 105 (13) 
 
100 112 (10) 104 (3) 107 (1) 99 (15) 104 (13) 
NBUP  5 111 (1) 112 (5) 103 (6) 119 (12) 106 (9) 
 
100 96 (5) 97 (6) 107 (6) 105 (4) 109 (1) 
NBUP3G  5 89 (8) 103 (1) 122 (5) 103 (4) 98 (4) 
 
100 98 (11) 87 (5) 101 (1) 92 (15) 82 (4) 
# Human urine was sourced from completed urine samples that were scheduled for destruction 
and contained no analytes of interest. 
** Matrix effect is expressed as the response obtained for a standard chromatographed along 
with matrix extract compared to that obtained with an unextracted standard chromatographed 
in mobile phase only, expressed as a percentage. Standard was spiked into matrix extract at a 
concentration of 5, 25 and 100 ng/mL. 
&
 R.S.D.: Relative standard deviation expressed as a percentage. 
 189 
Table 7-4: Method precision 
 
Table 7-5: Stability studies (% relative to starting concentration) 
 
Analytes Nominal  
Concentration 
Intra-day  
precision 
Inter-day   
precision 
 Measured concentrations (ng/mL) * (R.S.D %#) 
BUP  5 4.7 (12) 5.2 (12) 
 
25 27 (3) 25 (14) 
 
100 102 (6) 98 (6) 
BUP3G  5 4.6 (7) 5.3 (6) 
 
25 26 (7) 25 (5) 
 
100 100 (9) 98 (3) 
NBUP  5 4.4 (10) 5.1 (10) 
 
25 24 (7) 22 (6) 
 
100 101 (7) 99 (8) 
NBUP3G  5 5.4 (9) 4.9 (11) 
 
25 24 (8) 23 (6) 
 
100 99 (6) 96 (4) 
* Value calculated from the average recovery for the replicate analyses (n=5) 
 
#
 R.S.D. %: Relative standard deviation expressed as a percentage. 
Storage 
 Conditions # 
 BUP  BUP3G  NBUP  NBUP3G  
  Mean % * (R.S.D % &) 
Room  Temperature 4 hours 115 (14) 105 (6) 103 (10) 99 (7) 
 
24 hours 94 (5) 102 (10) 105 (6) 109 (1) 
Freeze-thaw  4 cycles 101 (2) 119 (6) 100 (8) 93 (12) 
Auto-sampler 48 hours 98 (11) 95 (3) 104 (5) 93 (3) 
 
Week 108 (1) 100 (6) 102 (10) 99 (6) 
Freezer at -20 0C 24 hours 101 (5) 104 (2) 94 (4) 96 (9) 
 
48 hours  106 (4) 98 (6) 101 (4) 96 (10) 
 
Week 105 (12) 97 (13 104 (8) 103 (6) 
 
Month 109 (3) 93 (9) 94 (7) 102 (6) 
Refrigerated 4 0C 24 hours 96 (8) 107 (4) 94 (11) 94 (10) 
 
48 hours 104 (5) 104 (12) 108 (3) 93 (2) 
 
Week 102 (14) 110 (7) 103 (4) 97 (2) 
 
Month 107 (5) 100 (12) 109 (10) 99 (10) 
#
 Starting concentration is 100 ng/mL;  
*
 Value calculated from the average recovery for the replicate analyses (n=3). 
&
 R.S.D. %: Relative standard deviations expressed as a percentage. 
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7.4.2 Case Samples 
The direct method developed was intended to be employed for routine analysis 
of urine samples for BUP and to be compared with the in-house hydrolysis 
method used at present for this analysis. All positive BUP cases received over the 
course of one year were analysed using the two methods in parallel. From the 
results listed in Table 7-6 and 7-7, twenty cases tested positive using the 
hydrolysis method, and twenty-one cases tested positive using the direct 
method. TBUP and TNBUP concentrations in positive cases obtained after 
hydrolysis ranged from not detected to 300 ng/mL and not detected to 294 
ng/mL with average concentrations of 52 and 69 ng/mL, respectively. However, 
the concentrations obtained by direct analysis ranged from 6 to 401 (average 61 
ng/mL) and 9 to 318 (average 85 ng/mL) for TBUP and TNBUP, respectively 
(Figure 7-3). 
Using the direct method, analyte concentrations averaged 53 ng/mL (range 2-
358 ng/mL) for BUP3G, 9 ng/mL (range not detected to 41 ng/mL) for NBUP, 8 
ng/mL  (range not detected to 43 ng/mL) for BUP and 76 ng/mL (range 9-288 
ng/mL) for NBUP3G (Table 7-7). BUP3G and NBUP3G were detected in all cases. 
However, BUP and NBUP were negative in several cases. Using the hydrolysis 
method, case 3 tested negative for NBUP and neither BUP nor NBUP were 
detected in case 13.   
Results from the two methods correlated well, with correlation coefficients (r2) 
of 0.994 and 0986 for TBUP and TNBUP respectively. Higher concentrations were 
obtained by the direct method compared to the hydrolysis procedure (Table 7-6 
and 7-7, Figures 7-4 and 7-5). The data given in Table 7-8 indicate that the 
differences between the two methods reach statistical significance (p<0.05) 
based on the confidence intervals for the intercepts and gradients, indicating  a 
systematic error in one of the methods 62.  Possible explanations are incomplete 
hydrolysis in the conventional method or interference in the direct method. The 
latter was examined during the validation procedure but no interferences were 
detected. However, for both methods the median ratio for TNBUP/TBUP was 2. 
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The median BUP3G/BUP and NBUP3G/NBUP ratios obtained by direct analysis 
when both were detected were 5 and 6, respectively.  
Table 7-6: Results obtained by in-house LC-MS/MS hydrolysis method 
(ng/mL) 
Case no. TBUP # TNBUB * TBUP+TNBUP TNBUP/TBUP  
 Measured concentration (ng/mL)    
1 63.0 78.0 141.0 1.2 
2 15.0 45.0 60.0 3.0 
3 29.0 n.d. & 29.0 n.d. 
4 32.0 67.0 99.0 2.1 
5 68.0 13.0 81.0 0.2 
6 19.0 66.0 85.0 3.5 
7 14.0 33.0 47.0 2.4 
8 19.0 11.0 30.0 0.6 
9 29.0 62.0 91.0 2.1 
10 300.0 29.0 329.0 0.1 
11 120.0 240.0 360.0 2.0 
12 198.0 277.0 475.0 1.4 
13 n.d. n.d. n.d. n.d. 
14 6.0 22.0 28.0 3.7 
15 52.0 294.0 346.0 5.7 
16 43.0 15.0 58.0 0.3 
17 17.0 46.0 63.0 2.7 
18 10.0 12.0 22.0 1.2 
19 24.0 25.0 49.0 1.0 
20 19.0 76.0 95.0 4.0 
21 15.0 45.0 60.0 3.0 
#
 TBUP: Total buprenorphine; * TNBUP: Total norbuprenorphine;  
&
 n.d: Not detected. 
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Table 7-7: Concentrations of BUP and metabolites obtained by the direct 
method (ng/mL). 
Case 
no. 
BU
P3
G
 
 
N
BU
P 
 
BU
P 
 
N
BU
P3
G
 
 
BU
P3
G
/ 
BU
P 
N
BU
P3
G
/ 
N
BU
P 
TB
U
P 
# 
TN
B 
U
P*
 
TN
BU
P/
 
TB
U
P 
TB
U
P+
 
TN
BU
P 
 Measured concentration (ng/mL)       
1 46.0 6.0 5.0 95.0 9.2 15.8 51.0 101.0 2.0 152.0 
2 20.0 n.d & n.d 52.0 n.d n.d 20.0 52.0 2.6 72.0 
3 34.0 5.0 3.0 15.0 11.3 3.0 37.0 20.0 0.5 57.0 
4 20.0 6.0 4.0 76.0 5.0 12.7 24.0 82.0 3.4 106.0 
5 60.0 5.0 13.0 13.0 4.6 2.6 73.0 18.0 0.2 91.0 
6 14.0 6.0 n.d 93.0 n.d 15.5 14.0 99.0 7.1 113.0 
7 10.0 6.0 6.0 14.0 1.7 2.3 16.0 20.0 1.3 36.0 
8 16.0 n.d n.d 9.0 n.d n.d 16.0 9.0 0.6 25.0 
9 28.0 7.0 6.0 44.0 4.7 6.3 34.0 51.0 1.5 85.0 
10 358.0 8.0 43.0 42.0 8.3 5.3 401.0 50.0 0.1 451.0 
11 130.0 15.0 14.0 260.0 9.3 17.3 144.0 275.0 1.9 419.0 
12 210.0 41.0 35.0 265.0 6.0 6.5 245.0 306.0 1.2 551.0 
13 5.0 n.d 4.0 16.0 1.3 n.d 9.0 16.0 1.8 25.0 
14 2.0 5.0 4.0 9.0 0.5 1.8 6.0 14.0 2.3 20.0 
15 52.0 30.0 23.0 288.0 2.3 9.6 75.0 318.0 4.2 393.0 
16 39.0 5.0 n.d 14.0 0.0 2.8 39.0 19.0 0.5 58.0 
17 15.0 14.0 n.d 62.0 n.d 4.4 15.0 76.0 5.1 91.0 
18 8.0 n.d n.d 17.0 n.d n.d 8.0 17.0 2.1 25.0 
19 20.0 12.0 1.2 35.0 16.7 2.9 21.2 47.0 2.2 68.2 
20 14.0 17.0 n.d 117.0 n.d 6.9 14.0 134.0 9.6 148.0 
21 20.0 n.d n.d 52.0 n.d n.d 20.0 52.0 2.6 72.0 
#
 TBUP: Total buprenorphine; * TNBUP: Total norbuprenorphine; & n.d: Not detected. 
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Figure 7-3: Mass chromatograms for buprenorphine and metabolites in Case 19. 
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Figure 7-4: Comparison of results from hydrolysis and direct methods for 
total buprenorphine obtained for 21 case samples. 
 
Norbuprenorphine Comparision
y = 1.0569x + 12.359
R2 = 0.9305
0.0
50.0
100.0
150.0
200.0
250.0
300.0
350.0
400.0
0 50 100 150 200 250 300 350 400
In-house method (ng/ml)
D
ire
ct
 
m
et
ho
d 
(m
g/
m
m
l)
 
Figure 7-5: Comparison of results from hydrolysis and direct methods for 
total norbuprenorphine obtained for 21 case samples. 
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Table 7-8: Regression data for comparison of hydrolysis and direct methods 
for total buprenorphine andtotal  norbuprenorphine in 21 cases 
 
7.5 Discussion  
7.5.1 Method validation 
This work was aimed at validating and developing a sensitive method with low 
LODs and LLOQs to be applied to routine analysis of BUP in urine samples. Both 
the SPE and LC methods were adapted from previously published method for the 
determination of 24 opioids and their metabolites in blood specimens (chapter 
5). There was no interference from drugs with similar structures such as opioids 
or from drugs routinely detected in forensic cases.  
A comparison of enzymatic and non-enzymatic hydrolysis methods for 
determining BUP metabolites was report by Kronstrand et al 354 using a direct 
injection method. They found the peaks of glucuronide metabolites were very 
small. The authors concluded that the used of a direct injection procedure may 
lead to inaccurate determination of analytes of interest at low concentrations 
due to the ion suppression in the ES interface which affects ionisation of the 
polar glucuronides. The authors also recommended using an SPE method for 
removing endogenous compounds from the matrix.  
  Total Buprenorphine Total Norbuprenorphine 
 
Correlation coefficient (r2) 0.994 0.986 
Intercept -7.29 9.51 
Intercept 95% confident 
interval  
-12.99 to  -1.59 0.056 to 18.97 
Intercept 
data 
p-value 0.015 0.05 
X-variable 1 1.31 1.08 
95% confident interval 1.25 to 1.38 0.997 to 1.168 
Slope 
data 
p-value 2.8 E-20 1.91E-16 
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Direct injection was excluded in the present method due to the higher LODs and 
LLOQs obtained and small peaks of analytes of interest, which indicate large 
matrix effects on the ionisation of glucuronide metabolites. The present method 
was intended to quantify BUP and NBUP with their glucuronides simultaneously. 
Therefore, a method of extraction which would concentrate the analystes was 
required due to the low concentrations of BUB and NBUP reported in real case 
samples, which led to them being excluded in the method by Hegstad et al 355. 
The assessment of the effects of matrix endogenous components on ionisation of 
analytes is a critical aspect of LC-MS method validation due to the susceptibility 
of the technique to ion suppression or enhancement 16,47,51,89. The mechanisms 
for these effects are unknown but are influenced by ionisation method (ESI or 
APCI), type of biological specimens and the adequacy of sample preparation 
51,119,120.  
Elimination of matrix effects is an objective of method optimisation 117,120. It has 
been suggested that improved sample preparation procedures could resolve and 
minimise the matrix effects. Also, improved LC separation was found to 
eliminate matrix effects 51,118,364. However, concentrating analytes of interest 
using SPE could also result in increased concentrations of matrix endogenous 
components.  
Murphy and Huestis 256 reported ion suppression after using an SPE method for 
BUP, BUP3G and NBUP. They concluded that SPE reduced the matrix effects to -
25 to -30% for plasma samples, plasma being considered a dirtier matrix than 
urine. In the same study, ion enhancement of +10% was observed for NBUP3G. 
Hegstad et al 355 reported ion enhancement of +153% and ion suppression of -14% 
with BUP3G and NBUP3G, respectively. The high ion enhancement for BUP3G 
indicated that SPE is a crucial step before analysis by LC-MS/MS and the authors 
recommended the production of internal standards for glucuronides which could 
overcome the matrix effects. Also, the short gradient of 7 min used in that study 
may have exacerbated the matrix effects.  
In the present study, there were no commercially available internal standards 
for the glucuronide metabolites and so BUP-D4 was used as internal standard for 
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BUP and B3G and NBUP-D3 was used as internal standard for NBUP and NBUP3G. 
A similar approach was used by Murphy and Huestis 256 whereas Huang et al  used 
M3G-D3 as internal standard to quantify BUP3G and NBUP3G and Hegstad et al 355 
used NBUP-D3 as internal standard for both glucuronides. In the present study, 
matrix effects were minimised (-4% and -8% suppression for BUP and NBUP3G, 
respectively) using SPE and a long gradient elution in which NBUP3G was the first 
analyte to be eluted at 14 min. 
7.5.2 Case samples  
Although BUP3G and NBUP3G standards have been available for many years, 
hydrolysis is still often used as a pre-treatment in the determination of TBUP and 
TNBUP 250,355 and only two studies have reported concentrations of BUP3G and 
NBUP3G in case urine samples 250. Huang et al reported concentrations of BUP 
metabolites in five subjects who were treated daily with 16 mg BUP for 21 days 
355. After 24 hours of administration, the average concentrations of analytes 
were 1, 112, 95 and 662 ng/mL for BUP, NBUP, BUP3G and NBUP3G, 
respectively.  
Hegstad et al 355 developed a method for detecting BUP3G and NBUP3G alone, 
without including BUP and NBUP. In that study, 928 urine cases were tested and 
concentrations of both glucuronides were less than 300 ng/mL. Tracqui et al 340 
reported concentration ranges of 4 to 1033 ng/mL and 7 to 230 ng/mL for BUP 
and NBUP respectively, with median and average ratios for NBUP/BUP of 0.7 and 
0.8. Kronstrand et al 354 reported concentrations of TBUP and TNBUP ranging 
from 3 to 796 ng/mL and 5 to 2580 ng/mL, respectively with a median ratio of 
TNBUP to TBUP of 2. The median and average ratios obtained in the present 
study were also in agreement with Kronstrand et al 354. The median and average 
ratios of TNBUP/TBUP were 2; the concentrations obtained in the current study 
ranged from 6 to 401 ng/mL (average 61 ng/mL) and 9 to 318 ng/mL (average 85 
ng/mL) for TBUP and TNBUP, respectively. 
George et al 365 determined the mean concentration ratio of NBUP to BUP using 
positive BUP urine samples which found to be 2.8. BUP and NBUP concentrations 
were range of 28 to 1458 ng/mL and 28 to 1843 ng/mL.   
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Miller et al 253 reported the concentrations of TBUP and TNBUP in clinical and 
drug abuse cases obtained using a hydrolysis method. The concentrations of 
TBUP and TNBUP were much higher in clinical cases, ranging from 123 to 1931 
ng/mL and 1001 to 7550 ng/mL respectively, compared to the abuse cases, 
which ranged from trace concentrations to 179 ng/mL and not detected to 97 
ng/mL for TBUP and TNBUP, respectively. In that study, NBUP was not 
detectable when BUP was at a low concentration.  
Fox et al 356 measured BUP and NBUP using LC-MS/MS before and after treatment 
with â-glucuronidase in real case urine samples. Interestingly, the percentages 
of free metabolites were in the range not detected to 67% and not detected to 
100% with means of 6.4% and 34.7% for BUP and NBUP respectively.  
The median TBUP/TNBUP ratios reported by Miller et al 253 and Huang et al 250 
for clinical cases were 12 and 8, respectively.  However, the ratio in Miller et al 
253  for abuse cases was very low, the average being 0.3 and the highest value 
being 1.8. The median ratios of TNBUP/TBUP in the present study were 2 for 
both the hydrolysis and direct methods. Differences in the ratio of TNBUP to 
TBUP could result from methodological parameters such as different â-
glucuronidase sources, incubation times and temperatures, from differences in 
the study groups, for example, as a result of population pharmacogenomic 
variations, or from differences in the urine collection protocol, affecting, for 
example, pH, frequency of collection and elapsed time after drug administration 
14.    
Enzymatic hydrolysis methods are usually optimised using BUP3G standard then 
applied to real case samples containing both BUP3G and NBUP3G. The rate of 
hydrolysis would be different for each glucuronide metabolite and could 
potentially lead to false negative results for NBUP3G. The hydrolysis of NBUP3G 
was much slower than BUP3G, with 85% being hydrolysed after incubation at 
37oC for 20 hours using â-glucuronidase from E.coli 354. Increased amounts of 
enzyme might have interfered in the analysis and for that reason the minimum 
amount of enzyme was used even though NBUP3G was not completely 
hydrolysed. George et al 365 used 30 minutes incubation at 60 oC with â-
glucuronidase from Helix pomatia to hydrolyse glucuronide metabolites to their 
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free form. The use of the same enzyme sources in another study found that 
BUP3G needed 4 hours of incubation at 60 oC and 16 hours at 37 oC to obtain 
complete hydrolysis for BUP3G 362.  
Elsohly et al 348 studied NBUP3G hydrolysis using â-glucuronidase from Helix 
pomatia and found NBUP3G completely hydrolysed after 4 hours at 60 oC. The 
authors reported poor hydrolysis of NBUP3G using P. vulgata. However, Fox et al 
356 used the latter enzyme source for the hydrolysis of glucuronide metabolites 
after incubation for one hour at 56 oC.  
The in-house method used in this study was similar to the method of Elsohly et 
al 348 but with a 3 hour incubation period. Also, hydrolysis followed by SPE and 
LC-MS/MS was compared to liquid-liquid extraction followed by GC-MS by Elsohly 
et al 348. The difference in incubation time could also cause some differences in 
analyte concentrations obtained by these two different studies and lead to 
incomplete hydrolysis of NBUP3G.   
7.6 Conclusions  
A sensitive and selective method for the direct determination of BUP and its 
metabolites in urine was developed and validated and compared with a 
conventional in-house hydrolysis method using 21 real case samples. Results 
from the two methods correlated well, although the direct method gave slightly 
higher concentrations for BUP metabolites compared to the hydrolysis method. 
However, it has confirmed that the in-house hydrolysis procedure was effective 
in cleaving glucuronide conjugates at the range of concentrations encountered in 
cases in this study, which indicate buprenorphine abuse. The concentrations of 
BUP metabolites are much higher in clinical cases and this should be taken into 
consideration when enzymatic hydrolysis procedures are used since the elevated 
concentrations may result in incomplete hydrolysis. Also, the hydrolysis rates of 
BUP3G and NBUP3G are different and it is important that hydrolysis methods are 
optimised using both glucuronide metabolites. The two methods used in this 
study gave the same ratios for TNBUP/TBUP. 
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The ratios between conjugated metabolites and their free forms are of interest 
and can be helpful in the examination of enzymatic hydrolysis methods. In 
addition, ratios may be of value in interpretation of cases but additional work is 
required involving controlled administration studies to allow this to be 
evaluated. Urine could be used as an indicator of recent use of diamorphine, for 
example if morphine is absent in urine but present in blood it would indicate 
recent diamorphine use. Lack of glucuronide metabolites in urine would indicate 
a single dose or intermittent user as opioid addicts administer once a day at 
least 9,125. The case is different with BUP as it is mostly excreted as glucuronide 
metabolites. Huang et al 250 reported that NBUP3G is the primary metabolite in 
both plasma and urine. A more research is needed to investigate the usefulness 
of using BUP metabolites in determining the time which has elapsed after the 
last administration. Finally, the sensitive and selective LC-MS procedures now 
available should replace traditional hydrolysis methods since these permit 
analysis of BUP and its individual metabolites as well as reducing the analysis 
time. 
 201 
8 Oxycodone Related Fatalities in the West of 
Scotland 
8.1 Introduction 
Oxycodone (Oxycontin, Roxicodone, Tylox) is a semisynthetic opioid derived 
from thebaine. Oxycodone can be used alone or in combination with other drugs 
such as acetaminophen and aspirin and has been successfully used clinically 
since 1917 for pain relief. A controlled-release form of oxycodone (OxyContin) 
has been available since 1995 for the treatment of acute to moderate pain 
extending over long periods of time (>12 hours) and it is completely absorbed in 
the stomach without being affected by the presence of food 132,366.  
Although the oxycodone controlled release preparation has been found to be 
safe and effective, it has gained wide popularity as a drug of abuse and deaths 
attributed to oxycodone intoxication have increased 367-369. OxyContin is an 
expensive and powerful analgesic with similar potency to morphine. A method 
for abusing controlled-release oxycodone tablets was developed by drug abusers, 
which makes oxycodone more immediately available by administration after 
crushing the tablets. Lethal overdose due to the consumption of numerous 
tablets has been reported. In many deaths intact tablets were found in stomach 
but the drug content had been completely absorbed and little or no oxycodone 
remained in the tablet, which was considered an indicator that suicide was the 
manner of death 368,369. Anderson et al  369 reported the presence of intact 
tablets in the stomach of 15 out of 36 oxycodone related deaths.  
Owing to the shortage of diamorphine in the United State of Amerca (USA), 
oxycodone misuse and related fatalities have been widely reported but it is 
hoped that stricter regulations will prevent a similar trend in the United 
Kingdom (UK). However, the number of prescriptions for oxycodone in Scotland 
has risen by 430% since prescribing began in 2002 370. This large increase in 
oxycodone prescriptions increases the possibility of the drug presenting in post-
mortem cases and being implicated in the cause of death of accidental or 
intentional poisonings.  
 202 
8.1.1 Metabolism and excretion 
Oxycodone is metabolised in the liver by cytochrome P450 3A4 and 2D6, 
primarily to noroxycodone through N-demethylation and to oxymorphone 
through O-demethylation 132,371,372. Oxymorphone is a minor metabolite but is 
100 times more potent than oxycodone. Noroxycodone is the most abundant 
metabolite but it is relatively inactive and is reported to be 3-4 times less potent 
than oxycodone 124,126,366. Oxycodone and its two primary metabolites also 
undergo reductive metabolism to form á- and â-oxycodol, á- and â-noroxycodol 
and á- and â- oxymorphol.  
Oxycodone and noroxycodone are excreted unchanged in urine while 
oxymorphone is excreted only as the glucuronide metabolite 366,371. Lalovic et al  
371 have reported on the pharmacokinetics of both oxidative and reduction 
metabolic pathways. The concentrations of metabolites were found to be dose 
dependent and the N-demethylation pathway gave the major metabolite. 
Oxidative metabolites comprised nearly 50% of the oxycodone dose excreted in 
urine, with only 10% as the unchanged drug and 18% as the reduced metabolites 
(Figure 8-1).  
8.1.2 Review of oxycodone related fatalities  
Symptoms reported for oxycodone overdose include severe respiratory 
depression, skeletal muscle flaccidity, cold, clammy skin, reduction of blood 
pressure and heart rate, coma, cardiac arrest and death 132,368. Although many 
studies focused on oxycodone related fatalities in the last decades, the actual 
role of oxycodone in fatalities is difficult to determine due to the combination 
with other central nervous drugs and overlap of concentration of drugs between 
single drug exposures and poly drug intoxications. Fatalities associated to 
oxycodone alone are rarely reported despite the high use and abuse pattern 
which raises a question of whether deaths happened intentionally or accidentally 
263,373.  
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Figure 8-1: Oxycodone metabolism, (GLU: Glucuronic acid). 
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Oxycodone deaths have mostly been reported in the United States of America 
due to the high rate of addiction to oxycodone as an alternative to heroin, 
especially in rural areas 368,370. However, the first report to discuss oxycodone 
fatalities was from Australia 25. Nine deaths involving oxycodone were 
investigated and it was found that oxycodone can cause death when the blood 
concentration is higher than 0.6 ìg/mL. The concentrations of oxycodone in 
these deaths ranged from 0.6-1.4 ìg/mL with a mean concentration of 0.9 
ìg/mL. Only one case was attributed to suicidal ingestion of oxycodone. 
Oxycodone was detected in another 3 cases at concentrations which were in or 
above the therapeutic range (0.1-0.3 ìg/mL) but was not involved in the cause 
of death. This study may be triggered research on oxycodone related fatalities 
because of concerns about co-administration of the drug with other central 
nervous system depressants and whether chronic use of oxycodone could 
increase user tolerance, resulting in overlap of clinical and toxic drug 
concentration ranges.  
Drugs with a low therapeutic index should be monitored to ensure their 
concentrations are within the therapeutic range. While this can be achieved 
under clinical conditions, it is difficult to achieve with drug abusers. Published 
pharmacokinetic studies on oxycodone involved administration of low doses of 
the drug and plasma concentrations below 0.1 ìg/mL, which are considered low 
compared to the toxic concentrations reported for overdoses cases and this 
indicates a higher safety margin between lethal and therapeutic levels. 
However, the availability of OxyContin tablets containing large doses (40 -80 mg) 
was believed to reduce the therapeutic window and increase the risk of serious 
consequences in adult patients receiving chronic treatment with oxycodone. 
Also, the risk of fatal poisoning is much higher in children who ingest OxyContin 
accidentally or as a result of homicide 374,375.  
The blood concentrations of oxycodone after acute intoxication or suicidal 
ingestion were investigated in 24 post-mortem deaths attributed to the use of 
oxycodone alone, in which no other drugs were detected 376. The average and 
median blood concentrations were 1.23 and 0.43 ìg/mL, respectively. Blood 
concentrations in suicides were 1 ìg/mL and higher, with average and median 
concentrations of 3.9 and 2.5 ìg/mL, in agreement with Cone et al 263, who 
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demonstrated that blood oxycodone concentrations were higher in suicides (1.55 
to 1.7 ìg/mL) than in other types of death (mixed intoxication, natural). 
In addition, Anderson et al 369 reported post-mortem oxycodone concentrations 
in heart and femoral blood from 10 suicides cases which ranged from 0.56-46 
ìg/mL and 0.59-13 ìg/mL respectively. Two of these deaths attributed to 
oxycodone intoxication had oxycodone levels in heart and femoral blood of 0.58-
1.8 and 1.1-3 ìg/mL, respectively 369. Elsewhere, eighteen fatalities related to 
oxycodone ingestion had post-mortem blood oxycodone concentrations ranging 
from 0.21-4.71 ìg/mL with a mean concentration of 0.69 ìg/mL and another 8 
cases in which oxycodone was the only drug detected oxycodone concentrations 
ranged from 0.21-1.22 with a mean concentration of 0.55 ìg/mL. One survivor 
had a blood oxycodone concentration of 2.4 ìg/mL 10 hours after ingestion of a 
massive dose of OxyContin tablets 377. 
High concentrations of oxycodone detected at autopsy may not always indicate 
suicide as the manner of death. Many deaths attributed to natural, traumatic 
and undetermined causes had post-mortem blood concentrations of oxycodone 
which overlapped those in the suicide cases mentioned earlier. Wolf et al 373 
reported 23 cases of death attributed to trauma in which the mean post-mortem 
blood oxycodone concentration was 0.62 ìg/mL, range 0.025-1.99 ìg/mL. In 
another study, the post-mortem blood oxycodone concentrations ranged from 
0.14-1 ìg/mL and 0.27 -1.3 ìg/mL in deaths attributed to natural and 
undermined causes, respectively 369. These results were in agreement with 
Spiller and Abat 376 who reported a mean oxycodone concentration of 0.7 ìg/mL 
and range of 0.17-1.6 ìg/mL.  
Suggestions have been made concerning why blood concentrations of oxycodone 
in these groups of cases overlap or why high concentrations are found in non 
oxycodone related fatalities. One explanation is that oxycodone could 
accumulate in tissue following chronic administration which is subsequently 
released back into the blood 25. The other explanation is oxycodone leaches out 
of controlled-release tablets after death and diffuses from the stomach to the 
blood 369. By contrast, lethal concentrations of oxycodone could be lower than 
0.6 ìg/mL in deaths attributed to intravenous or nasal administration. Langman 
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et al 378 reported a case in which oxycodone was injected and another in which 
it was inhaled nasally. The oxycodone concentrations in blood and urine were 
0.5, 21.7 ìg/mL and 0.05, 6.858 for intravenous and inhalational administration, 
respectively.   
In most publications concerning oxycodone fatalities, the cause of death has 
been attributed to concomitant use of other drugs although the mechanism is 
still not clear 263. Cone et al 263 reported 919 deaths involving oxycodone, of 
which 889 (96.7 %) were attributed to multiple drug intoxication and only 30 (3.3 
%) to intoxication by oxycodone alone. Similarly, Wolf et al 373 reported 172 
deaths involving oxycodone of which only 18 deaths were attributed to 
oxycodone alone and the rest to mixed drug intoxication. Potentially lethal 
concentrations of oxycodone were detected in natural and traumatic deaths as 
well as in suicidal overdose cases. The authors concluded that it may not be 
possible to establish a toxic oxycodone blood concentration due to the overlap in 
concentrations between groups; also, identification of the cause of death in 
cases involving multiple drugs becomes more difficult. Backer and Poklis 379 
reported 70 oxycodone related fatalities of which 38 cases were attributed to 
mixed drug intoxication and only 4 cases to oxycodone alone. There was no 
significant difference between the mean oxycodone concentrations in these 
groups (0.42 and 0.5 ìg/mL) or between the ranges of concentrations (0.06-1.6 
ìg/mL and 0.23-0.76) for mixed drug intoxication and oxycodone only, 
respectively. Natural deaths had a low mean oxycodone concentration of 0.19 
ìg/mL.  
The most commonly co-administered drugs detected with oxycodone are 
benzodiazepines, ethanol, cocaine, other opioids, marijuana and tricyclic 
antidepressants 25,263,373 . In one study of 172 oxycodone related deaths, 
benzodiazepines were detected in 96 cases, of which 37 involved diazepam 
and/or nordiazepam 373. Cone et al 263 found that diazepam was present in 286 
cases in their study. However, the role of diazepam was not examined further 
and the concentrations of diazepam were not provided. Diazepam 
concentrations were within the therapeutic range in cases reported by Drummer 
et al 25 which suggested that the deaths may be attributed to oxycodone with 
only minor contributions from benzodiazepines. The role of ethanol in heroin 
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deaths is well known and the same role could be expected in oxycodone related 
fatalities 150,151,264,267. Other opioids could have additive effects on the 
respiratory centre or higher centres 263.   
8.1.3 Aims  
Methods for identification and quantification of oxycodone using Gas 
chromatography with nitrogen-phosphorus 368,380 or mass spectrometry detectors 
(GC-MS) 25,247,381-387 and High performance Liquid chromatography with 
electrochemical 388,389, ultraviolet 84,390, or tandem mass spectrometry detectors 
(LC-MS/MS) 249,252,391-394 have been reported. In current study, an LC-ESI-MS/MS 
method for the identification and quantification of oxycodone and N- and O-
demethylation metabolites in post-mortem specimens (blood, urine and vitreous 
humour) has been developed and validated. The optimised method was applied 
to the routine analysis of autopsy blood and urine samples from fatalities in the 
West of Scotland. While the role of oxycodone in fatalities has been studied 
25,263,367-369,373-376,378,379,395-397, the role of its metabolites has not yet been 
investigated and in the present study oxycodone and its N- and O-demethylated 
metabolites were measured in deaths attributed to oxycodone intoxication for 
the first time. In addition, the results for free oxycodone are compared with 
those from other studies. 
8.2 Methods and Materials  
8.2.1 Reagents and Standards 
Methanol and acetonitrile were obtained from BDH (Poole, UK). Ammonium 
carbonate, formic acid and ammonium hydroxide were also purchased from BDH. 
Ammonium formate was obtained from Acros Organics (New Jersey, USA). 
Oxycodone, oxycodone-d6, noroxycodone, noroxycodone-d3, oxymorphone and 
oxymorphone-d3 were purchased from LGC Standards (Middlesex, UK). 
All standards and internal standards were obtained as solutions in methanol at a 
concentration of 0.1 mg/mL or 1 mg/mL and each had a purity of more than 
99%.  Bond Elut LRC-C18 cartridges were purchased from Varian Inc (CA, USA).  
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Individual working standards were prepared at concentrations of 20, 10 and 1 
µg/mL by dilution of the stock solutions. Working mixtures of standards and 
internal standards (1 µg/mL) were similarly prepared. 
8.2.2 Solid Phase Extraction and Chromatography conditions 
In the current procedure, SPE and HPLC methods were as described in a 
previously method for the analysis of opioids and their metabolites in autopsy 
blood samples, refer to chapter 5 (section 5.3.2 and 5.3.3). 
8.2.3 Instrumentation 
Analysis of opioids was carried out using a Thermo Finnigan LCQ DECA XP Plus ion 
trap instrument (Thermo Finnigan, San Jose, USA) equipped with a surveyor LC 
system interface. During the analysis the auto-sampler and column oven 
temperatures were maintained at 4 o C and 25 o C, respectively. Ionisation of 
analytes of interest was carried out using electrospray positive ion mode. The 
capillary temperature, sheath gas flow rate, auxiliary gas flow rate and collision 
energies were optimized for each analyte separately. The spray voltage used was 
5 kV.   
Analytes and their internal standards were identified and quantified based on 
their retention times and the presence of two product ions or one product ion in 
addition to the parent ion and adjusted to 10% in comparison to the major 
product ion in selected reaction monitoring (SRM) mode as following: m/z, 298 
and 316 for oxycodone, m/z 284, 229 and 302 for noroxycodone and  284 and 302 
for oxycmorphone, m/z 287 and 305 for both noroxycodone-D3 and 
oxymorphone- D3 and m/z 304 and 322 for oxycodone- D6. The MS/MS 
parameters are detailed in Table 8-1. 
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Table 8-1: LC-MS/MS data 
 
Parameters Oxycodone Noroxycodone Oxymorphone 
Precursor Ion  (m/z) 316 302 302 
Product  Ion(s) (m/z) 298, 316 284, 229 284, 302 
Quantifier  Ion (m/z) 316→298 
 
302→284 
 
302→284 
 
Qualifier Ion(m/z) 316→316 302→302 302→302 
SRM * Transition Ions 
(R.S.D % # ) 
18 ± 2 (11) 10 ± 1 (7) 5.4 ± 0.3 (5) 
A
n
a
ly
te
s 
RT &  (min) 14 12.5 9.3 
Internal  Standard (IS) Oxycodone-d6 Noroxycodone- 
d3 
Oxymorphone- 
d3 
IS Precursor  Ion(s) (m/z) 322 305 305 
In
te
rn
a
l s
ta
n
da
rd
s 
Product Ion (m/z) 322→304 305→287 305→287 
Sheath Gas (AU) 25 15 5 
Auxiliary Gas (AU) 10 20 5 
Capillary Temperature (ºC) 250 300 250 
Collision energy (%) 30 35 26 
Retention Widow No. (min) 3 
(13-17) 
2 
(11-13) 
1 
(6-11) 
    
LOD##  Blood (ng/mL) 
 
0.2 0.4 0.3 
LLOQ **  Blood (ng/mL) 1 1 1 
LOD Urine (ng/mL) 0.2 0.2 0.3 
A
n
a
ly
te
s 
a
n
d 
th
ei
r 
in
te
rn
a
l s
ta
n
da
rd
s 
LLOQ Urine (ng/mL) 1 1.2 1 
 
* SRM: Selective reaction monitoring. 
#
 R.S.D: Relative standard deviations (%). 
&
 Retention time of drugs. 
 ## LOD: Limit of detection. 
 
** LLOQ: Lower limit of quantitation; 
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8.2.4 Method Validation 
8.2.4.1 Linearity 
Two sets of calibration standards were prepared in both blood and urine and 
extracted in accordance with method reported in Chapter 5 (section 5.3.5.1): 
one calibration curve of lower concentrations (5, 10, 20, 25, 50, 100 and 250 
ng/mL) and the other with higher concentrations (50, 100, 250, 500, 750, 1000, 
2500 and 5000 ng/mL).  
Blank and spiked controls with internal standard added at 100 ng/mL were 
included with each run. Calibration curves were plotted of the ratios of analyte 
peak areas to internal standards against concentration. The correlation 
coefficient (r2) was obtained for each linear regression curve.   
8.2.4.2 Matrix Effects and Extraction Recoveries  
Matrix effects and extraction recoveries were measured using the approach of 
Matuszewski 51.  For matrix effects, blood and urine were obtained from five 
different human sources (n=3) and spiked after solid phase extraction with 
analytes of interest at 100 ng/mL. Neat standards were diluted in initial mobile 
phase and injected directly onto the LC-MS/MS. Matrix effects of endogenous 
components were calculated by comparing peak areas of these two sets of 
standards.  
Recoveries were investigated for oxycodone and its metabolites using five 
different concentrations in blood and urine across the two calibration curve 
ranges (5, 25, 100, 750 and 2500 ng/mL). Internal standards were added after 
extraction and recoveries were calculated by comparison of the peak area ratios 
of the extracted and unextracted standards analysed under identical conditions.  
8.2.4.3 Limits of Detection and Lower Limits of Quantification 
The sensitivity of the method was evaluated by determining the limit of 
detection (LOD) and the lower limit of quantification (LLOQ) for each analyte of 
interest. The lower range calibration curves were used for this purpose (n=5) and 
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were prepared using blood spiked at eight different concentrations (0.1, 0.2, 
0.3, 0.5, 0.75, 1, 2.5, and 5 ng/mL) plus blank without internal standard and 
blank containing internal standards. The LODs and LLOQs were calculated as 
reported in Chapter 5, see section 5.3.5.3.  
8.2.4.4 Intra-assay and Inter-assay Precision 
Five different concentrations (5, 25, 100 750 and 2500 ng/mL) of analytes were 
spiked into five replicate blood and urine samples to assess the intra-assay and 
inter-assay precision for the optimised method. Intra-assay precisions of 
oxycodone, noroxycodone and oxymorphone were determined by analysing these 
samples (n=5) in one day while inter-assay precision was measured by analysing 
them on five different days.   
8.2.4.5 Stability  
Stability was assessed using human whole blood and urine spiked with the 
analytes of interest at 100 ng/mL (n=3). Short-term temperature stability at 
room temperature was investigated for human whole blood and urine stored for 
4 and 24 hrs.  Freeze-thaw stability of analytes of interest was determined after 
four cycles (thawed, left at room temperature for 3 hrs then refrozen) on 
consecutive days. Auto-sampler stability using reconstituted extracted sample 
was determined at 48 hrs and at one week after extraction. Long-term stability 
of analytes of interest was evaluated at 4 oC for a period of 1 month, and at -20 
oC for periods of 6 months. Calibration curves were prepared for each batch of 
samples using standards in whole blood at 5, 10, 20, 25, 50, 100, 200 and 250 
ng/mL plus negative controls. 
8.2.4.6 Specificity  
These were similar to those described in Chapters 6 (section 6.7.5.6).  
8.2.5 Case samples 
Samples of autopsy blood were analysed using the proposed method as part of 
the investigation of medico-legal cases involving drug-related deaths submitted 
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to Forensic Medicine and Science, University of Glasgow.  Analyses were 
repeated after dilution of the blood sample when analyte concentrations outside 
the upper calibration range were obtained. 
8.2.5.1 Case 1 
66 year old female, heavy smoker and suffered from high blood pressure as well 
as anxiety and depression, with history of previous suicide attempts.  She was 
last seen alive the night before she died. She stated that she was going to bed 
and took two diazepam tablets, which were prescribed to her. However the 
following morning she was found dead in bed with four empty blister packs of 
OxyContin next to the bed. There were no suspicious circumstances. 
8.2.5.2 Case 2 
42 year old female had a long history of alcohol, and possibly drug abuse, and 
also had chronic obstructive airways disease.  Medication and painkillers had 
been prescribed to her for lung disease. She was seen lying on a sofa in the living 
room the evening before death. The following morning she was still in the same 
position, had no response and was apparently dead. A packet of Oxycontin 
tablets and a bottle of vodka were beside the deceased.  
8.2.5.3 Case 3  
45 year old woman with a history of depression and known to have taken an 
overdose many years ago. She did not drink alcohol but was on a number of 
prescribed medications including Oramorph, amitriptyline, Oxynorm 
(oxycodone), temazepam and acetaminophen.  She was last seen the day before 
death, she did not complain of anything more than the usual stomach pain due 
to a longstanding illness.  The following day she was found lying dead on the 
kitchen floor. 
8.2.5.4 Case 4 
45 old lady who suffered from depression, hypertension and hypothyroidism, and 
had previously undergone a hip replacement operation. She was prescribed 
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numerous medications including diazepam, zopiclone and propranolol.  She was 
last contacted on the day before death at which point she appeared depressed 
and was witnessed to consume a number of diazepam tablets.  The following 
day, following concerns as to her whereabouts, her body was discovered lying on 
top of her bed within her bedroom.  There were no suspicious circumstances. 
8.2.5.5 Case 5 
33 old male who had told his flatmate not to disturb him when he returned home 
as he wished to sleep late.  When his flatmate returned home in the early hours 
of the evening before death he heard this man snoring in his bedroom and left 
him to sleep.  The following morning the flatmate went to the decedents 
bedroom and found the deceased fully dressed on the floor with a suicide note 
to his girlfriend by his feet. The deceased was depressed about the break-up of 
this relationship. The flatmate had a prescription for OxyContin 80mg and two 
blister packs of this medication were missing.   
8.2.5.6 Case 6 
32 year old man had a melanoma removed from his back ten years prior to his 
death.  His medication included oxycodone, Nozinan (levomepromazine), 
Oxynorm, omeprazole, dexamethasone and acetaminophen. He was under 
treatment in hospital for palliative chemotherapy on the day before his death. 
He asked medical staff if he could go outside for fresh air. Then he was reported 
missing to police by medical staff when he did not return to the hospital. The 
following day he was found in undergrowth, unconscious but breathing, and was 
taken to Accident & Emergency at the local hospital.  On admission to hospital 
his GCS was 3/15 and he was hypothermic.  Resuscitation was attempted but this 
was unsuccessful. Three ampoules of oxycodone hydrochloride had been found 
next to the deceased as well as a broken syringe driver.  
8.2.5.7  Case 7 
28 year old man had a history of drug abuse which included diamorphine and 
cocaine.  In 2005 he attempted suicide by hanging and was subsequently on anti-
depressant medication. He was involved in a fight and was arrested by the 
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police. He was taken to hospital for treatment of minor facial injuries and was 
subsequently released from custody.  The following afternoon, he was drinking 
with friends, and at about midnight they went to the home of one of them 
where he later fell asleep on a settee in the living room.  He remained there for 
much of the rest of that day and, to the others, appeared to be sleeping.  In the 
early evening however, they became concerned and found him to be 
unresponsive.  An ambulance was called but the crew found him to be dead.  
8.2.5.8 Case 8 
79 year old female who suffered from osteoporosis and chronic back/shoulder 
pain for which she was prescribed several medications. She suffered post-
operative atrial fibrillation and possible myocardial infarct and was transferred 
to another hospital for further rehabilitative care. On admission she was found 
to be frail and lethargic, and was suffering from an apparent infection for which 
she was prescribed intravenous antibiotics.  Over the next couple of days, her 
condition failed to improve significantly and continued to suffer from a chest 
infection.  She was prescribed analgesic control, and over the next 24 hours or 
so her condition continued to deteriorate until her death. There were, however, 
no suspicious circumstances. 
8.2.5.9 Case 9 
26 year old man with a history of alcohol abuse and depression.  He was 
prescribed Cipramil (citalopram) in July 2008 for the latter. He had previously 
attempted to take his own life by overdosing on an unknown non-prescribed 
medication. On the last evening before his death, the deceased was at a party. 
According to a witness, at some point during the evening the deceased took 
approximately 5g of cocaine, two morphine tablets and alcohol. A witness said 
that the deceased informed him that he had jumped from the window and was 
presently within the garage and was returning to the flat. On arriving a short 
time later he was observed to be breathing heavily and taking extremely deep 
breaths which was causing him some difficulty. The witness suggested that he 
should go to hospital for treatment but he refused. The party continued 
throughout the weekend with witnesses speaking of seeing the deceased having 
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a drink but having difficulty walking and breathing. A witness observed the 
deceased retire to bed; another witness went into the small bedroom of the 
house where she saw the deceased lying on his back fully clothed, not breathing. 
He was cold to the touch. Paramedics were contacted but attempts at 
resuscitation were unsuccessful.   
8.2.5.10 Case 10 
40 year old man suffering from chronic alcohol and illicit drug abuse (reportedly 
using only ecstasy and diazepam), pancreatitis and depression.  As such he was 
prescribed numerous medications including oxycodone. He spent most of the 
weekend in bed, although at one point he reportedly left the flat to buy 
diazepam and on his return claimed to have overdosed on this drug whilst out.  
Soon after he complained of feeling unwell and retired to bed which was the last 
time he was seen alive.  That afternoon he was found unresponsive, paramedics 
in attendance found no signs of life and he was formally declared dead.  
8.3 Results 
8.3.1 Method Validation  
8.3.1.1 LC-MS/MS 
A method for quantification of multiple opioids in fatalities, including oxycodone 
and oxymorphone, was established in previous work (Chapter 5). In the current 
study another oxycodone metabolite, noroxycodone and its internal standard, 
were included and the method was full validated for whole blood and urine.  
The SRM transition ratios were calculated for both calibration standards and 
samples analysed. Oxycodone and its O-demethylated metabolite are 
fragmented to only one major product ion at m/z 298 and 284, respectively. 
Noroxycodone is fragmented to two product ions at m/z 284 and 229. In the 
SOFT guidelines 54, the use of two product ions is recommended but it is 
mentioned that two product ions are not always obtainable using LC-MS 
techniques. Although LC-MS/MS techniques are more sensitive and specific and 
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one product ion is acceptable for quantification purposes, a survival precursor 
ion after fragmentation could be used as qualifier ion by adjusting the cone 
voltage. This was examined in the current study and Chapter 7. Ratios of 90% of 
major product ion to 10% of parent ion were adjusted by tuning with standards 
of oxycodone and oxymorphone and the ratios between precursor and product 
ions were used to confirm SRM transition (see Table 8-1). Complete separation 
was necessarily to avoid co-elution between oxymorphone and noroxycodone 
which have the same precursor ion (mz= 302) and the same major product ion 
(mz= 284). In addition, their deuterated internal standards also have the same 
ions. In the current method full separation between all oxycodone metabolites 
was achieved and each analyte had its own segment window which minimised 
the issues associated with co-elution. Oxymorphone was eluted first at 9.25 min 
followed by noroxycodone and oxycodone at 12.25 and 13.75 min, respectively. 
A low collision energy was required for fragmentation of oxymorphone compared 
to noroxycodone (Table 8-1).  
8.3.1.2 Specificity and selectivity  
Opioids may share similar chemical structure characteristics and for that reason 
specificity should be investigated to ensure that there are no co-elution 
problems. Common drugs and opioids encountered regularly in routine post-
mortem cases were spiked into blood and urine specimens that tested free from 
oxycodone and its N- and O-demethylated metabolites. Also, blank specimens 
were spiked with low concentrations of oxycodone and its two metabolites and 
with the deuterated internal standards of oxycodone, noroxycodone and 
oxymorphone, to investigate the effects of endogenous components on the 
ionisation of analytes of interest and their internal standards. 
Co-elution of interfering substances during LC-MS is a critical problem and could 
occur due to similar masses of parent ions or due to undetected endogenous 
components from the matrix. In the current study, dihydrocodeine had the same 
molecular ion as noroxycodone and noroxymorphone. The major product ion 
obtained from these substances was at the same m/z value as the product ion of 
dihydrocodeine, which required complete separation from both metabolites.  
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Using the current method of separation, dihydrocodeine eluted close to 
noroxycodone with about 1 min difference in retention time. The use of 
deuterium internal standards of noroxycodone and dihydrocodeine has increased 
method reliability and selectivity even with high concentrations of 
dihydrocodeine. In one case sample, a high concentration of dihydrocodeine was 
found not to cause interference with noroxycodone. Similarly, no interference 
was detected after injection of a mixture of drugs commonly encountered in 
routine post-mortem cases. 
8.3.1.3 Linearity  
Linear regression lines were obtained for each analyte over the calibration 
ranges 5-250 ng/mL and 50-5000 ng/mL. Correlation coefficients were greater 
than 0.999 for oxycodone and metabolites in both ranges.  
8.3.1.4 LOD and LLOQ 
Method sensitivity was investigated using the low range calibration curves which 
encompassed the expected LOD values for each analyte. Analytes could be 
identified and quantified at concentrations of 1-1.2 ng/mL. LODs and LLOQs are 
given in Table 8-1 and Figure 8-2.   
8.3.1.5 Matrix effects 
The effects of endogenous matrix components on ionisation of analytes of 
interest during LC-MS/MS were assessed by analysing extracts of blank blood and 
urine samples to which were added analytes of interest at a concentration of 100 
ng/mL. Little or no matrix effects were observed with both blood and urine from 
five different human sources, with an average of less than ± 20 % of spiked 
standard vlue, indicating that there were no undetected endogenous matrix 
components co-eluting with the analytes of interest and that the solid-phase 
extraction (SPE) steps resulted in clean extracts (Table 8-2).  
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Table 8-2: Matrix effects in LC-MS/MS analysis of blood and urine samples. 
 
 
Blood Specimens * 
%  (RSD  %) (n=3) 
Urine Specimens * 
%  (RSD  %) (n=3) 
Source 
of blank 
matrix # Oxycodone Noroxycodon
e 
Oxymorphone Oxycodone Noroxycodone Oxymorphone 
1 102 (1) 105 (7) 93 (6) 100 (13) 87 (13) 102 (4) 
2 102 (12) 107 (11) 96 (4) 100 (5) 108 (4) 113 (14) 
3 107 (4) 98 (2) 96 (6) 98 (6) 87 (7) 103 (10) 
4 98 (3) 115 (10) 103 (1) 116 (7) 109 (8) 124 (4) 
5 105 (3) 106 (4) 101 (2) 97 (5) 113 (6) 105 (2) 
#
 Human blood and urine were sourced from completed urine samples that were scheduled for destruction 
and contained no analytes of interest. 
*
 Matrix effect is expressed as the response obtained for a standard chromatographed along with matrix 
extract compared to that obtained with an unextracted standard chromatographed in mobile phase only, 
expressed as a percentage. Standard was spiked into matrix extract at a concentration of 100 ng/mL. 
&
 R.S.D. %: Relative standard deviation expressed as a percentage. 
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Figure 8-2: Oxycodone metabolites in blood (concentration 1 ng/ml). 
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8.3.1.6 Recoveries 
Recoveries were investigated using five different concentrations across the two 
calibration curve ranges. The recoveries for oxycodone, noroxycodone and 
oxymorphone were in the range of 84-101%. Recoveries are listed in Tables 8-3 
and 8-4. 
Table 8-3: Recoveries from blood. 
Analyte Nominal  
Concentration 
(ng/mL)  
Matrix effects # 
 % * (RSD%) & 
 
SPE 
Recovery ** 
%  (RSD%) 
Oxycodone 5 98 (11) 94 (5) 
 
25 100 (6) 96 (4) 
 
100 102 (0.2) 99 (10) 
 
750 102 (7) 100 (6) 
 
2500 100 (6) 101 (5) 
Noroxycodone 5 98 (3) 95 (9) 
 
25 100 (7) 100 (9) 
 
100 99 (5) 101 (5) 
 
750 104 (4) 101 (11) 
 
2500 105 (7) 100 (10) 
Oxymorphone 5 111 (2) 87 (13) 
 
25 96 (3) 99 (8) 
 
100 102 (6) 99 (9) 
 
750 103 (7) 100 (6) 
 
2500 99 (4) 100 (2) 
#
 Human blood was sourced from completed urine samples that were scheduled for 
destruction and contained no analytes of interest. 
*
 Matrix effect is expressed as the response obtained for a standard chromatographed 
along with matrix extract compared to that obtained with an unextracted standard 
chromatographed in mobile phase only, expressed as a percentage. Standard was spiked 
into matrix extract at a concentration of 5, 25, 100, 750 and 2500 ng/mL. 
** Value calculated from the average recovery for the replicate analyses (n=5) 
&
 R.S.D. %: Relative standard deviation expressed as a percentage. 
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Table 8-4: Recoveries from urine (n=5). 
 
Analyte Nominal  
Concentration 
(ng/mL)  
 
Matrix effects 
% (RSD %) 
 
SPE Recovery 
%  (RSD %) 
 
Oxycodone 5 100 (9) 88 (10) 
 
25 96 (6) 91 (10) 
 
100 102 (1) 94 (9) 
 
750 106 (11) 102 (6) 
 
2500 105 (6) 101 (4) 
Noroxycodone 5 87 (13) 85 (1) 
 
25 105 (7) 92 (10) 
 
100 105 (8) 99 (4) 
 
750 109 (4) 101 (11) 
 
2500 104 (8) 101 (5) 
Oxymorphone 5 102 (4) 84 (4) 
 
25 111 (3) 93 (5)) 
 
100 109 (6) 95 (3 ) 
 
750 108 (3) 96 (6) 
 
2500 110 (4) 102 (8) 
#
 Human urine was sourced from completed urine samples that were scheduled for destruction and 
contained no analytes of interest. 
*
 Matrix effect is expressed as the response obtained for a standard chromatographed along with matrix 
extract compared to that obtained with an unextracted standard chromatographed in mobile phase only, 
expressed as a percentage. Standard was spiked into matrix extract at a concentration of 5, 25, 100, 750 
and 2500 ng/mL. 
** Value calculated from the average recovery for the replicate analyses (n=5) 
&
 R.S.D. %: Relative standard deviation expressed as a percentage. 
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8.3.1.7 Precision  
Percentage relative standard deviations (RSD) were used to assess the intra- and 
inter-assay precision of the method for oxycodone and its metabolites at the 
same five concentrations used for the recovery study. RSD values better than 
12% and 14% were obtained for intra- and inter-assay precision, respectively. The 
intra and inter-day precisions are listed in Table 8-5. 
8.3.1.8 Stability  
Oxycodone and metabolites were stable after being subjected to different 
storage conditions, including (a) at 4 °C for up to one month (b) in the auto-
sampler at 5°C for up to week (c) at 20°C for long storage periods up to 6 
month (d) at room temperature up to 24 hours and (e) during four freeze/thaw 
cycles, which are the most frequently encountered conditions in a forensic 
toxicology laboratory. Stability results for oxycodone, noroxycodone and 
oxymorphone under different storage conditions are detailed in Table 8-6.   
8.3.2 Case samples 
Autopsy specimens collected during post-mortem examination were stored in the 
refrigerator until analysed. The interval between death and post-mortem 
examination differed between cases, within the range of 24 hours to several 
days. Full toxicological analysis was carried out for alcohol by GC-FID, drugs of 
abuse, using ELISA as the screening method and GC-MS or LC-MS/MS for 
confirmation, prescribed drugs, using GC-MS or LC-MS/MS for screening and 
confirmation and volatile substances, by GC-FID.  
Oxycodone is not recognised as an abused drug in Scotland and is not included in 
routine post-mortem analysis. If one of the criteria below was met in any case, 
oxycodone analysis was requested: background information on the deceaseds 
drug abuse, the use of oxycodone for medication, oxycodone tablets found near 
to the deceased or intact tablets recovered from the stomach. During the period 
of this study, oxycodone was detected in ten post-mortem cases. Nine of these 
have been categorised as drug overdose deaths involving one or more drugs, and 
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in one case as death due to disease, in which oxycodone was used for palliative 
care.  
Table 8-5: Intra- and inter-assay precision and accuracy (n=5). 
 
 Blood * 
 
Urine * 
 
Analytes 
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(n
g/
m
L)
 
ng/mL   
(R.S.D.%)# 
ng/mL  
(R.S.D.%) 
%  
(R.S.D.%) 
ng/mL 
(R.S.D.%) 
ng/mL 
(R.S.D.%) 
% 
(R.S.D.%) 
Oxycodone 5 5 (12) 5 (10) 98 (6) 5.2 (5) 4.7 (12) 103 (11) 
 
25 26 (6) 25 (7) 99 (1) 24 (4) 23 (11) 102 (10) 
 
100 103 (8) 97 (3) 105 (3) 107 (5) 100 (3) 98 (4) 
 
750 752 (2) 748 (3) 99.5 (3) 746 (4) 743 (2) 99 (2) 
 
2500 2505 (1) 2492  (1) 100 (0.7) 2498 (1) 2520 (1) 100 (2) 
Noroxycodone 5 5 (3) 4.8 (5) 104 (10) 4.7 (7) 5.1 (7) 99 (3) 
 
25 25 (4) 25 (9) 98 (4) 23 (10) 23 (9) 99 (5) 
 
100 100 (2) 100 (3) 102 (2) 104 (2) 102 (6) 101 (2) 
 
750 755 (3) 750 (3) 99.7 (3) 748 (3) 750 (3) 101 (2) 
 
2500 2513 (2) 2506 (3) 99.8 (2) 2496 (3) 2509 (3) 99 (4) 
Oxymorphone 5 5 (8) 5 (8) 98 (7) 4.8 (11) 5.2 (12) 100 (7) 
 
25 25 (3) 25 (3) 99 (4) 25 (8) 25 (8) 100 (3) 
 
100 99 (2) 100 (7) 100 (3) 99 (4) 99 (8) 102 (5) 
 
750 754 (1) 750 (1) 100.3 (1) 752 (1) 750 (1.5) 100 (0.5) 
 
2500 2520 (1) 2510 (2) 99 (3) 2470 (2) 2512 (1) 101 (3) 
* Value calculated from the average recovery for the replicate analyses (n=5) 
 
#
 R.S.D. %: Relative standard deviation expressed as a percentage. 
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 Table 8-6: Stability (n=3). 
  
 Blood specimens * 
%  (R.S.D.%) & 
Urine Specimens * 
%  (R.S.D.%) 
Storage 
 Condition # 
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e 
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N
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o
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4 Hours 109 (11) 107 (2) 105  (4) 104 (9) 112 (4) 110 (4) 
R
o
o
m
 
 
Te
m
pe
ra
tu
re
 
24 hours 110 (8)  108 (1) 106 (3) 100 (9) 103 (10) 99 (4) 
Freeze-thaw  
4 cycles 
105 (2) 103 (0.5) 99 (6) 100 (9) 103 (10) 99 (4) 
48 hours 103 (3) 94 (1) 101 (1.5) 93 (4) 96 (15) 102 (9) 
A
u
to
-
sa
m
pl
er
 
4 
0C
 
Week 99 (4) 105 (6) 106 (8) 108 (5) 97 (5) 104 (1) 
24 hours 105 (3) 103 (12) 110 (9) 97 (1) 103 (2) 106 (6) 
48 hours 108 (6) 105 (9) 103 (5) 104 (6) 109 (8) 113 (1) 
Week 101 (12) 106 (3) 99 (9) 95 (5) 97 (13) 96 (8) 
Month 103 (7) 111 (5) 97 (1) 107 (6) 100 (8) 110 (2) 
Fr
ee
ze
 
a
t  
-
20
 
 
0C
 
6 month 98 (7) 99 (11) 95 (2) 95 (3) 91 (12) 95 (6) 
24 hours 109 (3) 105 (4) 108 (10) 93 (1) 104 (6) 94 (11) 
48 hours 107 (6) 106 (8) 99 (11) 102 (5) 106 (14) 117 (2) 
Week 96 (8) 108 (5) 106 (7) 103 (2) 106 (6) 97 (5) 
R
ef
ri
ge
ra
te
 
a
t  
4 
0C
 
Month 99 (3) 103 (9) 97 (13) 92 (7) 96 (12) 91 (3) 
#
 Starting concentration is 100 ng/mL;  
*
 Value calculated from the average recovery for the replicate analyses (n=3). 
&
 R.S.D. %: Relative standard deviations expressed as a percentage. 
Intact tablets were recovered from the stomach in four oxycodone overdose 
deaths. Oxycodone was prescribed as a pain killer either as OxyContin (2 
cases) or OxyNorm (one case) and an undetermined type of oxycodone 
preparation in one case. In all cases at least one or more than one centrally-
acting drug was detected.  A summary of the toxicology results is given in 
Table 8-7.  
Blood samples were available in all cases while urine specimens were not 
available in two cases. Oxycodone and its N-demethylated metabolite were 
determined in all cases. Oxymorphone was not detected in cases 4, 7, 8 and 
10 which may indicate that a short time had elapsed after ingestion of 
oxycodone before death occurred or else that oxymorphone had been 
conjugated prior to elimination from the body. In cases 5, 6 and 9, 
oxymorphone was negative in blood but positive in urine. In case 4, a low 
level of noroxycodone was detected in blood at a concentration of 0.1 ìg/mL 
along with a high concentration of oxycodone (4.9 ìg/mL) which indicated 
acute oxycodone intoxication. However, propranolol was also present at an 
overdose level and the cause of death was attributed to intoxication by both 
oxycodone and propranolol. 
In all cases the parent drug was the most abundant analyte detected 
compared to the major metabolites, with the exceptions of cases 3 and 7.  In 
case 3, oxycodone and noroxycodone had the same concentration and death 
was attributed to mixed drug intoxication. Oxymorphone was present at low 
levels in the current study although these were higher than reported in 
oxycodone pharmacokinetics studies, in which most samples had levels of 
0.001-0.003 ìg/mL or less 371,391,398,399. An understanding of oxycodone 
pharmacokinetics in human subjects could provide information to assist in the 
interpretation of the cause of death and whether or not oxycodone was taken 
with suicidal intent. In fact, most cases involved intoxication after oral 
ingestion of oxycodone controlled-released tablets (OxyContin), and it is not 
known if the deceased damaged the controlled release system of the tablets, 
for example by crushing them before administration, which resulted in high 
concentrations of oxycodone in the blood immediately after ingestion or if the 
deceased just ingested numerous tablets which resulted in an overdose of 
oxycodone.  
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Table 8-7: Concentrations of oxycodone and metabolites in blood and 
urine samples from 10 forensic autopsy cases 
 
Oxycodone 
(ìg/mL) 
Noroxycodone 
(ìg/mL) 
Oxymorphone 
(ìg/mL) 
Cas
e 
no. Blood Urine Blood Urine Blood Urine 
Other drugs 
detected 
(ìg/mL) 
INS ô Cause  
of death 
1 5.5 7.6 0.86 2.3 0.04 1.3 Ethanol 28  mg%;  
Diazepam 0.14; 
Nordiazepam 0.13 
No Oxycodone 
overdose 
2 0.95 6.8 0.39 2.5 0.06 0.22 Ethanol 111 mg% 3  Combination 
of oxycodone 
and ethanol 
intoxication 
3 0.08 0.4 0.08 0.6 0.01 0.1 Codeine 0.12; 
Morphine 0.06; 
Temazepam 0.15; 
Amitriptyline 1.1; 
Tramadol 1.7; 
Paracetamol 24 
No Mixed drug 
intoxication 
4 4.9 N/Aḁ 0.1 N/A - N/A Propranolol 3.3; 
Diazepam 0.68; 
Nordiazepam 0.56; 
Valproic acid < 40 
> 44 Oxycodone 
and propanol 
overdose 
5* 3.6 53 1.5 82 - 0.2 Diazepam 0.98; 
Nordiazepam 0.76; 
Temazepam 0.05; 
Morphine 0.025; 
THC 0.025; 
2  Oxycodone 
intoxication 
6 3.6 40 0.5 7.6 - 0.36 Levomepromazine 
<0.10, 
Ethanol 17 mg%; 
Acetaminophen  < 20 
No Oxycodone 
intoxication 
7 1.5 N/A 2.3 N/A - N/A Citalopram 0.4 No Oxycodone 
intoxication 
8 0.09 1.6 0.03 0.5 - - Fentanyl  0.005; 
Diazepam 0.16; 
Desmethyldiazepam 
0.16 
No Broncho-
pneumonia 
due to non-
small cell 
carcinoma of 
the lung 
9 0.76 45 0.5 43 - 0.1 Cocaine 0.20; 
Benzoylecgonine 3.1; 
Ecgonine methyl 
ester 0.72; Diazepam 
<0.05; 
Desmethyldiazepam 
0.16ìg/mL; 
Acetaminophen  24; 
4  Oxycodone 
intoxication 
10 0.82 30 0.55 24 - - Total morphine 0.46; 
Total codeine; 0.03; 
Diazepam 0.11; 
Desmethyldiazepam 
0.23; 
Temazepam <0.05; 
Citalopram 0.36; 
Amitriptyline 0.35; 
No Heroin and 
oxycodone 
intoxication 
ô
 INS: noumber of the intact tapletes recovered on stomch. 
*Vitreous Humour (Oxycodone 2.1 and Noroxycodone 0.76ìg/mL);  Vitreous Humour (Oxycodone 0.63 and 
Noroxycodone 0.19ìg/mL); ḁ (N/A) samples not analysed;  (-) negative result; (case 4 and 5)  Gastric contents 
were analysed qualitatively and tested positive for oxycodone and noroxycodone. 
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The latter is more likely for those cases in which intact tablets were 
recovered from the stomach (cases 2, 4, 5 and 9). In three cases the tablets 
were not dissolved and in case 5 many tablets were present but it was 
difficult to distinguish these from the gastric contents and only two OxyContin 
80 mg tablets were identified. Gastric contents in case 4 and tablets in cases 
2, 5 and 9 tested positive for oxycodone and noroxycodone. 
In case 1, no intact tablets were recovered from the stomach, which may 
indicate that oxycodone was injected or crushed and dissolved before 
administration, but the route of administration is not known. The LC-MS/MS 
analysis of oxycodone and its metabolites is shown in Figure 8-3. In all cases 
blood oxycodone concentrations ranged from 0.08 to 5.5 ìg/mL with average 
and median concentrations of 2.18 and 1.2 ìg/mL, respectively. The 
concentrations in overdose deaths ranged from 0.76 to 5.5 ìg/mL with mean 
and median concentrations of 2.7 and 2.6 ìg/mL, respectively. Oxycodone 
concentrations in overdoses attributed to oxycodone alone ranged from 0.76-
5.5 ìg/mL with average and median concentrations of 3 and 3.6 ìg/mL, 
respectively, while concentrations of oxycodone in cases of mixed drug 
intoxication were 0.08-4.9 ìg/mL, with average and median concentrations of 
1.6 and 0.9 ìg/mL, respectively.  
Noroxycodone was detected in all cases with blood concentrations ranging 
from 0.03 to 2.3 ìg/mL and average and median concentrations of 0.8 and 0.5 
ìg/mL, respectively. In oxycodone overdose deaths the blood noroxycodone 
level ranged from 0.5 to 2.3 ìg/mL with average and median concentrations 
of 1.1 and 0.9 ìg/mL, respectively. Noroxycodone levels in multiple drug 
intoxication cases were lower and ranged from 0.08-0.5 ìg/mL; mean and 
median concentrations were 0.28 and 0.25ìg/mL, respectively. Oxymorphone 
was present in blood (3 cases) and urine (6 cases); blood levels ranged from 
0.01 to 0.06 ìg/mL and the average and median blood concentrations were 
0.04 and 0.04 ìg/mL, respectively.  
Urine samples were analysed for oxycodone in order to determine chronic or 
single use 9,125. in the current investigation, urine oxycodone concentrations 
were higher than 6 ìg/mL (6.8-53 ìg/mL) in overdose cases attributed to the 
use of oxycodone. However, in Cases 3 and 8 low levels of oxycodone were 
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detected at 0.4 and 1.6 ìg/mL, respectively, indicative of a single dose of 
oxycodone. In case 3, noroxyxcodone and oxymorphone were present at 
concentrations of 0.6 and 0.1 ìg/mL , respectively. 
 
Figure 8-3: Oxycodone metabolites detected in a case of oxycodone intoxication. 
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In cases 1 and 2, the concentrations of oxycodone detected were 5.5 and 0.95 
ìg/mL, respectively and noroxycodone was lower in both cases at 0.86 and 
0.39 ìg/mL, respectively. Urine levels in both cases were quite similar with 
7.6, 2.3 and 6.8, 2.5 ìg/mL for oxycodone and noroxycodone, respectively. 
The lower concentration in case 2 compared to case 1 can be explained by the 
additional presence of a moderate level of alcohol found in case 2, which 
would increase the risk of fatal oxycodone poisoning even though oxycodone 
at this concentration could potentialy be a cause of death in the absence of 
alcohol. 
A fatal level of oxycodone was detected in case 6; noroxycodone was also 
found at a concentration lower than that of the parent drug but oxymorphone 
was absent from the blood, which indicated a short time had elapsed between 
administration and death. In this case the cause of death was attributed solely 
to oxycodone intoxication despite the deceased being in the late stages of 
cancer. Three ampoules of oxycodone hydrochloride were found next to the 
deceased as well as a broken syringe driver, which may be an indication that 
oxycodone was injected. A high dose of oxycodone was administered, as 
indicated by blood and urine analysis which showed the presence of a high 
concentration of oxycodone compared to noroxycodone and oxymorphone. 
The level detected was high and indicative of having taken an excessive dose, 
whether intentionally or not.  
The level of noroxycodone was higher than oxycodone in only one case (7). 
The cause of death was attributed to oxycodone as no other toxicants were 
detected apart from citalopram which was found at a therapeutic 
concentration. The ratio of oxycodone/noroxycodone was 0.7, which is the 
lowest encountered in the current study, indicating that a longer time had 
elapsed after administration. Witnesses stated that the deceased had 
consumed alcohol but none was detected in this case. However, a lack of 
tolerance for opioids could lead to fatal intoxication: oxycodone was not 
prescribed for the deceased and the high concentration of oxycodone is 
indicative of a fatal overdose.    
In another two cases, 9 and 10, the concentrations of oxycodone were lower 
than 1 ìg/mL while noroxycodone was above 0.5 ìg/mL. The urine 
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concentrations of oxycodone were 45 and 30 ìg/mL and of noroxycodone 
were 43 and 24 ìg/mL, respectively. Death via a centrally-acting respiratory 
depressant in those with no tolerance to its sedating effects is more likely to 
cause death despite the presence of cocaine and cannabis in case 9. However, 
the presence of heroin was more likely to contribute to the cause death in 
case 10, since the level of morphine detected was consistent with a fatal 
heroin overdose. This case is in agreement with case 2 and those reported in 
previous work in which deaths occurred with lower drug concentrations in 
cases of poly-drug intoxication.  
Diazepam and its metabolites were found in cases 1, 4, 5, 8, 9 and 10 and 
temazepam tested positive in cases 3, 5, and 10. It is known that the 
combination of other centrally-acting depressant drugs along with opioids may 
increase the risk of overdose and death compared to a single opioid alone.  
8.4 Discussion 
There were two main goals for the current study - to validate a method for 
identification and quantification of oxycodone and its N- and O-demethylated 
metabolites in blood and urine and to apply the method to routine casework. 
A previously published method (Chapter 5) based on SPE and LC-MS/MS was 
adapted and used for analysis of blood, urine, vitreous humour and gastric 
contents for the current study but was fully validated for blood and urine only 
since these are available for most cases. Apart from the introduction of a new 
matrix (urine) validation was necessary to include a new metabolite of 
oxycodone and its internal standard (noroxycodone and noroxycodone-d3). The 
original method for determination of 26 opioids in a single run is expensive to 
operate due to the cost of standards but can be used conveniently for small 
groups of opioids when specific analytes need to be determined.  
This project provided new information about the concentrations of oxycodone 
and its metabolites after overdose administration, in some of the cases 
examined in this study, which involved bypassing the controlled-released 
system of OxyContin tablets by crushing them, such that the drug was rapidly 
absorbed after intake. Usually, oxycodone from these slow-release tablets 
requires 24 hours to be completely absorbed in the stomach. The dose 
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required for pain relief is limited to a few tablets a day, but in the present 
work up to 44 tablets were recovered from the stomach of the deceased also 
indicating that oxycodone overdose can also occur without crushing the 
tablets (Figure 8-4). LC-MS/MS has been used widely in forensic toxicology.  
However, no reports have appeared concerning its application to the 
quantification of oxycodone and its metabolites in autopsy blood from 
oxycodone-related fatalities, although many pharmacokinetic studies have 
reported plasma and urine concentrations of oxycodone and its metabolites 
including noroxycodone, oxymorphone and other oxidative and reductive 
metabolites. Previous studies of oxycodone-related fatalities have looked only 
at the concentration of unchanged oxycodone. High concentrations of 
oxycodone were encountered in most cases of death attributed to oxycodone 
alone but noroxycodone and oxymorphone were not measured despite the fact 
that noroxycodone was known to be the major metabolites of oxycodone.  
 
Figure 8-4: More than forty four OxyContin tablets recovered in  
the stomach of case 4. 
 
8.4.1 Method validation 
Most validated methods for oxycodone and its metabolites have been based on 
GC-MS or HPLC coupled with electrochemical or UV detection. LLOQ values 
varied between procedures and oxycodone metabolites. Previous GC-MS 
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procedures generally reported LLOQs higher than 20 and 40 ng/mL for 
oxycodone and oxymorphone, respectively 381, although some methods 
achieved LLOQs as low as 1.2 and 3.7 ng/mL for these analytes 382. In one 
study using both GC-MS and LC-MS/MS for the determination of oxycodone, 
LC-MS/MS was 100 times more sensitive than GC-MS 393. LLOQs of 0.1 to 0.25 
ng/mL were reported for oxycodone, oxymorphone and noroxycodone in 
plasma samples 391. An LLOQ lower than or equal to 1 ng/mL is required in 
cases involving oxycodone although it is often found at concentrations higher 
than 600 ng/mL 25,373. However, oxycodone has been reported at 
concentrations as low as 25 ng/mL 391. Concentrations of analytes in this 
group vary widely, between oxycodone and noroxycodone on one hand and O-
desmethyl metabolites on the other. LLOQs in the present study were in the 
range I-1.2 ng/mL for both blood and urine.   
The calibration intervals used in several previous studies have been in the 
range 1-100 ng/mL, which is lower than the concentrations of oxycodone and 
noroxycodone concentrations in overdose cases but is consistent with 
therapeutic use of oxycodone 400-390. Wider ranges from 0.1-100 ng/mL and 
from 25-10000 ng/mL have also been used for a pharmacokinetic study 391 and 
for overdose cases respectively 381,382. The selection of the calibration interval 
depends on the intended application of the method, to clinical or overdose 
cases or both and is also influenced by the need to avoid re-analysis of 
samples with high analyte concentrations.  Also, the presence of oxycodone 
and its metabolites at therapeutic concentrations does not mean they are not 
implicated in the cause of death.  
During this study, ten deaths involving oxycodone were investigated and two 
calibration curves were necessary to accommodate the high concentrations of 
the parent drug and its major metabolites and the low concentrations of the 
minor oxycodone metabolite, oxymorphone. Also, low concentrations of 
analytes could be encountered in non-suspicious deaths or in cases of multiple 
drug intoxication, as in case 3, in which all analytes were within the lower 
concentration calibration range. Analyte concentrations in autopsy urine 
samples were higher than the upper calibration interval, and most cases 
required dilution and re-analysis. No differences were observed between 
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calibration curves prepared using blood and urine matrices and one set of 
calibration curves could be used for both types of sample.   
The method developed was capable of simultaneously detecting oxycodone 
and its metabolites within the recommended ratios for SRM transition 
recommended. Small sample volumes were used for analysis, 0.1-0.5 mL in 
most cases, which was possible because of the low LLOQs of the optimised 
method. Liquid-liquid extraction and SPE have been found to produced good 
recoveries of oxycodone and its metabolites 391,33-35. In the present study, 
recoveries of analytes and matrix effects were assessed at five different 
concentrations across the calibration range using  the approach of 
Matuszewski et al  51. Matrix effects are now a routine requirement of method 
validation. But, although ion suppression and enhancement are reported, 
there are no guidelines concerning the acceptable limits of matrix effects. No 
matrix effects were found in the current method, for both blood and urine 
samples, and did not affect the accuracy of results.  
Neuvonen et al 391 studied the effect of plasma matrix on ionisation in MRM 
quantification of oxycodone and its metabolites at the LLOQ using a post-
column infusion method.  In their work, mixtures of other opioids (50 ng/mL) 
and oxycodone metabolites (2.5 ng/mL) were spiked into plasma and analysed 
by LC-MS/MS in order to assess interference from structurally similar 
compounds.  Ion suppression ranged from 2-13% in a zone extending from the 
start of the run to 5.7 minutes. No interference was observed from 
structurally similar compounds.  
Similar findings were obtained in the present study although a different 
method of examining matrix effects was used and five different blood and 
urine specimens from different human sources were examined. Recoveries 
obtained in previous studies were often higher than 100%, indicating ion 
enhancement had occurred while in the present method recoveries from blood 
and urine were from 87-101% and 84-102% respectively after excluding matrix 
effects.  
Oxycodone, noroxycodone and oxymorphone were reported to be stable in 
plasma for up to 6 months under different storage conditions 388,400 and for 12 
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weeks in another study 392. Dawson et al 252 found oxycodone stable at room 
temperature for at least 24 hours after three freeze/thaw cycles and for up to 
24 hours in the auto-sampler tray. Recently, Neuvonen et al 391 examined the 
stability of oxycodone, noroxycodone, and oxymorphone at two different 
concentrations in plasma (1 and 100 ng/mL) under three storage conditions 
and found that less than 10% degradation of oxycodone and its metabolites 
occurred.  
In our previous report (Chapter 5), oxycodone and oxymorphone were found 
to be stable in blood under different storage conditions and in the present 
study noroxycodone was also found to be stable (Table 8-6). During the study 
period, repeat analyses were performed which gave results identical to those 
from the original analysis, indicating that oxycodone and its metabolites are 
stable in the refrigerator for up to month. No degradation of analytes was 
observed during SPE. Also, dilution of specimens was examined when urine 
samples with high drug concentrations were encountered, in one case by 50 to 
100 times. Results obtained after different dilutions were identical. 
8.4.2 Case studies 
Cone et al 263 noticed that lower blood oxycodone concentrations were found 
in cases involving combined drug toxicity compared to those involving single 
drug exposure. Blood oxycodone ranged from 0.7-0.93 ìg/mL in multiple drug 
deaths compared to 1.55-1.7 ìg/mL in single drug deaths. 
In the present study, oxycodone concentrations in mixed drug intoxication 
cases were in the range 0.08-4.9 ìg/mL with average and median 
concentrations of 1.6 and 0.9 ìg/mL respectively. In overdose cases 
attributed to oxycodone alone, blood concentrations ranged from 0.76-5.5 
ìg/mL and the average and median concentration were 3 and 3.6 ìg/mL, 
respectively. Despite the overlap between the two groups, it is clear that 
deaths due to multiple drug intoxication can occur at oxycodone 
concentrations below 1 ìg/mL, whereas most cases involving oxycodone alone 
have oxycodone concentrations higher than 1 ìg/mL, with the exception of 
naïve users who had no tolerance to oxycodone.  
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Oxycodone case attributed to multiple drug intoxication by Cone et al 263 
involved 3.5 drugs on average. In the current investigation an average of 4 
drugs was found in oxycodone related cases. Benzodiazepines were found with 
concentrations either within or slightly higher than the therapeutic range and 
were considered to have only a minor contribution to the cause of death. A 
similar conclusion could be reached with respect to the low morphine, 
cannabis and valproic acid concentrations in cases 4 and 5. Clear effects of 
multiple drug intoxication were found in case 3, in which morphine, codeine, 
tramadol, acetaminophen, temazepam and amitriptyline were detected. 
Although codeine, morphine, acetaminophen and temazepam were within the 
therapeutic ranges, higher than therapeutic concentrations of amitriptyline 
and tramadol were detected and could have contributed with other drugs to 
the cause of death, since oxycodone is known to potentiate the effects of 
both other opioids and antidepressants 401. Alcohol was detected in three 
cases but it was only considered to have contributed to the cause of death in 
case 2.  
In the present study, oxycodone was used only as a painkiller by patients 
suffering from an acute illness or disease apart from one case in which 
oxycodone was prescribed to the flatmate of the deceased who administered 
the drug with clear suicidal intent (case 5). In most cases the deceased was 
depressed and some had previously attempted suicide, which may indicate 
that these were suicides, but this is not certain. The median ratio of 
oxycodone/noroxycodone was 2.4 and ranged from 0.7-49. This ratio may be 
helpful for estimating the time interval after ingestion before death occurred. 
A high ratio may indicate a short survival time after ingestion, not excluding 
other factors surrounding the death such as the presence of other centrally 
acting drugs which can add to the risk of intoxication with oxycodone.    
Oxymorphone is now classified as a drug of abuse in the United State of 
America as increasing numbers of young people dying due to oxymorphone 
intoxication have been reported 402-404. In one study, the median level 
encountered in post-mortem blood from oxymorphone related fatalities was 
0.14 ìg/mL with a range of 0.05-0.31 ìg/mL 402. Two other deaths attributed 
to oxymorphone had blood levels of 0.08 and 0.09 ìg/mL. Interestingly, these 
two cases were known OxyContin users 403. Recently, Garside et al 404 
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reported 33 cases of oxymorphone related fatalities. The level of 
oxymorphone in post-mortem central and peripheral blood were in the range 
of 0.011-0.59 ìg/mL and 0.017-0.82 ìg/mL, respectively. The mean and 
median level of oxymorphone in both matrices were 0.15 and 0.1 ìg/mL, 
respectively 404.   
Oxymorphone levels in the current study were within the range for cases 
attributed to oxymorphone intoxication as mentioned above. Thus, the 
current study recommended that both oxycodone and oxymorphone be 
analysed in order to differentiate between the presence of oxymorphone as a 
consequence of oxymorphone administration or as metabolite of oxycodone.  
Very high concentrations of oxycodone and its N-demethylated metabolite 
were detected in urine in cases 5, 6, 9 and 10. However, oxymorphone 
concentrations in urine were low compared to the other metabolites and 
oxymorphone was not detected in the corresponding blood samples. The 
question arises whether oxycodone was used for first time (single dose) or if it 
was chronically abused. It is known that oxymorphone is eliminated from the 
body as the glucuronide 366,371,372 and in the current procedure no hydrolysis 
method was applied and only free drug was detected in these cases. It is, 
therefore, expected that the level of total oxymorphone in urine and blood 
would be higher than reported here if a hydrolysis method was used. In 
contrast, oxycodone and its major metabolites (noroxycodone) are mostly 
excreted in the free form which explains the high concentrations encountered 
here. In one study, the concentrations of oxycodone and noroxycodone in 
urine samples after a hydrolysis procedure (HM) were not significantly 
different from those of the free analytes using a non-hydrolysis method 405. 
Oxycodone and noroxycodone constituted 8.9% ± 2.6% for the HM versus 8% ± 
2.6% for the non-hydrolysis method and  22.1% ± 9% for HM versus 23.1% ± 
7.6%, respectively 371.  
In the current study, the concentrations are in agreement with previously 
published pharmacokinetic studies which indicated that oxymorphone in urine 
accounted for 10.7% ± 5.5% of an oxycodone dose with only 33% ± 0.4% of 
oxymorphone excreted as the free drug; total oxymorphone excreted in urine 
accounted for 14.2% ± 7.5% of an oxycodone dose. Oxymorphone was the 
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lowest concentration metabolite of oxycodone present in urine, with a 
maximum concentration of 1 ng/mL 366,371.  The absence of O-demethylated 
metabolite of oxycodone in blood may result from a low concentration below 
the method detection limits or because death happened rapidly, with no time 
to convert oxycodone to oxymorphone. The high concentrations of drug and 
its major metabolites in urine were as expected in acute overdose cases. 
By contrast, the urine oxymorphone concentration in case 1 was 1.3 ìg/mL, 
the highest detected in the current study and the blood level was 0.04 ìg/mL. 
In this case, the deceased may have been a chronic user of oxycodone due to 
her illness. The oxycodone and noroxycodone urine concentrations were not 
high at 7.6 and 2.3 ìg/mL, respectively. Similar concentrations have been 
found in another study involving two subjects who had received 10 mg of 
oxycodone. The total oxymorphone did not exceed 2.5 ìg/mL and urine 
oxycodone and noroxycodone concentrations after daily use were 13 and 18 
ìg/mL respectively 132.  
A recently published pharmacokinetic study of oxycodone revealed that 
noroxycodone concentrations always exceeded those of the parent drug a few 
hours after administration 371,391. In the current study, it was observed that 
the parent drug was the major substance detected in overdose cases rather 
than its N-demethylated metabolite, which suggested deaths occurred within 
a few minutes up to three hours after administration, the point at which both 
analytes should be found at similar concentrations until noroxycodone 
exceeds the parent drug. Another explanation was suggested by Anderson et 
al 369: the oxycodone level at autopsy does not reflect its concentration at the 
time of death because oxycodone continues to be released from controlled-
release tablets after death while the intact tablets remain in the stomach. 
The authors also point out that tablet could be found free of oxycodone as all 
of the drug was leached out and the tablets remain as ghost pills. This may 
elevate the parent drug level in gastric compared to its metabolites as the 
drug released after death was not metabolised. In the current study, the 
stomach contents of case 4 were tested for oxycodone and found positive with 
huge concentrations which may be in contrast with the findings of Anderson et 
al  369, taking into consideration that the interval time between death and 
post-mortem examination was 6 days for case 4. 
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One of the limitations of the current study was the restricted availability of 
sample types for analysis, which limited the investigation of correlations 
between the levels of oxycodone and its metabolities in blood and urine with 
those in other biological matrices such as vitreous humour (VH). VH is clean 
and potentially comparable to blood results; unfortunately it is not always 
collected at autopsy. VH was collected in two cases, 5 and 9. In case 5, VH 
levels were positive for oxycodone and noroxycodone at levels of 2.1 and 0.76 
ìg/mL, respectively, giving an oxycodone/ noroxycodone ratio of 2.7.  In case 
9, VH levels were 0.63 and 0.19 ìg/mL for oxycodone and noroxycodone, 
respectively, with a ratio of 3.3 between oxycodone/noroxycodone. The 
average ratios between blood/vitreous humour (B/VH) oxycodone and 
noroxycodone levels were 1.5 and 2.4, respectively. In both cases, 
oxymorphone was not detected in VH. Few reports are available concerning 
the B/VH ratios in oxycodone related fatalities: Drummer et al 25 reported one 
case in which the levels of oxycodone in blood and VH were 1.5 and 1.8 
ìg/mL, respectively, giving a B/VH ratio of 0.8. Anderson et al 369 determined 
oxycodone in blood (heart or femoral blood) and VH in seven fatalities. The 
B/VH ratios were 1.5 and 1.8 for heart blood/VH and femoral blood/VH, 
respectively. VH oxycodone levels in that study ranged from 0.18 to 0.82 
ìg/mL.  
8.5 Conclusions 
A sensitive and selective method has been developed and validated for the 
simultaneous determination of oxycodone, noroxycodone and oxymorphone in 
autopsy blood and urine samples and has been successfully applied to routine 
cases involving oxycodone intoxication. To the authors knowledge, this is the 
first application of LC-MS/MS to oxycodone related fatalities and the first 
report of blood and urine noroxycodone and oxymorphone levels following 
acute oxycodone overdose. Oxycodone prescriptions have risen sharply in 
Scotland in recent years and the identification of ten oxycodone-related 
deaths in the study period (18 months) in the Strathclyde region of Scotland 
alone has highlighted the importance of including this drug in routine 
laboratory screening and confirmation procedures. High levels of oxycodone in 
combination with low levels of noroxycodone and oxymorphone are likely to 
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be diagnostic for suicides involving the deliberate ingestion of multiple tablets 
of OxyContin. The current study presents a novel approach to investigating 
oxycodone-related fatalities and further research is required to better 
understand the role of oxycodone metabolites in oxycodone-related deaths. 
The presence of noroxycodone in vitreous humour following oxycodone 
intoxication and the stability of noroxycodone in blood and urine was reported 
for the first time. 
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9 Identification Criteria for Opioids and 
Metabolites Using LC-MS/MS 
9.1 Introduction 
Confirmation of the identity of illicit and licit drugs in a given matrix is a 
paramount task in forensic and clinical toxicology 406. Although many reviews 
have been published on the potential advantages of LC-MS (/MS) in toxicology, 
only one review has focused on identification issues 59. After LC-MS was 
successfully introduced to analytical toxicology in the last decade, the 
identification of analytes is the most challenging topic needing addressed in 
order for LC-MS/MS to be used more confidently in the field. Special criteria 
are needed that fit with most LC-MS/MS techniques and, at the same time, 
are comparable with GC-MS. At first glance, identification of targetted 
analytes is not always problematic if standards are available, a suitable 
method of extraction is used and there is an adequate chromatographic 
separation. However, problems arise when trying to follow identification 
criteria using guidelines based on GC-MS analysis 407. These requirements are 
easy to meet in theory but few of them can be achieved practically and the 
final results will depend on the toxicologists knowledge and assessment of 
the quality of the  results 31,59,407. 
The recommendation given in SOFT/AAFS guidelines is to use  two different 
techniques based on different chemical principles for drug identification and 
confirmation 54,408,409. The suspected substances are usually identified in two 
steps. First, using preliminary techniques as a screening method and second, 
the tentatively identified drug should be confirmed using another technique, 
mostly a chromatographic method. Screening methods are limited to small 
drug classes 39 and guide toxicologists to confirm target analytes. 
Immunoassay techniques are still the methods of choice for drug screening as 
a first line in systematic toxicological analysis (STA) and could be used as 
identification power but they are usually unable to discriminate individual 
drugs as they respond to a group or class of drugs 28. Monoclonal antibodies, 
for example to morphine as opposed to opiates, are specific but are not 
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accepted in the field as being sufficiently reliable for legal purposes. 
Similarly, thin layer chromatography (TLC) could provide identification power 
for analytes by a comparison of retention factor (Rf) between standards and 
samples but could not stand on its own in court 408.  
The highest goal in order to avoid misinterpretation of medico-legal cases is 
the correct identification by laboratories of drugs or poisons; drugs should be 
discriminated accurately from all other possible interferences, which are 
more likely to be encountered using LC-MS methods, taking into consideration 
that other compounds of similar chemically structure may be major source of 
potential interference 16,59,408.  
In many cases, the drugs or poisons that have been consumed or involved in 
toxicity are unknown. Also, many substances can be detected in each case 
which share similar properties or else possess different actions. Some of them 
are considered toxic, therapeutic or sub-therapeutic and some are 
endogenous components from the matrices themselves. These substances are 
metabolised by different mechanisms and rates, i.e. heroin can be easily 
hydrolysed either in in-vivo or in-vitro within 2-5 min, while some drugs exist 
for long periods of time in the free form or as phase I and phase II metabolites 
such as morphine glucuronide and ethanol conjugates. As indicated earlier in 
Chapter 8, a drug like oxymorphone is a product of oxycodone metabolism; 
drugs such as hydromorophone or hydrocodone may be found in urine samples 
as minor metabolites in cases involving high concentrations of morphine and 
codeine, respectively 410,411. Cone et al 412 found that hydromorphone was 
excreted in urine with concentrations in the range 120-1400 ng/mL in ten out 
of thirteen patients treated with morphine using a high method cut-off of 100 
ng/mL, which may mean that hydromorphone could be found in negative 
cases if a lower cut-off than 100 ng/mL was applied.  
General unknown screening (GUS) is intended to identify or exclude as many 
harmful substances as possible. This objective is far from achieved as there 
are millions of substances present in the human environment and only a small 
portion of them are known to toxicologists 59. As indicated earlier, known 
compounds could be subject to interference by unknown compounds. GUS is 
often based on quick methods of extraction and GC-MS analysis which may 
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lead to an incompletely resolved peak in which some of the minor metabolites 
of a drug may be completely overlooked. In addition, the occurrence of non-
volatile or thermally labile compounds and the unsuitability of some analytes 
for derivatisation or which require multiple derivatisation steps could enhance 
the risk of a false negative result 410,413,414. The chemical properties of drugs 
and metabolites to be identified and quantified differ widely, ranging from 
highly hydrophilic to moderate polarity and basic, acidic or neutral 
properties. The extraction procedure is still the most important part of 
identification of drugs even with the availability of highly accurate LC-MS/MS 
techniques despite the drawbacks of being time consuming, tedious and 
expensive. However, an extraction procedure using SPE is not only a 
concentration procedure for trace analytes, but provides more confidence and 
improved quantification by ruling out the risk of unwanted interferences 
17,65,415.  
In the field of forensic toxicology, analysis of many target analytes in a  
method is the preferred approach which can be fulfilled with high-throughput 
LC-MS/MS procedures in which multiple toxicants and metabolites can be 
determined in one single procedure, which reduces the cost, labour and time 
of analysis 16,31,109,416. However, in most circumstances, only a few metabolites 
or single drugs need to be determined with mostly known target metabolites 
31,54. In fact, methods for analysis of these known analytes should already be 
validated and used routinely. Therefore, non-targeted analytes will not be 
determined leading to the potential risk of false positive results due to non-
targeted compounds having similar mass spectra to included analytes 
17,59,180,417-419.   
Many tissue and matrices are available for analysis in post-mortem cases such 
as blood, urine, liver, bile, stomach contents, vitreous humour, hair, bone 
marrow and many others. In contrast, few specimens are available from living 
subjects, for example, in work place drug testing and driving under the 
influence of drugs (DUID). Urine samples are usually obtained at both post-
mortem and from living subjects but are less important in interpretation of 
abused drugs, especially in post-mortem cases. Urine is more likely to be used 
in screening methods using immunoassay or chromatographic methods. 
However, urine samples are potentially open to manipulation by adulteration 
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and the interpretation of drug concentrations detected in urine is usually 
complex 14,202.  
LC-MS/MS is new a tool providing simultaneous determination of various drug 
groups with smaller sample volumes and solvent usage 86; lower drug cut-offs 
can be obtained which were found to be 100-fold less than the corresponding 
GC-MS cut-offs in one study in which  the hydrolysis step was removed 
because free analytes like MOR can be determined with LLOQs of 2 ng/mL 393.  
9.2 Aims 
The aim of this work was to develop and validate a method for the 
determination of twenty six opioids and their metabolites which are 
commonly encountered in post-mortem toxicology in unhydrolysed urine. The 
method was intended to be complementary to the method for opioids in 
autopsy blood described in Chapter 5, with addition of new metabolites and 
their corresponding internal standards (a complete list is given in Table 9.1). 
The method was then applied to routine analyses of autopsy urine samples in 
parallel with blood analysis to investigate the value of using both matrices in 
the interpretation of the cause of death and source of the opioids detected. 
In addition, it was intended to evaluate identification criterion for drug 
confirmation recommended by many guidelines using the results obtained and 
the problems encountered with these identification criteria proposals.  
9.3 Methods and Materials 
These were similar to those described in Chapters 7 and 8.  
 244 
9.4 Results and Discussion 
9.4.1 Method validation  
A method for general routine opioid screening using urine samples was 
validated as complementary method to that previously developed for blood. 
Mass spectral data for all analytes were obtained in the electrospray positive 
ion mode. Difficulties in obtaining product ions for B3G were reported in 
Chapter 5 has been solved by extanding the mass range of BUP3G to 2 amount 
mass unit instead of 1 used in Chapter 5 .  
Partial cross talk between the internal standards of morphine glucuronide was 
present even with the use of MS3 and after decreasing the mass range to 0.5 
amu. The morphine glucuronide internal standards improved the method 
selectivity which can be used in the cases that are positive for morphine or 
codeine and negative for DHC as few cases were found positive for both 
MOR/COD and DHC. Morphine glucuronide internal standards are very 
important in overcoming the matrix effects, especially since both metabolites 
are eluted early at low percentages of organic modifier. Therefore, these 
internal standards could be used in cases that were negative for DHC, but for 
general screening MOR-D6 was employed as internal standard which resulted 
in good linearity and precision. It is better to have penta- or hexadeuterated 
morphine glucuronides to avoid cross talk phenomenon with DHM 
glucuronides. Although optimising LC mobile phase and/or the use of different 
columns would solve this phenomenon, this would be consuming time. In the 
first method (Chapter 5) data for all analytes were collected using full scan 
mode. In the current method, two of the major product ions were chosen for 
selected reaction monitoring (SRM) for each analyte to obtain two SRM 
transitions. Only one transition was used with the corresponding internal 
standards. More internal standards were included in the current method and 
tested using the SRM mode instead of the SIM mode used in the previous blood 
autopsy method (Table 9-1). Fourteen internal standards were used in the 
current method compared to 9 internal standards in the previous method. 
 
 245 
Table 9-1: Selected reaction monitoring (SRM) transitions 
 
 
Analytes  
 
SRM #  
Transition A 
Quantifier ion 
m/z 
SRM   
Transition B  
Qualifier ion  
m/z 
Confirmation  
ratio A/B  
 (R.S.D. %) * 
RT & 
(min) 
n=35.0 
Morphine  286 → 201 286 → 286 1.5 (4.0) 8.0 
Morphine-D6 292 → 201 n.d.& n.d. 7.9 
Morphine-3-glucuronide 462 → 286 462 → 462 5.3 (7.0) 3.4 
Morphine-3-glucuronide-D3 465 → 289           n.d. n.d. 3.3 
Morphine-6-glucuronide 462 → 286 462→ 462 5.6 (10.0) 6.6 
Morphine-6-glucuronide-D3 465 →  289 n.d. n.d. 6.5 
6-Monoacetylmorphine 328 → 211 328 → 268 1.6 (3.0) 13.9 
6-Monoacetylmorphine-D3 331 → 211 n.d. n.d. 13.9 
Normorphine 272 → 254 272 → 229 2.5 (2.0) 4.8 
Codeine 300 → 215 300 → 243 1.4 (5.0) 12.4 
Codeine-D3 306 → 218 n.d. n.d. 12.4 
Codeine-6-gluucronide 476 → 300 476 → 467 21.0 (12.0) 11.0 
Codeine-6-glucuronide-D3 479 → 303 n.d. n.d. 10.9 
Norcodeine 286 → 268 286 → 243 5.0 (2.0) 11.1 
6-Acetylcodeine 342 → 225  342 → 225 2.4 (2.0) 18.4 
Hydromorphone 286 → 185 286 → 229 2.0 (10.0) 10.3 
Hydromorphone-D3 289 → 185 n.d. n.d. 10.3 
Hydromorphone-3-glucuronide 462 → 268 462 → 462 5.6 (7.0) 4.8 
Dihydrocodeine 302 → 245  302 → 201 1.6 (6.0) 11.8 
Dihydrocodeine-D6 308 → 248 n.d. n.d. 11.7 
Dihydrocodeine-6-glucuronide 478 → 302 478 → 245 14.8 (6.0) 11.0 
Dihydromorphine 288 → 213 288 → 231 1.1 (4.0) 6.9 
Dinudromorphine-3-gluucronide 464 → 288 464 → 464 4.0 (10.0) 3.1 
Dihydromorphine-6-glucuronide 464 → 288 464 → 464 5.0 (2.0) 7.1 
Buprenorphine 468 → 414 468 → 396 2.6 (8.0) 23.0 
Buprenorphine-D4 472 → 415 n.d. n.d. 22.9 
Buprenorphine-3-glucuronide 644.5 → 468 644.5→ 644.5 7.0 (17.0) 18.4 
Norbuprenorphine 414.4 → 396 414.4 → 340 1.6 (4.0) 19.7 
Norbuprenorphine-D3 417 → 399 n.d. n.d. 19.6 
Norbuprenorphine-3-glucuronide 590.5 → 414 590.5→ 590.5 5.8 (5.0) 14.3 
Naloxone 328 → 310 328 → 328 15.8 (8.0) 12.3 
Naloxone-3-glucuronide 504 → 486 504 → 328 1.6 (4.0) 7.9 
Oxycodone 316 → 298 316 → 316 18.0 (11.0) 13.7 
Oxycodone-D6 322 → 304 n.d. n.d. 13.7 
Noroxycodone 302 →284 302 → 229 10.0 (7.0) 12.9 
Noroxycodone-D3 305 → 287 n.d. n.d. 12.8 
Oxymorphone 302 → 284 302 → 302 5.4 (5.0) 9.3 
Oxymorphone-D3 305 → 287 n.d. n.d. 9.2 
Methadone 310 → 265 310 → 310 11.0 (10.0) 23.5 
Methadone-D3 313 → 268 n.d. n.d. 23.5 
#
  SRM: Selected reaction monitoring  
*
  RT: retention Time.  
 
&
 n.d.: only one SRM transition was determined.  
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9.4.1.1 Linearity     
Two calibration curves were prepared for most analytes included in this work 
with the exception of BUP metabolites, HMOR and HMOR glucuronide due to 
their expensive standards and only low level calibration curves were used. 
Two calibration ranges, 5-250 and 50-5000 ng/mL, were spiked into samples. 
The product ions of standards and internal standards were used to obtain peak 
area ratios of opioids and their metabolites. Linear regression lines were 
obtained with correlation coefficients (r2) greater than 0.999 for all analytes.  
High level calibration curves were found sufficient for urine cases but samples 
were diluted to bring them within the calibration range. SRM transitions are 
easily monitored for all analytes at high concentrations but the identification 
criteria may be affected by analyte concentration, for example, retention 
times can be shifted when a high concentration of target analyte is present. 
SRM transition ratios and retention times of analytes were similar to those of 
reference standards within the two calibration ranges used in the current 
study. Low sample volumes were used for analysis (0.1-0.25 mL) which 
reduced the matrix effects from endogenous components and avoided repeat 
analyses due to analyte concentrations being outside the calibration range.  
9.4.1.2 LOD and LLOQ 
LODs and LLOQs obtained for the analytes compared well with previous work 
(Chapter 5) and were 0.2 - 0.4 ng/mL and 0.5 - 1.5 ng/mL, respectively. 
LLOQs were calculated using equations 1-1, 1-2, 1-3 and 1-4. LODs and LLOQs 
for all analytes of interest are listed in Table 9-2.   
9.4.1.3 Intra- and inter-assay precision 
Intra- and inter-assay precision were assessed as the percentage relative 
standard deviation (RSD) on analyses of standards at three different 
concentrations (10, 50, and 200 ng/mL). Good precision was obtained for all 
analytes in the range from 1-14 and 1-15 % RSD for intra-and inter-assay 
precision, respectively (Tables 9-3 and 9-4). 
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Table 9-2: Linear correlation coefficients, LODs and LLOQs of opioids 
extracted from human urine. 
 
Analytes  r2 # y-intercept Standard 
error 
Gradient 
(m) 
LOD * 
(ng/mL) 
LLOQ & 
(ng/mL) 
MOR 0.998 0.000105 0.000128 0.001601 0.2 0.8 
M3G 0.998 -0.00047 0.000934 0.013056 0.2 0.7 
M6G 0.999 -0.000042530 0.000135512 0.002574273 0.2 0.5 
6-MAM 0.999 -0.00179 0.001055 0.01998 0.2 0.5 
NMOR 0.997 -0.000072 0.0000733 0.000743 0.3 1 
COD 0.994 -0.00015 0.000262 0.001912 0.4 1.4 
C6G 0.994 0.000863 0.000886 0.00632 0.4 1.4 
NCOD 0.992 0.002959 0.003244 0.020331 0.5 1.6 
6-AC 0.999 -0.00337 0.002166 0.030524 0.2 0.7 
HMOR 0.995 -0.000047 0.000295 0.002304 0.4 1.3 
H3G 0.999 0.0000442 0.000133 0.001202 0.3 1.1 
DHC 0.997 -0.000081 0.000111 0.001182 0.3 0.9 
DHC6G 0.995 0.00002 0.000352 0.002526 0.4 1.4 
DHM 0.999 -0.0005 0.000471 0.00347 0.4 1.4 
DHM3G 0.999 0.000173 0.000532 0.0045 0.4 1.2 
DHM6G 0.998 0.000178 0.000237 0.002739 0.3 0.9 
BUP 0.998 0.0000342 0.0000305 0.000413 0.2 0.7 
BUP3G 0.998 0.002654 0.019688 0.272071 0.2 0.7 
NBUP 0.996 -0.00196 0.001347 0.010989 0.4 1.2 
NBUP3G 0.998 0.0000624 0.000254 0.003479 0.2 0.7 
NALOX 0.995 -0.03249 0.043185 0.325067 0.4 1.3 
NALOX3G 0.993 -0.00028 0.0006 0.004101 0.4 1.5 
OXY 0.997 0.00027 0.000431 0.008459 0.2 0.5 
NOXY 0.994 -0.0002 0.000856 0.00687 0.4 1.2 
OXYM 0.997 0.000123 0.000974 0.009486 0.3 1.0 
METH 0.995 0.0000278 0.00012 0.00097 0.4 1.2 
#
  r 
2: Correlation coefficients. 
*
 LOD: Limit of detection. 
&
 LLOQ: Lower limit of quantitation. 
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9.4.1.4 Recovery and matrix effects 
Matrix effect and recovery experiments were investigated using five different 
concentrations across the two calibration ranges using five different sources 
of human urine at two concentration 5 and 100 ng/mL. Both ion suppression 
and ion enhancement were observed with average values less than 15% and 8% 
respectively, which were within the accepted limits of the validation 
procedure (± 20 %). Matrix effect results are detailed in Tables 9-5 and 9-6. 
Analytes recoveries were calculated at five different concentrations, 5, 25 
and 100, 750 and 2500 ng/mL, in the same manner as matrix effects but a 
third set was included in which analytes were spiked before extraction.  The 
recoveries for analytes were found to be 84-103%. Recoveries of opioids and 
their metabolites are listed in Table 9-7. 
9.4.1.5 Application to case samples 
Forty seven post-mortem blood and urine samples were analysed using the 
validated method. Total morphine (TMOR) to total codeine (TCOD) ratios were 
calculated to determine which opioid had been administered. The validated 
method was compared with the existing method in the routine laboratory, 
which was used only for blood analysis and no urine analysis results were 
available. Therefore, only blood results were compared. Buprenorphine and 
oxycodone cases have been discussed in detail in Chapters 7 and 8, 
respectively. Methadone, DHC, and heroin cases are discussed here.    
9.4.1.6 Stability 
The stability of many opioid metabolites has not been studied before in urine, 
such as DHC and its metabolites, naloxone and its glucuronide, 
hydromorphone glucuronide and acetylcodeine. In the present study, most 
opioids and metabolites were found to be stable under different conditions: 
storage at room temperature, long and short term at -20 0C and 4 0C, and 
freeze/thaw cycles, with the exception of 6-AC and 6-MAM which were found 
to be unstable after 24 hours at room temperature; 6-MAM decreased more 
than 30 % after a month at 4 0C. However, 6-AC decreased approximately 80% 
at the same time.  
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 Table 9-3: Intra-day precision between extractions. 
 
 Nominal Concentrations  * 
Analytes 5.0 
(ng/mL) 
25.0 
(ng/mL) 
200.0 
(ng/mL) 
750.0 
(ng/mL) 
2500.0 
(ng/mL) 
 Mean Measured Concentration ng/mL (R.S.D. % ) # 
Morphine 5.6 (3) 23.0 (2.0) 99.0 (6.0) 742.0 (4.0) 2492.0 (5.0) 
Morphine-3-glucuronide 4.9 (13) 26.0 (11.0) 104.0 (6.0) 753.0 (2.0) 2501.0 (3.0) 
Morphine-6-glucuronide 4.8 (7) 26.0 (7.0) 103.0 (2.0) 734.0 (3.0) 2526.0 (3.0) 
6-monoacetylmorphine 4.7 (8) 23.0 (2.0) 96.0 (1.0) 746.0 (2.0) 2518.0 (3.0) 
Normorphine 5.1 (11) 25.0 (8.0) 96.0 (5.0) 731.0 (2.0) 2514.0 (1.0) 
Codeine 4.6 (9) 25.0 (12.0) 100.0 (4.0) 745.0 (2.0) 2510.0 (2.0) 
Codeine-6-glucuronide 4.5 (11) 29.0 (4.0) 95.0 (5.0) 767.0 (3.0) 2533.0 (2.0) 
Norcodeine 5.7 (1.0) 23.0 (9.0) 105.0 (4.0) 741.0 (4.0)  2505.0 (3.0) 
6-Acetylcodeine 5 (10.0) 25.0 (10.0) 98.0 (6.0) 740.0 (2.0) 2472.0 (1.0) 
Hydromorphone 5.2 (6.0) 21.0 (7.0) 95.0 (7.0) N/A & N/A 
Hydromorphone-3-glucuronide 4.9 (14.0) 26.0 (11.0) 101.0 (4.0) N/A N/A 
Dihydrocodeine 4.5 (7.0) 25.0 (9.0) 98.0 (4.0) 742.0 (4.0) 2498.0 (6.0) 
Dihydrocodeine-6-glucuronide 5.5 (8.0) 25.0 (10.0) 100.0 (6.0) 743.0 (3.0) 2507.0 (3.0) 
Dihydromorphine 4.7 (10.0) 25.0 (10.0) 98.0 (7.0) 755.0 (7.0) 2502.0 (4.0) 
Dihydromorphine-3-glucuronide 5.5 (7.0) 25.0 (14.0) 96.0 (5.0) 743.0 (5.0) 2476.0 (2.0) 
Dihydromorphine-6-glucuronide 5.5 (13.0) 25.0 (7.0) 97.0 (6.0) 751.0 (4.0) 2485.0 (3.0) 
Buprenorphine 4.7 (12.0) 27.0 (3.0) 102.0 (6.0) N/A N/A 
Buprenorphine-3-glucuronide 4.3 (7.0) 26.0 (7.0) 100.0 (9.0) N/A N/A 
Norbuprenorphine 4.4 (10.0) 24.0 (7.0) 100.0 (7.0) N/A N/A 
Norbuprenorphine-3-glucuronide 5.4 (9.0) 24.0 (8.0) 101.0 (6.0) N/A N/A 
Naloxone 5.5 (14.0) 24.4 (12.0) 106.0 (5.0) 751.0 (4.0) 2489.0 (6.0) 
Naloxone-3-glucuronide 5.3 (5.0) 26.0 (9.0) 99.0 (6.0) 744.0 (2.0) 2474.0 (3.0) 
Oxycodone 5.2 (5.0) 24.0 (4.0) 107.0 (5.0) 740.0 (3.0) 2488.0 (1.0) 
Noroxycodone 4.7 (7.0) 23.0 (10.0) 104.0 (2.0) 751.0 (3.0) 2482.0 (2.0) 
Oxymorphone 4.7 (11.0) 25.0 (8.0) 99.0 (4.0) 750.0 (1.0) 2492.0 (2.0) 
Methadone 4.8 (4.0) 25.0 (5.0) 96.0 (3.0) 754.0 (3.0) 2475.0 (5.0) 
* Value calculated from the average recovery for the replicate analyses (n=5) 
 
#
 R.S.D. %: Relative standard deviation expressed as a percentage. 
 
&
 N/A: Not analysed. 
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Table 9-4: Inter-day precision between extractions. 
 Nominal Concentrations *  
Analytes 5.0 
(ng/mL) 
25.0 
(ng/mL) 
200.0 
(ng/mL) 
750.0 
(ng/mL) 
2500.0 
(ng/mL) 
 Mean Measured Concentration ng/mL  (R.S.D. % ) # 
Morphine 4.9 (9.0) 24.0 (6.0) 100.0 (5.0) 748.0 (3.0) 2506.0 (1.0) 
Morphine-3-glucuronide 5.2 (12.0) 25 (7.0) 95.0 (4.0) 741.0 (5.0) 2534.0 (2.0) 
Morphine-6-glucuronide 5.6 (11.0) 24.0 (5.0) 99.0 (5.0) 743.0 (2.0) 2481.0 (1.0) 
6-monoacetylmorphine 4.8 (14.0) 25.0 (4.0) 100.0 (3.0) 746.0 (3.0) 2496.0 (5.0) 
Normorphine 5.0 (13.0) 23.0 (10.0) 100.0 (4.0) 752.0 (5.0) 2495.0 (7.0) 
Codeine 5.0 (15.0) 27.0 (8.0) 99.0 (6.0) 743.0 (3.0) 2487.0 (8.0) 
Codeine-6-glucuronide 4.9 (13.0) 26.0 (10.0)  99.0 (4.0) 733.0 (6.0) 2480.0 (3.0) 
Norcodeine 4.8 (15.0) 24.0 (11.0) 102.0 (3.0) 743.0 (5.0) 2514.0 (3.0) 
6-Acetylcodeine 4.8 (14.0) 27.0 (6.0) 101.0 (3.0) 741.0 (2.0) 2496.0 (5.0) 
Hydromorphone 5.0 (13.0) 23.0 (12.0) 100.0 (2.0) N/A & N/A 
Hydromorphone-3-glucuronide 5.5 (11.0) 25 (12.0) 100.0 (6.0) N/A N/A 
Dihydrocodeine 4.7 (14.0) 26.0 (6.0) 96.0 (5.0) 753 (6) 2487 (2) 
Dihydrocodeine-6-glucuronide 5.6 (9.0) 24.0 (7.0) 101.0 (4.0) 745.0 (4.0) 2523.0 (3.0) 
Dihydromorphine 4.8 (7.0) 25.0 (4.0) 103.0 (7.0) 756.0 (2.0) 2515.0 (1.0) 
Dihydromorphine-3-
glucuronide 
5.7 (5.0) 24.0 (1.0) 100.0 (7.0) 742.0 (2.0) 2488.0 (3.0) 
Dihydromorphine-6-
glucuronide 
5.5 (15.0) 24.0 (6.0) 102.0 (4.0) 747.0 (5.0) 2483.0 (2.0) 
Buprenorphine 5.2 (12.0) 25.0 (14.0) 98.0 (6.0) N/A N/A 
Buprenorphine-3-glucuronide 5.6 (6.0) 25.0 (5.0) 98.0 (3.0) N/A N/A 
Norbuprenorphine 5.8 (10.0) 22.0 (6.0) 98.0 (8.0) N/A N/A 
Norbuprenorphine-3-
glucuronide 
4.9 (12.0) 23.0 (11.0) 96.0 (4.0) N/A N/A 
Naloxone 4.8 (11.0) 23.0 (5.0) 103.0 (2.0) 743.0 (2.0) 2484.0 (1.0) 
Naloxone-3-glucuronide 5.5 (14.0) 26.0 (11.0) 100.0 (3.0) 760.0 (6.0) 2480.0 (2.0) 
Oxycodone 4.7 (12.0) 23.0 (11.0) 100.0 (3.0) 743.0 (2.0) 2506.0 (3.0) 
Noroxycodone 5.1 (7.0) 23.0 (9.0) 102.0 (6.0) 754.0 (3.0) 2507.0 (2.0) 
Oxymorphone 5.2 (12.0) 25.0 (8.0) 99.0 (8.0) 746.0 (3.0) 2507.0 (2.0) 
Methadone 5.3 (13.0) 25.0 (8.0) 102.0 (2.0) 752.0 (4.0) 2531.0 (3.0) 
* Value calculated from the average recovery for the replicate analyses (n=5) 
 
#
 R.S.D. %: Relative standard deviation expressed as a percentage. 
 
&
 N/A: Not analysed 
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Table 9-5: Matrix effects at 5 ng/mL (% relative to drug in buffer). 
 
 Urine Sources # spiked at  5 ng/mL after SPE extraction 
% *  (R.S.D. %) & 
Analytes  1 2 3 4 5 
Morphine 109 (8) 105 (3) 92 (4) 107 (10) 108 (7) 
Morphine-3-glucuronide 104 (3) 90 (7) 99 (9) 119 (6) 107 (11) 
Morphine-6-glucuronide 91 (10) 108 (4) 103 (6) 116 (2) 99 (14) 
6-monoacetylmorphine 113 (5) 108 (11) 102 (12) 116 (10) 93 (3) 
Normorphine 95 (5) 110 (8) 84 (2) 117 (10) 114 (9) 
Codeine 111 (9) 117 (3) 98 (14) 103 (7) 112 (13) 
Codeine-6-glucuronide 126 (7) 107 (10) 106 (9) 118 (3) 115 (6) 
Norcodeine 110 (7) 94 (12) 102 (11) 115 (11) 109 (8) 
6-Acetylcodeine 95 (2) 94 (11) 97 (6) 109 (3) 101 (3) 
Hydromorphone 116 (9) 105 (14) 107 (7) 113 (5) 96 (9) 
Hydromorphone-3-glucuronide 106 (9) 96 (15)  116 (15) 118 (8) 103 (14) 
Dihydrocodeine 104 (8) 91 (5) 87 (13) 115 (2) 98 (11) 
Dihydrocodeine-6-glucuronide 121 (7) 106 (14) 93 (4) 104 (1) 106 (10) 
Dihydromorphine 103 (2) 103 (13) 95 (7) 105 (3) 94 (11) 
Dihydromorphine-3-glucuronide 99 (3) 89 (10) 87 (8) 98 (10) 105 (6) 
Dihydromorphine-6-glucuronide 101 (10) 108 (4) 91 (6) 116 (1) 100 (5) 
Buprenorphine 115 (12) 118 (1) 105 (11) 117 (3) 103 (3) 
Buprenorphine-3-glucuronide 113 (13) 109 (10) 108 (13) 114 (2) 105 (13) 
Norbuprenorphine 111 (1) 112 (5) 103 (6) 119 (12) 105 (13) 
Norbuprenorphine-3-glucuronide 89 (8) 103 (1) 122 (5) 103 (4) 98 (4) 
Naloxone 108 (6) 102 (9) 96 (7) 94 (6) 86 (4) 
Naloxone-3-glucuronide 112 (9) 103 (10) 92 (2) 108 (14) 113 (13) 
Oxycodone 100 (13) 100 (5) 98 (6) 116 (7) 97 (5) 
Noroxycodone 87 (13) 108 (4) 87 (7) 109 (8) 113 (6) 
Oxymorphone 102 (4) 113 (14) 103 (15) 124 (4) 105 (2) 
Methadone 101 (12) 98 (12) 96 (10) 91 (8) 104 (4) 
#
 Human urine was sourced from completed urine samples that were scheduled for destruction and 
contained no analytes of interest. 
*
 Matrix effect is expressed as the response obtained for a standard chromatographed along with 
matrix extract compared to that obtained with an unextracted standard chromatographed in mobile 
phase only, expressed as a percentage. Standard was spiked into matrix extract at a concentration of 
5 ng/mL. 
&
 R.S.D. %: Relative standard deviation expressed as a percentage. 
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Table 9-6: Urine matrix effects at 100 ng/mL (% relative to drug in buffer). 
 Urine Sources * Spiked at 100 ng/mL after SPE 
Extraction  
% ¥ (R.S.D. % ß) 
Analytes 1 2 3 4 5 
Morphine 118 (6) 95 (14) 99 (7) 95 (6) 100 (10) 
Morphine-3-glucuronide 100 (1) 91 (3) 87 (1) 105 (5) 102 (2) 
Morphine-6-glucuronide 98 (3) 101 (1) 98 (7) 114 (1) 116 (2) 
6-monoacetylmorphine 100 (7) 91 (11) 97 (3) 100 (2) 100 (1) 
Normorphine 95 (3) 93 (9) 80 (14) 98 (6) 90 (5) 
Codeine 93 (3) 98 (3) 90 (1) 103 (1) 99 (5) 
Codeine-6-glucuronide 100 (3) 101 (7)    98 (4) 101 (6) 112 (2) 
Norcodeine 106 (9) 93 (4) 98 (5) 106 (3) 87 (2) 
6-Acetylcodeine 104 (2) 84 (7) 93 (3) 116 (13) 118 (8) 
Hydromorphone 97 (3) 93 (5) 102 (9) 97 (3) 99 (8) 
Hydromorphone-3-glucuronide 100 (1) 95 (11) 96 (1) 108 (2) 100 (10) 
Dihydrocodeine 98 (3) 102 (8) 93 (6) 111 (1) 112 (3) 
Dihydrocodeine-6-glucuronide 95 (1) 98 (7) 103 (8) 113 (8) 110 (5) 
Dihydromorphine 117 (13) 106 (5) 99 (10) 102 (2) 96 (7) 
Dihydromorphine-3-glucuronide 116 (15) 103 (10) 103 (11) 113 (2) 107 (9) 
Dihydromorphine-6-glucuronide 118 (7) 103 (7) 100 (8) 105 (2) 100 (5) 
Buprenorphine 103 (1) 103 (4) 91 (8) 88 (1) 95 (5) 
Buprenorphine-3-glucuronide 112 (10) 104 (3) 107 (1) 99 (15) 104 (13) 
Norbuprenorphine 96 (5) 97 (6) 107 (6) 105 (4) 109 (1) 
Norbuprenorphine-3-glucuronide 98 (11) 87 (5) 101 (1) 92 (15) 82 (4) 
Naloxone 100 (5) 99 (2) 111 (6) 98 (1) 89 (1) 
Naloxone-3-glucuronide 93 (1) 100 (4) 99 (7) 108 (4) 97 (8) 
Oxycodone 102 (1) 102 (12) 107 (4) 98 (3) 105 (1) 
Noroxycodone 105 (7) 107 (11) 98 (2) 115 (10) 106 (1) 
Oxymorphone 111 (3) 103 (2) 100 (4) 100 (4) 101 (7) 
Methadone 93 (6) 96 (4) 96 (6) 103 (1) 101 (2) 
#
 Human urine was sourced from completed urine samples that were scheduled for destruction and 
contained no analytes of interest. 
*
 Matrix effect is expressed as the response obtained for a standard chromatographed along with 
matrix extract compared to that obtained with an unextracted standard chromatographed in mobile 
phase only, expressed as a percentage. Standard was spiked into matrix extract at a concentration of 
5 ng/mL. 
&
 R.S.D. %: Relative standard deviation expressed as a percentage. 
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Table 9-7: Recoveries in extracted human urine 
  
Nominal concentration  
 5 ng/mL 25 ng/mL 200 ng/mL 750 ng/mL 2500 ng/mL 
 ME * RE # ME RE ME RE ME RE ME RE 
Analytes  Mean concentration measured % (R.S.D. %) & 
MOR 109 (8) 80 (8) 117 (12) 91 (14) 118 (6) 96 (7) 104 (7) 97 (6) 97 (6) 99 (9) 
M3G 104 (3) 89 (9) 101 (6) 86 (10) 100 (1) 91 (4) 103 (1) 99 (2) 104 (3) 101 (2) 
M6G 91 (10) 84 (11) 88 (12) 91 (11) 98 (3) 93 (2) 106 (3) 98 (1) 109 (3) 97 (2) 
6-MAM 113 (5) 91 (9) 100 (5) 90 (12) 100 (7) 94 (11) 107 (4) 95 (2) 92 (5) 100 (3) 
NMOR 95 (5) 72 (5) 97 (6) 88 (8) 95 (3) 93 (5) 111 (2) 100 (5) 102 (9) 100 (3) 
COD 111 (9) 78 (8) 100 (10) 91 (2) 93 (3) 97 (9) 115 (7) 99 (3) 100 (8) 100 (2) 
C6G 126 (7) 79 (3) 102 (9) 87 (14) 100 (3) 94 (11) 117 (5) 93 (7) 103 (2) 101 (5) 
NCOD 110 (7) 78 (11) 97 (9) 92 (6) 106 (9) 95 (9) 113 (6) 96 (8) 105 (13) 97 (7) 
6-AC 95 (2) 81 (11) 99 (4) 94 (9) 104 (2) 91 (8) 108 (5) 92 (4) 105 (5) 94 (1) 
HMOR 116 (9) 80 (2) 100 (7) 84 (12) 97 (3) 90 (11) N/A ** N/A N/A N/A 
H3G 106 (6) 79 (15) 96 (12) 98 (6) 100 94 (1) N/A N/A N/A N/A 
DHC 104 (8) 78 (13) 98 (8) 89 (7) 98 (3) 97 (13) 108 (5) 93 (5) 108 (7) 98 (5) 
DHC6G 121 (7) 75 (8) 103 (10) 85 (5) 95 (1) 92 (5) 102 (2) 99 (6) 103 (10) 98 (4) 
DHM 103 (2) 76 (2) 106 (10) 95 (6) 117 (13) 94 (10) 109 (4) 91 (7) 107 (8) 97 (5) 
DHM3G 99 (3) 75 (7) 111 (4) 90 (5) 116 (5) 99 (6) 99 (11) 100 (4) 110 (10) 101 (3) 
DHM6G 101 (10) 78 (7) 108 (11) 87 (7) 118 (7) 100 (5) 107 (8) 100 (7) 107 (9) 99 (11) 
BUP 115 (12) 76 (3) 113 (8) 78 (6) 103 (1) 87 (10) N/A N/A N/A N/A 
BUP3G 113 (13) 85 (12) 116 (7) 91 (12) 112 (10) 96 (3) N/A N/A N/A N/A 
NBUP 111 (1) 77 (9) 106 (5) 88 (13) 96 (5) 89 (11) N/A N/A N/A N/A 
NBUP3G 89 (8) 93 (10) 108 (6) 95 (3) 98 (11) 92 (4) N/A N/A N/A N/A 
NALOX 108 (6) 84 (11) 112 (2) 87 (7) 100 (5) 89 (4) 109 (3) 92 (7) 112 (9) 90 (12) 
NALOX3G 112 (9) 91 (13) 103 (10) 89 (6) 93 (1) 90 (6) 103 (10) 98 (6) 107 (11) 96 (4) 
OXY 100 (9) 88 (10) 96 (6) 91 (10) 102 (1) 94 (9) 106 (8) 102 (6) 105 (6) 101 (5) 
NOXY 87 (13) 85 (1) 92 (10) 105 (7) 105 (7) 99(4) 106 (4) 100 (11) 104 (10) 101 (11) 
OXYM 102 (4) 84 (4) 93 (3) 101 (3) 101 (3) 95 (3) 103 (3) 96 (6) 110 (4) 102 (8) 
METH 101 (12) 76 (9) 103 (4) 93 (6) 93 (6) 87 (6) 106 (4) 85 (5) 98 (10) 90 (2) 
* Matrix effect is expressed as the response obtained for a standard chromatographed along with matrix extract compared to that obtained with an unextracted 
standard chromatographed in mobile phase only, expressed as a percentage. Standard was spiked into matrix extract at a concentration of 5, 25 and 100 ng/mL. 
# Value calculated from the average recovery for the replicate analyses (n=5) 
 
&
 R.S.D. %: Relative standard deviation expressed as a percentage. ** N/A: Not analysed. 
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Stability of opioids and metabolites during sample processing was investigated 
using four freeze/thaw cycles and room temperature for four hours. The stability 
of all other opioids and their metabolites were in ranges of 89-119% and 94-115% 
respectively. Opioid metabolites in urine samples were stable for a week on the 
auto-sampler (4 0C). Long-term stability studies were performed at two different 
storage temperatures used routinely in the forensic toxicology laboratory, 4oC 
and -20oC, to assess the stability of analytes of interest. Stability results are 
listed in Table 9-5.  
Opioids and their metabolites were stable for the whole period of this stability 
study (Table 9.5).  However, the concentration of 6-AC decreased sharply by 30% 
after a month at 4oC. 10% of 6-MAM was lost after a week and 25% after a month 
at 4oC. Concentration changes with other analytes were less than ± 20% which 
was within the acceptable limits of the validation procedure.  
The stability of naloxone-3-glucuronide, dihydrocodeine-6-glucuronide, 
dihydromorphone-3-glucuronide and dihydromorphone-6-glucuronide in urine 
samples was reported for the first time in this work. In Chapter 5, most opioids 
and metabolites in blood were found stable with the exception of 6-AC and 6-
MAM in which large losses were observed previously during blood storage at room 
temperature and at 4 oC temperature (Figure 9-1 and 9-2).  
The same finding was observed with urine in the current study and a decline in 
their concentrations was observed but with a lower rate than in blood, possibly 
because of the lower pH of urine (Figures 9-2 and 9-3). 6-MAM was detected in 
urine from most heroin-related deaths but in blood in only a few cases. The low 
concentration of 6-AC plus instability in both matrices has resulted in 6-AC being 
undetected in all cases except one, in which 6-AC was detected in urine at a 
very low concentration but in the presence of a high concentration of 6-MAM. 
ONeal and Poklis 420 studied the stability of 6-AC in urine at pH 4.7 and pH 8 and 
found it to be more stable at the lower pH. Also, the authors found 6-AC in 6 out 
of 69 urine samples testing positive for morphine and codeine. They found 6-
MAM in all cases testing positive for 6-AC. In that study, levels of 6-AC and 6-
MAM ranged between 1-48 ng/mL and 100-1470 ng/mL, respectively. In the 
current study, the concentrations of 6-AC and 6-MAM in one living DUID subject 
were 11 and 329 ng/mL.  
 255 
Table 9-8: Stability studies (% relative to starting concentration). 
Storage  
condition # 
Room  Temperature Freeze-thaw  
 
Auto-sampler at 
4 0C 
Freezer at  
-20 0C 
Refrigerator at  
4 0C 
 4 
 hours 
24 
hours 
4 cycles 48  
hours 
week 24 
hours 
48 
hours 
week month 24 
hours 
48 
hours 
week month 
Analytes  Mean concentration measured % *  (R.S.D. %)& 
MOR 95 (9) 97 (7) 97 (7) 99 (14) 98 (9) 94 (10) 93 (7) 100 (5) 107 (6) 93 (10) 93 (14) 110 (2) 115 (1) 
M3G 97 (7) 104 (9) 103 (9) 96 (5) 90 (8) 95 (5) 96 (10)  93 (2) 102 (5) 98 (6) 91 (9) 91 (12) 89 (8) 
M6G 98 (8) 103 (6) 103 (6) 91 (11) 94 (12) 105 (3) 101 (12) 96 (3) 99 (8) 102 (7) 94 (7) 93 (7) 95 (7) 
6-MAM 101 (3) 95 (9) 89 (5) 93 (6) 95 (7) 107 (3) 100 (4) 95 (6) 94 (2) 93 (5) 101 (15) 90 (8) 75 (4) 
NMOR 98 (1) 100 (4) 100 (4) 100 (11) 101 (5) 109 (11) 101 (1) 91 (5) 96 (8) 100 (2) 104 (4) 104 (7) 108 (5) 
COD 115 (5) 108 (3) 109 (2) 94 (5) 103 (2) 108 (14) 114 (5)  97 (10) 102 (5) 95 (7) 114 (8) 100 (8) 110 (6) 
C6G 100 (7) 105(11) 105 (11) 99 (4) 102 (5) 104 (2) 102 (3) 87 (3) 115 (7) 91 (7) 101 (8) 91 (6) 103 (6) 
NCOD 100 (6) 104 (5) 104 (5) 96 (9) 101 (3) 96 (2) 100 (5) 101 (1) 93 (4) 89 (3) 109 (4) 91 (2) 93 (5) 
6-AC 114 (4) 94 (8) 95 (8) 97 (5) 96 (9) 116 (5) 101 (2) 97 (8) 91 (3) 107 (6) 105 (10) 93 (10) 72 (1) 
HMOR 104 (6) 102 (2) 102 (2) 97 (5) 109 (1) 104 (7) 102 (7) 94 (6) 95 (6) 93 (13) 104 (7) 94 (2) 101 (10) 
H3G 94 (3) 110 (1) 112 (3) 93 (8) 90 (7) 92 (2) 94 (12) 104 (2) 97 (10) 96 (14) 113 (9) 101 (14) 89 (7) 
DHC 110 (7) 96 (6) 96 (6) 98 (6) 97 (6) 109 (8) 107 (1) 96 (5) 108 (4) 98 (2) 106 (4) 98 (8) 103 (5) 
DHC6G 100 (4) 98 (9) 98 (9) 94 (5) 100 (1) 106 (6) 94 (5) 98 (9) 110 (5) 95 (1) 92 (4) 97 (2) 118 (7) 
DHM 96 (8) 95 (6) 95 (6) 108 (4) 104 (3) 93 (5) 105 (8) 101 (11) 105 (7) 93 (3) 97 (6) 111 (1) 106 (9) 
DHM3G 97 (2) 102 (2) 102 (2) 103 (8) 96 (12) 94 (2) 93 (3) 103 (3) 105 (11) 92 (4) 88 (6) 95 (2) 108 (6) 
DHM6G 94 (8) 98 (6) 98 (6) 98 (5) 90 (4) 95 (8) 97 (7) 95 (7) 100 (2) 93 (11) 93 (6) 99 (8) 117 (5) 
BUP 115 (14) 94 (6) 94 (5) 98 (11) 108 (1) 101 (5) 106 (4) 105 (12) 109 (3) 96 (8) 104 (5) 102 (14) 107 (5) 
BUP3G 105 (6) 102 (10) 102 (10) 95 (3) 100 (6) 104 (2) 98 (6) 97 (13) 93 (9) 107 (4) 104 (12) 110 (7) 100 (12) 
NBUP 103 (10) 105 (6) 105 (6) 104 (5) 102 (10) 94 (4) 101 (4) 104 (8) 94 (7) 94 (11) 108 (3) 103 (4) 109 (10) 
NBUP3G 99 (7) 108 (1) 109 (1) 93 (3) 99 (6) 96 (9) 96 (10) 103 (6) 102 (6) 94 (10) 93 (2) 97 (2) 99 (10) 
NALOX 114 (5) 98 (2) 98 (2) 105 (5) 106 (8) 112 (12) 111 (12) 106 (3) 98 (11) 94 (8) 109 (8) 91 (5) 101 (8) 
NALOX3G 94 (11) 106 (7) 105 (7) 89 (5) 96 (4) 96 (7) 106 (9) 92 (2) 112 (4) 93 (9) 90 (5) 86 (8) 114 (2) 
OXY 104 (9) 100 (9) 100 (9)  93 (4) 108 (5) 97 (1) 104 (6) 95 (5) 107 (6) 93 (1) 102 (5) 92 (7) 103 (2) 
NOXY 112 (4) 103 (10) 103 (10) 96 (15) 97 (5) 103 (2) 109 (8) 97 (13) 100 (8) 104 (6) 106 (14) 96 (12) 106 (6) 
OXYM 110 (4) 99 (4) 99 (4) 102 (9) 104 (1) 106 (6) 113 (1) 96 (8) 110 (2) 94 (11) 117 (1) 91 (3) 97 (5) 
METH 100 (5) 99 (11) 99 (10) 95 (10) 100 (2) 96 (2) 106 (5) 95 (6) 112 (1) 95 (11) 107 (2) 95 (4) 109 (8) 
#
 Starting concentration is 100 ng/mL;  
*
 Value calculated from the average recovery for the replicate analyses (n=3). 
&
 R.S.D. %: Relative standard deviations expressed as a percentage.   
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Figure 9-2: Comparison between 6-acetylcodeine stability in blood and urine. 
Figure 9-1: Comparison between 6-acetylmorphine stability in blood and urine. 
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Figure 9-3: Negative results for 6-MAM and 6-AC in blood from a living 
subject having positive results in urine. 
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Figure 9-4: LC-MS chromatogram for a case testing positive for both 6-
MAM and 6-AC. 
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6-Acetylcodeine has been detected in heroin users due to impurities which arise 
from the process of manufacturing heroin. It has been mentioned that heroin 
contains between 2-20% of 6-AC depending on the source of heroin and could be 
higher than 80%. ONeal and Pokils 258 investigated the use of 6-AC as a specific 
marker of heroin use as an alternative to 6-MAM in urine sample and discovered 
that small amounts of 6-AC were detected compared to 6-MAM. They concluded 
that determining 6-AC could be used as a complementary marker of heroin use 
together with 6-MAM. However, it was not detected when the concentration of 
6-MAM was low. Therefore, 6-AC might be a useful tool to distinguish between 
street heroin and pure heroin given in those programmes where patients are 
treated with pure heroin and samples were freeze directly to prevent of 6-AC 
hydrolysis to codeine 258-260. 
The present study agrees with previous studies mentioned above that no 6-AC 
can be present alone without the presence of 6-MAM, dismissing the hypothesis 
of using 6-AC as heroin biomarker when 6-MAM is absent. Only one case was 
quantified for 6-AC in the current investigation. A few other cases in which 6-AC 
was found in trace levels could not be quantified due to the low concentrations 
present.  
9.4.2 Cases samples 
9.4.2.1 Methadone  
Methadone was included in this method due to the increased incidence of 
methadone in opioid related deaths. Methadone was detected using autopsy 
blood in eight cases in the previous study using its pseudomolecular ion at m/z 
310 which produced only a single product ion (mz 265). The cone voltage was 
adjusted to keep 10% of the parent drug in order to calculate the SRM transition 
ratio between mz 265 and 310. A good recovery and no matrix effects were 
observed for methadone in both blood and urine. Methadone was eluted at a 
very high organic modifier content, up to 80 %, which helped to enhance its 
MS/MS response. LLOQs were 1 and 1.2 ng/mL in blood and urine, respectively.  
The stability of methadone was examined in blood at 100 ng/mL, when it was 
found stable at room temperature for up to 24 hours. Also, methadone was 
stable after subjection to four freeze/thaw cycles (98%), in the autosampler for 
 260 
up to 1 week (104%) and in the refrigerator or freezer for up to one month (106% 
and 103% respectively).   
Table 9-9: Comparison between the routine and optimised LC-MS/MS 
methods for analysis of methadone in autopsy blood samples 
 
 Optimised LC-MS/MS methods  # 
results  
SOP result * 
 
 
No cases Blood 
(ìg/mL) 
Urine 
(ìg/mL) 
Blood (ìg/mL) Cause of death 
1 0.21 5.10 0.23 Inhalation of gastric 
contents; diazepam and 
methadone intoxication 
2 0.41 1.40 0.44 Heroin and methadone 
intoxication 
3 0.25 5.80 0.23 Head injury 
4 0.70 5.30 0.70 
 
methadone and alcohol 
intoxication 
5 0.35 1.10 0.34 Heroin, alcohol and 
methadone intoxication 
6 0.90 3.50 0.80 Methadone and cocaine 
intoxication  
7 1.60 25.90 2.20 Methadone intoxication 
8 1.20 3.10 1.30 Data not available  
9 0.92 6.20 0.80 Methadone and alcohol 
intoxication  
10 5.40 12.00 5.50 Stab wound of heart  
11 0.18 0.80 0.14 DHC and methadone 
intoxication 
12 1.40 0.90 1.60 Methadone, olazepine 
and diazepam 
intoxication 
Liver cirrhosis  
13 1.80 8.20 1.90 Methadone intoxication 
14 0.50 3.70 0.43 Heroin and methadone 
intoxication 
#
 LC-MS/MS method for the analysis of opioids and their metabolites. 
*
 SOP: Standard operation procedure or in-house GC-MS method used for routine general opioids 
analysis in Forensic Medicine and Science; University of Glasgow. 
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Methadone is usually identified in biological fluids by the presence of methadone 
itself or its metabolite EDDP. The latter eluted near to methadone and good 
method validation parameters were obtained for it. However, the calibration 
curve for EDDP was not linear during analysis of real case samples. The problem 
occured suddenly and may have been the result of standard contamination. As 
there was limited time left for this study, EDDP was excluded in the final 
validation process. The results obtained for 14 cases positive for methadone are 
listed in Table 9-9. Benzodiazepines were detected in all methadone cases, most 
of which were poly-drug intoxications in which heroin, DHC and alcohol were 
implicated in the deaths. The results obtained for these cases using the routine 
laboratory GC-MS (standard operation procedure (SOP)) method were compared 
with those from the new method. A good correlation was obtained with r2 of 
0.996 (Figure 9-6 and Table 9-9).  
9.4.2.2 Heroin and codeine 
In Chapter 5, ratios between drugs and metabolites were used for interpretation 
of the cause of death and the type of opioid administered and these will not be 
discussed again here.  
Figure 9-5: Correlation between the routine and optimised methods for the 
analysis of methadone samples in autopsy blood samples. 
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Total MOR and total COD were not measured in all cases using SOP so only free 
MOR and COD results were available for direct comparison between optimised 
autopsy blood method and the SOP. A good correlation was obtained for free 
MOR and COD with r2 of 0.99 and 0.996 for FMOR and FCOD, respectively, 
(Figures 9-7 and 9-8 and Table 9-10). 
It can be seen from the results for 29 urine samples from heroin and codeine 
cases (Table 9-11) that M3G is the most abundant metabolite with average and 
median concentrations of 45 and 70 ìg/mL. The TMOR/TCOD ratios were higher 
than one in all cases with the exception of five cases (16, 23-25, and 27) 
suggesting that the opioid ingested was codeine. Levels of COD in urine may be 
higher than 1 ìg/mL following heroin administration. The ratio of free MOR/free 
COD ranged between 0.05-56 with an average and median of 12 and 10, 
respectively, suggesting that heroin was used in most cases where the ratio was 
higher than 1. 6-MAM tested positive in most heroin related fatalities, 
Norcodeine, considered a marker of codeine use, was detected in most of the 
heroin cases,  probably due to the hydrolysis of 6-AC to codeine and oxidation to 
norcodeine.  
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 Figure 9-6: Comparison between free morphine in blood obtained using 
optimised LC-MS/MS and routine methods. 
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From the results listed in Tables 9-10 and 9-11 for 32 cases, the causes of death 
was identified in 28 cases in the pathology reports. In cases where heroin was 
implicated in the death, the causes of death can be classified into three types: 
sole heroin intoxication, poly-drug intoxication (in which at least another drug 
contributed to toxicity) and not related to death (in which the cause of death 
was attributed to another drug or disease) 157. Eight cases were sole heroin 
intoxication according to pathology reports: blood MOR levels were in the range 
0.2-1.1 ìg/mL with average and median concentrations of 0.46 and 0.38 ìg/mL, 
respectively; MOR in urine was in the range of 0.02-8.5 ìg/mL with average and 
median concentrations of 2 and 0.6 ìg/mL, respectively. COD concentrations in 
blood were in the range 0.003-0.1 ìg/mL with average and median 
concentrations of 0.05 and 0.03 ìg/mL, respectively. However, in urine, COD 
ranged between not detected to 3.6 ìg/mL. 
Heroin contributed with another drug in deaths of nine of these cases; four cases 
were attributed to a combination of heroin and methadone, three cases to 
heroin and cocaine and two cases consisted to heroin and alcohol. Blood MOR 
Figure 9-7: Comparison between free codeine in blood obtained using 
optimised LC-MS/MS and routine methods. 
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was in the range of 0.08-0.7 ìg/mL with average and median concentrations of 
0.38 and 0.33 ìg/mL, respectively. Urine MOR was in the range of 0.04-14.4 
ìg/mL with average and median concentrations of 3.57 and 0.7 ìg/mL, 
respectively. COD in blood ranged between 0.01-0.1 ìg/mL with average and 
median concentrations of 0.05 and 0.04 ìg/mL, respectively; COD in urine was in 
the range 0.03-1 ìg/mL with average and median concentrations of 0.31 and 
0.17 ìg/mL, respectively.  
In the third category, in which the presence of MOR was not related to the cause 
of death, blood MOR was 0.02-1.1 ìg/mL with average and median 
concentrations 0.4 and 0.2 ìg/mL; MOR in urine was 0.04-5.1 ìg/mL with 
average and median concentrations of 2.2 and 1.5 ìg/mL, respectively. Three of 
these cases were attributed to co-codamol intoxication in which high blood 
levels of COD were encountered ( 0.001-2.3 ìg/mL) with average and median 
concentrations of 0.6 and 0.1 ìg/mL; urine COD levels were in the range of 0.2-4 
ìg/mL with average and median concentrations of 1.2 and 0.4 ìg/mL. There was 
overlap between cases using free MOR levels in blood and urine even in non-drug 
related fatalities. 
The present work strongly supports the use of the ratio of free MOR/ free 
codeine in urine to distinguish between heroin and codeine users in which the 
detectable amount of free MOR was higher than 10 ìg/mL and if 6-MAM was not 
present; these ratios should not be less than one for both free and total drug 257. 
Codeine has often been included in the analysis of morphine in biological 
samples to interpret the opiate administered 201-203,257. However, interpretation 
of the ratio of morphine/codeine in urine samples has often been brought into 
question. Many factors have been found to affect this ratio, such as the pH 
variation between cases, unusual frequency of urination and amount of urine in 
the bladder, which influence the reliability of the ratio in forensic analysis. 
Therefore, the ratio of morphine/codeine in blood is considered strong proof of 
the source of opiates even if a urine sample is not analysed 202,421.  
The absence of codeine and the presence of morphine does not indicate that 
heroin was used but may suggest codeine intake. A high ratio of COD/MOR in 
urine could be an indicator for recent codeine ingestion but low ratios cannot be 
used to distinguish the source of opioid intake 422. 
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Table 9-10: Comparison between free morphine and codeine in blood 
obtained using optimised LC-MS/MS and routine methods  
 
Sam 
no. 
MOR 
ìg/mL 
Codeine 
ìg/mL 
 U# 
(LC) ## 
B * 
(LC) 
B   
(SOP) ** 
U 
(LC) 
B 
(LC) 
B 
(SOP) 
Cause of death 
1 0.60 0.4 0.4 0.02 0.033 0.03 Heroin intoxication 
2 0.20 0.26 0.23 0.00 0.028 0.029 Heroin intoxication 
3 2.80 0.28 0.36 0.30 0.04 0.035 Methadone intoxication 
4 0.60 0.48 0.5 0.20 0.032 0.036 Heroin intoxication 
5 3.70 0.4 0.41 0.70 0.01 0 Methadone and heroin intoxication 
6 0.30 0.4 0.4 0.02 0.035 0.04 Not-drug related 
7 0.04 0.4 0.5  0.03 0.05 Heroin  and alcohol intoxication 
8 4.30 0.17 0.18 0.40 0.001 0 Morphine and cocaine intoxication 
9 4.00 0.35 0.4 3.90 0.028 0.03 Heroin intoxication 
10 8.50 0.19 0.23 0.70 0.003 0 Heroin intoxication 
11 5.10 1.1 1.09 0.09 0.04 0.03 Hanging 
12 1.10 0.08 0.08 0.30 0.05 0.03 Heroin  and methadone intoxication 
13 0.02 0.17 0.2  0.07 0.03 Heroin intoxication 
14 8.00 0.22 0.27 0.50 0.03 0.03 Combined heroin and cocaine 
toxicity 
15 14.40 0.54 0.52 1.00 0.115 0.08 Heroin and cocaine intoxication 
16 0.70 0.68 0.71 0.03 0.08 0.1 Heroin and alcohol intoxication 
17 0.30 0.023 0.02 1.40 0.124 0.16 not drug related 
18 141 0.3 0.3 21.00 0.177 0.2 No information 
19 1.50 0.15 0.19 4.00 1 0.98 Co-codamol toxicity 
20 0.04 0.93 0.95 0.02 0.1 0.13 Head injury 
21 0.25 0.111 0.13 0.03 0.01 0.01 Cocaine, heroin, ecstasy and 
dihydrocodeine intoxication 
22 1.00 1.1 1.1 0.08 0.1 0.13 Heroin intoxication 
23 0.50 0.26 0.21 0.04 0.038 0.03 Heroin and methadone intoxication 
24  0.65 0.62  0.07 0.05 Heroin and methadone  intoxication 
25  0.16 0.1  0.7 0.6 No information 
26  0.03 0.02  0.52 0.53 No information 
27  0.12 0.1  0.01 0.01 No information 
28  0.2 0.2  0.02 0.02 Not drug related 
29  0.16 0.17  1.1 1.05 Co-codamol overdose 
30  0.13 0.12  2.25 2.2 Co-codamol overdose 
31  0.024 0.02  0.3 0.21 No information 
32  0.73 0.74  0.09 0.07 Heroin intoxication 
#
 U: Urine samples result; * B: Blood samples result 
##
 LC-MS/MS method for the analysis of opioids and their metabolites. 
**SOP: Standard operation procedure or in-house GC-MS method used for routine general opioids 
analysis in Forensic Medicine and Science; University of Glasgow. 
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Table 9-11: Concentrations of heroin, morphine and codeine metabolites (ìg/mL) in urine samples
Analytes  
Sam. no. 
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1 0.6 0.02 30.5 2 0.08 0.02 0.04 0.7 33.18 0.76 43.66 0.02 3.33 15.25 0.02 0.09 0.02 30.00 
2 0.2  0.1 0.04  0   0.34 0.00  2.00 0.20 2.50 1.43 2.40 0.59  
3 2.8 0.18 40 2.3 0.04 0.3 0.04 0.4 45.14 0.74 61.00 0.07 0.82 17.39 0.07 0.13 0.06 9.33 
4 0.6 0.02 23.5 1.9 0.05 0.2 0.07 1.5 26.05 1.77 14.72 0.03 3.17 12.37 0.02 0.11 0.02 3.00 
5 3.7 0.3 118 7.8 0.4 0.7 0.2 3.5 129.90 4.40 29.52 0.03 2.11 15.13 0.03 0.10 0.03 5.29 
6 0.3 0.02 12 0.7 0.1 0.02 0.08 0.3 13.10 0.40 32.75 0.03 2.33 17.14 0.02 0.08 0.02 15.00 
7 0.04 0.04 0.1 0.04 0.06  0.1  0.24 0.10 2.40 0.40 1.00 2.50 0.29 0.80 0.17  
8 4.3 0.7 26.2 8.8 0.04 0.4  6.3 39.34 6.70 5.87 0.16 2.05 2.98 0.12 0.50 0.11 10.75 
9 4 0.1 20.4 7.9 0.2 3.9 0.08 3.9 32.50 7.88 4.12 0.20 1.98 2.58 0.14 0.58 0.12 1.03 
10 8.5 0.5 47.5 20.8 0.3 0.7  14.8 77.10 15.50 4.97 0.18 2.45 2.28 0.12 0.62 0.11 12.14 
11 5.1  5.5 1.2 1.3 0.09 0.09 0.5 13.10 0.68 19.26 0.93 0.24 4.58 0.76 1.15 0.39 56.67 
12 1.1 0.02 0.7 1.3 0.15 0.3 0.08 1.3 3.25 1.68 1.93 1.57 1.18 0.54 0.55 3.43 0.34 3.67 
13 0.02 0.03 0.2 0.05     0.27 0.00  0.10 2.50 4.00 0.08 0.35 0.07  
14 5.9 0.14 253 18 1 0.5 0.1 1 277.90 1.60 173.69 0.02 3.05 14.06 0.02 0.09 0.02 11.80 
15 14.4 2 428 31.2 0.6 1 0.1 7.8 474.20 8.90 53.28 0.03 2.17 13.72 0.03 0.11 0.03 14.40 
16 0.4  0.7   0.7 0.2 9 1.10 9.90 0.11 0.57 0.00  0.57 0.57 0.36 0.57 
17 0.7  6.8 1.6 0.4  0.03  9.50 0.03 316.67 0.10 2.29 4.25 0.08 0.34 0.07  
18 0.8  3.9 0.9 0.15 0.05 0.08 0.01 5.75 0.14 41.07 0.21 1.13 4.33 0.17 0.44 0.14 16.00 
19 0.05  1 0.3 0.05 0 0.01  1.40 0.01 140.00 0.05 6.00 3.33 0.04 0.35 0.04  
20 0.2 0.01 0.8 0.2 0.02 0.01 0.02 0.2 1.22 0.23 5.30 0.25 1.00 4.00 0.20 0.50 0.16 20.00 
21 0.7 0.2 3.4 0.9 0.06 0.08 0.01 1.4 5.06 1.49 3.40 0.21 1.29 3.78 0.16 0.47 0.14 8.75 
22 0.05  0.4 0.1 0.02 0.01 0.01 0 0.57 0.02 28.50 0.13 2.00 4.00 0.10 0.38 0.09 5.00 
23 0.14  3.2 0.6 0.6 12 0.9 67 4.54 79.90 0.06 0.04 4.29 5.33 0.04 0.23 0.03 0.01 
24 0.17  3.5 0.7 2.1 22 7.6 67 6.47 96.60 0.07 0.05 4.12 5.00 0.04 0.25 0.03 0.01 
25 0.4  3.5 0.9 0.3 1.4 0.14 20 5.10 21.54 0.24 0.11 2.25 3.89 0.09 0.37 0.08 0.29 
26 0.7 0.02 4.2 1.2 0.03 0.03  0.25 6.13 0.28 21.89 0.17 1.71 3.50 0.13 0.45 0.11 23.33 
27 1.5  0.55 0.5 0.5 3.8 0.13 28 3.05 31.93 0.10 2.73 0.33 1.10 1.43 3.64 0.49 0.39 
28 0.9 0.5 2.8 0.2 0.01 0.08   3.91 0.08 48.88 0.32 0.22 14.00 0.30 0.39 0.23 11.25 
29 0.5  6.8 1.1 0.2 11 3.4 12.5 8.60 26.90 0.32 0.07 2.20 6.18 0.06 0.24 0.06 0.05 
Ave 2.39 0.28 44.76 4.74 0.23 0.87 0.23 3.62 42.35 11.04 39.03 0.37 1.98 6.78 0.25 0.66 0.14 10.78 
Med 3.95  69.7 7.75 0.4 0.8 0.15 4.54 6.13 1.49 14.72 0.13 2.05 4.13 0.10 0.38 0.09 9.04 
# TMOR: Total morphine; * TCOD: Total codeine; ## FMOR: Free morphine; ** FCOD: Free Codeine; & MORG: Morphine conjugates. 
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Although the ratio of COD/MOR (0-6 hours) after codeine intake was found to be 
different between the CYP2D6 genotypes poor, ultra and extensive metabolisers, 
ratios were higher than one in all three genotypes 136. He et al 188 also reported 
that the ratio of COD/MOR did not change and remained higher than one in all 
subjects after codeine administration in the ultra-rapid and extensive 
metaboliser subjects. Codeine concentrations in urine following codeine 
intoxication ranged from 0.78 to 108.8 ìg/mL, averaging 38 ìg/mL 423. In the 
present study, total codeine concentrations ranged from not detected to 96 
ìg/mL with an average concentration of 11 ìg/mL. However, in codeine 
intoxication case, codeine levels ranged from 21.5 to 96 ìg/mL with an average 
concentration of 51.4 ìg/mL. Total MOR ranged from 3.1 to 8.6 ìg/mL with an 
average of 5.6 ìg/mL in these cases. The ratio of total COD/total MOR ranged 
between 3.1 and 17 with an average of 10.  
9.4.2.3 Dihydrocdeine  
DHM and its glucuronides were determined in blood in DHC related deaths and 
levels of DHM glucuronides were lower than reported previously 24,212. In the 
current study, urine and blood samples were analysed in cases attributed to DHC 
overdose. DHC is metabolised mainly to DHC6G and nordihydrocodeine (nor-
DHM); unfortunately, standards of nor-DHM and its glucuronide were not 
available at the time of this study which would aid in the investigation of their 
contribution to DHC toxicity. It is estimated that 28 %, 16 % and 32 %, 20% of a 
DHC dose are metabolised to DHC6G and nor-DHM in extensive and poor 
metabolisers, respectively. A low percentage is metabolised to DHM, DHM3G and 
DHM-6-G, estimated to be 9% and 1.3% in the extensive and poor metaboliser 
populations, respectively 126,208,216.  
Previous reports indicate that DHM is responsible for DHC analgesia. DHM has a 
high affinity to opioid receptors (ì-, ä- and ê) similar to that of morphine and 
100 times higher than DHC while nor-DHM and its glucuronide have a lower 
affinity to opioid receptors, similar to DHC 216. Reports also suggest that DHM 
and DHM-6-glucuronide may contribute to DHC toxicity 24,207,209. Concentrations 
greater than or equal to 100 and 74 ng/mL, respectively, are believed to be 
toxic and to contribute to the respiratory depression effect of DHC 24. Therefore, 
inclusion of DHM metabolites may add some information to the interpretation of 
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the cause of death due to DHC intoxication 212. Levels of DHM and its glucuronide 
in DHC intoxication were reported in two studies. DHM was found lower or equal 
to 0.2 ìg/mL; DHM3G was always higher than DHM (range 0.3-1.08 ìg/mL) and 
DHM6G was lower or equal to 0.1 ìg/mL ( range 0.07-0.111 ìg/mL) in both 
studies 24,212. 
DHC levels in autopsy blood obtained with the current method were compared 
with results of routine analysis of free DHC. There were no routine results for 
urine; twenty eight cases were involved in this comparison and both methods 
compared well for the analysis of free DHC; good correlation was obtained with 
an r2 of 0.996 (Figure 9-9 and Table 9-12). Unfortunately, urine samples were 
not collected at autopsy in many of these cases and only blood samples were 
analysed using SOP method.  
DHC and its glucuronide were found in all cases investigated in blood and urine 
matrices. However, DHM and its glucuronide were present at lower levels than 
DHC and its glucuronide. Unchanged parent drug is the most abundant DHC 
metabolite in blood samples while DHC glucuronide is the most abundant DHC 
metabolite in urine. In blood, DHM was found in three cases ≤ 0.1 ìg/mL while 
DHM6G ranged from not detected to 0.01 ìg/mL.  
Deaths involving DHC can also be classified into three categories: DHC only, DHC 
related deaths and not DHC related 157,219. Three cases out of twenty eight were 
attributed to sole DHC intoxication (blood DHC level, range 0.5-1.7 ìg/mL; 
average and median 1 and 0.8 ìg/mL), thirteen deaths were due to polydrug 
intoxication involving DHC (range 0.6-24.5 ìg/mL; average and median 6 and 2 
ìg/mL) and seven cases where DHC was detected but not related to the cause of 
death (range 0.04-0.6 ìg/mL; average and median 0.3 and 0.2 ìg/mL) . The role 
of DHC was not reported in the other cases.  
There was an overlap between DHC only and DHC-related groups and levels in 
non-DHC related were lower than 0.6 ìg/mL. Methadone plus DHC intoxication 
was encountered in five out of thirteen DHC-related cases, heroin plus DHC in 
three cases and DHC and alcohol in two cases.  
No urine samples tested positive for hydromorphone. One case sample was 
positive for naloxone-3-glucuronide and trace levels of naloxone.  
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9.4.3 Identification Criteria 
Identification criteria proposed by the EU 61 have been employed in the current 
and previous studies 357-359,419,424,425 and problems encountered with identification 
using current LC-ion trap mass analysers are discussed below. Many 
identification parameters are available which may give toxicologists added 
confidence in making decisions as to the presence of toxicants in biological fluids 
408.  
The most undesired problem is interference occurring from another drug or from 
endogenous components that share the same molecular mass. Although the 
presence of interference is rare in LC-MS/MS 90, high throughput LC-MS/MS 
methods are needed which aim to shorten the HPLC run time while method 
sensitivity and selectivity are not affected 31,417. That leads to an increase in the 
possibility of matrix effects from co-eluting endogenous components as discussed 
earlier; however, a greater risk may be caused by cross-talk from drug-related 
metabolites. 
Figure 9-8: Comparison between free DHC results in real autopsy cases 
using the optimised LC-MS/MS and routine methods for the analysis.  
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Table 9-12: DHC metabolites in positive case samples (ìg/mL) using routine and optimised methods. 
Case no DHC DHM3G  DHM6G  DHM  DHC6G  DHM3G DHM6G DHM DHC6G Cause of death 
 Blood  BSOP *  Urine Blood (optimised LC-MS/MS method ) # Urine (optimised LC-MS/MS method )  
1 2.2 2 29 0.1 n.d.  0.01 2.1 6.3 0.93 0.8 122 No information  
2 9 8.5 40 0.3 n.d.  7.2 42 6 4 77 Methadone, DHC  
3 0.2 0.2 7.2 0.08 n.d. 0.3 0.3 9.3 1.1 0.8 24 Hanging 
4 25 24 1.6 0.04 n.d. 0.2 0.2 0.01 0.01 0.01 0.2 DHC, alcohol   
5 0.83 0.95 9.5 0.2 0.006 0.06 0.7 6 0.4 0.4 54 Heroin, DHC, diazepam  
6 1 0.9 42 0.1 n.d. 0.02 0.3 25 2.4 477 41 Methadone, DHC  
7 0.03 0.04 1.2 0.03 n.d. 0.01 0.04 4.5 0.15 0.26 21 Not drug related death 
8 2.1 2 31 n.d. n.d. n.d. 0.3 5.5 0.34 0.1 68 Heroin, DHC  
9 4.1 3.7 20 0.006 n.d. n.d. 5.6 14 1.1 1.1 163 No information 
11 0.22 0.4 0.1 0.002 n.d. n.d. 0.07 0.02 n.d. n.d. 0.7 Not drug related death 
12 5.2 4.5 159 0.02 n.d. n.d. 3.3 2 0.2 n.d. 500 DHC, methadone  
13 25 24.5 0.2 0.004 n.d. 0.2 4.6 n.d. 1.8 n.d. 0.4 DHC, temazepam  
14 2.25 1.8 62 0.007 n.d. n.d. 0.8 0.7 0.08 0.2 73 Clozapine, DHC, Paracetamol  
15 0.45 0.6 9 n.d. n.d. n.d. 0.8 0.5 0.14 0.15 45 Cocaine, heroin, ecstasy, DHC  
16 0.48 0.6 0.9 n.d. n.d. 0.004 0.3 n.d. n.d. n.d. 0.2 Not drug related death 
17 3.6 1.7 109 n.d. n.d. n.d. 0.8 6 0.55 0.26 267 DHC  
18 0.4 0.4 N/A  0.1 0.01 0.02 1.8 N/A Ù N/A N/A N/A Not drug related death 
19 2.6 2.1 N/A 0.01 n.d. 0.02 0.4 N/A N/A N/A N/A Methadone and DHC  
20 1.1 0.84 N/A 0.07 0.01 0.1 0.15 N/A N/A N/A N/A DHC intoxication, 
21 2 1.6 N/A 0.004 n.d. 0.001 5.4 N/A N/A N/A N/A DHC and amitriptyline  
22 0.04 0.04 N/A 0.01 n.d. 0.002 0.1 N/A N/A N/A N/A No information 
23 0.44 0.5 N/A 0.03 n.d. 0.04 0.02 N/A N/A N/A N/A DHC intoxication 
24 0.06 0.07 N/A 0.003 n.d. n.d. 0.02 N/A N/A N/A N/A Stab wound of heart  
25 3 2.9 N/A 0.06 0.01 0.09 2 N/A N/A N/A N/A No information 
26 0.1 0.15 N/A 0.01  0.01 0.08 N/A N/A N/A N/A Methadone intoxication 
27 2.1 2 N/A 0.001 0.003 0.005 0.7 N/A N/A N/A N/A DHC and amitriptyline  
28 3.3 3.7 N/A 0.01 0.004 0.02 0.8 N/A N/A N/A N/A DHC and alcohol intoxication 
#
 LC-MS/MS method for the analysis of opioids and their metabolites. 
* SOP: Standard operation procedure or in-house GC-MS method used for routine general opioids analysis in Forensic Medicine and Science; University of Glasgow. 
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This phenomenon results from elution of the two analytes at the same retention 
time and fragmentation to give similar product ions used for identification; this 
also so-called isobaric metabolic interference could be the result of in-source 
contamination or due to degradation products of phase I and II metabolites 
28,90,115. 
In the current work, many of the drugs analysed share the same precursor ion 
such as morphine, hydromorphone and norcodeine, which have a pseudo-
molecular ion at m/z 286. Despite the use of a selective mass analyser, these 
analytes also share some of their product ion(s), affecting identification and 
quantification of these drugs, especially if these shared product ions are used as 
quantifier or qualifier ions, which results in different SRM transition ratios. 
Moreover, problems of co-elution are more critical when analytes are not only 
sharing the same precursor ion but also have the same single product ion. This 
was encountered with both morphine glucuronide and hydromorphone-3-
glucuronide in the present work; they have the same precursor ion at m/z 462 
and the same single product ion at m/z 286. Further fragmentation to MS/MS/MS 
(MSn=3) can be used to produce a new product ion 426 but this was at the expense 
of sensitivity and would not solve the problem of co-elution of the drugs. 
Retention time can play a crucial role in identification in these cases and 
analytes should be fully separated from each other. In addition to 
chromatographic separation, sample preparation also is an important issue to 
eliminate unwanted drugs and interference 90,419. It has been suggested that 
derivatising agents can be used to shift analytes from the co-elution zone to be 
fully separated but these would lose the advantage of LC-MS in being able to 
analyse metabolites directly 74,95.    
The retention time is a crucial identification power in all chromatography 
systems which is required to be identical to reference standards or positive 
controls that should be included in the same run; reliable and repeatable 
retention time intra and inter-laboratory should be examined 408. The acceptable 
limit of difference in the retention time of analytes detected in real cases and 
that of reference or control materials are recommended to be in the range of 2% 
(± 0.4 minutes) 409  and 2.5 % 61 using HPLC and 5%  for LC-MS.  When using a 
second chromatography system or when using the same system but with a 
different derivative, the retention times of the analyte should be different in 
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the two systems, with preference being given to using a second aliquot of the 
sample and a new extract to rule out the possibility of faulty sample preparation 
and contamination 54. The peak of an analyte diagnostic ion should be higher 
than background with signal-to-noise ratio of at least 3:1 409. In the current 
study, good chromatography separation was obtained as often as possible with a 
wide range of analytes that were eluted from 3 - 24 minutes; retention times 
were recorded with each run and compared with calibration standards which 
were analysed at the same time.  
Opioids and their metabolites were included as often as possible in the method 
which can be a helpful tool for drug identification, with two advantages: firstly, 
to exclude the potential interference caused by metabolites on drug ionisation 
and secondly, to increase the method specificity and selectivity for 
identification 113,418,419. 6-monoacetylmorphine, for instance, is commonly used 
as a heroin marker in forensic investigations; 6-acetylcodeine is also considered 
a heroin marker. However, these two markers are metabolised quickly in vivo to 
morphine and codeine, respectively. However, morphine and codeine are the 
most commonly detected drugs after heroin, codeine intoxication which could be 
a metabolite of heroin, codeine, morphine or after ingestion of poppy seeds. 
Therefore, the presence of 6-MAM are strongly evidence of idenftification of 
heroin used.  
Drugs such as opioids have relatively similar chemical structures which are 
metabolised in the same way and many metabolites may be formed from many 
drugs. For example, oxymorphone is a drug in use and a metabolite of 
oxycodone. In addition, oxymorphone and noroxycodone share the same 
molecular weight and product ion. Noroxycodone shares some of its major 
product ion with DHC: both have the same molecular weight with a slight 
difference between their mass of 0.2 atomic mass units 425. This is another 
reason for the importance of adequate chromatographic separation for correct 
identification and quantification. Contamination from the ion source can be 
tackled by the use of high or 100% organic modifier percentages and allowing the 
LC column to be equilibrated before the next injection in order to eliminate 
potential in-source dissociation of metabolites 90,113.   
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The use of internal standardisation has been recommended but is not essential 
for drug identification according to SOFT/AAFS and WADA recommendations 
54,409. However, in practice internal standard should be included whenever 
available to provide an accurate identification and quantification procedure 
115,427,428. The recommendation is that an internal standard should be eluted near 
to the analytes of interest. Three different types could be used in LC-MS 
applications: analytes labelled with stable isotopes - hydrogen (deuterium) is the 
most common isotope used in forensic toxicology, structurally similar compounds 
such as a homologue of the analyte of interest, and any other compounds such as 
a drug 97,428. However, the latter are not recommended since they could be 
present in biological samples due to drug ingestion, leading to a 
misinterpretation of results and affecting method reproducibility and linearity 
16,97,115.  
Stable isotopically labelled analogues are the internal standards of choice with 
masses different from the analytes by at least three mass units in order to avoid 
interference between analytes and their internal standards, which probably 
increase if the differences in their masses were less than three amu 427. In the 
current work, interferences between isotopically labelled internal standards 
have been observed with other analytes that differ by 1 amu such as DHM3G 
(464) and M3GD3 (m/z 465) which interfered with each other, which led to these 
internal standards not being used in cases positive for both MOR and DHC. This is 
another example of when full separation of analytes is required to identify 
metabolites of similar structure, but separation of analytes is not always easily 
achievable, especially if the analytes are very polar and a reverse phase liquid 
chromatography method is used.      
In addition, internal standards are expensive and not available commercially for 
all compounds of interest. As indicated earlier, internal standards are the best 
way to tackle the matrix effect phenomenon and should be treated and 
extracted together with standard calibration curves and samples. This is also the 
best way to examine the efficiency of extraction and ionisation of analytes 97,427. 
Isotopically labelled internal standards should be free from interference and 
their fragmentation should be checked to investigate the ratio between analytes 
and internal standards; this could be checked by injection of similar amounts 
e.g. 100 ng/mL of both and calculating the intensity ratio of their ions. A ratio of 
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one is expected in most cases but if the ratio is higher than one the increase 
could be from interfering ions from the internal standard 428.  
LC-MS/MS libraries in most laboratories are created in-house with a collection of 
the identification parameters from known certified standards and real cases 
results 30,59. Manual optimisation of single analytes is facilitated using a direct 
infusion T connection in the LC-MS/MS instrument. Certified standards are 
important for both identification and quantification; however, some analytes are 
not available commercially. In this case analytes were identified tentatively, for 
example, norbuprenorphine-3-glucuronide was tentatively identified for the first 
time by Polettini and Huestis using LC-MS/MS 332 and some time later a certified 
standard was made available. In contrast, some believe that a correct 
identification cannot be achieved without a certified standard; published mass 
spectra reported for some analytes could be used for preliminary identification 
with extreme caution due to the possibility of incorrect data or differences 
caused by the environment of assays and instrumentation 59,408.   
The possibility of creating a universal LC-MS/MS library of analytes is low 
compared to that of GC-MS for many reasons 66. Many factors can influence the 
performance of instruments, ionisation and retention of analytes due to the use 
of different mobile phases and columns and the many interface and mass 
analyser available, leading to differences in mass fragmentation patterns, such 
as ESI, APCI and IT-MS, TQ-MS, Q-TOF, respectively. For example, the 
differences between CID data collection using IT and TQ lead to different 
fragment ions for the same drugs 30,44,66,72,429. Nevertheless, some scientists have 
established their own library using in-house LC-MS/MS methods; the largest 
libraries were reported by Dresen et al 430 (800 compounds) and Mueller et al 39 
(301 drugs).  
There is an agreement to using a minimum of three identification points (IPs) for 
identification criteria as proposed by the EU for drug of abuse confirmation using 
LC-MS/(MS) 61. IPs are accumulation points depending on the mass spectrometer 
attached to HPLC whether it is high or low resolution, single or tandem mass 
spectrometry. For example, in the case of LC tandem MS, four IPs can be 
obtained by determining one parent drug with two of its product ions (Table 9-
13). Also, it is recommended to measure at least one ion intensity ratio in order 
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to ensure the quality of identification points and the ratio should not exceed EU 
criteria listed in Table 9-14 61,418.  
The same criteria have been recommended by the World Anti-Doping Agency 
(WADA) 409. If these IPs cannot be met, the recommendation is that a second 
ionisation or fragmentation technique should be used which should result in 
different diagnostic ions by applying a second derivative. However, SOFT and 
WADA accepted that the identification of anaytes can be appropriate by 
monitoring single product ions but it depends on the uniqueness and resolution 
of the ion 54,409.  Also, another identification system should be used whenever 
possible. SOFT/AAFS guidelines state that in some cases, drugs or toxicants can 
only be determined using single identification techniques. Furthermore, single 
non-selective identification techniques such as validated radioimmunoassay of 
digoxin are only required to confirm the identity of drug if evidence behind the 
case strongly indicates no suspicion of suicide or crime.  
Table 9-13: Example of Number of IPs earned for confirmation of identity by 
a range of LC-MS instruments. 
 
Techniques  No. of Ions IP 
LC-MS N & N 
LC-MS/MS One precursor ion, two 
products  
4 
LC-MS/MS Two precursor ions, each 
with one product  
5 
LC-MS/MS/MS One precursor ion, one 
product and two grand-
products  
5.5 
HR *-MS N 2N 
LC-MS and GC-MS 2+2 4 
LC-MS and HR-MS 2+1 4 
&
 N: an integer, *HR: High resolution 
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Table 9-14: Maximum tolerance widows for relative ion intensities in LC-
MS(MS) according to European Union criteria for drug identification 
(Adapted from WADA) 
 
Maralikova and Weinmann 407 monitored at least two MRM transitions for each 
analyte in order to collect IPs as recommended by EU guidelines 61. The major 
product ions were chosen for quantification in all drugs with the exception of 
opioids in which precursor ions were used for quantification ions. Three Collision 
Energies (CE) were applied with all drugs at 20, 35 and 50 eV; then suspected 
analytes were compared with reference standards stored in the MS/MS library at 
the same CEs for proper identification. Also, the ratio of relative intensity of at 
least one MRM transition was calculated. The ratios obtained from the standard 
calibration curve (5-50 ng/mL) and from samples positive for the analytes of 
interest were compared using the percent deviations recommended by EU 
guidelines.  
Fox et al 425 reported work using LC-TQ-MS/MS recently using the same EU 
criteria 61 of identification with opiates: four IPs per analyte have been obtained 
by monitoring two MRM transitions; the relative retention time and co-eluted 
internal standards counted as another IP at tolerance of ± 2.5% according to EU 
criteria  61. They used two mobile phases A and B; in mobile phase A at pH 6.8, 
the relative ion intensity did not meet EU criteria when signal-to-noise was less 
than 10 of one or more MRM transitions of morphine, 6-MAM, codeine and DHC. 
Also, retention times could not fulfil the criteria when opiate concentrations 
were above the level of calibration curve (> 10 ìg/mL). Isobaric phenomenon 
between DHC and noroxycodone was detected in one case.  However, the 
authors reported an improvement of morphine and codeine identification when 
using mobile phase B at pH 8; they could identify 97% of morphine cases using 
mobile phase B compared to 59% using mobile phase A. They attributed that to 
Relative Abundance  
(% base ion) 
Maximum Permitted Tolerance (relative %) 
> 50 ± 20 
> 20-50 ± 25 
> 10-20 ± 30 
≤ 10 ± 50 
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the improvement of analytes separation. However, no improvement was 
achieved with 6-MAM and DHC. The levels of DHC and oxycodone metabolites are 
known to be high in urine due to use or abuse of both analytes (Chapter 8 for 
oxycodone cases). They believed that potential risks of interference between 
DHC and oxymorphine were impossible due to the excretion of the latter in urine 
only in glucuronide form, which was untrue. In Chapter 8, oxymorphone was 
detected in free form in both blood and urine and was more likely to be present 
in clinical cases than in overdoses in non-regular users. Many analytes can cause 
isobaric interference with opioids. Naloxone, for example, was eluted in the 
current study near to 6-MAM which could interfere with 6-MAM as they share the 
same molecular weight of parent ion but they are fragmented to different 
product ions. In addition, there is a risk that hydromorphone could also 
potentially interfere with norcodeine and morphine.  
Fox et al 425 concluded that the problem of isobaric phenomena due to 
metabolite interference is a major risk that leads to false positive results which 
can be tackled by employing more than one MRM transition to confirm the 
identity of analytes accurately. They also stressed that better chromatographic 
separation and sample clean up could improve the efficiency of MRM transition 
of analytes and avoid isobaric interference problems. Parent drugs or 
metabolites could interfere with each other which should be taken into 
consideration when detecting MRM transition. They also recommended the use of 
LC-MS/MS with ion trap mass analyser which can acquire mass spectra of 
selected metabolites in full scan mode and so enhance method identification as 
comparable to GC-MS.  
In addition to the monitoring of two MRM transitions for increased method 
selectivity, the calculation of relative ion intensity between the abundances of 
the two diagnostic fragment ions provides confidence for analyte identity 
confirmation in which the ratio should be within the acceptable limits proposed 
by EU guidelines 37,425,431. The ion ratios are measured as the peak area of the 
quantifier ion / the peak area of qualifier ion which is also described as the 
peak area of the quantifier transition (100/ion ratio) in such a way that, for 
instance, the peak area of qualifier ion is half of that of quantifier ion when 
relative ion intensity is 50% 424,432. Relative ion intensity has been monitored in 
many LC-TQ-MS/MS methods reported for forensic toxicology. 
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LC-IT-MS/MS has been used successfully in clinical and forensic toxicology but 
few reports have concerned the identifications criteria. Although these 
techniques are able to produce two or more selected reaction monitoring (SRM) 
transitions, relative ion intensities were not calculated according to EU 
guidelines in most of these methods. One of the earliest methods described by 
Fitzgerald et al 44 using LC-IT-MS/MS showed that some analytes such as 
benzylecogonine only fragmented to single product ions but morphine was 
fragmented to five fragments. They mentioned that isobaric interference was 
expected due to chromatographic overlap between morphine and 
hydromorphone as both analytes have the same parent and some product ion; 
good chromatographic separation is recommended for accurate quantification.  
Although they calculated the relative ion intensity, it was not used to confirm 
analyte identity as EU guidelines were only published many years later. In fact, 
the isobaric interference could still be problematic especially as norcocaine has 
the same parent mass spectrum as benzoylecogonine and they are eluted near to 
each other. Norcocaine can be detected in urine samples which could co-elute 
with benzyolecogonine. Therefore, retention time and co-eluted internal 
standard play a great role to proving an accurate identification when chosen ions 
were not well separated 419,433. Cocaine could be interfered by norcocaethylene 
as they have the same mass and fragment to similar product ions.  
In the present work, SRM ratios were calculated with a minimum single to noise 
of 10 for each transition. It has been noticed that the higher single to noise are 
used the more accurate the SRM ratio obtained. In the work with diamorphine 
with clinical plasma samples, three SRM transitions could be determined with 
ratios of 1-1.3 between them which was also found with 6-MAM in blood, plasma 
and urine. Ion trap mass spectrometry is known to have a limited product ion 
mass range in which less energy is needed for fragmentation compared to triple 
quadrupole mass spectrometry. Ion trap tends to lose water from 
pesudomolecular ion 42,426. For opioids in general, two SRM transitions can be 
obtained such as with heroin, morphine, codeine, DHC, hydromorphone but in 
some opioids and metabolites only one SRM transition can be obtained. 
Therefore, in order to obtain two SRM transitions for identification, adjusting 
the cone voltage has been used in current study. Maralikova and Weinmann 407 
applied three different collision energies setting in order to calculate MRM ratios 
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at 20, 35 and 50 eV. Dresen et al 430 also applied this procedure for the same 
purpose.  
A method using the same LC-MS/MS instrument as in the current study was 
reported by Murphy and Huestis 116; they  used a single product ion for 
identification and quantification of opioids glucuronide while two product ions 
were used for morphine and codeine but SRM ratio was not calculated. Rook et 
al 75 identified opioids and metabolites using a single MRM transition. Therefore, 
it is acceptable to use one single product ion for identification if it is a unique 
indicator of the parent drug but further SRM ratios calculated could help in 
providing sufficient IPs for toxicant identification. The adjustment of collision 
energies for opioids and metabolites that fragment to only one product ion was 
reliable and repeatable in this study. However, it is not always guaranteed that 
the criteria proposed by EU guidelines could provide an accurate discrimination 
between analytes of interest, especially analytes that have the same mass 
spectra data and are eluted at the same time, even when using relative ion 
intensities, which could be similar 37,433. Therefore, good chromatographic 
separation could be an additional identification point according to the analyte 
retention time and the presence of internal standards whenever possible 
36,90,113,419.  
9.5 Conclusions 
A sensitive, selective and validated method was described for simultaneous 
determination of 26 opioids and metabolites by LC-ion trap-MS/MS. The 
influence of matrix effects was investigated and eliminated by using SPE for 
sample preparation. It was applied to routine case work as a complementary test 
to autopsy blood analysis using the same procedure in order to confirm blood 
analysis, especially in the case of heroin intoxication with no 6-MAM levels 
detected in the autopsy blood. Stability of heroin markers in urine was compared 
with blood and the markers were found to be more stable in urine. The results 
obtained using the optimised LC-MS/MS method in blood samples were compared 
with those obtained using the routinely laboratory method for analysis of 
opioids; good correlations were observed for free methadone, MOR, COD and 
DHC.  
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The application of identification criteria proposed by EU guidelines, FDA and 
SOFT/AAFS to the current method were evaluated along with problems 
encountered with the current LC-MS/MS instrument in providing sufficient 
identification points. It was found that two SRM transitions can be obtained in 
most opioids with the exception of some polar metabolites, especially 
glucuronide metabolites which fragment to only one product ion. Therefore, the 
adjustment of collision energy voltages was used to obtain two SRM transitions 
which were found reliable and reducible using both standard and case samples.  
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10 Direct Determination of Ethyl Glucuronide and  
Ethyl sulfate in Post-mortem Urine Specimens 
using Hydrophilic Interaction Liquid 
ChromatographyESI-MS  
10.1 Introduction  
Ethanol (ethyl alcohol, alcohol) is the most common drug used and abused across 
the world 132,434,435 with the exception of some Islamic countries. For example, in 
Saudi Arabia, alcohol is not allowed due to religious reasons. There is no doubt 
that alcohol is a serious problem, for health, workplace and social 
consequences, if it is misused 436-438. The risk of sudden death is higher among 
alcoholics compared to the non-alcoholic person 434,436.  
The interpretation of alcohol results for post-mortem specimens can be difficult 
due to the possibility of post-mortem production of alcohol, which may take 
place in the body or in the autopsy samples 439-442. Ethyl glucuronide (ETG) and 
ethyl sulfate (ETS) are primary ethanol metabolites and have been shown to be 
useful markers of alcohol consumption for several hours after death or when 
ethanol itself has been completely eliminated from the body. ETG and ETS are 
very polar metabolites requiring very low percentages of organic modifiers (less 
than 5%) for elution from a conventional reversed phase column, which results in 
poor retention, large matrix effects and low sensitivity in reverse phase LC-MS 
methods. Post-column addition of organic solvents can enhance ESI-MS/MS 
response while preserving good chromatographic peak shapes. Recently, 
hydrophilic interaction chromatography (HILIC) has been introduced as an 
alternative to reverse phase LC separation of polar compounds. HILIC is suitable 
for ESI-MS as a high percentage of organic modifiers can be used, up to 95%, 
without reducing analyte retention. 
10.2 Metabolism and Excretion 
Ethanol is metabolised to acetic acid by two enzymatic steps in the liver. The 
formation of acetaldehyde by alcohol dehydrogenase occurs first which in turn is 
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converted to acetic acid by another liver enzyme, aldehyde dehydrogenase. 
Then, acetic acid is involved in the Krebs cycle and is rapidly converted to water 
and carbon dioxide. The oxidised metabolites of ethanol (acetaldehyde and 
acetic acid) are estimated to account for 90-95 % of ethanol elimination. The 
rest of the ethanol is excreted unchanged by the kidney (0.5-2%), the lungs (1.6-
6%) and skin (0.5%) 132,443.  A small fraction of ethanol undergoes phase two 
conjugation reactions which is less than approximately 1% of the ethanol dose. 
These non-oxidative direct ethanol metabolites include ethyl glucuronide (ETG), 
ethyl sulfate  (ETS), phosphatidyl ethanol and fatty acid ethyl esters (FAEE). 
These metabolites are excreted in the urine with longer elimination times than 
ethanol, which is attributed to the low molecular weight of ethanol (mz 46) 
compared to these polar metabolites for example ethyl glucuronide (m/z 222) 
444.  
Although many researchers have studied alcohol metabolism, few have 
addressed the pharmacokinetics of polar metabolites of ethanol which are now 
the most reliable alcohol biomarkers in use. Most of the data available has been 
obtained with living subjects in whom putrefaction and contamination with 
bacteria are of no concern. Ethyl glucuronide and ethyl sulfate  are formed by 
two different pathways. The estimated percentage of ETG and ETS are 0.1 % of 
ethanol consumption using UDP-glucuronosyltransferase (UGT) and 
sulfotransferase enzyme (SULT) for ETG and ETS, respectively. Although many 
types of UGT and SULT are found to be involved in the formation of ETG and 
ETS, the greatest portions are attributed to the UGT1A1, 2B7 and SULT1A3 for 
ETG and ETS, respectively 445,446.  
However, there is a time gap between detection of ethanol and their polar 
metabolites in blood or urine which was found to be about 2 hours in blood and 1 
hour in urine excretion. Subsequent to starting to drink, ETG in serum and blood 
was found to reach its peak after 2.3 to 5 and 1.3 to 2.1 hours while ETS reached 
its peak after 2.1 to 3.9 and 0.5 to 2 hours, respectively. The urinary peaks of 
both analytes were much longer as ETG reaches its peak between 5 to 7.5 hours 
and ETS reaches its peak between 3.1 and 7.4 hours 447. ETG could be detected 
in serum up to 8 hours after complete elimination of ethanol 448-451. ETG had 
longer detection times in urine than in blood and could be detected between 15-
25 hours after complete elimination of ethanol 452 and up to 80 hours in urine 
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after intake of alcohol 451,453. ETS is found to have the same detection window as 
ETG; ETS was detected in urine after one hour of starting to drink; a longer 
detection widow for ETS was reported to be between 16-27 hours 454,455.  
10.2.1 Production of alcohol after death 
The presence of alcohol after death can be interpreted in three ways: ante-
mortem alcohol ingestion; post-mortem alcohol synthesis; ante-mortem and 
post-mortem alcohol formation by microorganisms 441,456,457. Therefore, it is 
crucial to distinguish between ante-mortem ingestion and post-mortem alcohol 
synthesis in medico-legal cases and this phenomenon has to be taken into 
consideration when investigating accidents on the road, sea or the air 458.  
Gas chromatography with a flame ionisation detector (GC-FID) is the method of 
choice for alcohol analysis in living or autopsy specimens. Although these 
methods are simple, robust and sensitive and can distinguish between alcohol 
and other volatile substances 459,460, the interpretation of alcohol results at 
autopsy is a challenging decision for toxicologists due to many factors associated 
with post-mortem fermentation which often differ between subjects i.e. 
diabetes and non-diabetes 461. In most reports, the cause of alcohol synthesis has 
been referred to the quality of specimens collected, for example, contamination 
with microorganisms during sampling or before autopsy. Also, environmental 
factors such as temperature and humidity with longer periods of time between 
death and post-mortem examination has been found to enhance the risk of post-
mortem alcohol production 440,441,462-465.   
ONeal and Poklis 440 found that ethanol is produced both in-vivo and in-vitro 
and 12-57% of alcohol encountered in post-mortem cases was attributed to post-
mortem production. In most cases production of ethanol after death was found 
to have no contribution to the cause of death and less than 12% of ethanol was 
reported as post-mortem ethanol synthesis. An exception to this is in certain 
situations where alcohol present reached significant levels such as decomposed 
and heavy putrefied bodies. The percentage of post-mortem ethanol synthesis in 
decomposed bodies was reported to be 20% and as high as 40-50% with less 
common cases such as aviation or naval accidents. 100% of ethanol found at 
autopsy after the USS Iowa disaster was attributed to post-mortem fermentation 
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440,466. Therefore, the condition of a body at post-mortem examination could 
indicate whether post-mortem ethanol production should be expected.  
Determining blood alcohol concentration (BAC) and/or urine alcohol 
concentration (UAC) is a part of the routine post-mortem toxicology analysis 
441,456,467. Reports state that a BAC of 40 mg/100mL or higher is indicative of 
ante-mortem alcohol ingestion 439. The authors reached their conclusion as a 
result of positive urine and vitreous humour for alcohol was decreased with a 
lower BAC range of 10-40 mg/100mL. In other work, it was mentioned that BAC 
of 10 mg/100mL or lower should be reported negative for two main reasons. The 
level of BAC is considered lower than the limit of quantification of GC-FID 
procedure which is commonly used for alcohol analysis. Also, it is most likely to 
be formed due to alcohol fermentation after death. Urine and vitreous humour 
have been suggested as complementary specimens for alcohol analysis. These 
specimens are less susceptible to post-mortem ethanol production due to low or 
zero glucose found in urine of non-diabetic subjects and microorganism 
contamination of vitreous humour is limited at the early stages of the 
putrefaction process 439,468.    
However, obtaining a false positive result for alcohol can occur at any 
concentration (high or low) and production of alcohol after death may be 
elevated with the passage of time to a significant level such as is detected in 
alcohol related fatalities 440,457,466,469. This formation of alcohol occurs by 
microorganisms and is believed to be part of the post-mortem degeneration or 
after severe trauma using glucose as a substrate 439. The ethanol fermentation 
process is a combination between internal and external factors which lead to 
body autolysis or self digestion of body tissues. Tissue softening and liquefaction 
occurs due to aerobic enzymatic digestion which disintegrates the cell 
membrane and tissues compartments dramatically. As indicated earlier, blood 
glucose has been found to be elevated after death and then used as a substrate 
for the alcohol fermentation process. The body starts to decompose using 
bacteria from the bowel. The skin of the deceased attains a greenish 
discoloration which is considered the first sign of bacterial activity before 
spreading to other parts of body. Bacteria reach the blood after death and 
produce ethanol from glucose using the Embden-Meyerhoff pathway 470.  
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The production of ethanol depends on the degree of putrefaction of the corpse 
and was found to be higher or more rapid depending on the type of 
microorganisms present, the substrate available (glucose), air circulation, in-
door or out door conditions, immersion in water, the temperature of storage 
before and after autopsy, and severe damage to the corpse after an accident. 
Ethanol synthesis is maximised in the presence of proper environmental 
conditions for the putrefaction process and specimens are more likely to be 
exposed to microorganisms 439,440,457,468,469,471.  
Post-mortem ethanol production can be avoided or minimised by subjecting the 
body to proper refrigeration within 4 hours of death 470. This is considered a very 
short time and unattainable in most cases, especially with drug related deaths in 
which bodies have been left for a long period of time. In this type of case, levels 
of ethanol may be elevated due to the post-mortem production up to 50 
mg/100mL in most cases 440,471. However, levels of ethanol higher than 150 
mg/100 mL have been reported in severely decomposed cases 441,457,466.  
10.2.2 Why are ethanol biomarkers needed? 
The blood alcohol concentration is known to decrease over the time due to its 
oxidation by the liver: ethanol is rapidly cleared from the body at 0.15 g/kg/hr 
in non-alcoholics and this rate is more rapid in alcoholics, who could reach zero 
concentration of BAC within hours of last ingestion 438,472,473. In addition, the 
presence of alcohol in biological fluids may be the result of recent alcohol 
consumption or due to ethanol production after death. All of these factors make 
the interpretation of alcohol complicated and caution should be applied to avoid 
misinterpretation of either positive or negative results at autopsy. Information 
available from the scene of accident or death would help but with some cases it 
is not available. Also, reports suggest that multiple analyses of different 
matrices, especially, blood, urine and vitreous humour may help in the 
interpretation of ethanol results. It is believed that positive results for blood 
with negative urine and vitreous humour are strong evidence of post-mortem 
ethanol production 434,460,462,474. However, in the case of putrefaction the 
specimen available in most cases is blood or urine.  
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The idea of alcohol biomarkers was established for clinical purposes and much 
attention was paid to overcome problems of impaired liver function for patients 
who have been alcoholic for a long term (at least 12 months). This period of 
excessive consumption causes severe damage to liver cells 434,475. The risks of 
alcohol-induced organ and tissue damage are considered higher with alcoholics 
compared to non-alcoholics 434. Diagnosis at the early stage of alcohol abuse is 
important to their treatment and prevention of reaching latter stages of which 
there may be no cure 438,476,477. Alcoholism is difficult to observe without medical 
complication or self reporting of use, the latter has been found unreliable and 
most alcoholics deny their alcohol abuse problem either because they believe it 
is part of their culture or to avoid the negative attitude toward them as being 
alcoholic 446,475,476,478,479. The level of BAC at post-mortem is only an indicator of 
recent alcohol ingestion and cannot be used to identify alcoholic abuse problems 
434,480. In one study, negative BAC was detected with half of alcoholics at death 
480. 
Pathological diagnostics of alcoholics are not unique and are relatively non-
specific with similarities between alcoholics and non-alcoholics in liver disease 
often encountered at post-mortem examination. Poor hygiene and multiple 
burises of different age has been used to distinguish alcoholics at post-mortem 
examination 434,480.  
In fact, searching for alcohol biomarkers has gained a great deal of interest due 
to the high alcohol abuse rate among forensic autopsy population which was 
estimated to be 10% or more 434,475. The early diagnosis of alcoholics using low 
cost biochemical makers are without a doubt crucial in order to lower and 
shorten treatment cost and time, respectively  434,438.  
The development of sensitive and specific alcohol biomarkers was found to be 
challenging due to errors encountered with most clinical ethanol biomarkers 
which were not direct metabolites of ethanol. Although ethanol blood, urine and 
breath tests are helpful tools that are complementary with self-reporting and 
other clinical diagnostics 481, accurate direct alcohol biomarkers are more 
objective and needed in order to maximise the sensitivity and specificity of the 
use of these alcohol biomarkers which in turn would reduce the error often 
encountered with non-alcoholics 434,436,472,476,482.  
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The availability of high resolution and accuracy mean analyses such as GC-MS 
and LC-MS(MS) have facilitated these objectives 448. Phase two metabolites of 
ethanol have been used as ethanol biomarkers only recently despite them being 
known since 1953 483. During this long journey many alcohol biomarkers have 
been tested until direct alcohol biomarkers became the method of choice for 
distinguishing between the sources of ethanol present at autopsy. This does not 
mean that the other alcohol biomarkers were found not useful but each one of 
them has its own advantages and disadvantages 482. 
Acetaldehyde is primary product of alcohol metabolism and can be as marker for 
alcohol consumption 484,485 but it has been found not useful as an alcohol 
biomarker due to its low concentration and lack of proper analytical procedure 
459,486. Methanol has been used to reflect recent alcohol use, as the methanol 
concentration in the body increases with presence of alcohol above 20 mg/dL 
due to the ethanol blocking the methanol metabolism pathway 434,479,487,488. In 
fact, a method for determining methanol is available and used routinely in many 
laboratories. It has demonstrated that a level of methanol above 1 mg/dl is an 
indicator of long-term overconsumption of alcohol. Therefore, it has been 
suggested that an increase in methanol level may be an indicator of chronic or 
continuous drinking rather than recent alcohol consumption 434,479,489,490. 
However, many alcoholic beverages contain methanol which should be taken 
into consideration when methanol is used for interpretation as the high 
methanol result could be a result of the presence of methanol in alcoholic 
beverages 434,491,492.  
Many other alcohol biochemical markers have been developed for more 
objective ways to identify the overconsumption of alcohol in clinical and 
forensic subjects. These biomarkers can be classed into short term and long 
term alcohol biomarkers or direct and indirect ethanol metabolites 472. The 
ethanol itself or its primary metabolite such as acetaldehyde has been used as 
alcohol direct biomarkers 434,484,493. Also, fatty acid ethyl ester or conjugates 
metabolites such as ethyl glucuronide, ethyl sulfate , and phosphatidylethanol 
are minor nonoxidative direct metabolites of ethanol which indicate short term 
of alcohol ingestion 434,436,448,476,482,494. The idea of using these biomarkers was to 
provide 100% sensitivity and specificity of alcohol consumption ante-mortem, 
however, this was never obtained with ethanol biomarkers 434.  
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Determining chronic use of alcohol is out of the scope of this Chapter but for 
completion these biomarkers are discussed briefly. The change of liver function 
was noticed after long term alcohol consumption and liver enzymes such as 
gamma-glutamyl transfererase (GGT), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), and mean corpuscular erythrocyte volume (MCV). In 
addition, carbohydrate-deficient transferase (CDT) is a useful biomarker 
associated with alcoholics. These biomarkers are indirect alcohol abuse 
biomarkers which are detected after long overconsumption of alcohol (50-80 g of 
ethanol daily) for at least one to two weeks 434,477,481,482. However, there are 
some limitations of their use which reduces their specificity and sensitivity as 
alcohol biomarkers, for example, the GGT value has risen with liver damage of 
non-alcoholics. Although these biomarkers require simple analytical methods for 
their application and they are available with low cost in each laboratory, these 
biomarkers are detected only in blood or its derivatives and some of them (GGT, 
ALT, AST and MCV) are unsuitable in autopsy specimens 436.  
Long term biomarkers have their applications with alcohol misuse problems but 
often suffer from low sensitivity and specificity and two or more biomarkers are 
used. The use of these biomarkers was found unreliable for diagnosis of 
alcoholism; only 20-50% of alcoholics can be determined using these biomarkers 
478,481,495. Although the combination of these biomarkers could increase the 
diagnostic accuracy, the interpretation of them is complex 434,438,477. False 
positive or negative results may be obtained for some cases of non-alcoholics 
who suffer from liver disease apart from those caused by misuse of alcohol as 
well as alcoholics who show normal levels of these markers 478,496.  
There is a gap between short term and long term alcohol biomarkers and single 
use cannot be detected using long term biomarkers 472,497. In post-mortem 
toxicology and Driving Under the Influence of Drugs (DUID) cases, the 
concentration of drug at the time of death or accident are more important for 
interpretation 434,447.  
In the last decades, many direct metabolites of alcohol have been studied and 
found useful to determine the recent use of alcohol. These short term markers 
are able to monitor the intake of alcohol after a single use which can not be 
identified using the traditional alcohol long term use. These metabolites were 
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formed from ethanol and are not influenced by liver disease and are detectable 
in variety of biological specimens and tissues 448,451,482.   
Fatty acid ethyl esters (FAEEs), which are esterification products of ethanol and 
endogenous fatty acids 473,498, have been used as alcohol biomarkers and found 
to be detectable up 24 hours after ethanol intake 499 and up 44 hours 500 and 99 
hours in heavy drinkers. Therefore, they seem to be good markers for the 
detection of short and long ethanol intake 486,499,501. Organs damaged by heavy 
alcohol drinking were found to have high concentrations of FAEEs which may be 
contributors to alcohol toxicity 486,502-504. However, their use is limited due to 
their faster elimination in blood compared to that of other acute alcohol 
biomarkers which reduces their sensitivity as recent alcohol consumption 
markers and they have not been found useful for forensic purposes 473. Levels of 
FAEEs were found to rapidly decrease after ethanol consumption within 29.4 
hours but were found higher than LOQ concentrations and remained stable with 
low concentrations. The same FAEEs levels were still detected after 4 days of 
abstinence which limits their usefulness as long term alcohol intake markers 473.  
The urinary ratio of the serotonin metabolites 5-hydroxytryptophol (5-HTOL) to 
5-hydroxyindole acetic acid (5-HIAA) has been found useful for detection of 
recent alcohol use. These analytes are not direct alcohol metabolites and are 
used to detect short term alcohol consumption up to 12 hours in urine; the level 
of 5-HTOL is increased after alcohol intake 434. 5-HTOL is excreted mostly in 
conjugated form as glucuronide or sulfate  conjugates and free 5-HTOL accounts 
for less than 5% of total elimination while about 80% is excreted as 5-
hydroxytryptophol glucuronide (GTOL) making the later metabolite promising as 
an alcohol biomarker for recent intake. Therefore, the urinary ratio of GTOL/5-
HIAA has been used for detection of recent alcohol consumption 505-508. However, 
these metabolites require sophisticated analytical methods based on GC-MS and 
LC-MS. In addition to a short detection window of this ratio, which was found to 
be less than 7 hours using free 5-HTOL, the false positive results after consuming 
a rich serotonin meal could be obtained 473,505.   
Ethyl glucuronide (ETG) and ethyl sulfate (ETS) are direct non-oxidative ethanol 
metabolites and have been shown to be useful markers of alcohol consumption 
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for several hours after death or when ethanol itself has been completely 
eliminated from the body.  
10.2.3 Ethyl Glucuronide and Sulfate   
10.2.3.1 Introduction 
As indicated earlier, two different alcohol biomarkers have been used in routine 
analysis with alcoholic patients. Blood alcohol concentration (BAC) or urine 
alcohol concentration (UAC) indicate recent alcohol consumption whereas 
alcohol biomarkers such as carbohydrate deficient transferrin (CDT), gamma 
glutamyl transferase (GGT) and mean corpuscular volume (MCV) indicate long 
term alcohol misuse. Ethyl glucuronide and ethyl sulfate  have been found to fill 
the gap between short and long alcohol biomarkers and show longer detection 
times. They can be detected while ethanol is still present and even after alcohol 
has been eliminated from the body, for up to 8 hours in serum and for several 
days in urine 447,472.  
The usefulness of ETG as a recent alcohol consumption biomarker has been 
studied widely 76,448-450,453,509,510. It has been found that ETG can only be formed 
after alcohol ingestion and has been found not to be formed endogenously but in 
one study ETG has been formed in infected urine samples by Escherchia Coli with 
present of ethanol 511. However, the presence of ETG is not definitive evidence 
of anti-mortem alcohol intake 451,495,512-514. However, negative results of ETG 
should be interpreted with caution as false negative results may be obtained. 
There is a time lag between alcohol present in blood and ETG which may lead to 
false negative results if death happened shortly after alcohol consumption 512. 
Although post-mortem alcohol fermentation has been acknowledged since the 
1930s, looking for specific alcohol biomarkers for recent alcohol consumption 
has gained great deal of interest recently 482.  The reason may be due to the 
availability of sensitive and selective methods of quantification 474. In the past, 
the detection of polar metabolites was tedious and involved extensive labour 
requiring many steps of isolation and hydrolysis which was often time consuming, 
expensive and unsuitable for routine analysis. Glucuronide metabolites contain a 
sugar which is a heavy compound to be detected using GC-MS which needs to be 
derivatised. At the early stage of discovering the importance of ETG as an 
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alcohol biomarker in 1990s, LC-MS instrumentation was considered expensive 
and unavailable in most forensic laboratories; therefore, the first application for 
the analysis of ETG in serum was conducted using the GC-MS method 449,450. A 
few years later, most methods reported were LC-MS or LC-MS/MS as they 
required less pre-treatment of samples and had high sensitivity and selectivity.  
Recently, the stability of ETG has been brought into question which was found to 
be degraded by bacteria 513,515-517. Therefore, ETS has been introduced as a 
complementary marker with ETG due to its stable pattern and resistance to 
bacterial infection 511; the presence of ETG and ETS provides strong evidence of 
recent alcohol consumption even with negative BAC or UAC 454,494,518-523.  
ETG and ETS are promising biomarkers because they are phase two ethanol 
metabolites and their excretion profiles have been studied and documented. 
Also, their standards and internal standards are available commercially and can 
be detected using LC-MS/MS method. Both were found specific and sensitive 
compared to long alcohol biomarkers with longer detection time from 1 to 5 days 
and are not influenced by disease 447,448,524,525. 
10.2.3.2 Previous Work 
As indicate earlier, the first application developed to determine ETG in serum 
was in the mid 1990s  using GC-MS 449,450. A simple protein precipitation (PP) 
procedure followed by acetic anhydride derivatisation were found sufficient to 
determine ETG; an LLOQ of 0.1 ìg/mL was achieved and a linear calibration line 
was obtained in the range of 0.1-150 ìg/mL. A few years later, ETG was 
determined using LC-ESI-MS techniques using PP extraction and RPLC-MS-ESI 
which resulted in lowering the LOD to 0.03 ìg/mL compared to 0.1 ìg/mL using 
GC-MS procedure 526. Both GC-MS 449,450,527-531 and LC-MS/(MS) 444,509,526,532-537 were 
successfully applied for routine analysis.   
The use of LC-MS/MS for identification and quantification of polar glucuronide 
metabolites has been established and led to establishing a new LC-MS method 
for direct determination of ETG. Wurst et al 453,536 reported LC-ESI-MS/MS and 
GC-MS methods for the determination of ETG, and both methods were employed 
for routine analysis in parallel. Good agreement was obtained between both 
method results from real case samples with correlation coefficient of 0.98. 
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In the last decade, many methods have been published for the direct 
determination of ETG using either gas chromatography coupled with mass 
spectrometry 449,450,527-531 or using LC coupled with electrochemical detection 
76,538 or LC-ESI-MS/(MS) 444,526,533,534,537,539 procedures.  
The first application for the simultaneous detection of ETG and ETS was reported 
a decade 447,454,521-523 after the Schmitt et al report 449. The same protein 
precipitation procedures used for ETG were applied for the direct determination 
of ETS 447,454,521-523 as well as direct injection of urine samples after dilution 
494,520,524. Three reports aimed at validating methods for detection of ETS in 
authentic samples 518,540,541. Protein precipitation of blood and urine samples or 
dilution of urine samples are the most common pre-treatment procedures for 
direct determination of both ETG and ETS using LC-ESI-MS/MS 447,454,494,516,520-
524,542.  
10.3 HILIC and RPLC 
ETG and ETS are very polar metabolites requiring very low percentages of 
organic modifiers (less than 5%) for elution from a conventional reversed phase 
column, which results in poor retention, large matrix effects and low sensitivity 
in LC-MS. Post-column addition of organic solvent can enhance ESI-MS/MS 
response while preserving good chromatographic peak shapes 447,454,516,520,522-524.  
Recently, hydrophilic interaction chromatography (HILIC) has been introduced as 
an alternative to reverse phase LC separation of polar compounds. HILIC is 
suitable for ESI-MS as a high percentage of organic modifiers can be used, from 
40 to 95%, without reducing analyte retention 93,543,544. 
Although the name HILIC was suggested by Alpert in 1990 545, HILIC was in use 
since the 1950s but with other names such as aqueous normal phase or reverse 
phase and pseudo normal phase 543,546. Early 1952 saw an application for the 
separation of monosaccharides using a gradient elution consisting of 99.5% of 
ethanol and water was reported. In HILIC phase water is the strong eluent and 
has been in use since 1975 for the analysis of sugar and oligosaccharides using 
HPLC 543,547. Recently, HILIC separations were used to determine cocaine and its 
metabolites 548 and opioid glucuronides 93,549. HILIC applications have increased 
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recently due to the need for analysis of polar compounds and biomarker analysis 
since in most cases they are very polar metabolites and lack retention using 
conventional RPLC 416,543,544,546,550-553.   
HILIC application could fill the gap between RPLC, ion chromatography liquid 
chromatography and NPLC. It is completely opposite to RPLC where early eluted 
compounds using RPLC are eluted later using HILIC systems. This could solve the 
problem with very polar compounds using HILIC with the possibility of using RPLC 
solvents. In addition, SPE extracts used with RPLC could be injected directly to 
HILIC phase saving time and preventing analyte loss during evaporation. HILIC is 
similar to normal phase liquid chromatography but with a very distinctive 
difference: HILIC could apply semi-aqueous mobile phase resulting in good 
solubility and matrix compatibility. However, low solubility of extracts in 
eluents, such as hexane, was encountered using NPLC mobile phase for the 
analysis of non-polar and polar metabolites 547,552. Also, high buffer percentages 
using RPLC and non-polar eluents from NPLC are not favoured for MS analysis due 
to susceptibility to matrix effects with RPLC and poor ionisation achieved in 
totally nonpolar organic mobile phase using NPLC. HILIC could also enhance the 
sensitivity of ESI-MS/MS techniques. HILIC was found to enhance MS sensitivity 
from 10-1000 times compared to RPLC for some polar compounds, and lowers 
the cost of analysis by direct injection which also saves the time of sample 
preparation 416,543,546,550-554.     
The analytes eluting near to the column void volume in RPLC are the most 
retained analytes using HILIC procedures. The water enriched layer is 
established within the stationary phase under HILIC phase, and the separation of 
analytes using HILIC is accomplished by partitioning of mobile phase contents 
into the HILIC phase. The retention of analytes is based on binding to water 
which is the primary function of the HILIC stationary phase 544,545,551,552. The 
primary HILIC retention is not important; a second HILIC retention has been 
added by charging the stationary phase which increases selectivity because it 
increases the interaction with polar metabolites. However, a high buffer 
concentration is required to disrupt these interactions to allow polar metabolites 
to be eluted, which is not good for MS detection and sensitivity. The use of 
columns having a combination of zwitterionic stationary phase and HILIC (ZIC-
HILIC) was found to make the overall effect of a weaker electrostatic interaction 
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leading to lower buffer concentrations, because the electrostatic forces of each 
charge are partly counterbalanced by the proximity of an ion with opposite 
charge 552,554. 
Another advantage of using ZIC-HILIC is that it is pH-independent which makes 
the optimisation of mobile phase pH solely determined by the polar metabolites. 
Other HILIC stationary phases such as silica and amino phases are pH dependent 
which in turn means the optimisation of mobile phase pH depends on the 
analytes and stationary phase ionisation 554.  
Until now, few studies have been concerned with optimisation of methods using 
ZIC-HILIC phases for forensic purposes. Only two studies have been reported for 
the use of ZIC-HILIC for the quantification of opioid polar metabolites 93,549, and 
two  HILIC method was reported for ETG during this work but using urine 555 and 
hair matrix 556. The use of HILIC has enhanced MS sensitivity for these polar 
metabolites which are known to be eluted near to the void volume in RPLC. 
However, RP is still the method of choice for the simultaneous determination of 
many drugs and their metabolites while HILIC is suitable for very polar 
metabolites only. 
10.4    Aims 
Until now, only one method to determine ETG using an ion trap mass analyser 
was published at the same time as the present work 539. However, ETS has not 
previously been determined using this technique. In addition, a method for 
combination of LC-ion trap-MS/MS with HILIC for direct determination of both 
ethanol metabolites has not yet been reported.  
This work was aimed at developing and validating an LC-ESI-ion trap-MS/MS 
method for identification and quantification of ETG and ETS as ethanol 
biomarkers. The second aim was to employ the optimised method for the 
separation of these polar metabolites for routine analysis of urine samples 
obtained at autopsy. 
295 
10.5 Methods and Materials  
10.5.1 Reagents and Standards 
Ethyl glucuronide, ethyl glucronide-D5, ethyl sulfate  and ethyl sulfate -D5 were 
obtained from Lipomed (Arlesheim, Switzerland).  Individual working standards 
were prepared at concentrations of 20, 10 and 1 µg/mL by dilution of the stock 
solutions. Working mixtures of standards and internal standards were similarly 
prepared. 
10.5.2 Extraction 
Following addition of pentadeuterated, internal standards for ETG and ETS, 
200 µl of acetonitrile were added to 0.1 mL of urine and centrifuged at 10,000 
rpm. The supernatant was then evaporated before reconstituting with 100 ìl of 
initial mobile phase and 5 µl was injected to LC-MS/MS. 
10.5.3 Chromatographic conditions and instrumentation 
Analytes of interest were separated on a ZIC-HILIC column (150 x 2.1 mm, 3.5 
ìm), protected by a guard column with identical packing material (4 x 2.0 mm, 
Merck SeQuant, Umea, Sweden). Gradient elution used a mobile phase with (A) 5 
mM ammonium acetate and (B) acetonitrile at a flow rate of 0.2 mL/min for the 
first 3 min, increasing to 0.4 mL/min at 4 min and maintained for the next 3 
min. After that, initial flow rate was applied until the end of analysis.  
The gradient conditions were initially 10 % of solution A for 3 min; increasing to 
30 % at 4 min, to 50 % at 12 min before returning to 10 % for 8 min prior to the 
next injection. Two retention segments were used to maximise the sensitivity of 
analysis: the first segment from 0-4 min was for ethyl sulfate  (ETS) and ETS-D5, 
the second segment from 4-8 min was for ethyl glucuronide (ETG) and ETG-D5.  
10.5.4 Instrumentation 
A Thermo-Finnigan LCQ Deca Plus LC-MS/MS instrument (Thermo Finnigan, San 
Jose, CA) equipped with a Surveyor LC system interface was used for 
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determination of both ethanol biomarkers. The column oven and autosampler 
tray were maintained at 25 0C at 4 0C, respectively. Ionisation of analytes was 
carried out using electrospray negative ion mode. Both ETG and ETS were 
optimised separately by infusing 10 ìg/mL of each analyte using a syringe pump 
at fixed flow rate. Then, the capillary temperature, sheath gas flow rate, 
auxiliary gas flow rate and collision energies were optimized for each analyte 
separately.   
ETG and ETS and their internal standards were identified and quantified based 
on their retention times, precursor ions using Selection Reaction Monitoring 
mode (SRM) and negative ESI mode. In the case of ETG and its deuterium 
internal standard two product ions can be obtained, the MS/MS transition with 
m/z 221→ 203 (precursor ion → product ion) was used as quantifier, m/z 221 → 
113 was used as qualifier; m/z 226 → 208 and 226 → 118 were used for ETG-D5 
as quantifier and qualifier ion, respectively . However, a single product ion was 
obtained with ETS and ETS-D5. Therefore, 90% of product ion and 10% of 
precursor ion were used for the calculation of SRM transition of ETS in which m/z 
125 → 97 was used as quantifier and 125 → 125 was used as qualifier; m/z 130 
→ 98 and 130 → 130 were used for ETS-D5 as quantifier and qualifier ion, 
respectively. The spray voltage used was 4 and 5 kV for ETG and ETS, 
respectively.  The MS/MS parameters are detailed in Table 10-1.  
10.5.5 Method Validation 
10.5.5.1 Linearity 
Calibration standards were spiked in urine over the range 0.05, 0.1, 0.25, 0.5, 
0.75, 1, 2.5, 5 and 10 mg/mL and extracted using the protein precipitation (PP) 
method described earlier.  Calibration curves were plotted by dividing the peak 
area ratios obtained at each concentration to internal standards.  The 
correlation coefficient (r2) was obtained for each linear regression curve.  
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Table 10-1: LC-MS/MS data 
 
 
 Parameters Ethyl glucuronide Ethyl sulfate  
Precursor Ion  
(m/z) 
221.5 125.5 
Product  
Ion(s) (m/z) 
103, 113 97,5 
Quantifier  
Ion (m/z) 
221.5 → 103.0 125.5 →97.5 
Qualifier 
Ion(m/z) 
221.5→113.0 125.5 →125.5 
A
n
a
ly
te
s 
RT  *  (min) 6.0 1.9 
Internal  
Standard (IS) 
Ethyl glucuronide-D5 Ethyl sulfate -D5 
IS Precursor  
Ion(s) (m/z) 
226.5 130.5 
In
te
rn
a
l s
ta
n
da
rd
s 
Product Ion 
(m/z) 
208.0 98.5 
Sheath Gas 
(AU) 
15.0 10.0 
Auxiliary Gas 
(AU) 
10.0 10.0 
Capillary 
Temperature 
(ºC) 
275.0 275.0 
Collision 
energy (%) 
32.0 30.0 
Retention 
Widow No.  
2.0 
(4.0-10.0) 
1.0 
(1.0-4.0) 
LOD #   
(ng/mL) 
0.13 0.2 
A
n
a
ly
te
s 
a
n
d 
th
ei
r 
in
te
rn
a
l s
ta
n
da
rd
s 
LLOQ  **  
(ng/L) 
1.0 1.0 
*
 Retention time;  
#
 LOD: Limit of detection; 
**
  LLOQ: Lower limit of quantitation. 
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10.5.5.2 Recovery and Matrix effect 
The method described by Matuzewski et al 51 was used for the assessment of the 
recoveries (RE) of and matrix effects (ME) on ethanol metabolites at three 
different concentrations 0.05, 0.5 and 2.5 ìg/mL with five replicates at each 
concentration point. REs and MEs of analytes of interest were calculated by 
dividing the mean peak area ratios of product ion of analytes of interest/their 
internal standards using equations 3-1 and 3-2, respectively.  
The effect of endogenous urine matrix components on analyte ionisation during 
LC-MS/MS was assessed by analysing blank urine obtained from five different 
human sources. Analytes of interest and their internal standards were spiked at 
three concentrations (0.05, 0.5 and 2.5 ìg/mL) and analysed by the optimised 
method.  
10.5.5.3 Limits of Detection and Lower Limits of Quantitation 
Limits of detection (LODs) and lower limits of quantification (LLOQs) were 
obtained by extending the calibration curves to the concentration of the 
expected LODs and LLOQs of analytes of interest. A linear calibration model was 
established for each analyte of interest at eight concentrations (0.1, 0.2, 0.3, 
0.5, 0.75, 1, 2.5 and 5 ng/mL) plus blank. Spiked urine samples were then 
extracted and analysed using the developed method. LODs and LLOQs values 
were determined at signal-to-noise ratios of 3 and 10, respectively, using 
equations 2-1, 2-2 and 2-3, 2-4, respectively. 
10.5.5.4 Intra-assay and inter-assay precision 
Five replicate human urine samples (n=5) were spiked with ETG and ETS at three 
concentrations (0.1, 0.5 and 2.5 ìg/mL). The extracts were analysed using the 
optimised method on the same day to determine intra-assay precision. The 
inter-assay precision was measured in a similar manner to the intra-assay 
precision on five different days. Linear calibration curve for ETG and ETS were 
performed with each run batch.  
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10.5.5.5 Stability 
Stability was assessed using human urine spiked with ETG and ETS at 1 ìg/mL 
(n=5). Short-term temperature stability at room temperature was investigated 
using spiked urine stored for 4 and 24 hrs. Freeze-thaw stability of analytes of 
interest was determined after four cycles (thawed, left at room temperature for 
3 hours then refrozen) on consecutive days. Auto-sampler stability using 
reconstituted extracted sample was determined for 48 hours after extraction.  
Long-term stability for analytes of interest at -20 and 4 oC for period of 24hrs, 
48hrs, 1 week and 1 month were investigated. Calibration curves were prepared 
for each batch of samples using standards spiked in human urine at 0.05, 0.1, 
0.25, 0.5, 0.75, 1, 2.5, 5 and 10 ìg/mL plus blanks. 
10.5.5.6 Specificity  
These were similar to those described in Chapters 6 (section 6.7.5.6).   
10.5.5.7 Case samples 
Samples of autopsy urine were analysed using the proposed method as part of 
the investigation of medico-legal cases submitted to Forensic Medicine and 
Science, University of Glasgow which were drug-related deaths. Measurements 
were repeated after dilution of the urine sample when analyte concentrations 
outside the calibration range were obtained. 
Ninety urine case samples were divided into three groups depending on the 
blood alcohol concentration (BAC) and analysed by the developed method: group 
A with BAC higher than 200 mg/100 mL; group B with BAC in the range 80 to 200 
mg/100 mL and group C with BAC less than 80 mg/100 mL. 
10.6 Results 
10.6.1 Method Validation  
The ZIC-HILIC column was first used for the separation of ETG and ETS which 
therefore required optimising of mobile phase strength, injection volume, and 
flow rate before applying this method for analysis. The HILIC guideline book 
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recommended some starting points for method validation such as using 5 mM of 
ammonium acetate plus high organic solvent from 40- 95% and flow rate at 0.1 
mL/min 554,557,558. These settings gave good separation of two ethanol biomarkers 
from the first run; however, ETG was eluted at 14 minutes while ETS eluted at 3 
minutes plus 15 min for column to be equilibrated before the second injection 
which resulted in a run time of 30 min. Different injection volumes were 
investigated at 10, 15 and 20 ìl. The sensitivity was good with an injection 
volume of 5 ìl and the peak started to broaden with more than 15 ìl, therefore, 
5 ìl was chosen for the remainder of this study.   
For acidic and polar metabolites, a pH of 6 to 7 plus low buffer concentration at 
room temperature is recommended 554. Mobile phase strength was also optimised 
using different organic percentages and different ammonium acetate buffer 
concentrations (5 and 10 mM). In addition, the pH of mobile phase was examined 
at 4.5 and 6.4. No differences in separation or peak shape of ETG and ETS were 
observed with these two pH values and buffer concentrations. However, changes 
in the percentage of organic modifier and flow rate were sufficient to change 
analyte retention. Therefore, 90% of acetonitrile (B) and 10 % of 5 mM 
ammonium acetate (A) were used as a starting point at 0.2 mL/min as flow rate 
for the first 3 min. A higher flow rate of 0.4 mL/min was necessary to achieve 
baseline separation in less than 7 minutes and then 3 minunts for column 
cleaning were used by increasing the buffer (B) percentage to 70% followed by 8 
minutes for column conditioning before the next injection (total run time 21 
minutes). The LC-chromatogram was divided to two segments for each analyte in 
order to enhance method selectivity and sensitivity. ETS was eluted first at 1.9 
minutes followed by ETG at 6 minutes; internal standards for each analyte were 
used to correct any matrix effect if present.  
10.6.1.1 Linearity  
Linear regression lines were obtained for ETG and ETS over the calibration range 
of 0.05-10 ìg/mL with R2 values greater than 0.999 for ETG and ETS (n=10). 
Although a higher range of calibration between 0.05 to 50 ìg/mL was also 
achieved with good correlation coefficients, the range of calibration was chosen 
to be between 0.05-10 ìg/mL in order to lower the test cost (Figure 10-1).  
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10.6.1.2 LOD and LLOQ 
Low LOD and LLOQ values were obtained using the ZIC-HILIC procedure. LLOQs 
of 0.001 ìg/mL were obtained which in fact lowered the method cut off of ETG 
and ETS by 1000 and 100 fold, respectively, see Table 10-1. This was the 
advantage of using high organic modifiers compared to an RPLC method (Table 
10-2 and Figure 10-2).  
Figure 10-1: Linear calibration curves for ETG and ETS. 
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10.6.1.3 Recovery and Matrix Effects 
ETG and ETS had high recoveries of 98-99 % using three quality control standards 
at 0.05, 0.5 and 2.5 ìg/mL. The matrix effects were investigated together with 
recovery experiments in order to determine the true recoveries.  
Figure 10-2: ETG and ETS at the LLOQ. 
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Matrix effects were investigated using five different human urine samples which 
tested negative for both ETG and ETS. There were no matrix effects observed 
using three quality control standards at low, medium and high concentration at 
0.05, 0.5 and 2.5 ìg/mL (Table 10-2).  
10.6.1.4 Specificity and Selectivity  
In addition, method specificity was examined by injecting high concentrations of 
common drugs and metabolites encountered with real forensic cases: no 
interference was observed.  
Table 10-2: Matrix effects and recoveries 
 
 
10.6.1.5 Method precision  
Percentage relative standard deviations (RSD) were used to assess the intra- and 
inter-day precision of the method for ETG and ETS at three concentrations (0.1, 
0.5 and 2.5 ìg/mL).  RSD values less than 8 % and 11% were observed for intra- 
Analytes Nominal 
Concentration 
ìg/mL 
Mean of matrix effects # 
 % * (R.S.D. %) & 
Mean Recovery  
% ** (R.S.D. %) 
Ethy glucuronide 0.05 106.0 (13.0) 101.0 (9.0) 
 
0.50 103.0 (7.0) 96.0 (6.0) 
 
2.50 99.0 (3.0) 100.0 (2.0) 
Ethyl sulfate  0.05 99.0 (7.0) 98.0 (5.0) 
 
0.50 105.0 (2.0) 101.0 (2.0) 
 
2.50 100.0 (2.0) 99.0 (5.0) 
#
 Human urine was sourced from completed urine samples that were scheduled for destruction 
and contained no analytes of interest. 
*
 Matrix effect is expressed as the response obtained for a standard chromatographed along with 
matrix extract compared to that obtained with an unextracted standard chromatographed in 
mobile phase only, expressed as a percentage. Standard was spiked into matrix extract at a 
concentration of 0.05, 0.5 and 2.5 ìg/mL. 
** Value calculated from the average recovery for the replicate analyses (n=5) 
&
 R.S.D. %: Relative standard deviation expressed as a percentage. 
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and inter-assay precision, respectively. Accuracy, intra-day and inter-day 
precision are detailed in Table 10-3.   
Table 10-3: Accuracy, Intra-day and inter-day precision of the optimised 
method 
 
10.6.1.6 Stability  
Stability is the major issue for ETG and ETS analysis. In the current study, 
stability of ETG and ETS were investigated over the short term, 4 and 24 hours at 
room temperature, long term stability at two storage conditions 4 oC and -20 oC 
up to month, four freeze/thaw cycles and auto-sampler for up to 48 hours. 
There was no degradation of ethanol metabolites observed in all storage 
conditions (Table 10-4).  
Drugs Nominal  
Conc.  
 
Intra-day   
Precision * 
Inter-day   
Precision * 
Accuracy  * 
 ìg/mL 
 
ìg/mL 
(R.S.D %) # 
ìg/mL 
(R.S.D %) 
% 
(RSD %) 
Ethyl 
glucuronide 
0.1 0.1 (8.0) 0.1 (10.0) 97.0 (6.0) 
 
0.5 0.5 (2.0) 0.5 (7.0) 99.0 (4.0) 
 
2.5 2.5 (1.0) 2.5 (2.0) 100.0 (5.0) 
Ethyl sulfate  0.1 0.1 (2.0) 0.1 (9.0) 103.0 (10.0) 
 
0.5 0.5 (6.0) 0.5 (5.0) 101.0 (2.0) 
 
2.5 2.5 (5.0) 2.5 (2.0) 101.0 (4.0) 
* Value calculated from the average recovery for the replicate analyses (n=5) 
 
#
 R.S.D. %: Relative standard deviation expressed as a percentage. 
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Table 10-4: Stability study 
 
10.6.2 Case Samples 
The method was used for analysis of ETG and ETS in case urine samples and has 
been shown to be a useful tool to indicate recent ethanol consumption. Ninety 
urine samples obtained at autopsy were tested for BAC and UAC using an in-
house GC-FID method. Urine samples were then divided into three groups 
depending on BAC because in some cases UAC was not determined.  
Group A, consisting of 31 cases, had BAC higher than 200 mg/100 mL, the 
median (mean) BAC and UAC were 261 (318) and 327 (335) mg/100 mL, 
Storage Condition # Ethyl glucuronide Ethyl sulfate   
 
Time  
Mean % * (R.S.D %) & 
Room  Temperature 4 Hours 103  (7) 109 (11) 
 24 hours 110 (8)  108 (1) 
Freeze/thaw  
 
4 cycles 105 (6) 105 (3) 
Auto-sampler 4 0C 48 hours 103 (12 105 (2) 
 Week 103 (0.5) 99 (4) 
Freezer at  -20  0C 24 hours 111 (5) 109 (3) 
 48 hours 105 (9) 99 (6) 
 Week 101 (12) 103 (3) 
 Month 103 (9) 99 (3) 
Refrigerator at  4 0C 24 hours 106 (8) 99 (11) 
 48 hours 98 (7 107 (2) 
 Week 96 (8) 108 (5) 
 Month 105 (4) 106  
# Starting concentration is 1 ìg/mL.  
*
 Value calculated from the average recovery for the replicate analyses (n=3). 
&
 R.S.D. %: Relative standard deviations expressed as a percentage.  
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respectively. All of these samples were positive for ETG and ETS with the 
exception of one case which had a negative result for ETS and positive result for 
ETG. This case had BAC and UAC of 290 and 78 mg/100 mL, respectively. Urine 
ETG (UETG) concentration was detected at low concentration (4 ìg/mL) which 
was above the ETG cut-off used in this study. The ratio of UAC/BAC was very low 
at 0.27 which may indicate rapid death within one hour and may indicate that 
some of the ethanol was still in the stomach 474. These results also indicate ante-
mortem alcohol ingestion due to the presence of UETG, (Figure 10-3 and 10-4, 
Table 10-5). 
In group A, the median and mean UAC/BAC ratios for all cases included were 1.2 
and 1.1, respectively. The median UETG and UETS concentrations detected were 
181 and 43 ìg/mL, with a range of 2 - 1480 and not detected - 340 ìg/mL for 
UETG and UETS, respectively. Mean UETG and UETS levels were 333 and 73 
ìg/mL, respectively.  
Results from 30 cases testing positive for both UETG and UETS correlated well 
with a correlation coefficient of 0.9. Also, the mean ETG/ETS ratio in group A 
was 5.3 i.e. UETS was approximately 20% of the UETG in post-mortem urine. 
Poor correlations were observed with UETG and both BAC and UAC with 
correlation coefficients of 0.3 and 0.2, respectively. Similarly, correlation 
coefficients for UETS were 0.137 and 0.2, respectively. In most cases high 
concentrations of UETG and UETS were detected. Only one case had UETG levels 
lower than 30 ìg/mL and most UETS levels were higher than the cut-off by a 
factor of at least 17.     
There were 22 cases in group B (BAC in the range 80 to 200 mg/100 mL) with 
median (mean) BAC and UAC of 146 (144) and 197 (209) mg/100 mL, 
respectively.  
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Figure 10-3: Cases sample positive for ETS. 
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Figure 10-4: Case sample positive for ETG. 
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Table 10-5: Concentration of ethanol conjugates in post-mortem cases in 
group A 
Case  
no. 
ETS  ETG  BAC  UAC  ETG/ETS UAC/BAC 
 ìg/mL ìg/mL mg/100 mL mg/100 mL   
1 31.8 220.3 460.0 520.0 6.9 1.1 
2 339.8 1047.2 229.0 236.0 3.1 1.0 
3 13.9 112.4 219.0 328.0 8.1 1.5 
4 5.9 31.6 238.0 365.0 5.4 1.5 
5 59.0 1141.8 388.0 390.0 19.4 1.1 
6 149.7 679.6 212.0 298.0 4.5 1.4 
8 72.0 156.2 243.0 327.0 2.2 1.4 
34 22.8 138.7 367.0 390.0 6.1 1.1 
40 5.8 34.5 203.0 276.0 6.0 1.4 
44 45.6 247.8 470.0 510.0 5.4 1.1 
46 12.3 84.5 228.0 256.0 6.9 1.1 
48 145.9 552.1 389.0 426.0 3.8 1.1 
49 322.3 1479.8 286.0 382.0 4.6 1.3 
52 43.0 222.6 252.0 325.0 5.2 1.3 
53 6.5 51.3 241.0 297.0 7.9 1.2 
59 1.8 36.8 307.0 254.0 20.4 0.8 
62 23.8 121.3 316.0 388.0 5.1 1.2 
63 76.4 265.6 217.0 273.0 3.5 1.3 
66 23.3 2.0 249.0 313.0 0.1 1.3 
70 32.8 154.5 234.0 319.0 4.7 1.4 
71 158.0 900.4 386.0 487.0 5.7 1.3 
75 111.5 373.0 314.0 404.0 3.4 1.3 
77 131.0 584.6 1050.0 370.0 4.5 0.4 
80 126.6 762.8 251.0 360.0 6.0 1.4 
81 28.0 204.1 253.0 332.0 7.3 1.3 
82 4.0 29.3 307.0 250.0 7.3 0.8 
83 n.d & 3.9 261.0 78.0 n.d 0.3 
84 62.8 181 383.0 261.0 2.9 0.7 
86 12.8 68.7 200.0 248.0 5.4 1.2 
87 61.2 163.4 293.0 214.0 2.7 0.8 
88 116.0 266.0 430.0 520.0 2.3 1.2 
Mean  72.5 332.9 318.6 335.4 5.9 1.1 
Median 43.0 181.0 261.0 327.0 5.3 1.2 
&
  n.d: Not detected. 
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Twenty cases had both BAC and UAC: the median and mean UAC/BAC ratio was 
1.5 in all these cases which also tested positive for UETG and UETS with higher 
concentrations than the method cut-off for both biomarkers. The median (mean) 
UETG concentrations detected in group B were 102 (246) ìg/mL, respectively, 
which were lower than that found with group A. The UETG level was higher than 
10 ìg/mL in these twenty cases and ranged from 10 to 750 ìg/mL. Furthermore, 
the median of UETS in group B was slightly higher than that of group A, while 
mean UETS concentrations in group B was lower than group A; the median 
(mean) UETS level was 44 (60) ìg/mL. The UETS levels detected in these cases 
were higher than 1.7 ìg/mL and ranged from 1.7 to 175 ìg/mL (Table 10-6).  
In group B, two cases had BAC of 133 and 180 mg/100 mL but tested negative for 
UETG and UETS. One of these cases had been left for many hours after death in 
an outdoor environment and was heavily putrefied, which suggested post-
mortem alcohol production. No information was available for the other case.  
In group B, UETG and UETG correlated well with a correlation coefficient of 
0.844. The median UETG/UETS ratio was 4.8 which was lower than that of group 
A and the UETS level was less than 21% of UETG in post-mortem urine specimens. 
In addition, poor correlation was obtained between UETG and both BAC and UAC 
with correlation coefficients of 0.13 and 0.4, respectively. The same was 
observed for UETS which had correlation coefficients of 0.3 and 0.26, 
respectively. In group B, case samples positive for UETG were also positive for 
UETS with concentrations higher than 1 ìg/mL for both alcohol biomarkers. 
Twenty four cases in group C (BAC in the range 0 to 80 mg/100 mL) were positive 
for both alcohol biomarkers. The median (mean) UAC/BAC ratio was 1.4 for 
these 24 cases with median (mean) BAC and UAC of 40 (68) and 35 (67) mg/100 
mL, respectively. Median (mean) UETG concentrations were found at 106 (197) 
ìg/mL. Also, a wide range of UETG levels were found with concentrations 
ranging from 5.6 to 996 ìg/mL, with approximately the same median as group B. 
However, a lower median concentration of UETS was observed at 23 ìg/mL 
compared to 43 and 44 in groups A and B, respectively. In addition, UETS 
concentrations were in the range of 0.3 to 219 ìg/mL, which were close to the 
UETS concentrations in group B.   
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Table 10-6: Concentrations of ethanol conjugates in post-mortem cases in 
group B 
 
Case  
no. 
ETS ETG  BAC  UAC ETG/ETS UAC/BAC 
 ìg/mL ìg/mL mg/ 100mL mg/ 100mL   
9 2.7 19.4 172.0 239.0 7.2 1.4 
14 18.2 79.8 183.0 123.0 4.4 0.7 
15 175.0 330.8 116.0 171.0 1.9 1.5 
16 120.7 565.9 90.0 173.0 4.7 1.9 
30 132.0 636.3 100.0 234.0 4.8 2.3 
33 87.5 357.2 139.0 230.0 4.1 1.7 
39 1.7 10.1 113.0 167.0 5.9 1.5 
42 110.1 487.6 135.0 196 4.4 1.5 
43 32.2 63.1 172.0 242.0 2.0 1.4 
45 17.0 87.5 87.0 188.0 5.2 2.2 
47 43.4 230.6 127.0 197.0 5.3 1.6 
50 15.0 57.5 153.0 181.0 3.8 1.2 
56 n.d.& n.d.  133.0 n.a. * n.d. n.a. 
57 78.0 661.4 157.0 243.0 8.5 1.6 
60 44.0 14.6 162.0 256.0 0.3 1.6 
65 61.4 117.6 129.0 190.0 1.9 1.5 
68 8.4 51.4 168.0 200.0 6.1 1.2 
73 47.8 350.2 174.0 270.0 7.3 1.6 
74 144.6 750.4 184.0 285.0 5.2 1.6 
79 7.0 67.5 146.0 193.0 9.6 1.3 
90 n.d. n.d.  180.0 n.a.  n.d. n.d. 
Mean  54.6 235.2 143.8 209.4 4.4 1.4 
Median 43.8 102.5 146.0 197.0 4.7 1.5 
&
  n.d: Not detected. 
*    n.a: Not analysed. 
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UETG and UETS correlated well with a correlation coefficient of 0.9. The median 
ratio of UETG/UETS was 4.5 which means UETS was 22 % of UETG in these urine 
samples. As before, a very poor correlation was observed between BAC and both 
UETG and UETS, but a slightly better correlation was obtained between UAC and 
both UETG and UETS with r 2 values of 0.5 and 0.4, respectively. Positive cases 
were higher than the method cut-off but UETS concentrations below 1 ìg/mL 
were noted in three cases wherreas the remainder of the cases had UETS higher 
than 4 ìg/mL. Results of group C are listed in Table 10-7.  
In group C, six cases tested positive for UETG but not for UETS and in these cases 
BAC was lower than 10 mg/100 mL, which is considered to be lower than the 
LLOQ of the GC-FID method used and no UAC results were available for most 
cases. The median and mean UETG level in these samples was 9 ìg/mL and the 
range was 2.5 to 17 ìg/mL. These cases were attributed to ante-mortem alcohol 
ingestion. In another seven cases in group C, both UETG and UETS tested 
negative, and in these cases BAC was above 10 mg/100 mL and in the range 11 
to 47 mg/100 mL. UAC levels were not available for three of these cases and 
ranged between 21 to 81 ìg/mL in the rest of these cases. The median and mean 
UAC/BAC ratios were 0.3 and 0.8, respectively. The presence of alcohol in these 
case may attributed to post-mortem synthesis.  
In group C, thirty seven cases had BAC lower than 80 mg/100 mL. The median 
(mean) BAC and UAC were 24 (34) and 27 (51) mg/100 mL, respectively. The 
median UAC/BAC was 1. Lower median UETG and UETS were obtained at 23 and 
6 ìg/mL. Correlations between BAC and both UETG and UETS were 0.2 which 
were poor. In contrast, better correlations were found between UAC and both 
UETG and UETS at 0.5 which were better than observed with group A and B.  
Both ethanol markers were detected in all groups with overall median 
concentrations of 114 ìg/mL and 23 ìg/mL for ETG and ETS, respectively. Nine 
negative cases were attributed to post-mortem ethanol synthesis out of 90 cases 
in which neither UETG or UETS was detected. Eighty one cases tested positive 
for UETG while only 74 cases tested positive for UETS.  
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Table 10-7: Concentrations of ethanol conjugates in post-mortem cases in  
group C 
 
Case ETS ETG  BAC UAC ETG/ETS UAC/BAC 
 ìg/mL mg/mL mg/ 100mL mg/ 100mL   
7 n.d & n.d 16.0 n.a. * n.d n.a. 
10 4.9 6.3 77.0 133.0 1.3 1.7 
11 0.4 6.4 18.0 n.d 16.0 n.a 
12 4.1 6.0 64.0 117.0 1.5 1.8 
13 15.0 99.5 78.0 77.0 6.6 1.0 
17 0.9 5.6 28.0 n.a 6.2 n.a 
18 22.8 91.1 26.0 66.0 4.0 2.5 
19 n.d n.d 26.0 n.d n.d n.a 
20 n.d 10.6 11.0 n.d n.d n.a 
21 n.d n.d 47.0 76.0 n.d 1.6 
22 n.d n.d n.a 81.0 n.d n.a 
23 35.5 132.3 n.a 17.0 3.7 n.a 
24 85.0 220.0 n.a 14.0 2.6 n.a 
25 42.0 213.9 n.a 14.0 5.1 n.a 
26 62.9 172.2 19.0 71.0 2.7 3.7 
27 n.d n.d 15.0 n.d n.d n.a 
28 28.0 118.6 15.0 37.0 4.2 2.5 
29 n.d n.d 35.0 21.0 n.d 0.6 
31 23.7 111.9 54.0 81.0 4.7 1.5 
32 123.0 595.4 55.0 120.0 4.8 2.2 
35 12.3 53.7 38.0 35.0 4.4 0.9 
36 3.5 14.5 43.0 34.0 4.1 0.8 
37 74.9 561.3 n.a 184.0 7.5 n.a 
38 n.d 6.8 n.a 12.0 n.d n.a 
41 33.3 166.3 n.a 12.0 5.0 n.a 
51 n.d 7.5 n.a 11.0 n.d n.a 
54 219.1 548.6 62.0 149.0 2.5 2.4 
55 n.d 2.5 n.a 10.0 n.d n.a 
58 64.4 390.2 70.0 145.0 6.1 2.1 
61 208.0 996.0 44.0 73.0 4.8 1.7 
64 6.3 68.9 53.0 64.0 10.9 1.2 
67 21.0 59.4 n.a 16.0 2.8 n.a 
69 n.d n.d 11.0 32.0 n.d 2.9 
72 n.d 17.2 24.0 14.0 n.d 0.6 
76 7.7 88.6 61.0 83.0 11.5 1.4 
78 n.d 9.3 15.0 n.d n.d n.a 
85 6.7 22.7 54.0 72.0 3.4 1.3 
Mean 29.9 130.0 28.6 50.6 5.3 1.3 
Median 6.3 22.7 24.0 34.0 4.5 1.3 
&
  n.d: Not detected. 
*    n.a: Not analysed. 
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Using the median concentration for UETG, there was a gradual decrease from 
high BAC to the low BAC groups. The case was different for UETS as the median 
was the same in groups A and B but noticeably lower in the low BAC group 
(Figures 10-5 and 10-6). This was due to many negative results for UETG and 
UETS in the low BAC group. Using the positive cases only in group C, the median 
UETG and UETS increased from 23 to 78 and 6 to 23 ìg/mL, respectively, but 
were still lower than group B.  
In addition, the BAC and UAC were plotted for the whole group and a good 
correlation was obtained, with a linear correlation coefficient of 0.96. Moreover, 
UETG and UETS correlated well, with a correlation coefficient of 0.91 for all 
cases positive for UETG and UETS (Figures 10-7 and 10-8).  
10.7 Discussion 
10.7.1 Method validation 
The object of the current study was to optimise and validate a sensitive and 
simple ZIC-HILIC-ESI-MS/MS method for direct determination of ETG and ETS in 
urine post-mortem samples. Previous methods using conventional RPLC were 
capable of separating ETG and ETS but both analytes were eluted near to the 
void volume and so may be affected by matrix effects. Matrix effects were 
absent using the ZIC-HILIC procedure in the current study due to the HILIC 
mobile phase which contained 70 to 90 % of organic solvent, which enhances ESI-
MS/MS sensitivity The ZIC-HILIC procedure, in which the sample is deproteinated 
and reconstituted using acetonitrile, is a good alternative to RPLC.  
The retention of polar analytes using HILIC phase is the opposite of that 
observed with RPLC. ETS is released easily from ZIC-HILIC. In contrast, a higher 
flow rate was needed to decrease the retention time of ETG. In contrast, ETG 
was eluted at lower organic modifier contents and low flow rates using RPLC 
followed by ETS.  
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Figure 10-5: Median concentration of UETG in each group (ìg/mL). 
Figure 10-6: Median concentration of UETS in each group (ìg/mL). 
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Figure 10-7: Scatter plot of UAC/BAC in 90 post-mortem cases. 
Figure 10-8: Scatter plot of UETG/UETS in 90 post-mortem cases. 
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In HILIC, very polar analytes are retained more strongly and buffer 
concentrations and pH have less of an effect compared to changing the 
percentages of organic modifier and buffer. The true HILIC phase is established 
with between 70 to 98 % of organic modifiers and less than that may be out of 
HILIC separation zone. This zone was found to be enough for the polar 
compounds included in this study to be separated.  
As indicated earlier for the RPLC method for the determination of a wide range 
of opioids and their metabolites (chapter 5-9), not all glucuronide metabolites 
are eluted near to the void volume but some required high organic modifiers to 
be eluted from a conventional RP columns. For example, buprenorphine-3-
glucuronide eluted at high organic modifier concentrations and 
norbuprenorphine-3-glucuronide, codeine-6-glucuronide and dihydrocodeine-6-
glucuronide also eluted several minutes after morphine. Problems caused by 
matrix effects with encountered with early eluting metabolites such as M3G, 
DHM3G, M6G and DHM6G which required very low percentages of organic 
modifiers to be released. SPE followed by RPLC were capable of removing the 
matrix effects and achieved fine peak shapes in the previous Chapters using 
RPLC-MS/MS. In contrast, ETG and ETS are very polar compounds and clean 
methods of extraction for both metabolites simultaneously are not yet available 
as well as the use of negative mode for identification which is considered less 
sensitive than that of positive ion mode. Therefore, ZIC-HILIC provides more 
retention for these polar compounds as well as more organic modifiers 
percentage helps in enhancing ESI-MS response with very good shape peaks.  
The effects of matrix on the ionisation of ETG and ETS in LC-ESI-MS/MS after 
protein precipitation or dilution have been investigated with RPLC methods. In 
all of these studies, matrix effects were present which required post-column 
addition of organic modifiers using RPLC, which was found to minimise the 
effects of matrices to a range of - 10% and - 20% 494,520,521,523. This post-column 
addition device is not available in all laboratories. The alternative is to use HILIC 
phases which were found to minimise the matrix effects due to the use of high 
organic modifiers. However, in one previous study using SPE followed by HILIC-
MS/MS for analysis of ETG in hair, matrix effects were reported to be between 
20-50%. The authors attributed that to the hair colour and sample pre-treatment 
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procedure and the matrix effects were corrected by using deuterated internal 
standard 556. 
In the present study, matrix effects were investigated using three quality control 
standards across the calibration range along with five different human urine 
sources. There were no matrix effects observed which was in agreement with 
most work that has been conducted with ZIC-HILIC-ESI-MS/MS procedures.  
Although the LLOQs of the optimised method were very low, at 0.001 ìg/mL, 
analyte cut-offs were established at 1 and 0.1 ìg/mL for ETG and ETS, 
respectively, to avoid reporting a false positive result due to the possibility of 
consuming medicine and mouthwash containing alcohol. Politi et al 520 reported 
the presence of ETG and ETS in wine at concentrations of 0.15-3.97 and 0.21-
39.14 ìg/mL, respectively. ETG was detected at concentrations up to 3 ìg/mL 
after alcohol exposure resulting from mouth wash but these results were 
questioned due to the use of excessive mouth wash 559.  Other research has 
reported that after accidental alcohol exposure from mouth wash the level of 
ETG ranged from 0.015 to 0.18 ìg/mL 560. Also, detectable levels of ETG in urine 
samples were reported after low doses of alcohol (0.5 and 1 g), in the range 0.15 
-0.35 ìg/mL 561.  
Although there is no cut-off established yet for ETG and ETS, the use of 0.5 
ìg/mL as a cut-off has been suggested for forensic cases and 0.1 ìg/mL as a cut-
off for ETS was used in two studies 519,562.  In the United States of America, the 
cut-off for ETG in urine is in the range of 0.1-1 ìg/mL563. In the current study, 
cut-offs of 0.1 and 1 ìg/mL for ETS and ETG were used and found acceptable 
and positive cases detected in this study were higher than the ETS and ETG cut-
offs. 
Most LC-MS/MS instruments used for the quantification of both ETG and ETS 
were single or triple quadrupole mass analysers which provide a sensitive and 
selective method of determination. Until recently, there was only one report of 
an LC-ion trap-ESI-MS/MS used for the determination of ETG 539. This method was 
published during the current study. The separation of ETG was achieved at 3 
minutes by using Synegy Polar-RP (250 X 2 mm, 4 ìl) column, i.e. ETG was within 
the range of the void volume. The authors reported no matrix effect problems. 
However, no post-column device addition of organic phase was used. The post-
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column addition device has been used with the same size and type of column in 
order to enhance MS sensitivity. This method was capable of producing a linear 
calibration curve over a wide calibration curve range of 0.5-20 ìg/mL and was 
then applied to real case samples. All method parameters were within the 
acceptable limits of validation 539.  
In the current study, a Synergi Polar (150 X 2 mm, 4 ì) column was used at first 
but found not useful due to high matrix effects, which led to the use of ZIC-HILIC 
because no post-column device was available. The same ETG fragmentation was 
obtained as reported by Kaufmann  and Alt 539. ETG (M + 221.3) was broken down 
to many fragment ions at m/z 203,157,129, 113.4, 85 and 75. ETS (M + 125.4) 
was fragmented to only one product ion at m/z 97.3. Also, ETS-D5 (130.4) was 
fragmented to a single product ion at m/z 98.3. For greater specificity, the 
intensity ratios between two products ions at m/z 203 and 113.4, the major 
product ions for ETG, were calculated and used as quantifier ion. In the case of 
ETS, the major product ion and remaining precursor ion were used instead. Both 
ETG and ETS intensity ratios were constant with both calibration curve range and 
positive case samples which were both ± 20.    
The first report of the quantification of ETG in serum and urine was a GC-MS 
method which had an LOD and LLOQ of 0.1 and 0.3 ìg/mL, respectively. The use 
of LC-MS was found to decrease the LOD and LLOQ which, in most reported 
cases, were in the range 0.02 to 0.1 ìg/mL 452,512,514,518,519,526,534. Also, HPLC with 
electrochemical detection procedures was employed for the same purpose and 
reported a LOD in the range 0.01-0.03 ìg/mL and 0.08 as LLOQ 76,538. LC-MS/MS 
techniques were also applied for urine and blood analysis to determine ETG or 
ETS with an LOD and LLOQ in the range 0.025-0.1 and 0.1-0.3 ìg/mL, 
respectively 444,453,454,494,509,520,521,523,527,535-537,539,564.  
The ion trap mass analyser used in this work provided an accurate identification 
and clean MS/MS spectra. The combination of ZIC-HILIC-and ion trap mass 
analyser were sensitive and selective and provided a low LLOQ for ETG 300 fold 
less than a method reported with the same ion trap mass analyser 539. This shows 
the great advantage of using ZIC-HILIC despite the differences in the type of 
matrix used in our study and the Kaufmann and Alt study 539. This is a large 
improvement using HILIC phases taking into consideration that most LC-MS/MS 
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methods used triple quadrupole instruments, which are known to be more 
sensitive and selective than ion trap analyser. Precision, sensitivity, linearity and 
recovery of the optimised method were within the acceptable limits of method 
validation proposed by SOFT/AAFS guidelines.   
10.7.2 Stability  
Although ETG has been extensively studied and reported to be a reliable marker 
for alcohol recent consumption 449,450,452,509,512,526,533-537,539, there was increased 
concern about its stability and possibility of the risk of false negative results due 
to the degradation by bacteria. The use of UETG as evidence of ethanol intake 
alone has been not recommended by SAMHSA which could be due to false 
positive and negative results 451. Although the use of a chemical preservative was 
found to stop ETG hydrolysis 565, hydrolysis of ETG to ethanol may occur in 
retained urine in bladder 517. In this perspective, positive ETG results is 
considered as a marker of ante-mortem alcohol intake, but negative ETG should 
be interpreted with caution. 
It is known that glucuronide conjugates are broken down to their free form by â-
glucuronidase. This enzyme is present in Escherichia coli (E. Coli) which is the 
most common bacterium found in urinary tract infections. Although sulfate 
conjugates can be cleaved by â-sulfatase, this enzyme is not present in E.Coli 
which may explain the resistance of ETS against urinary tract infections and lead 
to the inclusion of ETS as complementary alcohol biomarkers 517.  
Few studies have investigated the stability of ETG in post-mortem material to 
answer the question of whether ETG is stable. Schloegl et al 533 studied the 
degradation of ETG in urine, liver, skeletal muscles and blood obtained at 
autopsy. ETG decreased by 27.7% after 4 weeks at room temperature and ETG 
was detectable in all samples with concentrations higher than 1 ìg/g. They also 
did not observe new formation of ETG in blood or liver specimens spiked with 0.1 
g % of ethanol with storage at room temperature 514.   
The disappearance of ETG during heavy putrefaction has been studied in blood 
samples under controlled conditions. Degradation of ETG was observed in non-
preserved blood samples stored at 30-40 oC; while no degradation or formation 
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of ETG were observed with preserved blood. They also reported the presence of 
ETG in urine while absent in blood 513. 
The stability of ETG and ETS has been compared and ETS was found to be more 
stable and not degraded by bacteria 516,517. ETG was reported to be degraded 
during putrefaction in the corpse but no formation or production of ETG post-
mortem has been reported 513,523,528. ETG and ETS were found stable after 
subjection to different storage conditions; after 24 hours in an autosampler tray 
at room temperature, four freeze/thaw cycles and up to 21 days at -20 oC 
494,521,524. 
ETS was found stable under degradadative conditions in all studies 516,517. In the 
current study, ETS was not detectable or was negative in some cases in which 
ethanol and ETG were present. Also, in one study, ETS was degraded by 84% 
after 6 days which should be taken into consideration when dealing with 
putrefied post-mortem cases 566. In addition, the metabolism of ethanol via 
sulfation may be affected by consuming food or alcohol beverages containing 
ETS which would lead to a false positive result of ETS 520,542.  
The stability of ETG and ETS were examined in the present work at different 
storage conditions. Both ethanol metabolites were stable which supported the 
previous reports mentioned above. The examined of the effect of urine tract 
infection on the stability was out of the scope of the present work.  
10.7.3 Case samples 
Since ethanol has a relatively short half-life 567, 50 % of alcoholics had negative 
BAC in one study 480: alternative ethanol biomarkers are needed. Other alcohol 
markers have been used to detect alcoholics but found not to be useful in some 
circumstances. They required long periods of alcohol abuse with large doses, 
were influenced by diseases and not sensitive for single alcohol intake 525.   
The combination of ingesting ethanol and other central nervous acting drugs can 
increase the risk of intoxication and death even with low drug concentrations. 
The BAC is important in assessing the role of ethanol in causing death where 
ethanol may increase toxicity as an additive factor, or be involved in cause of 
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death, or, at concentrations higher than 300 mg/100 mL, could be the cause of 
death150,151,264.  
As indicated earlier, the source of ethanol detected in blood after death can be 
interpreted in three different ways: short elapsed time between alcohol intake 
and death, ethanol is formed post-mortem, or a combination of both 
circumstances 456. The phenomenon of alcohol post-mortem production results 
makes the interpretation of BAC more complicated especially when there is any 
sign of body putrefaction. In order to distinguish between ante-mortem and 
post-mortem alcohol, procedures such as testing UAC and vitreous humour 
alcohol concentration (VAC) were proposed 439. The C3 alcohol n-propanol for 
example has been used as a marker of post-mortem alcohol synthesis.  However, 
ethanol can also be formed subsequent to severe damage of the body, which 
provides suitable conditions for microorganism to form ethanol even in a living 
body 161. 
Although many alcohol biomarkers have been used, ETG and ETS have received a 
great deal of interest due to their longer half-lives compared to ethanol, and 
due to their high sensitivity and selectivity. These alcohol biomarkers have also 
been found useful to confirm abstinence in alcohol treatment programs. Ethyl 
glucuronide (ETG) and ethyl sulfate  (ETS) are direct non-oxidative ethanol 
metabolites and have been shown to be useful markers of alcohol consumption 
for several hours after death or when ethanol itself has been completely 
eliminated from the body. The presence of ETG and ETS in blood and urine give 
strong evidence of recent alcohol ingestion 452.  
The correlation of BAC or UAC with both ETG and ETS was often poor, which 
makes the prediction of BAC from ETG or ETS impossible. Also, the rapid 
clearance of alcohol with differences in distribution and elimination, 
pharmacokinetic variation and activity of enzyme is responsible for the 
metabolism of both ethanol metabolites. A positive correlation between UETG 
and both BAC and UAC were reported with r 2 values of 0.549 and 0.617 76. Also, 
r 2 of 0.579 was reported between UAC and normalised UETG in other work 535. 
Bicker et al 494 tested 50 post-mortem urine cases and found poor correlation 
between both ethanol biomarkers and BAC or UAC. In the present study, 
although positive correlations were obtained with group C between UAC and 
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both alcohol biomarkers, BAC was poorly correlated in all groups which was in 
agreement with the work of Bicker et al work 494. 
In the current study, urine samples were divided into three groups depending on 
BAC in order to determine if there was any correlation between BAC and ETG 
and ETS levels in the urine samples. There was overlap between UETG and UETS 
levels in all three BAC groups using the median concentration. Higher UETG were 
observed with low BAC as well as median and high BAC groups which can be 
explained by a longer half-life in blood and urine than ethanol itself and also 
may depend on the number of drinking periods, which are difficult to detect.  
Few studies have reported the concentrations of both UETG and UETS in post-
mortem cases; most published cases were for living subjects and mostly after 
controlled administration of alcohol. Eighty six clinical urine samples tested 
positive for UETG and UETS, the mean (median) concentrations were 77 (7.52) 
ìg/mL, and in the range of 0.13 -997 ìg/mL for UETG; and were 18.5 (2.86) 
ìg/mL and ranged from 0.05-264 ìg/mL for UETS. In that study, 3 and 4 urine 
samples tested positive for only UETS and UETG, respectively 518.  
Bicker et al 494 tested 50 post-mortem urine samples and found 48 cases positive 
for UETG using 0.1 ìg/mL as the cut-off. The median UETG detected in this 
study was 98.4 ìg/mL, ranging from 0.1-1348 ìg/mL; they also reported a 
median concentration of 27.8, ranging from 0.1-220 ìg/mL for UETS. A method 
using an electrochemical detector was applied for routine post-mortem analysis 
of 29 cases: BAC was higher than 70 mg/100 mL, and all cases tested positive for 
UETG with concentrations in the range of 47-1371 ìg/mL 76.  
In the current study, UETG and UETS were in the same range as the Bicker et al 
494 study with overall median of 114 and 23 ìg/mL and similar ranges, 
respectively. The ratios between UETG/UETS were reported previously. Bicker et 
al 494 reported a median of 2 and 1.7 was reported by Helander and Beck 518.  In 
recent work, Helander et al 519 reported mean UETG/UETS ratios of 2.5. In the 
present study, the median was 4.8 which was higher than that reported before 
(Figure 10-7). This could be interpreted by differences in analysis protocol or 
differences in population size. Also, the HILIC phase could be more sensitive for 
ETG than ETS.  
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10.8 Conclusions  
A sensitive and selective method for direct determination of ETG and ETS in 
post-mortem urine samples was developed and validated. In the current study, 
ethanol was attributed to post-mortem synthesis in 9 out of 90 cases. It can be 
concluded that the risk of false positive ethanol results increased in the low 
ethanol concentration group as several cases tested negative for both 
biomarkers in group C. ETG was detected at low concentrations in some cases 
for which ETS tested negative, suggesting that ETG may have a longer half-life in 
urine or else ETS is unstable. False positive results for ethanol can be obtained 
at any BAC which makes interpretation of the presence of alcohol more difficult, 
especially with putrefied cases. In the present study, two putrefied cases tested 
positive for BAC and UAC but no ETG and ETS were detected in the urine 
samples. Although ETS is stable after being subjected to many stability 
conditions, the use of ETS as sole evidence of alcohol ingestion may lead to a 
false negative result as noticed in groups A and C in the present study. The use 
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Figure 10-9: Comparison of the ratios of UETG/UETS between BAC 
groups. 
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of ETG is more a reliable ethanol biomarker. Both ethanol biomarkers should be 
determined in heavily putrefied cases and when the ethanol concentration in 
post-mortem blood is low, in agreement with previous studies.  To the authors 
knowledge, this is the first report of the determination of ETS using an LC-ESI-
ion trap-MS/MS method, and of a HILIC-ESI-ion trap-MS/MS method for the 
simultaneous determination of ETG and ETS in post-mortem urine samples.  
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11 General Conclusions  
The focus of the current work was to investigate the use of LC-MS/MS for 
different applications relating to forensic and clinical toxicology. Chapter 5 
focused on an analytical method for multiple target analytes and the use of this 
method for the interpretation of the cause of death, survival time after last 
injection and identification of the source of opioid intake. In Chapter 6, a 
method for analysing trace levels of diamorphine metabolites in paediatric 
plasma following diamorphine administration was validated in order to study the 
pharmacokinetics of diamorphine following intravenous and intranasal 
administration. Chapter 7 studied the efficiency of the hydrolysis method of 
analysis and direct determination of opioids. Chapter 8 investigated case studies 
regarding current problems with oxycodone fatalities in the West of Scotland. 
Chapter 9 addressed identification criteria for opioids and their metabolites 
using a current LC-ion trap-ESI-MS/MS instrument. Finally in Chapter 10, the new 
trend of biomarker analysis was interpreted in this project with ethanol 
biomarkers and a procedure for polar glucuronide and sulfate  metabolites of 
ethanol was validated and successfully used for separation of analytes using a 
HILIC phase. 
Opioids are widely abused drugs due to their euphoria-producing properties and 
it is estimated that about 0.3% of the worlds population misuse heroin each 
year. However, the use of opioids for pain management also continues to 
increase and deaths related to opioid abuse and medications are encountered 
regularly. The identification of illicit or licit opioid use depends on analytical 
toxicology findings which, until recently, involved tedious procedures for 
hydrolysis, extraction and derivatisation, and samples might need to be analysed 
several times to achieve these requirements. The arrival of LC-MS techniques in 
analytical toxicology has allowed these expensive, time-consuming procedures to 
be replaced by methods involving a single extraction and chromatographic 
analysis.  
In Chapter 5, the aims were to develop a validated method for determining 
commonly encountered opioids and metabolites in unhydrolysed post-mortem 
specimens and apply it to interpreting the cause of death and source of the 
opioids detected. The stability was investigated in human whole blood of some 
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analytes which have not previously been studied, such as NAL3G, DHC6G, 
DHM3G, and DHM6G. In general, opioids and their metabolites were stable for 
the whole period of this stability study (Table 5-7). However, the concentration 
of 6-AC sharply decreased by 56% after 24 hours at 4 °C and by more than 77% 
after 48 hours. 6-MAM was stable up to 24 hours at 4 °C but decreased by 15% 
after 48 hours and continued decreasing over time by more than 30 % within the 
week of the stability study. MOR and COD concentrations increased after storage 
for 24 hours at 4 oC by 8 and 9% respectively and increased by 45% and 48%, 
respectively, after one month of storage as a result of the hydrolysis of 6-MAM 
and 6-AC to MOR and COD respectively. Increases in MOR and codeine 
concentrations after 24 hours at room temperature were similar to those 
observed after one month at 4 oC. 
Deaths attributed to heroin use were classified into three types using the 
concentration of free morphine and its glucuronides (in blood: immediate death, 
sub-acute death (death in less than 3h), and delayed death (death after 3h). The 
poly-drug intoxication phenomenon, especially with ethanol, has been discussed 
in detail in this chapter as well as the presence of other central acting drugs and 
their role in heroin and other opioid related fatalities. The method was found 
useful for differentiating between users of heroin and other opioids, such as 
codeine and morphine, and for determining the survival time in deaths 
attributed to heroin use.  
In addition to the value of using LC-MS techniques in forensic toxicology, Chapter 
6 describes an application for clinical toxicology that has been developed for the 
analysis of diamorphine in paediatric samples; In recent years, intra-nasal 
diamorphine (DIM) has been recommended as an alternative to intravenous 
administration in children for the treatment of acute, severe pain because it is a 
less traumatic means of administering rapid, powerful analgesia to children in 
whom obtaining intravenous access may be technically difficult and distressing. 
This work was aimed at obtaining pharmacokinetic data for DIM and its 
metabolites in children following intravenous (IVDIM) and intranasal (INDIM) 
administration in a blind study. Since DIM is known to act as a pro-drug and to 
achieve analgesia via its metabolites, it was intended that the concentrations of 
active DIM metabolites would be used to evaluate whether or not INDIM can 
deliver rapid and efficient analgesia in children comparable to that obtained 
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with IVDIM. The need for a sensitive technique for the detection and 
quantitation of heroin and its metabolites is essential due to low concentrations 
of heroin and metabolites in childrens plasma, as a result of the low dose of 
heroin given, and the limited sample volume obtained from children (0.25 mL or 
less). In addition, diamorphine can be easily hydrolysed to 6-
monoacetylmorphine (6-MAM) during sample preparation and extraction, so this 
must be considered when developing a solid-phase extraction (SPE) method to 
prevent the hydrolysis of heroin. 
The pharmacokinetics of DIM and its metabolites following IN and IV 
administration in children have been compared for the first time in this study, 
which confirmed that INDIM can achieve therapeutic plasma concentrations of 
active metabolites, although these are lower than those obtained with IVDIM and 
occur at later times after administration. 
In Chapter 7, the efficiency of a hydrolysis method used for opioid analysis has 
been examined by comparison with direct analysis without the hydrolysis step, in 
the case of buprenorphine analysis for the first time using 21 real case samples.  
Results from the two methods correlated well, although the direct method gave 
slightly higher concentrations for BUP metabolites compared to the hydrolysis 
method.  However, it was confirmed that the in-house hydrolysis procedure was 
effective in cleaving glucuronide conjugates at the range of concentrations 
encountered in cases in this study, which indicate buprenorphine abuse. Also, 
the hydrolysis rates of BUP3G and NBUP3G are different and it is important that 
hydrolysis methods are optimised using both glucuronide metabolites. The two 
methods used in this study gave the same ratios for TNBUP/TBUP. The ratios 
between conjugated metabolites and their free forms are of interest and can be 
helpful in the examination of enzymatic hydrolysis methods. In addition, ratios 
may be of value in interpretation of cases but additional work is required 
involving controlled administration studies to allow this to be evaluated.   
The focus of Chapter 8 was to report fatalities involving oxycodone in the West 
of Scotland using an LC-ESI-MS/MS method developed for the determination of 
oxycodone and N- and O-demethylated metabolites, noroxycodone and 
oxymorphone, in unhydrolysed post-mortem specimens. 
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Ten oxycodone positive post-mortem cases were detected during the period July 
2007-December 2008 in which nine deaths were drug related fatalities. Five of 
these were attributed solely to oxycodone intoxication and four cases to mixed 
drug intoxication. High levels of oxycodone in combination with low levels of 
noroxycodone and oxymorphone were identified in one case of suicide involving 
the deliberate ingestion of multiple tablets of OxyContin. In four cases a 
number of undigested oxycodone tablets were identified in the stomach 
contents. Although there was overlap between blood oxycodone concentrations 
in deaths attributed to oxycodone only and poly-drug intoxication, the latter 
were associated with oxycodone concentrations less than 1 mg/L, while most 
cases in which oxycodone was the cause of death often had blood concentrations 
higher than 1 mg/L. 
The role of parent drug in oxycodone fatalities has been fully studied but the 
role of the metabolites noroxycodone and oxymorphone in oxycodone fatalities 
was investigated in this report for the first time. Oxycodone was most commonly 
present in blood, urine and vitreous humour followed by noroxycodone. In some 
cases oxymorphone was not detected in blood but was found in urine. The ratio 
between parent drug and its N-demethylated metabolite is a useful tool for 
determining whether death occurred shortly after drug overdose ingestion or if it 
was delayed. It was found that the higher the ratio the shorter the elapsed time 
after ingestion before death occurred.  
The current study (Chapter 8) is the first to report blood and urine noroxycodone 
and oxymorphone concentrations after acute oxycodone overdoses. It is also the 
first to report the vitreous humour level of noroxycodone following oxycodone 
intoxication in two cases. In addition, it is the first reported LC-MS/MS 
application to oxycodone related fatality cases in forensic toxicology. Also, 
stability of noroxycodone in blood and urine matrices and vitreous humour levels 
of noroxycodone following oxycodone intoxication was reported for the first time 
in this work. Oxycodone prescriptions have risen sharply in Scotland in recent 
years and the identification of ten oxycodone-related deaths in the past 18 
months highlights the importance of including this drug in routine laboratory 
screening and confirmation procedures. 
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In Chapter 9, a complementary method using urine samples was developed and 
applied for routine opioid analysis together with blood samples. The results 
obtained by the optimised LC-MS/MS method in blood samples were compared 
with standard operation procedure routinely used for analysis of opioids; good 
correlation coefficients were observed between the concentrations obtained 
using the two methods for the free drug analytes methadone, MOR, COD and 
DHC. The use of two different chemical principle techniques is the method of 
choice for identification of drug in forensic toxicology. In addition, the 
identification criteria proposed by EU guidelines, FDA and SOFT/AAFS were also 
discussed in Chapter 9. A problem encountered with current LC-MS/MS 
instruments in providing sufficient identification points was discussed. It was 
discovered that two SRM transitions can be obtained for in most opioids with the 
exception of some polar metabolites, especially glucuronide metabolites which 
only fragment to one product ion. Therefore, the adjustment of collision energy 
voltages was used to obtain two SRM transitions which were found reliable and 
reproducible using both standard and case samples.  
The interpretation of alcohol results in post-mortem specimens can be difficult 
due to the possibility of post-mortem production of alcohol, which may take 
place in the body or in the autopsy samples. Ethyl glucuronide (ETG) and ethyl 
sulfate  (ETS) are primary ethanol metabolites and have been shown to be useful 
markers of alcohol consumption for several hours after death or when ethanol 
itself has been completely eliminated from the body. ETG and ETS are very polar 
metabolites requiring very low percentages of organic modifiers (less than 5%) 
for elution from a conventional reversed phase column, which results in poor 
retention, large matrix effects and low sensitivity in LC-MS. Post-column 
addition of organic solvent can enhance ESI-MS/MS response while preserving 
good chromatographic peak shapes. Recently, hydrophilic interaction 
chromatography (HILIC) has been introduced as an alternative to reverse phase 
LC separation of polar compounds. HILIC is suitable for ESI-MS as a high 
percentage of organic modifiers can be used, up to 95%, without reducing 
analyte retention. 
In Chapter 10, a novel method using an ion trap mass analyser in combination 
with a hydrophilic interaction liquid chromatography column has been validated 
and applied for routine urine analysis for the first time. The second aim was to 
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employ the optimised method for the separation of these polar metabolites for 
analysis of urine samples obtained at autopsy. In the current study, urine 
samples were divided into three groups depending on BAC in order to determine 
if there was any correlation between BAC and ETG and ETS levels in the urine 
samples. 
The method has been used for analysis of ETG and ETS in routine case samples 
and has been shown to be a useful tool to indicate recent ethanol consumption. 
It was found that a false positive BAC is more likely to be encountered when the 
BAC is low. The use of ETG as ethanol biomarker is more reliable than applying 
the method using ETS as sole evidence of alcohol ante-mortem consumption 
which may lead to false negative results. This was because ETG was found 
positive in cases negative for ETS but there were no positive ETS cases found 
negative for ETG. However, it is highly recommended to use both ethanol 
biomarkers in heavily putrefied cases and when the ethanol level in post-mortem 
blood is low. To the authors knowledge, this is the first report of the 
determination of ETS using an LC-ESI-ion trap-MS/MS method, and of a HILIC-ESI-
ion trap-MS/MS method for the simultaneous determination of ETG and ETS in 
post-mortem urine samples 
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12 Future Work 
LC-MS/MS has become the cornerstone in forensic and clinical toxicology 
investigations; this technique has moved from development stages to practical 
routine work 16. In the current project, initial work was established using this 
technique for many applications to help toxicologists make decisions for 
identification and quantification of opioids and ethanol accurately. 
However, the matrix effects phenomenon is still under investigation and still the 
major drawback in modern analytical methods using LC-MS/MS; a proper matrix 
effects investigation is necessary. A new trend in using fast extraction 
procedures or new materials for extraction and analyte separation has recently 
appeared. It is dependent upon the intended purpose of the method; liquid-
liquid extraction is still in use due to enhanced sensitivity of LC-MS/MS 
instrumentation available. A direct injection procedure with simple sample pre-
treatment is employed with clean matrices such as oral fluid and urine which 
need to be diluted in order to reduce the effects of matrices. 
Solid phase extraction is the method of choice with new SPE materials appearing 
such as molecular imprinted SPE which is an inexpensive and can be used up to 
100 times. However, it is limited to groups of drugs compared to that of 
conventional SPE cartridges such as mixed mode SPE.  In addition, HILIC 
materials could be used in future for extraction of very polar metabolites. 
The application of high organic modifier content in mobile phases is favoured for 
enhancing the response of ESI-MS/MS analysis. Few applications using HILIC 
phase for the separation of polar metabolites in forensic toxicology have been 
reported. Although these methods are efficient for very polar metabolite 
separation, it is still unsuitable for the simultaneous analysis of a wide range of 
drug and metabolite analysis. In addition, a recent shortage of acetonitrile  has 
created urgency in finding an alternative solvent that can replace acetonitrile in 
both RPLC and HILIC phases without affecting method sensitivity and selectivity.  
Highly accurate mass analyser instrumentation is now available and direct 
methods for drug and metabolite analysis should replace traditional hydrolysis 
method. Future work should entail simplifying the extraction method to be low 
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cost, fast and able to obtain as much information that could help on 
interpretation to avoid misinterpretation. An increase in the number of analytes 
included in each run is necessary to avoid overlooked analytes and false or 
positive results due to interference of isobaric fragment ions between analytes 
of interest.  
At the time of the study reported in Chapter 9, few cases had been measured for 
both morphine and codeine as total and free drug. However, the laboratory 
method for general opioids screening was not optimised for analysis of total and 
free morphine, which reduces the value of comparing total morphine with heroin 
or codeine cases. In the routine method for analysis of heroin cases, an 
enzymatic hydrolytic method is used. As mentioned in the thesis with respect to 
buprenorphine, the laboratory enzymatic hydrolysis method may produce 
inaccurate results due to incomplete hydrolysis. For example, Wang et al. 
reported that enzymatic methods of hydrolysis are not accurate for the cleavage 
of morphine-6-glucuronide and codeine-6-glucuronide to their free form. They 
reported a negative result for morphine tested positive by immunoassay (400 
ng/mL) and GC-MS method using acidic hydrolysis (271 ng/mL).  Optimisation of 
the hydrolysis method was considered, but due to the limited time available, 
this work will need to be continued in future.  
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Method for Quantification of Opioids and their Metabolites in 
Autopsy Blood by Liquid Chromatography-Tandem Mass 
Spectrometry. 
 
Ahmed I. Al-Asmari and Robert A. Anderson; Forensic Medicine and Science 
Department, University of Glasgow,University Place, G12 8QQ, Scotland 
 
Abstract  
A method using LC/ESI/MS/MS was developed and validated for the 
determination of morphine, codeine, hydromorphine, dihydrocodeine, 
oxycodone, buprenorphine, and naloxone with their metabolites morphine-3-
glucuronide, morphine-6-glucuronide, normorphine, 6-acetylmorphine, 6-
acetylcodeine, codeine-6-glucuronide, norcodeine, hydromorphine-3- 
glucuronide, dihydrocodeine-6-glucuronide, norbuprenorphine, buprenorphine-3-
glucuronide, norbuprenorphine-3-glucuronide, and naloxone-3-glucuronide in 
human whole blood. Polar metabolites (glucuronides) and other analytes were 
extracted by SPE using Bond Elut. Chromatographic separation was performed on 
a Synergi reverse phase column with gradient elution based on a mobile phase 
consisting of 10 mM ammonium formate adjusted to pH 3 (A) and acetonitrile (B) 
at flow rate 0.3 mL/min in the first 13 min, following by 0.2 mL/min for the next 
13 min, after that the initial flow rate was applied until the end of analysis. The 
gradient conditions were: initially, 97% of solution A for 3 min, decreasing to 
84.5% at 8 min, to 74% at 13 min and to 20% at 26 min. 5% of solution A was 
maintained for the next 3 min before returning to 97% for 7 min prior to the next 
injection. Intra-day and inter-day precision for all analytes were between 0.6 to 
13.8% and recoveries were between 82% and 101.4%. Calibration curves were 
linear for all analytes over the concentration range 5-400 ng/mL and correlation 
coefficients (R2) were better than 0.999. Limits of detection and limits of 
quantitation were 0.16 - 1.2 ng/mL and 0.5 - 4.09 ng/mL, respectively. The 
method described consolidates previous work on opioids and their metabolite 
published in the literature and is the first to include the detection of naloxone-
3-glucuronide. The method has been applied in routine post-mortem cases after 
opiate overdose with three. 
 
Ai ms: it has been used to interpret the cause of death, to determine type of 
death (rapid or immediate death, sub-acute death, or delayed death) and to 
distinguish between heroin, morphine and codeine users. 
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A Method for the Quantification of Heroin and its Metabolites in 
Plasma by Liquid Chromatography-Tandem Mass Spectrometry 
 
Ahmed I. Al-Asmari* and Robert A. Anderson 
Department of Forensic Medicine& Science, University of Glasgow, UK  
 
AIMS: In recent years, intra-nasal heroin has been recommended as an 
alternative to intravenous administration for the treatment of acute severe pain 
in children. This provides a rapid and less painful route of administration without 
decreasing the effectiveness of the analgesic properties. The need for a 
sensitive technique for the detection and quantitation of heroin and its 
metabolites is essential due to low concentrations of heroin and metabolites in 
childrens plasma, as a result of the low dose of heroin given, and the limited 
sample volume obtained from children (0.25 mL or less). In addition, Heroin can 
be easily hydrolysed to 6-monoacetylmorphine (6-MAM) during sample 
preparation and extraction, so this must be considered when developing a solid-
phase extraction (SPE) method to prevent the hydrolysis of heroin.  
METHODS: 250 ìl of plasma was added to 300 ìl of 0.01 M ammonium 
carbonate, pH 9.3 and 25 ìl of the internal standard working solution (1 
ìg/ml) was added. The mixture was vortex mixed. The supernatant was applied 
to a Bond Elut C18 SPE cartridge preconditioned with 2 ml methanol, 1 ml of 
deionised water, and 2 ml of 0.01 M ammonium carbonate (pH 9.3).  The SPE 
cartridge was washed twice with 1 ml 0.01 M ammonium carbonate (pH 9.3), and 
then dried for 10 minutes.  Retained drugs were eluted with 2 ml methanol, 
after which the eluate was evaporated to dryness under nitrogen at 50 oC. The 
extract was reconstituted with 80 ìl of initial mobile phase and the 20 ìl were 
injected into using a Thermo Finnigan LCQ DECA XP Plus ion trap instrument 
(Thermo Finnigan, San Jose, USA) equipped with a surveyor LC system interface. 
Chromatographic separation was achieved using a Synergy Polar RP column (150 
x 2.0 mm, 4-ìm particle size), protected by a guard column with identical 
packing material (4 x 2.0 mm, Phenomenex, Torrance, CA).  Gradient elution 
was based on a mobile phase consisting of 10 mM ammonium formate adjusted 
to pH 3 (A) and acetonitrile (B) at a flow rate of 0.3 ml/min in the first 8 min, 
decreasing to 0.2 ml/min at 13 min for the next 13 min.  After that, the initial 
flow rate was applied until the end of analysis.  The gradient conditions were 
initially 97% of solution A for 3 min; decreasing to 84.5% at 8 min, to 74% at 13 
min and to 20% at 26 min, 5% of solution A was maintained for the next 3 min 
before returning to 97% for 7 min prior to the next injection. 
RESULTS: Intra-day and inter-day precision for all analytes were determined at 
three concentration 1, 5, and 25ng/ml and these were found to be 2.5-13.4% and 
1.8-15% respectively. Recoveries of analytes of interest were between 81% and 
109%. Calibration curves were linear for all analytes over the concentration 
range 0.1-50 ng/mL and correlation coefficients (R2) were better than 0.999. 
Limits of detection and limits of quantitation were 0.08-0.37 ng/mL and 0.28-
1.22 ng/mL respectively.  CONCLUSIONS: A sensitive and specific method for the 
quantitation of heroin metabolites, namely heroin, 6-MAM, morphine, morphine-
3-glucuronide, morphine-6-glucuronide and normorphine in human plasma was 
developed and validated. This method was developed for testing plasma samples 
obtained from children who are under treatment for acute severe pain and data 
of samples tested will be presented in the future.  
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Comparison between of a nonhydrolysis method and hydrolysis 
method for the detection of Buprenorphine metabolites in urine by 
LC-MS-MS. 
 
Ahmed I. Al-Asmari* , Robert A. Anderson; Department of Forensic Medicine& 
Science, University of Glasgow,  Glasgow, UK. 
 
Abstract 
 
BACKGRAOUND: Buprenorphine (BUP) is a semisynthetic opioid obtained from 
thebaine after a seven step  chemical procedure. BUP has been used for the 
treatment of moderate to severe pain for more than 20 years  for case in 
surgical and neoplastic origin 266, and in the treatment of opiate dependence, 
BUP has become an abused drug. Therefore, method for quantification BUP 
metabolites in urine was required due to the fact that most cases submitted for 
BUP analysis were urine samples.  Although enzymatic hydrolysis method for 
quantification of total BUP and its main metabolites norbupenorphine (NBUP) 
were widely employed, hydrolysis method were found to be consuming time and  
inaccurate due to many limitation, including incomplete hydrolysis, introduction 
of interferences in the analysis. AIMS: the aims of this work was to develop and 
validate a method for the direct determination (DM) of buprenorphine (BUP), 
norbuprenorphine (NBUB), buprenorphine-3-glucuronide (B3G), 
norbuprenorphine-3-glucuronide (NBUP3G). This method was compared with in 
house enzymatic hydrolysis method (HM) using â-glucuronidase from  Helixa 
which used routinely by Forensic Medicine and Science department, University of 
Glasgow for the determination of  total buprenorphine (TBUP) and 
norbuprenorphine (TNBUP) using real positive BUP urine case sample. METHODS: 
Analytes of interest were extracted by Bond Elute C18 for DM, following by 
LC/MS/MS analysis using a Synergy Polar RP column (150 x 2.0 mm, 4 ìm particle 
size). Gradient elution was based on a mobile phase consisting of 10 mM 
ammonium formate adjusted to pH 3 (A) and acetonitrile (B). RESULTS :  Over 
one year of this study, all positive BUP cases  were tested using HM and DM at 
the same time.17 cases were tested positive using DM and 14 case by  using HM. 
The ratios of TNBUP/TBUP were calculated for both method and the ratios of 
free drugs over its glucuronides were also calculated using DM. CONCLUSIONS: 
The DM was more sensitive and all BUP metabolites were detected in most cases 
with comparing to HM. The comparison between the direct detection of 
buprenorphine metabolites including BUP, NBUP and their glucuronides obtaine 
by DM with TBUP and TNBUP using HM was reported for the first time in this 
work.  
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Determination of 27 Opioids and Their Metabolites in Urine by LC-
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AIM: The aims were to develop a validated method for the determination of 27 
commonly encountered opioids and metabolites in unhydrolysed post-mortem 
urine. and apply it to matched autopsy urine and blood samples, to assess the 
value of using both matrices in interpreting the cause of death and source of the 
opioids detected. METHODS: Following addition of 14 deuterated internal 
standards, analytes were extracted by SPE with Bond Elut C18 cartridges, 
followed by LC-MS-MS analysis using a Thermo-Finnigan LCQ Deca Plus 
instrument in the ESI SRM mode, fitted with a Synergy Polar RP column (150 x 
2.0 mm, 4 ìm). Gradient elution used a mobile phase with (A) 10 mM ammonium 
formate, pH 3 and (B) acetonitrile, at a flow rate 0.3 ml/min. Analytes were 
identified on the basis of their retention times and the relative intensities of 
their pseudo-molecular ions and two product ions.RESULTS: Method validation: 
acceptance criteria for linearity, precision, and recovery were achieved for all 
27 analytes. Intra-day and inter-day precision were between 1-15 %.  Calibration 
curves were linear for all analytes over the concentration range 5-250 ng/mL and 
correlation coefficients (R2) were better than 0.999.  LOD and LLOQ were 0.2- 
0.5 ng/mL and 0.5  1.6 ng/mL, respectively. Recoveries were 71-111%.  No 
interference was detected with other common drugs.  Matrix effects: matrix 
effects on analyte ionisation were investigated using five different human urine 
sources at two concentrations (5 and 100 ng/ml). Analyte responses were within 
±20% of values obtained with unextracted standards. Stability: analytes were 
stable under different storage conditions, apart from 6-acetylmorphine (6-MAM) 
and 6-acetylcodeine (6-AC) at room temperature or at 4 °C. The rates of 
hydrolysis of 6-MAM and 6-AC in urine were low compared to blood samples. The 
stabilities of naloxone-3-glucuronide, dihydrocodeine-6-glucuronide, 
dihydromorphine-3-glucuronide and dihydmorphine-6-glucuronide in urine 
samples are reported for the first time.  Case Samples: Matched blood and urine 
samples from 47 post-mortem cases and urine samples from 13 living subjects 
were analysed using the validated method for urine and our previously published 
method for autopsy blood. Total morphine to total codeine ratios were 
calculated to determine which opioid had been used. Also, survival time after 
last injection was investigated by calculating ratios between free drugs and 
metabolites, as described in our previous publication [Al-asmari and Anderson 
(2007). J Anal Toxicol 31, 394-408]. The role of opioids in combination with 
other drugs, including alcohol, cocaine and benzodiazepines, in opioid-related 
deaths is discussed. CONCLUSIONS: A sensitive and selective method was 
developed for the simultaneous determination of 27 opioids and metabolites in 
urine. The method could differentiate between users of heroin and other 
opioids, such as codeine and morphine. Furthermore, urine was the sample of 
choice for detection of buprenorphine and norbuprenorphine and their 
glucuronides.  
 
 
369 
Pharmacokinetics of Diamorphine in children following intravenous 
and intranasal administration  
A.I. AL-ASMARI, R.A. ANDERSON 1 and Susan Kidd2 
1Forensic Medicine & Science Section, University of Glasgow,  
2 A&E, Royal Hospital for Sick Children, Sciennes Road, Edinburgh 
In recent years, intra-nasal heroin has been recommended as an alternative to 
intravenous administration in children for the treatment of acute, severe pain 
because it is a less traumatic means of administering rapid, powerful analgesia 
to children in whom obtaining intravenous access may be technically difficult 
and distressing. Aims:  This work was aimed at obtaining pharmacokinetic data 
for DIM and its metabolites in children following intravenous (IV-DIM) and 
intranasal (IN-DIM) administration in a blind study. Since DIM is known to act as a 
pro-drug and to achieve analgesia via its metabolites, it was intended that the 
concentrations of active DIM metabolites would be used to evaluate whether or 
not IN-DIM can deliver rapid and efficient analgesia in children comparable to 
that obtained with IV-DIM. METHODS: Plasma samples were obtained from 
twenty three children receiving DIM at the A & E department of a city-centre 
paediatric teaching hospital in Edinburgh. 13 children received IV-DIM (dose 
0.1mg/kg) and 10 subsequent children had IN-DIM at the same dose in 0.2 ml 
normal saline dripped into both nostrils. The children were aged 3-13 years, with 
clinical diagnosis of isolated deforming limb fractures. Sequential blood samples 
were taken at 2, 5, 10, 20, 30 and 60 minutes post DIM administration. The blood 
tube was then centrifuged at 4000 rpm for 2 minutes and plasma was transferred 
to plain Ependorph tubes that were immediately placed in a -70oC freezer until 
analysed. Plasma samples were subsequently analysed for DIM, 6-monoacetyl 
morphine (6-MAM), morphine (MOR), morphine-3-glucuronide (M3G), morphine-6-
glucuronide (M6G) and normorphine (NMOR) using a method involving solid phase 
extraction and liquid chromatography-tandem mass spectrometry (LC-MS-MS) 
that was validated for this purpose. RESULTS: Concentrations of analytes were 
found to depend on the route of administration. The concentration of DIM 
metabolites using IN-DIM were lower than IV-DIM at the same dose and body 
weight, DIM concentrations were range of 190 to 2062 ng/ml and 2 to 43 ng/ml 
for IV-DIM and IN-DIM, respectively. The median peak concentrations of analytes 
of interest after IV-DIM were achieved at 2 min for DIM, 6-MAM and MOR, and at 
20 and 60 min for M3G and M6G respectively. After IN-DIM, median peak 
concentrations were achieved for DIM at 2 min. However, DIM metabolites 
achieved different median peak concentrations after IN-DIM, it was achieved at 
5 and again at 10 for 6-MAM, for MOR at 20 min and for both morphine 
glucuronides at 60 min. Ratios of concentrations (IV-DIM/IN-DIM) were calculated 
using the median peak concentrations and were 34, 26.4, 6.2, 3.8 and 2.9 for 
DIM, 6-MAM, MOR, M3G and M6G respectively. Following IV-DIM, the 
concentrations of DIM, 6-MAM and MOR decreased sharply after 2 min whereas 
the rate of decrease was slower after IN-DIM. Pharmacokinetic parameters i.e. 
Cmax, Tmax, t½ and the area under the plasma curve were calculated for the two 
patient groups.  These were compared with each other and with previous work in 
adult patients. CONCLUSIONS: The pharmacokinetics of DIM and its metabolites 
following IN and IV administration in children have been compared for the first 
time in this study, which confirmed that IN-DIM can achieve therapeutic plasma 
concentrations of active metabolites, although these are lower than those 
obtained with IV-DIM and occur at later times after administration. 
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Direct Determination of Ethyl Glucuronide and Ethyl Sulphate in 
Post-mortem Specimens using Hydrophilic Interaction Liquid 
ChromatographyESI-MS. 
A.I. Al-asmari*, R.A. Anderson. Forensic Medicine and Science, Division of Cancer 
Sciences and Molecular Pathology, Faculty of Medicine, University of Glasgow, 
Glasgow G12 8QQ, United Kingdom. 
 
Background: The interpretation of alcohol results in post-mortem specimens can 
be difficult due to the possibility of post-mortem production of alcohol, which 
may take place in the body or in the autopsy samples. Ethyl glucuronide (ETG) 
and ethyl sulphate (ETS) are primary ethanol metabolites and have been shown 
to be useful markers of alcohol consumption for several hours after death or 
when ethanol itself has been completely eliminated from the body. ETG and ETS 
are very polar metabolites requiring very low percentages of organic modifiers 
(less than 5%) for elution from a conventional reversed phase column, which 
results in poor retention, large matrix effects and low sensitivity in LC-MS. Post-
column addition of organic solvent can enhance ESI-MS-MS response while 
preserving good chromatographic peak shapes. Recently, hydrophilic interaction 
chromatography (HILIC) has been introduced as an alternative to reverse phase 
LC separation of polar compounds. HILIC is suitable for ESI-MS as a high 
percentage of organic modifiers can be used, up to 90%, without reducing 
analyte retention. Aims: This work was aimed at developing and validating a 
HILIC-ESI-ion trap-MS-MS method for identification and quantification of ETG and 
ETS as ethanol biomarkers and at employing this method for routine analysis of 
post-mortem samples. Methods: Following addition of pentadeuterated internal 
standards for ETG and ETS, 200 µl of acetonitrile was added to 0.1 ml of urine 
and centrifuged at 10000 rpm. The supernatant was then evaporated before 
reconstituting with 100 ìl of initial mobile phase. Analytes of interest were 
separated on a ZIC-HILIC column (150 x 2.1 mm, 3.5 ìm) (SeQuant, Umea, 
Sweden) connected to a Thermo-Finnigan LCQ Deca Plus LC-MS-MS instrument 
operated in the ESI-SRM mode. Gradient elution used a mobile phase with (A) 5 
mM ammonium acetate and (B) acetonitrile. Analytes were identified on the 
basis of their retention times and the relative intensities of their pseudo-
molecular ions and two product ions. Case samples: 90 urine case samples were 
divided into three groups depending on the ethanol concentration found in blood 
and analysed by the developed method: group A with post-mortem blood ethanol 
higher than 0.2 g/100 mL; group B with ethanol concentration in the range 0.08 
to 0.2 g/100 mL and group C with ethanol concentration less than 0.08 g/100 
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mL. Results: ETG and ETS had high recoveries of 98-99 % and the HILIC column 
produced fine, sharp peak shapes and achieved baseline separation in less than 7 
min. The calibration model was linear over a concentration range of 0.05-10 
mg/L and correlation coefficients (R2) were better than 0.999.  In addition, a 
lower limit of quantification of 0.001 mg/L was obtained and no matrix effects 
were observed. The method has been used for analysis of ETG and ETS in routine 
case samples and has been shown to be a useful tool to indicate recent ethanol 
consumption. Both ethanol markers were detected in all groups with overall 
median concentrations of 113.6 mg/L and 23.2 mg/L for ETG and ETS, 
respectively. Discussion and Conclusions: It can be concluded that the risk of 
false positive ethanol results increased in the low ethanol concentration group 
as several cases tested negative for both biomarkers in group C. ETG was 
detected at low concentrations in some cases for which ETS tested negative, 
suggesting that ETG may have a longer half life in urine or else ETS is unstable. 
Our data were compared with previous studies and confirm that both ethanol 
biomarkers should be determined in heavily putrefied cases and when the 
ethanol level in post-mortem blood is low, which suggest the production of 
ethanol after death. To the authors knowledge, this is the first report of the 
determination of ETS using an LC-ESI-ion trap-MS-MS method, and of a HILIC-ESI-
ion trap-MS-MS method for the simultaneous determination of ETG and ETS in 
post-mortem urine samples.  
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Oxycodone Related Fatalities in the West of Scotland   
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Objectives: In the United Kingdom, oxycodone is available on prescription in two 
forms, OxyContin (slow-release tablets) and OxyNorm (liquid/capsules). In 
Scotland, the number of prescriptions for oxycodone has risen by 430% since 
prescribing began in 2002 due to a shortage of diamorphine. Oxycodone misuse 
and related fatalities have been widely reported in the USA but it is hoped that 
stricter regulations will prevent a similar trend in the UK. The focus of this study 
is to review fatalities involving oxycodone in the West of Scotland using an LC-
ESI-MS-MS method developed for the determination of oxycodone and its 
metabolites in post-mortem specimens. Methods and Materials: Four cases were 
identified where oxycodone was implicated in the death. Deuterated internal 
standards were added to blood samples collected post-mortem and analytes 
extracted using Bond Elut C18 cartridges. Separation was achieved using a 
Synergy Polar RP column (150 x 2.0 mm, 4 ìm), gradient elution (mobile phase 
with (A) 10 mM ammonium formate, pH 3 and (B) acetonitrile), at a flow rate 0.3 
ml/min using a Thermo-Finnigan LCQ Deca Plus instrument in the ESI SRM mode.    
Results: The developed method for oxycodone and its metabolites noroxycodone 
and oxymorphone was linear over the concentration ranges 5 - 250 ng/mL and 50 
- 5000 ng/ml with correlation coefficients (R2) greater than 0.999. Limits of 
detection and lower limits of quantification were 0.2 - 0.4 ng/mL and 1.0 - 1.2 
ng/mL, respectively. Oxycodone, noroxycodone and oxymorphone were detected 
in three cases of oxycodone intoxication. In one case of poly-drug intoxication, 
oxycodone and noroxycodone were detected at low levels but oxymorphone was 
not present.  Conclusion: A sensitive, selective and robust method for the 
determination of oxycodone, noroxycodone and oxymorphone was validated and 
applied to oxycodone intoxication cases. High levels of oxycodone in 
combination with low levels of noroxycodone and oxymorphone were identified 
in three cases of suicide involving the deliberate ingestion of multiple tablets of 
OxyContin. In all cases a number of undigested OxyContin tablets were identified 
in the stomach contents. Oxycodone prescriptions have risen sharply in Scotland 
in recent years and the identification of four oxycodone-related death in the 
past 10 months in the Strathclyde region of Scotland alone highlights the 
importance of including this drug in routine laboratory screening and 
confirmation procedures. 
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Introduction: In the United Kingdom, oxycodone is available on prescription in two 
forms, OxyContin (slow-release tablets) and OxyNorm (liquid/capsules). In Scotland, the 
number of prescriptions for oxycodone has risen by 430% since prescribing began in 2002.  
Aim: The focus of this study was to review fatalities involving oxycodone in the West of 
Scotland using an LC-ESI-MS-MS method developed for the determination of oxycodone 
and N- and O-demethylated metabolites, noroxycodone and oxymorphone, in 
unhydrolysed post-mortem specimens. 
Methods: Deuterated internal standards were added to samples collected post-mortem and 
analytes extracted using Bond Elut C18 cartridges. Separation was achieved using a 
Synergy Polar RP column (150 x 2.0 mm, 4 ìm), gradient elution (mobile phase with (A) 
10 mM ammonium formate, pH 3 and (B) acetonitrile), at a flow rate 0.3 ml/min using a 
Thermo-Finnigan LCQ Deca Plus instrument in the ESI SRM mode.   
Results: The developed method for oxycodone and its metabolites noroxycodone and 
oxymorphone was linear over the concentration ranges 5 - 250 ng/mL and 50 - 5000 ng/ml 
with correlation coefficients (R2) greater than 0.999. Limits of detection and lower limits 
of quantification were 0.2 - 0.4 ng/mL and 1.0 - 1.2 ng/mL, respectively. Ten oxycodone 
positive post-mortem cases were detected during the period July 2007-December 2008 in 
which nine deaths were drug related fatalities. Five of these were attributed solely to 
oxycodone intoxication and four cases to mixed drug intoxication. High levels of 
oxycodone in combination with low levels of noroxycodone and oxymorphone were 
identified in one case of suicide involving the deliberate ingestion of multiple tablets of 
OxyContin. In four cases a number of undigested oxycodone tablets were identified in 
the stomach contents. Although there was overlap between blood oxycodone 
concentrations in deaths attributed to oxycodone only and poly-drug intoxication, the latter 
were associated with oxycodone concentrations less than 1 mg/L, while most cases in 
which oxycodone was the cause of death often had blood concentrations higher than 1 
mg/L. The role of parent drug in oxycodone fatalities has been fully studied but the role of 
the metabolites noroxycodone and oxymorphone in oxycodone fatalities was investigated 
in this report for the first time. Oxycodone was most commonly present in blood, urine and 
vitreous humor followed by noroxycodone. In some cases oxymorphone was not detected 
in blood but was found in urine. The ratio between parent drug and its N-demethylated 
metabolite is a useful tool for determining whether death occurred shortly after drug 
overdose ingestion or if it was delayed. It was found that the higher the ratio the shorter the 
elapsed time after ingestion before death occurred.  
Conclusion: Oxycodone prescriptions have risen sharply in Scotland in recent years and 
the identification of ten oxycodone-related deaths in the past 18 months highlights the 
importance of including this drug in routine laboratory screening and confirmation 
procedures. 
 
